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Premature infants, born before 37 weeks of gestation, represent an important 
patient group at risk of developing numerous diseases such as necrotising 
enterocolitis and bacterial sepsis. This risk is correlated with changes in the 
preterm gut microbiome, which is influenced by multiple post-natal factors 
including gut immaturity, C-section delivery, exposure to antibiotics and 
difficulties in establishing breastfeeding. To reduce the risk of disease development 
in premature infants and reduce colonisation of bacterial pathogens, oral 
supplementation with beneficial bacteria including Lactobacillus and 
Bifidobacterium is used.  
 
Before widespread uptake of this intervention, there is a pressing need to 
understand the impact of post-natal factors and how probiotic supplementation may 
modulate the preterm microbiome. In this thesis, I comprehensively examined the 
bacterial colonisation patterns of the preterm microbiome in health and disease 
using next-generation sequencing approaches. I also evaluated if probiotic 
supplementation can modify the gut microbiome in premature infants.  
 
Short- and long-read metagenomics sequencing was used, complemented with 
culturing and phenotypic testing. A 16S rRNA microbiome profiling pipeline was 
optimised to characterise faecal samples from premature infants with and without 
probiotic supplementation. The methods developed provided the foundation for a 
large-scale clinical study (BAMBI) which sought to explore the impact of probiotic 
supplementation on the preterm gut microbiome in 233 infants. A subset of these 
faecal samples (96 samples) were examined using shotgun metagenomics to study 
the gut bacterial reservoir of antibiotic resistance genes (the ‘resistome’) after 
antibiotic treatment and to elucidate whether probiotic supplementation impacts the 
prevalence of AMR genes. Finally, MinION Nanopore sequencing was used to 
rapidly profile faecal samples from critically ill premature infants. 
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Overall, this multidisciplinary work provides novel insights into the preterm gut 
microbiome in health and disease, emphasises the protective role of probiotic 
supplementation when administered to premature infants, and evaluates whether 
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1.1 Gut microbiome: importance and advances in the field 
The microbes that reside in the human gastrointestinal (GI) tract comprise a vast 
ecosystem of organisms including bacteria, fungi, viruses and protozoans, 
estimated to weigh ~2 kg1, 2. The gut microbiome is often described as a “virtual 
organ”3 comprised of ~1014 microbial cells that work in concert with the host and 
are able to promote health, but may sometimes cause disease. The gut microbiome 
constitutes a complex and diverse web of microorganisms which require an array 
of different and bespoke techniques for their study.  
 
In the last decade, the study of the human gut microbiome has become a rapidly 
moving field due to advances in new ‘omic’ technologies (in particular next-
generation sequencing and metabolite profiling). These approaches allow the 
identification and functional characterisation of complex microbial communities 
without the need to cultivate individual bacteria4. Microbiome research is 
providing new insights into the associations between bacterial composition and 
health or disease. Indeed, large-scale studies have been completed or are underway 
that are investigating how beneficial bacterial populations may be associated with 
human wellbeing by facilitating nutrient intake5, supporting the host’s immune 
system6, or providing antimicrobial protection7 against other bacterial pathogens. 
These studies can be complemented by others exploring how microbiome 
disturbances caused by exposure to antibiotics or different diets, are linked to 
incidence of chronic diseases including; ulcerative colitis8, obesity9, autoimmune 
conditions10 and infection with multi-drug resistant microbes11. 
 
There are significant new developments underway to harness the therapeutic 
properties of the gut microbiome. Microbiota therapies (MT) aim to alter the 
bacterial community gut composition of the individual, whilst at the same time 
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providing improvements in  health outcomes12. Many of these therapies are 
currently at an early stage of development, but their future has an exciting potential 
of influencing both health and disease. Examples of these innovations include 
untargeted approaches such as faecal microbiota transplantation (FMT) or more 
targeted ones using oral supplementation with beneficial bacteria, commonly 
known as “probiotics”13. FMT has become very effective for treating recurrent 
Clostridioides difficile infections; the success of this therapy has been shown to be 
dependent on the microbial diversity of the donor, which should be able to provide 
colonisation resistance against overgrowth of C. difficile (treatment is now 
available on the UK NHS)14. The use of empiric probiotic supplementation in 
adults, on the other hand, appears to be more challenging when crediting to health 
claims. This is likely due to two main reasons: (i) the vast diversity of “healthy” 
microbiomes among study-individuals making colonisation of supplemented 
strains difficult and (ii) important differences between ‘beneficial’ traits of 
probiotic strains15. Further characterisation of underlying mechanisms of action of 
these microbiota therapies is needed in conjunction with large-scale clinical studies 
to determine health outcomes. This will help integrate these therapies into 
mainstream clinical practice and, importantly, will reduce variability in patient 
response. 
 
The intestinal gut microbiome in early life and its role in maintaining 
health 
Early life represents a key developmental window when the foundations for life-
long health are laid down. Crucially, colonisation of the gut with beneficial 
bacterial pioneers (e.g. Bifidobacterium and Lactobacillus), contributes to optimal 
health and immune programming in the newborn16. The newborn gut is believed to 
be sterile17, and then become rapidly colonised during the first hours and days of 
life.  
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A naturally-born and breastfed infant is considered to be the ‘gold standard’ for a 
healthy infant gut microbiome. Immediately after birth, the intestine of the 
newborn infant is colonised by bacteria residing in the mother’s birth canal, the 
gut, and the environment, a mixed inoculum of facultative anaerobic bacteria 
(Enterobacter, Enterococcus, Staphylococcus and Streptococcus)18 able to grow in 
an environment low in oxygen. As oxygen diminishes within the gut other obligate 
anaerobic bacteria thrive (e.g. Bifidobacterium, Bacteroides and Clostridium)19. 
These microbial pioneers probably represent the most important bacterial inoculum 
for the infant gut colonization. Oral feeding (by breast milk or formula) is key to 
stimulating the growth of these bacterial colonisers during the first four month of 
life. Then with weaning to solid foods (four to six months of age) the infant gut 
microbiome becomes exposed to additional stimuli and by about eighteen months 
to three years the infant gut bacterial ecosystem is established representing the 
infant’s microbiome signature for life20, 21. 
 
Among these initial colonisers, members of the Bifidobacteriaceae family are 
important commensals which typically dominate the breastfed infant gut, reaching 
in some cases almost full dominance at 99%22. This is due, in part, to their ability 
to digest certain dietary components of breastmilk and produce acetate and 
bacteriocins which directly inhibit the growth of other bacteria23. Breastmilk 
represents a continued source of complex sugars called human milk 
oligosaccharides (HMOs) which act as a specialised nutrient source for the first 
bacterial communities such as Bifidobacteriaceae. Studies have demonstrated that 
there is a close association between gut bifidobacterial species and their ability to 
degrade the HMOs present in breastmilk24. This close relationship between gut 
bacteria and nutrient source in exclusively breastfed infants has been shown to 
provide beneficial health outcomes for these infants; for example, clinical studies 
demonstrated protective effects against diarrhoea and less incidence of long-term 




Figure 1 Microbiome in a healthy infant 
The early life gut microbiome plays three main roles during infancy; (i) break-
down of dietary components which results in synthesis of vitamins and the 
production of metabolites such as short chain fatty acids (SCFAs), (ii) prevention 
of pathogen colonisation through a mechanism called colonisation resistance26, and 
(iii) contribution to the maturation of the infant immune and neurocognitive 
development27 (Figure 1).  
 
Vitamin synthesis and metabolite production 
One of the ways the gut microbiome has been associated with the development of 
the infant is by synthesising important vitamins during the postnatal period. 
Intestinal bacteria can provide vitamin K which is necessary to synthesise certain 
coagulation factors in the liver, or group B vitamins such as folate which is 
required for cell division28. These vitamins in adults would be acquired by a diverse 
diet, but in small infants receiving a milk-based diet they can remain at low levels. 
Bacterial fermentation of carbohydrate products in the gut can result in production 
of SCFAs (e.g. butyrate, propionate and acetate) which can be used as energy by 
intestinal cells, and also transported from the intestinal lumen into the bloodstream 
where they are taken up by organs and act as substrates or signalling molecules. 
Butyrate for example is a SCFA which has been studied mostly for its interaction 
with colonocytes, improving mucosal and barrier integrity29. Acetate is absorbed in 
the liver where it is used as both an energy source and for cholesterol synthesis. 




The commensal early life gut microbiome forms a stable bacterial ecosystem which 
can provide protection against the colonisation of potential bacterial pathogens. 
This phenomenon is known as “colonisation resistance” and has an important role 
for not only preventing potential infections, but in fighting against them as well31. 
There are several ways in which commensal bacteria can confer colonisation 
resistance including; (i) killing other bacteria by producing small peptides called 
bacteriocins which inhibit the growth of other bacteria, or by (ii) competition for 
nutrients and specialising in utilising a unique “nutritional niche” which can help 
gut colonisation. In early life, Bifidobacterium taxa plays an important role in 
conferring colonisation resistance as described later. 
 
Maturation of infant immune system 
The maturation of the infant immune system32 develops at the same time as the 
infant gut microbial colonisation. Bifidobacteriaceae taxa have been associated 
with a role in programming the infant immune system33. Alterations in this process, 
are considered to be potential determinants of health outcomes later in life. Recent 
studies revealed reduced gut Bifidobacterium levels in 3-month-old infants were 
associated with higher incidence of atopy at 2 years of age, or asthma at 4 years of 
age33. In vitro studies have already demonstrated evidence of cross-talk among this 
taxa and immune cells. Bifidobacterium strains have been shown to induce 
cytokine production by peripheral blood mononuclear cells (PBMCs)34, 35. These 
studies concluded that cytokine production was strain-dependent, and careful 
selection should be taking into consideration when using them for therapeutic use. 
 
Experimental work using murine models has shown that secondary bacterial 
metabolites produced by commensal bacteria (i.e. butyrate, propionate and acetate) 
enhance T-cell differentiation which can have effects on decreasing tissue 
inflammation and enhancing immunity36. Furthermore, some commensal members 
of the gut microbiome (i.e. Lactobacillus, Bifidobacterium, Bacteroides, and 
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Clostridium) have been shown to influence the production of non-inflammatory 
IgA, which contributes to overall gut homestasis37.  
 
As highlighted in this section, this natural process of microbial colonisation of the 
infant gut is believed to be instrumental in influencing the composition of the adult 
gut microbiome. Alterations in this process, are considered to be potential 
determinants of health outcomes later in life. Some researchers refer to this process 
as a “window of opportunity”, whereby the timing of colonisation by these early 
life bacterial pioneers is crucial. Importantly, the process of microbial colonisation 
is known to be dependent on several intrinsic and extrinsic factors including; 
gestational age (i.e. time when the infant is born), mode of delivery (i.e. vaginal vs 
C-section delivery), type of feeding (i.e. breastmilk vs formula), and environmental 
exposures (i.e. antibiotic treatment). 
 
1.2 Premature infants and its unique conditions which shape their gut 
microbiome 
Every year approximately 15 million infants are born premature, i.e. before 37 
weeks of gestation, accounting for 1 in 10 live births38. Premature infants have an 
underdeveloped immune system and are administered numerous courses of 
antibiotics to prevent bacterial infections. Compared to term infants, premature 
infants are exposed to many more pre- and post-natal factors which disrupt the 
natural establishment of the early life gut microbiome. Premature infants spend 
long periods in the neonatal intensive care unit (NICU) and they received multiple 
clinical procedures (intubation, mechanical ventilation and vascular access) which 
increases the incidence of acquiring catheter-related bloodstream infections39. 
These factors contribute to an altered profile of the gut microbial ecosystem with 
an increase in relative abundance of pathobionts (i.e. Staphylococcus, 
Enterobacter, Klebsiella or Escherichia) which are gut resident microbes with 
pathogenic potential, and decrease abundance of commensal bacteria (i.e. 
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Bifidobacterium). Clinical systematic reviews have linked an increased risk of 
infectious diseases during the NICU stay, and later life health problems such as 
asthma or eczema in premature infants40, 41. 
 
Elucidating the influence of post-natal factors involved in the developing preterm 
gut microbiome (Figure 2) is one of the main aims of this thesis. The following 
introductory pages summarise the latest research findings examining the impact of 
mode of delivery, gestational age, antibiotics, and diet on the preterm gut 
microbiome. The two most common diseases associated with disturbances of the 
preterm gut microbiome during their residency in NICU are necrotising 
enterocolitis (NEC)42 and bacterial sepsis43, which are discussed in more detail 
below. Samples from premature infants suffering from these diseases were used in 
this research work (Chapter 4). Microbiota therapies are highlighted, in particular 
those that use oral supplementation with early life bacterial members that favour 
the establishment of beneficial communities in the at-risk preterm gut microbiome 
ecosystem. Finally, as this research work was conducted using sequencing and 
metabolomic approaches there is a section summarising the advantages, as well as 





Figure 2 Post-natal factors affecting the preterm gut microbiome 
Post-natal factors that have been shown to affect the establishment of the preterm 
gut microbiome. 
 
1.2.1 Delivery mode and the gut microbiome of premature infants 
Premature infants are often born via C-section44, which prevents exposure to 
beneficial vaginal (and gut) microbes (e.g. Bifidobacterium and Lactobacillus) 
involved in the stimulation of the infants’ immune system45. 
 
To date, most research studies on premature infants agree that their gut is mainly 
colonised by pathobionts such as Staphylococcus, Escherichia, Klebsiella, 
Enterococcus and Enterobacter46, 47, irrespective of their mode of delivery (vaginal 
vs. C-section). Interestingly, a recent study performed in premature infants 
associated a higher relative abundance of Bifidobacterium in those born vaginally, 
exclusively breastfed and not exposed to antibiotics48, which resemble the post-
natal conditions of a full-term infant. 
 
The findings of these studies suggest that delivery mode may not have such an 
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1.2.2 Gestational age and the effect on the preterm microbiome 
development 
Gestational age has been described as one of the main factors influencing the gut 
microbiome development in early life. Korpella and colleagues studied the effect of 
gestational age on the preterm gut microbiome throughout the first 60 days of 
life49. They described the preterm microbiome as being typically dominated by four 
main genera; Staphylococcus, Enterococcus, Enterobacter and Bifidobacterium, 
representing >50% relative abundance in a given sample. They found that infants 
often switched from one pattern of microbiome to another as postmenstrual age 
increased. The microbiome of the premature infant progressed from 
Staphylococcus-Enterococcus-dominated composition (at 25- and 30-weeks 
postmenstrual age) to Enterobacter (peaking at 35 weeks postmenstrual age) and 
finally towards Bifidobacterium-dominated microbiome, which began to develop 
gradually after 30 weeks postmenstrual age. This study concluded that the 
microbiome development in the extremely low birth weight premature group (<28 
gestation weeks) appeared to lag behind the moderate premature group (≥28 
gestation weeks).  
 
Maturity, indicated by postmenstrual age, is a major determinant of the preterm 
microbiome development, and a key factor which influences the ability of 
Bifidobacterium to reach dominance. More research investigating new 
interventions to improve the microbial colonisation in extremely premature infants 
(<28 gestation weeks) is needed. 
 
1.2.3 Antibiotic treatment and the preterm gut microbiome  
Antibiotics are the most commonly prescribed drugs in premature infants. The 
exposure rate of premature infants to antibiotics is in the range of 75-84%50, and 
higher still for very low birth weight (VLBW) infants (<1.5 Kg). Even though 
antibiotic therapy is necessary when an infant suffers from a bacterial infection, in 
many cases antibiotics are prescribed at a very early stage before the infant 
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presents any sign of infection or before there is any evidence from microbiological 
analysis51. 
 
The type of antibiotic treatment given to premature infants differs widely. Most 
NICUs use benzylpenicillin and gentamicin as the first-choice antibiotics for 
empirical treatment. This combination of antibiotics should protect the premature 
infant from the majority of Gram-positive and Gram-negative pathogens. If the 
premature infant presents no signs of improvement, after a short period of time, 
other antibiotics are used such as cefotaxime (when there is suspicion of Gram-
negative infection), vancomycin (targets Gram-positive bacteria) and 
metronidazole (if there is suspicion of necrotising enterocolitis). Table 1 
summarises the variety of antibiotics used in the NICUs which have contributed to 
this research work. 
 
Table 1 Antibiotics used in NICU, activity spectrum and mode of action 
Antibiotic Activity spectrum Mode of action Antibiotic Class 
Benzyl 
penicillin Narrow 
Binds to the enzymes (transpeptidases) responsible for assembling the principal components of the 
cell wall (peptidoglycans). As a result, the cell wall formation process is affected and the bacterium 
dies. Targets most Gram-positive and a few Gram-negative bacteria. 
b-lactam 
Gentamicin Broad Binds to the 30S subunit of the bacterial ribosome, disrupting protein synthesis. Targets mostly Gram-negative bacteria and Staphylococcus as Gram-positive. Aminoglycosides 
Cefotaxime Broad 
Binds to the enzymes (transpeptidases) responsible for assembly the principal components of the 
cell wall (peptidoglycans). As a result, the cell wall formation process is affected, and the bacterium 
quickly dies. Targets numerous Gram–positive and Gram-negative bacteria. 
b-lactam 
Flucloxacillin Narrow 
Binds to the enzymes (transpeptidases) responsible for assembling the principal components of the 
cell wall (peptidoglycans). As a result, the cell wall formation process is affected, and the bacterium 
quickly dies. Targets most Gram-positive bacteria. 
b-lactam 
Vancomycin Narrow Inhibits the synthesis of peptidoglycan. In addition, vancomycin alters cell-membrane permeability and RNA synthesis. Targets Gram-positive bacteria. Glycopeptide 
Metronidazole Narrow 
Inhibits nucleic acid synthesis thus disrupting the DNA of bacterial cells. It works in a reduced form, 
which take place in anaerobic bacteria. Targets Gram-negative anaerobic and Gram-positive 
anaerobic bacteria. 
Nitroimidazole 
During the first weeks of life most antibiotics given to premature infants are 
administered intravenously. As the infant matures and starts feeding, oral 
administration is used. In general, oral administration presents a moderate 
absorption and bioavailability when compared to intravenous administration52. The 
majority of the infants recruited in this research work, received antibiotics 
intravenously due to their poor feeding skills.	
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Premature infants often receive antibiotic empirically, as early as the first day of 
life. This coincides with the initial stages of microbial gut colonisation. Disruption 
of this initial colonisation caused by antibiotic therapy has been associated with 
higher probability of premature infants developing eczema53 and asthma54. Long 
antibiotic treatment, particularly broad-spectrum antibiotics, applies a selective 
pressure on the gut microbial community that diminishes colonisation resistance 
and favours the growth of antibiotic-resistant bacteria.  
 
Antibiotics do not discriminate between commensal or pathogenic bacteria, the 
immediate effect after treatment is an overall decrease in gut microbiome 
diversity55. The gut microbiome establishes a complex network of co-dependence56 
where bacteria are producing and exchanging secondary metabolites. Therefore, 
the effect of antibiotics on the gut microbiome needs to be evaluated considering 
the gut bacteria populations as a whole entity, and factors such as mode of action of 
the antibiotic (broad or narrow spectrum), length of antibiotic treatment, and route 
of administration (oral or intravenous) will differentially impact the gut 
microbiome community. 
 
Antibiotics might prevent susceptible pathogens from colonising the gut, but at the 
same time they might benefit the colonisation of bacterial strains that are 
antimicrobial resistant (AMR). Recent studies in adults have shown that the human 
gut microbiome acts as a huge reservoir of antibiotic resistance genes57 referred to 
as the resistome58. How stable the gut resistome is throughout life, or how easily 
this reservoir of antibiotic resistance genes could be mobilised through horizontal 
gene transfer to dangerous pathogens are important questions that warrant further 
research59. 
 
Within the context of the resistome, more work has been done in adults than in 
premature infants. In 2014 Lu and colleagues studied the gut resistome by 
analysing the faeces of 124 volunteers from different age groups and showed that 
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the resistome is accumulative with age60. More recently, Gibson and colleagues 
published the first work describing the preterm gut resistome by analysing faecal 
samples taken during the first three months of life55. They correlated an increase of 
AMR genes with antibiotic treatment, but interestingly they also found an increase 
of AMR genes with no known activity against the antibiotic(s) administered. 
However, it is difficult to make specific conclusions associated with specific 
antibiotic treatments as the control group used in this study only received a short 
antibiotic treatment, and the time points of the study are not equally distributed 
amongst the babies. 
 
Although antibiotic-induced bacterial alterations in the premature gut microbiome 
are only starting to be understood, there is a clear agreement that antibiotic 
treatment enhances the growth of multidrug resistant bacteria within gut-associated 
communities. There are still important gaps in our understanding of how this 
disruption can: (i) enhance or reduce the gut resistome as the infant ages, (ii) 
predispose premature infants to certain diseases/infections, or (iii) be modified if 
oral probiotic supplementation is used. The work presented in Chapter 3 
contributes to our understanding of some of these questions. 
 
1.2.4 Effect of diet on the preterm gut microbiome 
Appropriate neonatal feeding is essential for enhancing growth, immune 
development and health in premature infants. Diet is considered to be one of the 
most influential factors at determining the composition and diversity of the 
neonatal gut microbiome. During the first week of life, premature infants often 
receive a mixture of parental nutrition (intravenously), and enteral feeding by 
mouth. As soon as it is possible, parental nutrition is discontinued, and infants are 
only fed by mouth with maternal expressed breast milk, or donor breastmilk or 
formula milk as alternative options in that order of priority. 
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Expressed breast milk (EBM) represents the preferred option for feeding premature 
infants due to its unique nutritional content (i.e. human milk oligosaccharides, 
lactoferrin, and beneficial bacteria) and elevated content of immunological factors 
(i.e. immunoglobulins, cytokines and growth factors), which provide protection to 
the infant against a range of diseases61. Breastmilk favours the growth of specific 
bacterial groups such as Bifidobacterium and have been shown to decrease the 
diversity of the gut microbial community62. 
 
In the absence of breastmilk, premature infants are fed with donor breast milk if 
available. Donor breast milk is normally fortified with protein, calcium, 
phosphorus, and vitamin D; premature infants are not able to take large amounts of 
milk, and so the fortification helps assure that they achieve adequate growth. 
However, this milk is often pasteurised which leads to a reduction of many 
beneficial bioactive components such as IgA, lactoferrin, post-natal or water-
soluble vitamins63. 
 
If breastmilk or donor breastmilk are not available, premature infants receive 
formula milk. A recent study by Quigley and colleagues64 on 1070 premature 
infants highlighted that infants fed with formula milk presented twice as high a risk 
of developing necrotising enterocolitis (described in more detail in the following 
section) than donor breastmilk-fed infants, despite the faster rates of growth 
observed. A greater variety of premature gut microbiomes from formula-fed infants 
has been observed, probably explained by the susceptibility of premature infants to 







1.3 Diseases associated with gut microbiome alterations in the 
premature infant 
As described in the sections above, premature infants are predisposed to have 
altered bacterial colonisation patterns, which has been linked to an increased risk of 
developing necrotising enterocolitis (NEC) and sepsis. 
 
NEC constitutes one of the most devastating diseases for premature infants. It is 
estimated that ~ 12% of premature infants <1500 g will develop NEC, and 30% of 
those will die66. NEC is a multifactorial disease, and its pathogenesis is not fully 
understood. It is believed that the pathological NEC process is characterised by a 
lack of beneficial commensal microbes in the gut, overall reduced bacterial 
diversity and colonisation resistance; all of which allows overgrowth of pathogenic 
bacteria67. NEC commences by an uncontrolled intestinal inflammation, induced by 
a presence in the gut of pathogenic bacteria linked to gut immaturity, which can 
lead to tissue necrosis, gut perforation and, if not controlled, sepsis68. Klebsiella 
pneumoniae is one the most frequent pathogenic bacteria associated with NEC-
pathogenesis in premature infants69; in animal model studies this genus favours 
Paneth cell depletion70. Pathogenic Shigella, found when the infant received 
extended antibiotic courses, was also shown to induce NEC in premature infants67. 
Interestingly, some commensal bacterial members such as Clostridium perfringens, 
Clostridium butyricum and Escherichia coli have also been isolated during NEC 
outbreaks from stools of premature infants71, 72. 
 
Neonatal sepsis (i.e. bacterial blood stream infections), are the leading cause of 
morbidity and mortality in premature infants, accounting for 6-10% in premature 
infants born at 34–37 of gestational age73. Neonatal sepsis is classified into two 
groups based on the time of presentation: early-onset sepsis (EOS, refers to sepsis 
in premature infants presented during the first 72 hours of life) and late-onset 
sepsis (LOS, refer to a sepsis episode after 72 hours). Amongst the Gram positive 
bacterial pathogens, Coagulase Negative Staphylococcus aureus (CoNS) represents 
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48% of all bacterial infections, followed by S. aureus, Enterococcus species and 
Group B Streptococcus74. Amongst the Gram negative bacteria, Klebsiella spp. 
stands out 75, while Candida albicans is reported to be isolated in the majority of 
fungal infections76.  
 
Considering the high incidence and mortality of these diseases in the premature 
infant, it is crucial to be able to rapidly diagnose them. To date, the gold standard 
used for diagnostics in reference laboratories are culture-proven techniques. This 
approach requires a minimum of 24-36 hours to obtain first results, and on 
occasions it is not always easy to culture the pathogenic bacteria. In this thesis the 
real-time MinION nanopore sequencer was used to rapidly profile faecal samples 
from premature infants suffering from NEC and sepsis, in order to diagnose the 
causative bacterial pathogen and characterise its antibiotic resistance profile 
(Chapter 4). 
 
1.3.1 Microbiota therapy to modulate the preterm gut microbiome 
In the last twenty years, many randomised clinical trials and systematic reviews 
have demonstrated that routine oral supplementation of premature infants with 
early life commensal bacteria (i.e. Bifidobacterium or Lactobacillus) reduces the 
incidence of NEC and sepsis77, 78. It is interesting to highlight that these studies 
agree that the efficacy of the oral supplementation is specific to the bacterial strain 
used (commonly named as probiotic). Recent work is starting to relate their 
beneficial effects to the infant’s feeding regime78; a meta-analysis review on 
twenty-five probiotic trials on premature infants confirmed that the beneficial 
health outcomes provided by the probiotics, were more elevated in exclusively 




While large scale clinical studies have demonstrated the potential of probiotics to 
reduce NEC and the incidence of sepsis, there is a requirement to accompany these 
studies with in-depth longitudinal profiling to determine the impact of this type of 
supplementation on the overall gut microbiome composition. Sequencing studies 
will allow to answer important questions; (i) did the supplemented strain colonise 
the preterm gut? (ii) what was the impact of the supplementation on the remaining 
gut bacterial populations? and (iii) for how long the supplemented strain colonised 
the gut? This data will be crucial to complement clinical trials if robust guidelines 
are to be introduced for implementing probiotic supplementation as routine clinical 
care for premature infants. The work presented in this thesis (Chapter 2) aims to 
examine the effects of Infloran, a widely used probiotic supplementation, in the 
preterm gut microbiome and uses sequencing and metabolomic approaches to 
evaluate this. 
 
1.4 Use of metagenomics techniques for characterizing preterm gut 
microbiome disturbances 
Metagenomics approaches have been instrumental in obtaining a better 
understanding of the microbial diversity present in a sample. This technology 
utilises directly the genetic material present in an environmental sample (e.g. faecal 
sample) without the need for culturing. Ongoing studies indicate that metagenomic 
approaches will transform clinical microbiology; which is also linked to the rapid 
drop in the cost of sequencing and turnaround time now making these technologies 
viable options for diagnosis in reference laboratories. 
Several metagenomics approaches can be used to analyse an environmental sample 
including: (i) 16S rRNA gene sequencing and shotgun metagenomics (with 
potential application in microbial diagnostics), and (ii) functional metagenomics. 
Each technique has advantages and limitations, and it is important to understand 
how they work in order to use them efficiently.  
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1.4.1 16S rRNA gene sequencing 
The 16S rRNA gene is the gold standard taxonomic marker for identifying bacteria 
in a metagenomics sample. Sequencing of 16S rRNA PCR amplicons has become a 
well-established and cost-effective method for profiling the bacteria community 
profile present in a metagenomics sample. Due to its low cost, it is normally used 
in large-scale studies where shotgun sequencing is not affordable. 
Previous studies examining the gut microbiome using 16S rRNA gene sequencing 
have highlighted the influence of the DNA extraction method in the representative 
profile of the bacterial community obtained79. The 16S rRNA gene encodes nine 
hypervariable regions (i.e. V1 to V9) known to offer specificity at genus level 
between most bacterial groups. These hypervariable regions are surrounded by 
highly conserved regions in most bacterial populations, making the 16S rRNA gene 
an ideal taxonomic marker for this methodology. The main disadvantage of 16S 
rRNA gene sequencing is that it is a PCR based approach which may introduce 
biases such as failing to amplify a fraction of the microbial community due to 
differences in PCR efficiency caused by primer annealing or hairpin formation in 
the DNA template or primers. In addition, there are several studies which have 
observed differences in the 16S rRNA microbial profile depending on the 
hypervariable region of the 16S rRNA gene amplified80. Therefore, it is essential to 
determine the optimum region which can provide the most representative 
taxonomic profile for each study cohort. Chapter 1 of this thesis optimises a 16S 
rRNA profiling protocol from DNA extraction to bioinformatics analysis to allow 
robust and reproducible analysis of premature infant’s samples. 
 
1.4.2 Shotgun metagenomics 
When quantifying the taxonomic diversity present in a faecal sample or evaluating 
the diversity of the different AMR genes present with their predicted functions, 
shotgun metagenomics is currently the fastest and most informative approach. 
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Most authors like to summarise the possibilities shotgun metagenomics data offers 
into two main questions: who is there and what are they capable of doing?81. In 
shotgun metagenomics, microbial DNA is extracted from the faecal sample and 
sheered into smaller DNA fragments, which is then end-repaired using adapters, 
and subsequently sequenced, typically on a sequencing-by-synthesis Illumina 
platform. Data from shotgun metagenomics allows quantification of the taxonomic 
diversity present in an environmental sample using multiple single-copy marker 
genes (e.g. rRNA genes or protein coding genes). Focusing on single-copy gene 
families may provide a more accurate taxonomic profile than considering methods 
using gene families which differ in copy number across genomes82. Furthermore, 
data from this analysis can be used to predict biological function, which is 
extremely useful to obtain an overview of potential metabolic pathways. Functional 
predictions are performed by selecting the protein coding sequences from the 
metagenomic reads and comparing these to protein coding sequences in a database. 
This analysis can help to predict a profile describing the potential biological 
functions present in the metagenome community.  
Currently, shotgun metagenomics serves as an excellent technology to study the 
diversity of AMR genes (the resistome). This technology can also give an 
indication of whether the AMR genes detected are linked to mobile genetic 
elements. Associating AMR genes to mobile genetic elements is fundamental to 
evaluate the potential each AMR gene has to be transferred to other bacteria, i.e. 
‘horizontal gene transfer’. A recent study published by Clemente and colleges in 
2015 compared the human gut resistome from an uncontacted Amerindian tribe 
(with no previous contact to modern medicine) and industrialised societies using 
shotgun metagenomics83. This study revealed that the Amerindian gut resistome, 
surprisingly, is not that different from those of an industrialised nation. However, 
the presence of AMR genes linked to mobile genetic elements was found to be 
higher in industrialised populations than in the Amerindian tribe. This work lays 
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the background for understanding the role that antibiotics play in promoting the 
mobilisation of AMR genes between bacteria84.  
Despite the advantages of shotgun metagenomics to predict biological function, 
this approach also has its limitations. Beyond the basic technical limitations (e.g. 
higher DNA yields are required, which may prove difficult in limited samples, such 
as in preterm faecal samples), and the computational issues surrounding ‘big’ data, 
which are constantly being improved, the main limitation is that this approach can 
only identify genes that have been previously identified. Therefore, if the main aim 
is to find a novel gene, then functional metagenomics are often used. 
 
1.4.3 Functional metagenomics 
Functional metagenomics involves isolating DNA from microbial communities to 
study the functions of the encoded proteins. This functional-based approach allows 
the discovery of novel enzymes whose functions would not be predicted based on 
DNA sequence alone. Functional metagenomics demands more time in the 
laboratory than shotgun metagenomics. Briefly, bacterial DNA from a 
metagenomic sample is extracted, sheared, cloned into a vector and transformed 
into a host such as E. coli. These clones can be later tested to gain understanding of 
their functional capabilities. 
The work by Gibson and colleagues on the preterm gut resistome used functional 
metagenomics from bacterial DNA isolated from preterm faecal samples55. Results 
from the functional metagenomics study show that the sequences of the functional 
AMR genes are very similar to each other (95.8% amino acid similarity), but the 
proteins they encoded were extremely rare (24.8% amino acid identity) and most of 
them were not known from current AMR databases.  
 
 32 
1.5 Use of whole genome sequencing for characterising clinical 
isolates 
Whole genome sequencing (WGS) on clinical isolates offers the best possibility to 
study the genomic evolution of a particular bacteria. This technology permits 
addressing specific questions such as how pathogenic bacteria acquire AMR genes 
during antibiotic treatment, and/or how multidrug resistance bacteria are 
transmitted between individuals85. WGS sequencing allows tracking disease 
outbreaks by comparison of bacterial strains among infected individuals. Other 
approaches used to answer these questions, such as metagenomics approaches are 
often limited by the difficulty of assembling complex metagenome read data. 
 
Many authors have used WGS on multidrug resistance isolates from the same host 
before, during and after an antibiotic treatment with the aim of studying the 
evolution of resistance in a bacterial lineage. Point mutations accumulated in their 
genomes throughout the antibiotic course, have been associated with evolution of 
resistance. As an example, Mwangi and colleagues studied the genomes of S. 
aureus strains isolated from the same patient during two months of extensive 
antibiotic treatment with vancomycin 86. They compared the genomes of 
susceptible vancomycin strains isolated at the beginning of the antibiotic course, 
with non-susceptible vancomycin strains isolated at the end of the course. They 
found that 35 point mutations had accumulated in the strain isolated at the end of 
the treatment. These mutations were hypothesised by the authors to have been 
selected by the pressure imposed by the antibiotic treatment. Another interesting 
finding from this work is that some of these point mutations generated resistance to 
other antibiotics not used in the study, indicating that these point mutations were 
pleiotropic in nature. 
 
WGS can also be used to reconstruct infection events between individuals. If the 
genomes of several bacterial isolates are sequenced from different infected hosts, it 
is possible to perform an ancestry analysis with their genomes and evaluate which 
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individual is the focus of the infection, which is key for epidemiological analysis of 
outbreak events87. 
 
1.6 Metabolomics studies allow to explore the metabolic capacity of 
the intestinal microbiota. 
Metabolomics studies on faecal samples provide a functional readout of the 
microbiome and reports on the metabolic profile among the host, diet and gut 
microbiome88. The metabolome is described as a collection of endogenous 
molecules including amino acids, organic acids, sugars, fatty acids, lipids, small 
peptides, and vitamins which all provide a “snapshot” of the biological processes 
taking place in the sample89. This technique complements sequencing-based 
approaches, by offering information into metabolites that mediate microbe–
microbe and microbe–host interactions. Presently the main application of 
metabolomics approaches in the clinic include: (iii) evaluate relationships between 
gut microbiome and host metabolism, (ii) elucidate functional alterations in the 
metabolite patterns of health and disease, and (iii) find specific metabolites which 
can be treated as diseases markers. 
 
A recent study on the faecal metabolome on 786 twins and examining at 1,116 
metabolites revealed the gut metabolome was largely explained by the composition 
of the gut microbiome, and host genetics did not seem to be that influencial90. In 
infancy, diet have been shown to have a strong association with the faecal 
metabolite profile. Human breastmilk contains elevated amounts of unique 
carbohydrates known as human milk oligosaccharides (HMOs), which act as 
selective nutrients for certain groups of microbiota populations (e.g. 
Bifidobacterium) in the production of short-chain fatty acids (SCFAs). These 
molecules have been shown to be major players in the maintenance of gut and 
immune homeostasis, and are found in high levels in the proximal colon. Changes 
in the proportions of SCFAs, related to a breastmilk or formula diet, have been 
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shown to influence programming effects on inflammatory-mediated diseases, 
obesity or allergies91, 92. Altogether, metabolomics investigations linked to 
microbiome and nutritional studies can help obtain a further insight into 
microbiota-host interactions. 
 
1.8 Overarching hypotheses 
My thesis work aims to study the preterm gut microbiome in heath and disease 
using next-gene sequencing techniques. My entire research work lays on two main 
hypothesis: 
 
- Early administration of antibiotics to premature infants can lead to disruption of 
gut microbiome colonisation and also contribute to increase the reservoir of 
antimicrobial resistance genes. 
- Probiotic supplementation can contribute to re-establishment of the commensal 
gut microbiome after antibiotic treatment and therefore reduce the reservoir of 
antimicrobial resistance genes. 
 
1.8.1 Study-case hypotheses 
This thesis is divided into four main chapters: 
 
Chapter 1: This is a methods chapter, where I used 16S rRNA gene profiling to 
accurately sequence the preterm gut microbiome. I hypothesise the 16S rRNA gene 
sequencing pipeline will be influenced by each of these stages: (i) bacterial DNA 
extraction method (ii) 16S rRNA hypervariable region amplified and primer 
choice, and (iii) bioinformatics pipeline used for data analysis. 
 
Chapter 2: This Chapter looks at the effects of probiotic supplementation in the 
preterm gut microbiome. I hypothesise probiotic supplementation using 
Bifidobacterium bifidum and Lactobacillus acidophilus can modify the gut 
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microbiome and metabolome of premature infants and reduce the presence of 
potential pathogenic bacteria. 
 
Chapter 3: This chapter focuses on antibiotic treatment and its impact on preterm 
gut microbiome. I hypothesise administration of empiric antibiotic treatment to 
premature infants using benzylpenicillin and gentamicin can favour the growth of 
multidrug resistance bacteria, and enhance the reservoir of antimicrobial resistance 
genes. 
 
Chapter 4: This chapter aims to sequence rapidly the preterm gut microbiome 
using MinION nanopore technology. I hypothesise the MinION nanopore 
sequencer will be able to profile rapidly faecal samples from premature infants to 
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Title: Optimisation of 16S rRNA sequencing pipeline for profiling faeces from 
extremely low birth weight infants  
Abstract 
The gut microbiome of premature infants, particularly extremely low birth weight 
(ELBW) infants is altered due to a variety of factors such as birth mode and 
antibiotic use. Thus, new microbiota therapies (e.g. probiotic supplementation) are 
becoming increasingly popular for manipulating the ELBW infant gut microbiome 
to improve infant health. Microbiome profiling, via metataxonomic 16S rRNA 
sequence profiling, represents an important tool for understanding the outcome of 
any probiotic supplementation. However, it is critical to optimise these types of 
studies for the cohort being characterised, in this case ELBW infants. In this work, 
a 16S rRNA profiling protocol was optimised, to allow robust and reproducible 
analysis of ELBW infant faecal samples, with or without probiotic 
supplementation. Three different DNA extraction methods were compared, 
followed by comparison of three hypervariable regions primer sets 
(V1 + V2 + V3), (V4 + V5) and (V6 + V7 + V8). Sequencing results were 
analysed using two bioinformatics approaches; Operational Taxonomic Unit and 
Paired End. Results from this work demonstrated that appropriate primer selection 
when using 16S rRNA gene profiling is essential and 16S rRNA gene region 
(V4+V5) should be avoided for analysing faeces samples from premature infants. 
 






Figure 3 Study pipeline 
a Recruitment of ELBW infants (<1000g) with no supplementation (AP1E, AP8C, AP5D 
and AP25D) and ELBW infants with supplementation (P29F, P30N, P31N, P35C) by nurses 
at the Rosie Hospital (RH) and the NNUH respectively. Term babies (V3J, V2A) were 
recruited by researchers. b Optimisation of the bacterial DNA extraction protocol from 
ELBW infant faeces by testing three different DNA extraction methods (QIAmp DNA Stool 
Mini Kit, Fast DNA Spin Kit Soil and enzymatic lysis + QIAmp DNA Stool Kit). Bacterial 
DNA from the study samples was extracted using the Fast DNA Spin Kit Soil and used to 
prepare three different 16S rRNA gene sequencing libraries. Each library was prepared using 
a specific pair of primers which target different hypervariable regions (prefixed by a V) of 
the bacterial 16S rRNA gene: (i) primers 27F-519R target (V1+V2+V3), (ii) primers 530F-
926R target (V4+V5) and (iii) primers 926F-1394R target (V6+V7+V8). c A preliminary 
bioinformatics analysis was performed on two samples using two different bioinformatics 
pipelines: OTU analysis and the PE protocol. Both bioinformatics approaches were used to 
compare the different 16S rRNA gene sequencing profiles obtained for the different 
hypervariable regions tested (V1+V2+V3, V4+V5, and V6+V7+V8). (*) Validation of the 






Fig. 1 (See legend on next page.)
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Mr Shabhonam Caim carried out QIIME bioinformatic pipeline. Specific details of 
all authors’ contributions can be found within the Methods section. 
 
Introduction 
Preterm birth occurs in 1:10 live births globally94. Premature infants, and in 
particular extremely low birth infants (ELBW), are born very immature, and 
consequently may have an underdeveloped gut and immune system95. Furthermore, 
they are often exposed to external factors which profoundly impact early life gut 
microbiome colonisation including; infections related to maternal health, 
Caesarean (C-) section delivery and long exposure to antibiotic treatments55. This 
is relevant as the microbiome plays a key role in immune programming96, pathogen 
resistance97 and neurocognitive development98. In comparison with full term 
infants, a distinct gut microbiome is found in premature infants, which is further 
altered in ELBW infants, and is characterised by lack of the genus Bifidobacterium, 
and overabundance of Enterobacteriaceae99. Importantly, these alterations in the 
gut microbiome can predispose premature infants to life threatening diseases such 
as necrotising enterocolitis (NEC)100, which is distinguished clinically by 
inflammation of the intestinal tissue, and in severe cases may lead to intestinal wall 
perforation. Furthermore, as deterioration of the infant can occur rapidly (between 
6-8 hours), there is an urgent requirement to optimally characterise microbiome 
profiles in patients at-risk (such as premature infants), particularly for studying the 
influence that novel microbiota therapies (e.g. probiotic supplementation) could 
offer for ecosystem restructuring and health outcomes. 16S rRNA gene 
metataxonomic profiling of faecal samples represents a cost-efficient method to 
gain insights into the bacterial components of the gut microbiome, and additionally 
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allows characterisation of cohorts where sample access and quantities are 
compromised (e.g. ELBW infants). Of the limited sequencing studies performed so 
far on ELBW infants, profiling clearly shows a lower abundance of 
Bifidobacteriaceae and Lactobacillus, which are commonly found in the gut 
microbiome of term infants and a higher abundance of Enterobacteriaceae, 
Enterococci and Staphylococci101. Importantly, Bifidobacteriaceae has been found 
in many studies as a dominant member of the full-term infant microbiome 
(particularly in vaginally delivered breast-fed infants) and has been associated with 
improved host wellbeing102, 103. Therefore, probiotic supplementation (or 
microbiota therapy) represents an attractive approach for manipulating the ELBW 
gut microbiome in order to improve health outcomes.  
 
Previous studies examining the gut microbiome using 16S rRNA gene sequencing 
have highlighted the influence of DNA extraction method in the representative 
profile of the bacterial community obtained79. Also, the hypervariable region (V1 
to V9) of the 16S rRNA gene targeted influences the ability to distinguish between 
different bacterial taxa, and only near-complete 16S rRNA gene sequences give 
accurate measures of taxonomic diversity104. Currently, the complete sequence of 
the 16S rRNA gene (~1400 bp) is outside the read length of short-read high-
throughput sequencing technologies (i.e. Illumina platforms). Therefore, it is 
essential to determine the optimum region which can provide the most 
representative taxonomic profile for the study cohort. 
 
In this study an optimised protocol for profiling the ELBW infant gut microbiome 
using 16S rRNA gene sequencing is presented. The study analysed faecal samples 
from ELBW premature infants (<1000 g; with/without probiotic supplementation) 
and samples from term infants as controls. Samples from ELBW infants receiving 
probiotic supplementation comprised the ‘spiked’ samples with known species of 
Bifidobacterium and Lactobacillus. A bacterial DNA extraction method was 
optimised for these samples, after comparing three different methods, and 
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generated amplicons to three different hypervariable regions of the 16S rRNA gene 
(V1+V2+V3), (V4+V5) and (V6+V7+V8) followed by Illumina sequencing were 
compared, with reads analysed using two different bioinformatics pipelines (OTU 
versus Paired End protocol). Finally, to further validate the sequencing results, 
shotgun sequencing was used on a subset of the tested samples. Results from this 
study demonstrate that inclusion of an extended bead-beating step was essential 
when extracting DNA from faecal samples, and that sequencing regions 
(V1+V2+V3) or (V6+V7+V8) of the 16S rRNA gene provided the most 
representative bacterial profile of the ELBW infant gut microbiome. 
 
Hypothesis and aims 
Hypothesis: The bacterial community 16S rRNA gene profile will be influenced by 
each stage of the 16S rRNA gene pipeline: (i) bacterial DNA extraction method (ii) 
16S rRNA hypervariable region amplified and primer choice, and (iii) 
bioinformatics pipeline used for data analysis.  
 
This study addressed 3 aims: 
a) Evaluation of three different bacterial DNA extraction methods, to 
determine the optimal extraction method for profiling DNA from ELBW 
infants’ faeces.  
b) Determination of which regions of the 16S rRNA gene (V1+V2+V3, 
V4+V5, and V6+V7+V8) were most accurate at representing the ELBW 
infant gut microbiome. Complementing this analysis with an in silico 
primer aligning study to evaluate alignment of the primer pairs used, 
among bacterial members commonly found in the gut microbiome of 
ELBW. 
c) Comparison of two popular bioinformatics pipelines (OTU clustering 
analysis and paired end protocol (PE) to assess whether the same 
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biological conclusions regarding ELBW microbiome composition, could 
be reached using different bioinformatics pipelines. 
 
Methods 
Subject recruitment and faecal sample collection 
This study was approved by the University of East Anglia (UEA) Faculty of 
Medical and Health Sciences Ethics Committee, and sample collection was in 
accordance with protocols laid out by the National Research Ethics Service 
(NRES) approved UEA Biorepository (Licence no: 11208). Infants admitted to the 
Neonatal Intensive Care Units (NICUs) of the Norfolk and Norwich University 
Hospital (NNUH, Norwich, UK) and the Rosie Hospital (Cambridge, UK) were 
recruited by doctors or nurses with informed and written consent obtained from 
parents. Both NICUs had similar protocols for feeding and the prescription of 
antibiotics and antifungal drugs, with the main exception being probiotic use; the 
Rosie Hospital does not use probiotics, the NNUH routinely prescribed all ELBW 
infants an oral probiotic treatment containing Bifidobacterium bifidum and 
Lactobacillus acidophilus (i.e. Infloran®, Desma Healthcare, Switzerland) in a 
twice daily dose of 1 x 109 of each species, given from birth until 34 weeks old. A 
total of eight ELBW infants were recruited, four received probiotic 
supplementation and four did not receive any supplementation. All recruited 
ELBW infants were <27 week’s gestation and weighed ≤1000 g at birth. Infants 
born vaginally and breast-fed were specifically selected, with the aim of 
normalising for other external factors which can influence gut colonisation of 
Bifidobacterium and Lactobacillus. A control group of two term babies were also 
recruited by the research team following the same protocol. Faecal samples were 
collected from nappies into a sterile stool container and stored at 4 °C. DNA was 




 Table 2 Subject details and metadata 















AP1E RH† Vaginal 25 830 No Breastfed 16 
AP5D RH Vaginal 25 800 No Breastfed 12 
AP25E RH Vaginal 25 786 No Breastfed 18 
AP8C RH Vaginal 23 576 No Breastfed 21 
AP10B RH Vaginal 26 710 No Breastfed 30 
P31B NNUH‡ Vaginal 23 605 Yes Breastfed 16 
P29F* NNUH Vaginal 26 1000 Yes Breastfed 12 
P30N* NNUH Vaginal 26 960 Yes Breastfed 15 
P35C NNUH Vaginal 23 565 Yes Breastfed 16 
P66F NNUH Vaginal 26 670 Yes Breastfed 20 
V3J NNUH Vaginal 40 3500 No Breastfed 58 
V2A NNUH Vaginal 40 3320 No Breastfed 60 
V3ZC NNUH Vaginal 40 3500 No Breastfed# 365 
*Baby P29F and P30N were twins.  
†Rosie Hospital 
‡Norfolk and Norwich University Hospital 
§Faecal samples were collected in a stool container and stored at 4⁰ C. DNA was extracted within 4 hours of 
collection. 
# Exclusively breastfed baby until six month old. 
DOB: date of birth 
 
Sample processing and DNA extraction 
Optimisation of tree bacterial DNA extraction methods was performed on faecal 
samples from two ELBW infants (with/without supplementation) and one term 
infant sample. Three different DNA extraction methods were used: (i) FastDNA 
Spin Kit for Soil (MP Biomedical, Santa Ana) following the manufacturer’s 
instructions and extending the bead-beating step to 3 minutes (ii) QIAmp DNA 
Stool Mini Kit (Qiagen) following the manufacturer’s instructions, and (iii) QIAmp 
DNA Stool Mini Kit (Qiagen) including an initial enzymatic lysis step of 1 hour at 
37⁰C (enzymatic mix: 50 mM Tris-HCl, pH 8.0, 10 mM MgSO4, 5 mg/mL 
lysozyme and 50 U/mL mutanolysin). The DNA recovered from these samples was 
assessed using a Qubit® 2.0 fluorometer (Invitrogen). I performed this procedure. 
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16S rRNA gene library preparation 
Fast DNA Spin Kit extracted DNA was used for preparing 16S rRNA Illumina 
MiSeq sequencing libraries. DNA concentration was normalised to 5 ng/mL using 
a Qubit® 2.0 fluorometer. Three hypervariable regions of the 16S rRNA gene 
(V1+V2+V3 (primers 27F-519R), V4+V5 (primers 530F-926R), and V6+V7+V8 
(primers 926F-1394R)) were amplified using the HotStarTaq Plus Master Mix Kit 
(Qiagen, USA). Details of the primer sequences used for amplification can be 
found in Table 3. 
 
Table 3 Primers used in 16S rRNA sequencing library 
Primer 
name 





27Fmod 27F V1+V2+V3 AGRGTTTGATCMTGGCTCAG 
ill519Rmod 519R V1+V2+V3 GTNTTACNGCGGCKGCTG 
    
530F 530F V4+V5 GTGCCAGCMGCNGCGG 
bac926R 926R V4+V5 CCGTCAATTYYTTTRAGTTT 
    
926F 926F V6+V7+V8 AAACTYAAAKGAATTGACGG 
bac1394R 1394R V6+V7+V8 ACGGGCGGTGTGTRC 
 
Each DNA sample was amplified using a primer pair tagged individually with a 
unique barcode. PCR amplification conditions were: 1 cycle of 94 °C for 3 
minutes, followed by 25 cycles of 94 °C for 45 s, 55 °C for 15 s and 72 °C for 30 s. 
Amplicons were pooled in equal proportions and purified using Ampure XP beads 
(Agencourt). The purified product was used to prepare the Illumina DNA library. 
Libraries were sequenced on the Illumina MiSeq platform using a read length up to 
2x300 bp. I prepared the samples for this analysis, and libraries were made and 
sequenced by company MrDNA. 
 
Whole genome shotgun metagenomics library preparation  
Genomic DNA (approximately 500 ng) from two ELBW infants’ samples 
(with/without supplementation) and one term infant sample was fragmented to an 
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average size of 250 bp and subjected to DNA library creation using established 
Illumina paired end protocols. Adapter-ligated libraries were amplified and indexed 
via PCR. A portion of each library was used to create an equimolar pool and 
enriched libraries were subjected to 100 base paired end sequencing (HiSeq 2000 
V3; Illumina). I prepared the samples for this analysis and samples were sequenced 
at Sanger Institute. 
 
Bioinformatics analysis 
16S rRNA gene sequencing analysis 
Two bioinformatics pipelines were used to analyse the 16S rRNA gene sequencing 
data: OTU clustering analysis and paired end protocol (PE). OTU clustering 
analysis was performed using the QIIME bioinformatics pipeline105. First, read 
pairs were assembled using PEAR106, a highly accurate pair-end read merger. 
Second, sequences were quality filtered using QIIME’s split_libraries_fastq.py and 
chimeras were identified and removed using identify_chimeric_seqs.py and 
filter_fasta.py respectively. Following, OTU picking step was run using 
pick_open_reference_otus.py (percent_subsample parameter set at 0.1) and QIIME 
SILVA_128 as our reference database. OTUs were formed by clustering to 97% 
similarity, and a representative sequence was picked for each OTU aligned using 
PyNAST 107 and taxonomy was assigned using uclust108. Filtering prior to build the 
tree that was done by removing the positions with gaps and specified as 0 in the 
lanemask. FastTree is used to create a tree file for the represented sequences. Final 
taxonomic output was saved as a biom file. 
 
An in-house PE protocol was used following the quality control of the raw paired 
reads using FASTX-Toolkit109 (with a minimum quality threshold of 33 for at least 
50% of the bases in each read sequence. Reads that passed the threshold were 
aligned against the SILVA database (version: SILVA_128_SSURef_tax_silva)110 
and BLASTN (ncbi-blast-2.2.25+; Max e-value 10e-3)111. The BLAST files 
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obtained were imported into MEGAN6112 to create MEGAN-own files (“rma6” 
files) using the following parameters: 100 as maximum number of matches per 
reads, and “Min Score = 50” and “Top Percent = 10”. All output files (rma6) of 
paired read sequences were then normalised and compared using MEGAN6. I 
performed the Paired End Protocol supervised by Dr Suparna Mitra, and Mr 
Shabhonam Caim performed the QIIME pipeline. 
 
Whole genome shotgun gene sequencing 
Whole genome paired sequences from samples AP8C (an ELBW infant without 
supplementation), P29F (an ELBW infant who received supplementation) and V3J 
(term infant) were obtained from an Illumina HiSeq 2000 V3 sequencer. The first 
10 bases were trimmed using FASTX-Toolkit113. Subsequently, trimmed sequences 
were aligned against the NCBI non-redundant database (version 04/2016)114 using 
DIAMOND115. All output files of paired read sequences were then imported and 
analysed using the PE protocol of MEGAN with non-default settings.  
 
Functional profiles were performed on the same samples using the KEGG pathway 
database. Mapping files used for this analysis were obtained from MEGAN’s 
website. This analysis was done by Dr Suparna Mitra. 
 
Sequencing reads statistics 
Read counts at different stages of the bioinformatics analysis are provided in 
Appendix 1. To compare study samples, sequences were normalised using values 
from the sample with the lowest number of reads. In other cases, read counts were 
displayed in percentage of number of reads.  
 
Principal Coordinate Analysis plot was performed using Bray-Curtis distances on 
the 16S rRNA bacterial community profiles using MEGAN. The Shannon diversity 
 47 
index was obtained by exporting genus level profile (normalised) from all 30 
samples in MEGAN and plotting them in Excel. I performed this analysis. 
 
Primer annealing study 
Amplicon sequences from the most common bacterial taxa found in sample P29F 
(ELBW infant with supplementation) were extracted using MEGAN 112. Full length 
sequences of the respective 16S rRNA genes were obtained from Genbank after 
identified the respective database entries using BLASTN 116. Primer annotation of 
the 16S rRNA sequences was performed using Genedoc 2.7 117. I performed this 
analysis with the help of Dr Udo Wegmann. 
 
Validation of primers 530F-926R: PCR and melting curves qPCR 
PCR 
DNA extracted from B. bifidum (isolated from the probiotic supplement) and seven 
different Bifidobacterium strains (from NCIMB strain collection, Aberdeen, 
Scotland), was amplified by PCR using primers 530F-926R. Table 4 provides the 
details of the NCIMB collection strains used in this study.  
 
Table 4 Bifidobacterium strains used for validating primers 530F-926R using PCR 
Bifidobacterium strains NCIMB collection number 
Isolated from 
B. longum 8809 Nursing stools 
B. bifidum 13922 Not described 
B. catenatum 702239 Human faeces 
B. angulatum 702236 Human faeces 
B. adolescentis 702204 Adult intestine 
B. breve 8807 Infant intestine 
B. infantis 702255 Infant intestine 
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A faecal metagenomic sample and a Lactobacillus acidophilus strain (isolated 
directly from the probiotic supplement) were used as positive controls. Amplicon 
samples were run on 1% agarose gel for 30 minutes at 100 V. DNA was visualized 
under UV light after staining with ethidium bromide. I performed this analysis. 
 
qPCR 
Melting curves of PCR amplicons obtained from the probiotic strains 
(Bifidobacterium bifidum and Lactobacillus acidophilus) and two bacterial isolates 
from an ELBW infant with supplementation (Enterococcus faecium and 
Streptococcus infantarius) were performed using a LightCycler 480 (Roche 
Molecular Diagnostics). Conditions for the melting curves were: 95 °C for 5 s, 65 
°C for 1 min and a final stage at 97 °C continuous. As an additional experiment, a 
melting curve from an amplicon obtained from a mixed DNA sample (containing 5 
ng DNA from of each of the above bacterial species) was run. Conditions used for 




Effect of DNA extraction method in sample preparation. 
DNA extraction is the first critical step in sample preparation for sequencing 
studies118. A preliminary study was performed with two faecal samples from two 
ELBW infants, and one term infant as a control. Two different DNA extraction kits 
(Fast DNA Spin kit and QIAamp) were tested with two different conditions with 
the aim of optimising the best extraction method for profiling DNA from ELBW 
infants’ faeces. Average DNA concentrations in elution from each method of 21.4 - 
1.97 ng µL−1, and 0.016 - <0.0005 ng µL−1 were obtained with the Fast DNA Spin 
Kit and QIAamp, respectively (Table 5). The DNA concentration was significantly 
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higher with the Fast DNA Spin kit than the QIAamp (p <0.05), and elevated 
amounts of DNA were obtained with the inclusion of a longer bead-beating step. 
 
Table 5 DNA yield from different DNA extraction methods 
Sample Extraction Method Qubit 
(ng/µl) 
ELBW infant no 
probiotics (AP10B) 
Fast DNA Spin Kit (3 min bead-
beating) 
2.25 
Fast DNA Spin Kit (30 sec bead-
beating) 
1.97 
QIAamp DNA stool kit <0.0005 
Enzymatic lysis and QIAamp DNA 
stool kit  
0.0146 
ELBW infant with 
probiotics (P66F) 
Fast DNA Spin Kit (3 min bead-
beating) 
13.8 
Fast DNA Spin Kit (30 sec bead-
beating) 
7.38 
QIAamp DNA stool kit <0.0005 
Enzymatic lysis and QIAamp DNA 
stool kit  
0.0156 
Term baby(V3ZC) Fast DNA Spin Kit (3 min bead-
beating) 
21.4 
Fast DNA Spin Kit (30 sec bead-
beating) 
7.7 
QIAamp DNA stool kit 0.0164 
Enzymatic lysis and QIAamp DNA 
stool kit  
0.77 
 
Assessing coverage of 16S rRNA sequencing data 
Coverage of sequencing data was assessed by performing rarefaction curves, which 
correlates numbers of reads sequenced with number of genus found in the sample. 
As a rule, when the rarefaction curve plateaus the majority of bacterial genus 
present in the sample are detected. This study was performed as there were 5x and 
10x differences in the number of reads obtained from regions (V1+V2+V3 and 
V6+V7+V8) compared to region (V4+V5). After discussions with the sequencing 
company, no specific reasons (e.g. library preparation or MiSeq settings) could 
explain the higher number of reads obtained when using region (V4+V5).  
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The coverage analysis using rarefaction curves indicated that at 25,000 reads the 
majority of bacterial populations were sequenced (Figure 4), with all samples 
presenting >25,000 reads, which subsequently enabled robust comparison and 
normalisation of the data. 
 
 
Figure 4 Rarefaction curves 16S rRNA gene sequencing data  
Rarefaction curves representing number of species (leaves) detected at genus level 
versus number of reads sampled. Three different 16S rRNA gene sequencing data 
were used for this study: (i) green curves represent sequencing data from 16S rRNA 
library prepared using primers 27F-519R, (ii) red curves represent sequencing data 
from 16S rRNA library prepared using primers 530F-926R and (iii) blue curves 
represent sequencing data from 16S rRNA library prepared using primers 926F-
1394R. Rarefaction curves are labelled with numbers to differentiate among the 
samples used in the study: 1 (V2A.530F), 2 (V2A.926F), 3 (V3J.926F), 4 
(AP8C.530F), 5 (V2AJ.27F), 6 (AP5D.530F), 7 (P35C.530F), 8 (V3J.530F), 9 
(P29F.530F), 10 (P31B.530F), 11 (P30N.530F), 12 (AP25E.530F), 13 
(AP25E.926F), 14 (AP25E. 27F), 15 (AP8C.926F), 16 (P35C.926F), 17 (V3J.27F), 
18 (P31B.926F), 19 (AP1E.530F), 20 (P31B.27F), 21 (P29F.27F), 22 (P30N.27F), 
23 (AP5D.926F), 24 (AP5D.27F), 25 (P29F.926F), 26 (AP1E.926F) ,27 
(AP1E.27F), 28 (AP8C.27F), 29 (P30N.926F), 30 (P35C.27F). Numbers 12, 13 and 
14 correspond to sample AP25E where majority of sequenced reads assigned at 






















































Optimisation of 16S rRNA bioinformatics pipeline (OTU pipeline versus 
paired end protocol) 
To evaluate and determine the optimal 16S rRNA bioinformatics pipeline a 
preliminary study was performed on one ELBW infant (AP1E) and one term infant 
sample (V3J) using two different bioinformatics approaches (OTU and paired end 
protocol). A reference-based OTU clustering analysis (QIIME) was used; this 
approach organises the raw reads within OTUs of 97% similarity, and then 
compares against public databases. In contrast, the paired end protocol (PE) aligns 
raw reads to the 16S rRNA gene databases directly after quality control. At genus 
level both methods tested showed similar taxonomic profiles for the majority of the 
bacterial populations (e.g. Bacteroides and Staphylococcus for sample AP1E 






Figure 5 Comparison of bioinformatics analyses (OTU versus PE protocol) 
Preliminary study comparing two different bioinformatics approaches: OTU 
clustering performed using QIIME and PE protocol. Both bioinformatics approaches 
used the same database (SILVA version 128). a Taxonomic profiles obtained using 
PE protocol and OTU clustering for sample AP1E (ELBW infant no 
supplementation). b Taxonomic profiles obtained using PE protocol and OTU 
clustering for sample V3J (term infant sample). Three different 16S rRNA gene 
libraries were prepared for each sample, (i) (V1+V2+V3, primers 27F-519R), (ii) 
(V4+V5, primers 530F-926R) and (iii) (V6+V7+V8, primers 926F-1394R).  
 
To complement this analysis, the Shannon Diversity Index (Figure 6) for OTU and 
PE approaches was calculated, with results between both pipelines comparable, 
except for region (V1+V2+V3, 27F-519R) where the OTU approach presented the 
lowest value. 
 
(Lactobacillus and Bifidobacterium) as control popula-
tions. Notably, when we examined the number of reads
assigned to these genera, the results indicated significant
dissimilarities between hypervariable regions.
In the case of Lactobacillus, the three hypervariable
regions (V1 + V2 + V3, V4 + V5, and V6 + V7 + V8) were
able to detect the presence of this genus at significant
levels (>1000 reads) in three (P29F, P30N and P35C) out
of the four samples from ELBW i fants who received sup-
plementation and in one (un-supplemented) term baby
sample (V3 J). Ampli on from region (V4 + V5) revealed
3 and 6 times higher number of reads for Lactobacillus
when compared t th other regions (V1 + V2 + V3 and
V6 + V7 + V8). These data indicate that region (V4 + V5)
may over-represent this bacterial genus, which is validated
and discussed in more detail in a later paragraph when
comparing to shotgun analysis.
The taxonomic assignments obtained for Bifidobacter-
ium reveal prominent differences between the different
regions. Analysis of region (V4 + V5) did not detect Bifi-
dobacterium at high levels (>1000 reads) in any of the
four samples (P29F, P30N, P31B a P35C) tested from
ELBW infants who received supplementation (i.e.
‘spiked’ samples). In contrast the other regions
(V1 + V2 + V3 and V6 + V7 + V8) did show Bifidobac-
t rium at >1000 reads assigned in three out of the four
a
b
Fig. 2 Comparison of bioinformatics analyses (OTU versus PE protocol). Preliminary study comparing two different bioinformatics approaches:
OTU clustering performed using QIIME and PE protocol. Both bioinformatics approaches used the same database (SILVA version 128). a
Taxonomic profiles obtained using PE protocol and OTU clustering for sample AP1E (ELBW infant no supplementation). b Taxonomic profiles
obtained using PE protocol and OTU clustering for sample V3 J (term infant sample). Three different 16S rRNA gene libraries were prepared for
each sample, V1 + V2 + V3, primers 27F-519R, V4 + V5, primers 530F-926R and V6 + V7 + V8, primers 926F-1394R. Further information on the
number of reads obtained for this study can be found in Additional file 8






Figure 6 Shannon diversity index on 16S rRNA gene sequencing data analysed using 
OTU and PE protocol 
Shannon diversity index was calculated using 16S rRNA bacterial community 
profiles for sample AP1E (ELBW infant without probiotic supplementation) and 
sample V3J (term infant). a Shannon diversity indexes comparison of three different 
16S rRNA libraries (27F-519R (region V1+V2+V3), 530F-926R (region V4+V5) 
and 926F-1394R (region V6+V7+V8)) using OTU and PE protocol pipelines for 
sample AP1E (premature infant no supplementation). b Shannon diversity indexes 
comparison of three different 16S rRNA libraries (27F-519R (region V1+V2+V3), 
530F-926R (region V4+V5) and 926F-1394R (region V6+V7+V8)) using OTU and 
PE protocol pipelines for sample V3J (term infant). 
 
This preliminary study served to highlight that different bioinformatics protocols 
provided similar bacterial profiles for high relative abundance taxa, however there 
were some differences, which is particularly relevant to bacterial populations 
present in low abundance (e.g. Lachnoclostridium and Corynebacterium for sample 



































































































Impact of 16S rRNA gene hypervariable region amplified on taxonomic 
assignments. 
Targeting different hypervariable regions of the 16S rRNA gene is known to be an 
important factor influencing the bacterial genus profiles obtained119. To determine 
which hypervariable region is optimal at profiling the ELBW infant gut 
microbiome, three 16S rRNA gene sequencing libraries were prepared amplifying 
different regions of the 16S rRNA gene (V1+V2+V3, V4+V5, and V6+V7+V8). 
 
Results from the taxonomic assignments showed that the most abundant bacterial 
populations found in ELBW samples (e.g. Enterococcus, Staphylococcus, 
Enterobacteriaceae and Streptococcus), were similar between regions (V1+V2+V3, 
V4+V5, and V6+V7+V8) (Figure 7). These data indicate that the three 
hypervariable regions similarly target these bacterial taxa, which agrees with 
previous studies120. 
 
Figure 7 Comparison of taxonomic assignments among the 16S rRNA gene hypervariable 
regions tested using PE protocol approach 
Heat map displaying number of reads assigned to the most common bacterial taxa found in the study 
samples. Top panel row divides the figure in the different regions of the 16S rRNA gene analysed, 
namely: V1+V2+V3 (primers 27F-519R), V4+V5 (primers 530F-926R) and V6+V7+V8 (primers 
926F-1394R). The vertical axis of the panel indicates 13 most common bacterial taxa found. The 
horizontal axis labels the different samples used in the study: premature infants without 
supplementation (AP1E, AP5D, AP8C, AP25C), premature infants with supplementation (P29F, P30N, 
P31B, P35C), and term baby samples (V2A, V3J). The intensity of the green colour highlights the 
abundance of the number of reads found. Probiotic supplementation has been abbreviated to supplem.  
samples (P29F, P31B, P30N) analysed from ELBW infants
who had received probiotic supplementation (Fig. 3).
Importantly, the remaining supplemented ELBW infant
(P35C) had recently finished a 5-day course of vancomycin,
which could explain the underrepresentation of Bifidobac-
terium in this sample. Furthermore, the results from region
(V4 + V5) in samples from term babies (which normally
contain a higher amount of Bifidobacterium than preterm
babies) followed the same trend as the ELBW infants
tested, revealing a 93% decrease in the number of reads
assigned to Bifidobacterium compared to the other regions
(V1 + V2 + V3 and V6 + V7 + V8). This underrepresenta-
tion of Bifidobacterium agrees with previous studies that
also highlighted problems with amplifying the (V4 + V5)
region of the 16S rRNA gene from faecal samples of adults
and infants [34, 35]. We also performed the same analysis
using the QIIME pipeline (using the same database as the
PE protocol). Interestingly, analysis via QIIME produced
very similar findings; overrepresentation of Lactobacillus
and underrepresentation of Bifidobacterium when using
region V4 + V5 (Additional file 10: Figure S4).
Notably, when we performed a Principal Coordinate
Analysis (PCoA) based on 16S rRNA community profiles of
the hypervariable r gio s ested (Fig. 4), the distribution of
samples amplified using region (V4 + V5) was distinct from
samples amplified using region (V1 + V2 + V3 and
V6 + V7 + V8). These differences were more accentuated in
faecal samples which contained Bifidobacterium such as
P31B and P29F (from supplemented ELBW infants) and
V3 J and V2A (from un-supplemented term infants). The
PCoA plot performed using the QIIME bioinformatics pipe-
line showed the same findings (Additional file 11: Figure S5).
Furthermore, we also performed Shannon diversity
analysis on all samples (Additional file 12: Figure S3),
which indicated that region V4 + V5 appeared to have
higher diversity, when compared to the other regions
particularly for Bifidobacterium-rich samples (V3 J and
V2A). Although sample number is limited, it should be
noted that targeting different regions of 16S rRNA may
lead to different diversity interpretations.
Primer annealing study and validation of primers 530F-
926R (region V4 + V5) against Bifidobacterium: PCR and
melting curve analysis
To investigate any possible primer annealing problems,
we aligned the sequences of the three primer pairs used
Fig. 3 Comparison of taxonomic assignments among the 16S rRNA gene hypervariable regions tested using PE protocol approach. Heat map
displaying number of reads assigned to the most common bacterial taxa found in the study samples. Top panel row divides the figure in the
different regions of the 16 s rRNA gene analysed, namely: V1 + V2 + V3 (primers 27F-519R), V4 + V5 (primers 530F-926R) and V6 + V7 + V8
(primers 926F-1394R). The vertical axis of the panel indicates a selection of the 13 most common bacterial taxa found. The horizontal axis labels
the different samples used in the study: preterms without supplementation (AP1E, AP5D, AP8C, AP25C), preterms with supplementation (P29F,
P30N, P31B, P35C), and term baby samples (V2A, V3 J). The intensity of the green colour highlights the abundance of the number of reads found.
Probiotic supplementation has been abbreviated to supplem. in the figure. Further information on the number of reads obtained for this study
can be found in Additional file 19
Alcon-Giner et al. BMC Genomics  (2017) 18:841 Page 8 of 15
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A novel feature of this study is that it includes faecal samples obtained from 
ELBW infants supplemented with probiotics. These samples can be considered as 
‘spiked samples’ containing known bacterial taxa (Lactobacillus and 
Bifidobacterium), which enabled more thorough comparison of profiles obtained 
when the different hypervariable region primer sets. 
 
Results for the taxonomic assignments assigned to Bifidobacterium indicated 
prominent differences between the different regions. Profiles obtained from regions 
(V1+V2+V3 and V6+V7+V8) highlighted Bifidobacterium in two out of the four 
samples (P29F and P30N) analysed from ELBW infants who had received 
probiotic supplementation (Figure 7). In contrast, analysis of region (V4+V5) did 
not indicate Bifidobacterium in any of the four samples (P29F, P30N, P31B and 
P35C) tested from ELBW infants who received supplementation (i.e. ‘spiked’ 
samples). Interestingly, one of the remaining two supplemented ELBW infants 
recently finished a five-day course of vancomycin, which could explain the 
underrepresentation of Bifidobacterium in this sample. Notably, when comparing 
the results from region (V4+V5) in samples which are known to contain a high 
proportion of Bifidobacterium i.e. full term infants, a 92% decrease in the number 
of reads assigned to Bifidobacterium was observed when compared to the other 
regions tested (V1+V2+V3 and V6+V7+V8), which is in agreement with the 
results found in ELBW infants receiving supplementation. 
 
In the case of Lactobacillus, the three hypervariable regions (V1+V2+V3, V4+V5, 
and V6+V7+V8) were able to detect the presence of this taxon in three (P29F, 
P30N and P35C) out of the four samples from ELBW infants who received 
supplementation, and in one term baby sample (V3J). Region (V4+V5) presented 
the highest number of reads obtained for this taxon, and amplicons amplifying 
region (V4+V5) revealed 3 and 4 times higher number of reads for Lactobacillus 
when compared to the other regions (V1+V2+V3 and V6+V7+V8). These data 
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indicate that the (V4+V5) region may over represent this bacterial population, 
which is discussed in more detail when comparing to the shotgun analysis. 
 
For additional bioinformatics comparison, the same analysis as described above but 
using the QIIME bioinformatics pipeline was performed. Similar findings were 
found when using the QIIME pipeline; region V4+V5 showed overrepresentation 
of Lactobacillus and underrepresentation of Bifidobacterium (Figure 8). 
 
Figure 8 Comparison of taxonomic assignments among the 16S rRNA gene 
hypervariable regions tested using QIIME approach 
Heat map displaying number of reads assigned to the most common bacterial taxa 
found in the study samples using QIIME bioinformatics pipeline. Top panel row 
divides the figure in the different regions of the 16S rRNA gene analysed, namely: 
V1+V2+V3 (primers 27F-519R), V4+V5 (primers 530F-926R and V6+V7+V8 
(primers 926F-1394R). The vertical axis of the panel indicates a selection of the 13 
most common bacterial taxa found. The horizontal axis labels the different samples 
used in the study: premature infants without supplementation (AP1E, AP5D, AP8C, 
AP25C), premature infants with supplementation (P29F, P30N, P31B, P35C), and 
term baby samples (V2A, V3J). The intensity of the green colour highlights the 
abundance of the number of reads found. Probiotic supplementation has been 
abbreviated to supplem.  
 
These data indicated that primer choice, or hypervariable region of the 16S rRNA 
gene amplified ply a stronger role in overall profiles obtained, rather than biases 














































































































Next, a Principal Coordinate Analysis (PCoA) based on 16S rRNA community 
profiles of the hypervariable regions tested (Figure 9) was performed to visualise 
the similarities and differences of all the bacterial communities assigned for each 
sample. Results highlighted that the distribution of samples amplified using region 
(V4+V5) was distinct from samples amplified using region (V1+V2+V3 and 
V6+V7+V8). These differences were more accentuated in faecal samples which 
contain Bifidobacterium such as P31B and P29F (from ELBW infants with 
supplementation) and V3J and V2A (from term infants).  
 
 
Figure 9 Principal Coordinate Analysis (PCoA) based on 16S rRNA community profiles 
analysed using PE protocol of the hypervariable regions tested  
PCoA was performed based on the taxonomic assignments obtained from the 16S rRNA gene 
sequencing libraries analysed. Samples used for this plot were classified in main three groups: 
(i) premature infants without supplementation (AP1E, AP5D, AP8C, AP25C), (ii) premature 
infants with supplementation (P29F, P30N, P31B, P35C), and (iii) term baby samples (V2A, 
V3J). Samples names are coded highlighting the 16S rRNA gene library they belong. Sample 
names ending in (.27F) belong to 16S rRNA gene library prepared using primers 27F-519R 
(target region V1+V2+V3), sample names ending in (.530F) belong to 16S rRNA gene 
library prepared using primers 530F-926R (region V4+V5), and sample names ending in 
(.926F) belong to 16S rRNA gene library amplified using primers 926F-1394R (region 
V6+V7+V8). PCoA plot indicates that distribution of samples targeting (V4+V5) region was 
distinct from samples targeting (V1+V2+V3) and (V6+V7+V8).  
to construct the 16S rRNA libraries to 16S rRNA gene
sequence from the probiotic strain Bifidobacterium bifi-
dum, and other bacterial members commonly found in
the samples from the ELBW infants. Surprisingly,
primers amplifying region (V4 + V5, 530F-926R) did not
reveal any obvious annealing disadvantage (mismatch)
towards Bifidobacterium (Additional file 13: Figure S6),
while primers amplifying region (V1 + V2 + V3, 27F)
and region (V6 + V7 + V8, 926F) presented mismatches
(previously highlighted in other studies (13)), against the
Bifidobacterium strains tested. The in-silico analysis was
complemented by direct amplification of the 16S rRNA
(V4 + V5) region, using genomic DNA isolated from
seven different strains of Bifidobacterium including the
probiotic strain B. bifidum (Additional file 14: Figure
S7). This experiment confirmed that the primer pair
530F-926R did not encounter any annealing problem
when working with DNA isolated from pure strains,
which is in agreement with our annealing study results.
Furthe investig tion focused on the GC content of
regio (V4 + V5) of the strains used in the probiotic sup-
pleme tation (B. bifidu and L. acidophilus) and two
other strains which were overrepresented by this region,
Enterococcus faecium and Streptococcus infantarius. Several
studies have described that templates with a high GC con-
tent (e.g. Bifidobacterium, as confirmed in Additional file 15:
Figure S8a) are more difficult to amplify than non-GC-
rich templates [36, 37]. In the context of a metagenomic
sample, where different genomes are competing against
the same pair of primers, differences in GC content would
be expected to significantly impact amplification, and thus
downstream analysis. Notably, using the same PCR condi-
tions, but in this instance using mixed template DNA (i.e.
combined genomic DNA from all strains (B. bifidum, L.
acidophilus, E. faecium and S. infantarius), to simulate a
mixed community sample, primers 530F-926R preferen-
tially amplified the region (V4 + V5) of other bacterial
genomes (confirmed by presence of peak 1 in
Fig. 4 Principal Coordinate Analysis (PCoA) based on 16S rRNA community profiles analysed using PE protocol of the hypervariable regions
tested. PCoA was perform d based on the tax nomic assignments obtained from the 16S rRNA gene sequencing libraries analysed. Samples
used for this plot were classified in main three groups: preterms without supplementation (AP1E, AP5D, AP8C, AP25C), preterms with
supplementation (P29F, P30N, P31B, P35C), and term baby samples (V2A, V3 J). Samples names are coded highlighting the 16S rRNA gene library
they belong. Sample names ending in (.27F) belong to 16S rRNA gene library prepared using primers 27F-519R (target region V1 + V2 + V3), sam-
ple names ending in (.530F) belong to 16S rRNA gene library prepared using primers 530F-926R (region V4 + V5), and sample names ending in
(.926F) belong to 16S rRNA gene library amplified using primers 926F-1394R (region V6 + V7 + V8). PCoA plot indicates that distribution of sam-
ples targeting (V4 + V5) region was distinct from samples targeting (V1 + V2 + V3) and (V6 + V7 + V8)
Alcon-Giner et al. BMC Genomics  (2017) 18:841 Page 9 of 15
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When performing the same analysis using the QIIME pipeline results were 
comparable (Figure 10), again suggesting bioinformatics analysis does not play a 
major role in explaining these differences. 
 
 
Figure 10 Principal Coordinate Analysis (PCoA) based on 16S rRNA community 
profiles analysed using QIIME of the hypervariable regions tested 
PCoA was performed based on the taxonomic assignments obtained from the 16S 
rRNA gene sequencing libraries analysed. Samples used for this plot were classified 
in main three groups: (i) premature infants without supplementation (AP1E, AP5D, 
AP8C, AP25C), (ii) premature infants with supplementation (P29F, P30N, P31B, 
P35C), and (iii) term baby samples (V2A, V3J). Samples names are coded 
highlighting the 16S rRNA gene library they belong. Sample names ending in (.27F) 
belong to 16S rRNA gene library prepared using primers 27F-519R (target region 
V1+V2+V3), sample names ending in (.530F) belong to 16S rRNA gene library 
prepared using primers 530F-926R (region V4+V5), and sample names ending in 
(.926F) belong to 16S rRNA gene library amplified using primers 926F-1394R 
(region V6+V7+V8). PCoA plot indicates that distribution of samples targeting 
(V4+V5) region was distinct from samples targeting (V1+V2+V3) and 
(V6+V7+V8).  
 
Finally, the Shannon diversity index on all samples was calculated, which is an 
indicator of sample diversity, and reflects how many different taxa are present, 
considering how evenly they are distributed. Results from this study indicated that 
the different hypervariable regions provided different indices (Figure 11); Shannon 










indexes were higher in samples containing high amounts of Bifidobacterium such 
as V2A and V3J, which agrees with results obtained by PCoA analysis. 
 
Figure 11 Shannon diversity index calculation of 16S rRNA gene sequencing data  
Shannon diversity index was calculated using 16S rRNA bacterial community 
profiles for the three different 16S rRNA libraries tested in this study (27F-519R 
(region V1+V2+V3), 530F-926R (region V4+V5) and 926F-1394R (region 
V6+V7+V8)). Sequencing data was analysed using the PE protocol. 
 
Validation of 16S rRNA gene primers used against Bifidobacterium 
A primer aligning study was performed to evaluate the alignment of the primer 
pairs used to construct the 16S rRNA libraries to Bifidobacterium bifidum (species 
in the probiotic supplementation) and other bacterial members commonly found in 
ELBW infants. Surprisingly, this study did not reveal any obvious annealing 
disadvantage (mismatch) for any particular pair of primers against the bacterial 










AP1E AP5D AP8C AP25E P29F P30N P31B P35C V2A V3J
Shannon	diversity	index
V1+V2+V3	(27F-519R) V4+V5	(530F-926R) V6+V7+V8	(926F-1394R) 
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Figure 12 Primer alignment study of the most common bacterial taxa found in ELBW (P29F) 
a Representation of primers used in this study along the 16S bacterial rRNA gene. b Primer 
alignment study using 16S rRNA gene from Bifidobacterium bifidum CP 010412 (isolated 
from Infloran) and the most common bacterial taxa found in an ELBW infant (P29F) with 
supplementation (Staphylococcus epidermis NR_074995, Enterobacter cloacae CP012165 
and Enterococcus faecalis CP014949). We also included two strains of Bifidobacterium as 
control samples (B. infantis M58738.1 and B. longum ATCC 156697) All sequences are 
represented in 5´-3´orientation using UPAC nucleotide code, where Y = C or T, R = A or G, 
K = G or T, M = A or C. 
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AGRGTTTGATCMTGGCTCAG                                         
16S rRNA B. bifidum CP010412         
16S rRNA S. epidermis NR_074995  
16S rRNA E. cloacae CP012165          
16S rRNA E. faecalis CP014949          
16S rRNA B. infantis M58738.1
16S rRNA B. longum ATCC 156697 
27Fmod primer
536 553
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16S rRNA B. longum ATCC 156697
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GTGCCAGCAGCCGCGG   
GTGCCAGCAGCCGCGG
GTGCCAGCAGCAGCGG   
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GTGCCAGCAGCCGCGG 
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16S rRNA E. faecalis CP014949                         
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To complement this in silico analysis, the primer pair 530F and 926R (region 
(V4+V5)) was used to amplified genomic DNA isolated from seven different 
strains of bifidobacteria including the probiotic strain B. bifidum (Figure 13). 
Results from this experiment confirmed that this primer pair did not encounter any 
annealing problem when working with DNA isolated from pure strains.  
 
Figure 13 PCR amplification using primers 530F-926R on 8 Bifidobacterium strains 
PCR amplification targeting the bacterial 16S rRNA gene using primers 530F-926R 
on Bifidobacterium collection strains. DNA extracted from B. bifidum (isolated from 
the commercial probiotic supplementation) and seven different Bifidobacterium 
NCIMB collection strains, was amplified using primers 530F-926R. Positive 
controls for this study were a faecal metagenomic sample and a L. acidophilus strain 
(isolated from the probiotic supplementation). Pure water was used as negative 
control. Amplicon samples were run on 1% agarose gel for 30 minutes at 100 V. 
DNA was visualised under UV light after staining with ethidium bromide. All tested 













































































































































































































































































































Subsequently, the melting curves of the amplicons generated using primers 530F-
926R were calculated, to check the GC content of region (V4+V5). Templates 
selected for this PCR were the strains used in the probiotic supplementation (B. 
bifidum and L. acidophilus), and two other species which were overrepresented by 
region (V4+V5), Enterococcus faecium and Streptococcus infantarius. As 
expected, B. bifidum contained the highest GC content, in comparison with the 
other strains (Figure 14a). When running the same PCR, this time using a mixed 
DNA sample as template DNA (in order to simulate the conditions of a 
metagenomic sample) of the four bacterial strains used previously (B. bifidum, L. 
acidophilus, E. faecium and S. infantarius), primers 530F-926R preferentially 
annealed to the other bacterial genomic DNA, showing peak 1 in Figure 14b, when 
compared to peak 2 which corresponded with the melting temperature of B. 
bifidum.  
 
Figure 14 Melting curves of PCR amplicons from probiotic strains and bacterial 
isolates 
a Melting curves of PCR amplicons from probiotic strains (Bifidobacterium bifidum and 
Lactobacillus acidophilus) and bacterial isolates (Enterococcus faecium and Streptococcus 
infantarius). Primers used to generate these amplicons were 530F-926R targeting region 
(V4+V5). Bifidobacterium bifidum displayed the highest melting temperature. b Melting 
curve of PCR amplicon obtained from a mixed DNA sample (5ng of Bifidobacterium 
bifidum, 5 ng of Lactobacillus acidophilus, 5 ng of Enterococcus faecium and 5 ng of 
Streptococcus infantarius). Primers used to generate these amplicons were 530F-926R 
targeting region (V4+V5). Peak name (2) presents a melting temperature (Tm) similar to the 
melting temperature (Tm) obtained for B. bifidum. 
1 Bifidobacterium bifidum (Infloran isolate) Tm (°C)= 88.60
2 Lactobacillus acidophilus (Infloran isolate) Tm (°C)= 85.90
3 Streptococcus infantarius (preterm isolate)  Tm (°C)= 85.24






a  Amplicon melting curves from single bacterial strains b  Amplicon melting curve from a mixed DNA sample 
1
2
Peak 1 Tm (°C)= 85.89
Peak 2 Tm (°C)= 88.93
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Validation of 16S rRNA gene sequencing data using shotgun metagenomics 
analysis 
To validate the 16S rRNA gene sequencing data, whole genome shotgun 
sequencing was performed on two ELBW infants (one receiving supplementation 
and another one without it), and one term baby sample as control. Whole genome 
shotgun sequencing allows the entire DNA content to be sequenced with less 
biases, therefore it can be considered as ‘gold-standard’. Results confirmed the 
presence of the predominant bacterial populations detected using 16S rRNA gene 
sequencing, namely Bifidobacterium, Enterococcus, Staphylococcus, Enterobacter 




Figure 15 Bacterial community profiles determined by shotgun and 16S rRNA gene 
sequencing data  
Comparison of bacterial profiles analysed by shotgun and 16S rRNA gene sequencing data. 
Relative abundance of the bacterial taxa was represented in percentages of number of reads. 
Bar colours represent different genus taxa, and bar lengths signify the relative abundance of 
each taxon. 16S rRNA bacterial profiles are named according to the different 16S rRNA 
hypervariable region amplified: (i) (V1+V2+V3, primers 27F-519R), (ii) (V4+V5, primers 
530F-926R) and (iii) (V6+V7+V8, primers 926F-1394R). a Bacterial community profiles 
determined by shotgun and 16S rRNA gene sequencing from an ELBW infant (sample 
AP8C) with no supplementation. b Bacterial community profiles determined by shotgun and 
16S rRNA gene sequencing from an ELBW infant (sample P29F) with supplementation. c 
Bacterial community profiles determined by shotgun and 16S rRNA gene sequencing from 
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The additional coverage that shotgun provides at species level (Figure 16) enabled 
confirmation of B. bifidum (present in the probiotic supplementation) in sample 
P29F (ELBW infant receiving supplementation). Lactobacillus acidophilus 
(present in the supplementation) was not detected in the sample tested (P29F). 
 
Figure 16 Shotgun taxonomic profiles from two ELBW infants with/without 
supplementation and a term infant  
Radial taxonomic tree displaying shotgun community profiles from faecal samples 
of an ELBW infant with no supplementation (AP8C, represented in green) an ELBW 
infant with supplementation (P29F, represented in yellow) and a term baby (V3J, 
represented in blue). Relative abundance was indicated according to the length of the 
coloured bars in the figure. The centre of the radial tree indicates phylum level, and 
the subsequent concentric layers of the radial tree indicate class, order, family, and 
genus and species level. Term baby (V3J) and ELBW infant with supplementation 
(P29F) samples presented a higher abundance of Bifidobacterium when compared to 
an ELBW infant with no supplementation (AP8C). 
 
Complementing the shotgun analysis, functional analysis (Figure 17) was 
performed on the same sample, which indicated increased representation of glycan 
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metabolism pathways. Some Bifidobacterium strains such as B. bifidum have been 
previously shown to metabolise breast milk-derived human milk oligosaccharides, 
which are known to contain these glycan structures 121. 
 
 
Figure 17 Shotgun functional profiles from two ELBW infants with /without 
supplementation and a term infant  
Radial tree displaying shotgun functional profiles from an ELBW infant with no 
supplementation (sample AP8C, represented by the number 2 in the figure) an 
ELBW infant with supplementation (sample P29F, represented by the number 3 in 
the figure) and a term baby sample (sample V3J, represented by the number 1 in the 
figure). Functional analysis was performed using the KEGG pathway analysis. 
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Results from the whole genome shotgun sequencing analysis confirmed previous 
16S rRNA metataxonomic analysis, in that (V4+V5) region failed to adequately 
discriminate gut bacterial populations in ELBW infants. This region 
overrepresented Streptococcus, Enterococcus and Lactobacillus populations, and 
underrepresented Bifidobacterium in comparison to the other regions tested. The 
percentages of the number of reads obtained for one ELBW infant no 
supplementation, one ELBW infant with supplementation, and one term baby are 
indicated in Table 6.  















   





















   
   


















   
   








   









   


















   
   
   









   
   










   
   









Bifidobacterium 0.02 0.70 0.11 1.03 72.39 37.33 0.60 49.56 95.01 81.00 6.46 75.31 
Enterococcus 61.75 69.54 55.17 59.87 13.60 34.19 53.35 22.94 0.02 0.65 1.83 0.94 
Enterobacter 0.26 0.37 0.66 0.74 7.87 18.29 13.43 15.68 0.00 0.06 0.13 0.12 
Staphylococcus 8.98 15.70 17.03 17.53 1.72 7.29 19.52 7.86 0.01 0.37 0.85 0.48 
Lactobacillus 0.09 0.42 2.14 0.63 1.45 2.10 9.86 3.24 0.36 1.89 6.61 2.00 
Streptococcus 9.20 10.86 19.62 15.87 0.32 0.26 1.81 0.41 2.95 14.63 74.26 15.65 
Escherichia 0.30 0.02 0.05 0.00 0.28 0.25 0.06 0.00 0.10 0.04 0.06 0.11 
Actinomyces 0.00 0.00 0.08 0.00 0.02 0.00 0.07 0.00 0.06 0.00 0.10 0.02 
Acinetobacter 0.02 0.03 0.02 0.00 0.00 0.02 0.02 0.00 0.00 0.02 0.01 0.00 
Bacteroides 0.00 0.25 0.89 0.33 0.00 0.20 0.71 0.22 0.00 0.21 0.57 0.30 
Granulicatella 0.00 0.00 0.19 0.00 0.00 0.00 0.14 0.00 0.00 0.00 0.01 0.00 
Haemophilus 0.99 1.96 3.48 3.42 0.00 0.00 0.07 0.03 0.09 0.38 5.25 3.41 
Lachnoclostridium 0.00 0.03 0.08 0.04 0.00 0.02 0.07 0.02 0.00 0.02 0.04 0.02 
 
To visualise if there were strong patterns between the 16S rRNA bacterial profiles 
of the different hypervariable regions tested (V1+V2+V3, V4+V5 and 
V6+V7+V8), and the shotgun sequencing data (used as gold standard), a Principal 
Coordinate Analysis (Figure 18) was performed using the PE protocol and QIIME 
pipelines. This investigation confirmed that region (V4+V5) presented the most 
diverse distribution among samples when Bifidobacterium was a resident member 
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of the gut microbiome (e.g. differences were greater in sample P29F belonging to 
an ELBW with probiotic supplementation and sample V3J from a term infant 
sample). 
 
Figure 18 PCoA plots based on 16S rRNA gene sequencing and shotgun data 
a PCoA based on 16S rRNA gene sequencing data analysed using PE protocol. b PCoA based 
on 16S rRNA gene sequencing data analysed using QIIME. Blue circles represent sequencing 
data of premature infants without supplementation (AP8C), yellow circles data of premature 
infants with supplementation (P29F), and green circles data of term baby (V3J). Each sample 
was analysed using three different 16S rRNA gene libraries (.27F, targets region 
(V1+V2+V3), .530F targets region (V4+V5), and .926F targets region (V6+V7+V8)). 
Samples ended with (_shotgun) represents shotgun data used as ‘gold standard’ in this study.  
 












PC1 (59.8%) vs PC3 (6.3%)
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Discussion 
Metataxonomic microbiome profiling using 16S rRNA gene sequencing is a cost-
effective amplicon sequencing method ideal for use when profiling large samples 
numbers (i.e. clinical trials). There are several studies examining the gut 
microbiome using 16S rRNA gene sequencing in adults and term infants that have 
highlighted that the DNA extraction method can significantly impact the 
representative profile of the bacterial community obtained79. Furthermore, the 16S 
rRNA hypervariable region (V1 to V9) targeted can influence the ability to 
distinguish between different bacterial taxa104 as well as the bioinformatics pipeline 
chosen for the data analysis. When profiling samples from at-risk cohorts (such as 
ELBW infants), it is essential to optimise and standardise sample preparation, 
sequencing methods, and bioinformatic tools among clinical studies, particularly 
for studying the influence of microbiota therapies (e.g. probiotic supplementation) 
on community profiles and health outcomes.  
 
In this study, an optimal protocol for 16S rRNA profiling of premature infants’ 
samples is described standardising the following specific steps: (i) DNA extraction 
method, (ii) primer choice and hypervariable region of the 16S rRNA gene, and 
(iii) bioinformatics pipeline. The first step in this pipeline evaluated different DNA 
extraction methods, which revealed the Fast DNA Spin Kit for Soil, including a 
bead-beating step, was the best method for extracting high quantity and quality 
DNA from ELBW infants (Table 5). Bead-beating has been previously been shown 
to facilitate disruption of cell membrane components such as high molecular 
weight capsules, and these results extend these findings to ELBW infant samples. 
Furthermore, extending the bead-beating time to 3 min lead to higher DNA yields 
from all samples, particularly for Bifidobacterium supplemented ELBW and 
Bifidobacterium-rich term infants. This highlights that samples expected to have 
high Bifidobacterium levels (genus known to express exopolysaccharide 
capsules)122 are optimally processed using an extended bead-beating DNA 
extraction protocol.  
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One of the critical stages when comparing microbiome studies is the influence that 
bioinformatics pipelines can have on the taxonomic assignments obtained when 
bacterial population are at lower levels. Faecal samples from ELBW infants 
generally exhibit low bacterial diversity, and therefore excellent sequencing 
coverage is obtained, and this may indicate why both bioinformatics pipelines used 
(OTU vs QIIME) showed similar trends (Figure 5), however this may be somewhat 
different if a more complex (e.g. adult) sample was compared. Interestingly, for 
low relative abundance bacterial populations such as Acinetobacter or 
Haemophilus, the results indicated small differences between the pipelines. This 
may be explained by the fact that the OTU approach accepts all assignments of 
taxa even when only one OTU is assigned (which may result in false positives), 
whereas the paired end protocol discards low-confidence taxa (assignments <25 
reads). Therefore, it is important to be aware of these differences in bioinformatics 
pipelines when studying low abundance bacterial populations. 
 
Characterisation of which hypervariable region of the 16S rRNA gene was most 
suitable for representing the gut microbiome of ELBW infants, was also 
determined in this study (Figures 7-8). Three hypervariable regions of the 16S 
rRNA gene (V1+V2+V3), (V4+V5) and (V6+V7+V8) were evaluated, and results 
revealed an underrepresentation of Bifidobacterium when amplifying region 
(V4+V5). This is in agreement with previous studies that also highlighted problems 
with amplifying (V4+V5) region of the 16S rRNA gene for Bifidobacterium-rich 
samples when using faeces samples from adults and infants 123,124. 
 
To probe why these striking differences were observed just for this 16S rRNA 
region, primer alignment studies (Figure 13) surprisingly did not reveal any 
specific mismatched with primers amplifying region (V4+V5, 530F-926R) for 
eight different Bifidobacterium strains, which suggests the DNA template used in 
the PCRs may be the issue. Indeed, several studies have described that templates 
containing a high GC content are more difficult to amplify than non-GC-rich 
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templates 125, 126 and in the context of a metagenomic sample where different 
genomes are competing against the same pair of primers this factor could play a 
role. Notably, the genus Bifidobacterium contains a high GC genome content (56-
67%), and B. bifidum (present in the supplementation) and contains a higher GC 
content in region (V4+V5) than other strains commonly present in the ELBW 
infant gut microbiome (Figure 14a). This may lead into an underrepresentation of 
Bifidobacterium when it is present in a metagenomic sample, and other studies 
using the same region (V4+V5), but different primers, have also encountered an 
underrepresentation of Bifidobacterium123. It is also interesting to highlight that 
primer 926R presented the lowest GC content among the primers used in this study 
and does not have a strong GC clamp at its 3’end, which could as well interfere 
with the binding to genomes with high GC content. Among the most common 
bacteria found in premature infants Bifidobacterium (GC ~ 60%), Lactobacillus 
(GC ~ 60%) and Corynebacterium (GC~53%) would more affected this by this 
issue. 
 
Finally, the 16S rRNA sequencing data was further benchmarked to shotgun 
sequencing by analysing a subset of the samples we used for 16S rRNA analysis 
(AP8C, P29F and V3J, Figure 15). Notably, shotgun metagenomics introduces less 
PCR biases and artefacts, but is significantly more expensive to scale up and 
requires additional computing power for downstream analysis, which in large-scale 
in vivo and clinical studies are important factors to consider. From a sample 
collection stand-point, shotgun also requires a higher yield of bacterial DNA (500 
ng is the recommended amount of DNA compared to 25 ng required for 16S rRNA 
gene sequencing) which can be challenging to obtain from case-specific ELBW 
infants (e.g. at an early time point of the study where most of infants are 
administered antibiotics). Results from shotgun metagenomics analysis validated 
an underrepresentation of Bifidobacterium in region (V4+V5) and over-




This study highlights the importance of selecting the optimal DNA extraction 
method when using 16S rRNA gene sequencing to analyse metagenomic samples; 
i.e. include a bead-beating step to lyse capsulated bacteria such a bifidobacteria, 
and is now considered gold standard by many research teams 127. We additionally 
underlined the influence that bioinformatics pipelines may have at detecting 
bacterial population present in low numbers. 
 
Appropriate primer selection when using 16S rRNA gene profiling is essential for 
analysing gut-associated metagenomic samples. Region (V4+V5) should be 
avoided in metagenomics studies where the genus Bifidobacterium, either resident 
or supplemented, is evident. More specifically, it was demonstrated differences in 
GC content of the (V4+V5) region of the 16S rRNA gene between Bifidobacterium 
and other low GC content bacterial populations present in the ELBW infant gut 
microbiome (e.g. Streptococcus and Enterococcus), significantly biases profiling in 
mixed bacterial communities.  
 
Future work 
16S rRNA gene sequencing is a more cost-efficient method than shotgun 
metagenomics and can be incredibly useful in large scale projects (e.g. clinical 
trials) with hundreds or thousands of samples. This metataxonomic profiling 
provides the added advantage that it can sequence samples with very low bacterial 
content, such as in ELBW infants, due to the PCR step. This optimised pipeline 
represents a good choice and has been used in large clinical trials such as the 
BAMBI study (Chapter 2).  
 
To complement this study, it would be interesting to analyse in more depth the 
bacterial populations present at lower levels, to potentially trace bacterial 
pathogens at initial stages of infection. This could initially be done by inoculating 
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different amounts of a ´known´ pathogen into the faecal sample, to estimate the 
sensitivity of the method. Once the sensitivity is established, a more practical 
outcome could be added to the study, by using clinical samples from ELBW infants 
profiled showing early signs of infection. 
 
An important factor which has not been covered in the present study is that 
bacterial species differ in their copy number of the 16S rRNA gene128. This can 
have a confounding effect on the ´relative abundance´ of the microbial community 
profile obtained. Notwithstanding, it was decided not to correct for copy number of 
the 16S RNA gene as the main aim of this study was to assure most of the bacterial 
communities comprising the preterm microbiome were detected. However, if we 
were to perform a study focusing on bacterial populations present at low 
abundance, correction for 16S rRNA gene copy number would be important, and 
publicly available bioinformatics tools can be used to correct for copy number 
variation (e.g. Copyrighter129 or rrNDB130 ). 
 
In the near future the use of 16S rRNA gene sequencing for microbial 
identification will likely be replaced by shotgun genome sequencing. Sequencing 
the whole genomes of the microbial communities provides a more complete picture 
(and it is not restricted to bacterial members, but also includes fungi, archaea and 
viruses) and has great potential to be applied in the clinical field (e.g. to identify 
antibiotic resistance profiles or virulence traits). Throughout my PhD, I have been 
fortunate to explore these options, using shotgun metagenomics in combination 
with: (i) the most widely used sequencing technology (Illumina, Chapter 3) and (ii) 





Title: Bifidobacterium and Lactobacillus supplementation modifies the 
microbiome and metabolome of premature infants residing in Neonatal 
Intensive Care Units 
 
Abstract 
Supplementation with early life bacterial members or ‘probiotics’ is becoming 
increasingly popular in neonatal intensive care units (NICUs), as a way of 
manipulating the gut microbiome of premature infants. The findings of numerous 
clinical studies support that this practice reduces the incidence of sepsis and 
necrotising enterocolitis (NEC) in premature infants131, 132. However, very few of 
these studies have explored how this supplementation modifies the early life 
microbiome, and none have done this for large patient cohorts using a combination 
of microbiome profiling and other characterisation approaches e.g. metabolomics 
and whole genome sequencing of bacterial strains. Thus, further studies are 
required if standardised guidelines are to be introduced for implementing this as 
routine clinical care for premature infants.  
 
The work presented here includes a large longitudinal study from two different 
cohorts of premature infants; 101 orally supplemented with Bifidobacterium and 
Lactobacillus (Bif/Lacto group) and 133 non-supplemented (control group). This 
work sought to determine the impact of this supplementation on the wider gut 
microbiome via 16S rRNA metataxonomic profiling, and additionally the impact 
on the metabolome using paired faecal samples and untargeted NMR metabolomics 
analysis. Microbiome profiling on 591 samples indicated higher relative 
abundances of beneficial Bifidobacterium, and lower relative abundances of 
potentially pathogenic Klebsiella, Staphylococcus and Escherichia in the Bif/Lacto 
group, when compared to non-supplemented control premature infants. A subset of 
these samples (n=157) analysed with NMR revealed elevated levels of lactate and 
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acetate in the Bif/Lacto group which correlated to a lower faecal pH, whilst the 
control group presented high level of human milk oligosaccharides (3-
Fucosyllactose, 2- Fucosyllactose). In addition, whole genome sequencing on the 
Bifidobacterium supplemented strain confirmed preterm gut colonisation, and 
ability to utilise human milk oligosaccharides from breastmilk. Phenotypic 
antibiotic testing suggested the Bifidobacterium strain used in this study was 
susceptible to most commonly prescribed NICU antibiotics.  
 
This study demonstrates that probiotic supplementation can modify the preterm 
microbiome and the gastrointestinal environment to more closely resemble the gut 
microbiomes profiles found in full-term infants133, 134. A graphical abstract 




Figure 19 Graphical abstract of the study 
a, Study outline and sample collection times. The study comprised two groups: (i) Bif/Lacto Group 
(received oral supplementation containing Bifidobacterium and Lactobacillus, and (ii) control group 
which was not administered any probiotic supplementation b, Taxonomic profiles showing percentage 
of number of reads of the most common bacterial taxa at each study time point (1 = <10 days from 
birth, 2 = 11-29 days, 3 = 30-49 days and 4 = >50 days) in the control group and the Bif/Lacto group 
c, Summary of main faecal metabolites derived from 1H-NMR spectra in the Bif/Lacto group and 
control group d, Comparison of whole genome sequencing analysis of Bifidobacterium bifidum from 
Infloran and other Bifidobacterium bifidum isolates. 
n = 101 preterms 1 NICU
≤ 34 weeks
Oral supplementation




< 10 days 11-29 days
4
> 50 days30-49 days
a) Sample collection (days) normalised across both study groups. Sex, birth mode and diet matched
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b) 16S rRNA gene profiling (n= 591 samples)
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This large body of work is available as a preprint, and has been submitted to Cell 
Reports Medicine where I am first author. I was involved from the very beginning 
of this large multi-centre cohort study (recruiting 233 at-risk premature infants), 
contributing to overall study design, contact point for clinical leads, sample 
preparation for genomic and metabolomic analysis, data analysis, figure 
preparation, and drafting of the manuscript. This chapter details the parts of the 
study I have specifically led. Specific details of authors’ contributions are 
highlighted in the method section of this chapter. 
 
Introduction 
Microbial colonisation of the gut during the early life developmental window plays 
an instrumental role in the maturation of the immune system, nutrient acquisition 
and pathogen exclusion (Chapter 1). Immediately after birth, and during the first 
days of life, the intestine of the newborn infant is colonised by bacteria residing in 
the mother’s birth canal and the environment, a mixed inoculum of facultative 
anaerobic bacteria (Enterobacter, Enterococcus, Staphylococcus and 
Streptococcus)18 able to grow under the presence of low amounts of oxygen. As 
oxygen diminishes within the gut environment this then allows obligate anaerobic 
bacteria to thrive (e.g. Bifidobacterium, Bacteroides and Clostridium)19. These 
microbial pioneers are key players in shaping the rapidly changing ecosystem until 
a climax or ‘adult-like’ microbiome is established at 2-3 years of age20, 21. 
 
Among these pioneers, Bifidobacterium comprise the most abundant group 
(representing up to 70-90% based on relative abundance of this genus in breast-fed 
infants), and importantly species and strains of this genus have been shown to 




In the case of premature infants (born before 37 weeks’ gestation), this natural 
process of bacterial gut colonisation is often disrupted due to a variety of factors 
including; C-section delivery, prolonged hospitalisation, and prescription of 
multiple courses of antibiotics. Due to these microbial-altering factors, premature 
infants have a particularly perturbed early life gut microbiome, with sequencing 
studies indicating low relative abundance of commensals (Bifidobacterium and 
Lactobacillus), while the relative abundace of potential pathogenic bacteria is 
increased (Enterobacter, Enterococcus, Escherichia and Klebsiella). Crucially, 
these microbiome disturbances in premature infants increase the risk of developing 
necrotising enterocolitis (NEC, with a 5-12% incidence in premature infants with 
birthweight lower than 1500 gr136) and late onset sepsis43 (LOS, 15-25%). 
Furthermore, these initial gut microbiome disruptions, also increase the risk of 
developing allergies, asthma, or eczema during childhood and as an adult40, 41. 
Therefore, modulating the preterm gut microbiome to increase the presence of 
beneficial commensal bacteria could overcome these disruptive effects. 
 
Oral supplementation of Bifidobacterium and Lactobacillus from birth in 
premature infants is becoming an alternative and cost-effective gut microbiota 
therapy while the infant resides in the Neonatal Intensive Care Unit (NICU). There 
are several clinical studies which support that oral supplementation of commensal 
bacterial such as Bifidobacterium or Lactobacillus exert a protective effect against 
NEC137, 138 despite the heterogeneity of results and the need for larger longitudinal 
studies139. Notably, the largest ever neonatal probiotic trial (PiPS study, n=1310 
infants recruited140) found no evidence of benefit for prevention of NEC and LOS 
in premature infants when using supplementation with Bifidobacterium breve 
BBG1. However, shortly after the publication, various researchers highlighted 
several inconsistencies141 in this study: (i) the probiotic dose given to the premature 
infants was lower (100 million CFU) than the one used in the pilot study which 
indicated beneficial effects (1 billion CFU), (ii) the PiPS study reported a cross-
colonisation of 49% of placebo samples at all trial sites by 36 weeks’ gestation, and 
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(iii) some authors question whether the size of the study cohort was sufficiently 
large to draw conclusions. These points serve to highlight there is currently not 
clear standardised guidelines to administer ‘probiotics’ for premature infants. 
Furthermore, most of the published clinical studies using microbiota therapy have 
not explored how this supplementation modifies the early life preterm microbiome, 
which is required if robust guidelines are to be introduced for implementing this as 
routine clinical care for premature infants.  
 
The work presented here analysed two different cohorts of premature infants, one 
group supplemented with Bifidobacterium and Lactobacillus strains (Bif/Lacto 
group), and a control non-supplemented group (control group). Infants in the 
Bif/Lacto group were routinely prescribed an oral supplementation containing 109 
colony forming units (CFU) of Bifidobacterium bifidum and 109 CFU of 
Lactobacillus acidophilus (Infloran®, Desma Healthcare). A recent clinical audit 
of the NICU administering this supplementation found a more than 50% reduction 
in NEC rates and late-onset sepsis when comparing 5-year epochs before and after 
introducing this probiotic supplementation142. Cohorts were matched by gestational 
age (< 34 weeks gestation), sex, birth mode, time points of sample collection, and 
diet across four different NICUs. 16S rRNA gene profiling was used to obtain an 
overview of their gut microbiomes (n = 591). Complementing this analysis and to 
evaluate the colonisation of the supplemented Bifidobacterium strain, genomes of 
different Bifidobacterium strains isolated from stool samples were compared to the 
supplemented strain using whole genome sequencing analysis. Finally, paired 
metabolomic analysis on a subset of stool samples from both cohorts (n=157) 
evaluated the effects of Bifidobacterium and Lactobacillus supplementation on the 
metabolite profile from both study groups. 
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Hypothesis and aims 
This study aims to investigate the outcome of Bifidobacterium and Lactobacillus 
supplementation on the microbiome and metabolome of premature infants residing 
in NICUs. 
 
Hypothesis: Microbial supplementation with the early life members 
Bifidobacterium and Lactobacillus facilitates colonisation of these strains in the 
preterm gut  modifying the wider microbiome and metabolome.  
 
The study involved three aims/sub-sections: 
a) A metataxonomic analysis using 16S rRNA gene profiling (n=591 
samples) aimed to (i) characterise the development of the preterm 
microbiome for both study groups (supplemented and non-supplemented), 
and (ii) evaluate the interaction of environmental factors such as antibiotic 
treatment, delivery mode, or diet. 
b) Whole genome sequence analysis of ten Bifidobacterium isolates from the 
supplemented group, aimed to investigate the colonisation of the 
supplemented Bifidobacterium strain. 
c) 1D-NMR metabolomic analysis (n=157 samples) aimed to (i) investigate 
potential metabolites significantly enhanced in any of the study cohorts, 
(ii) relate them alongside their bacterial community profiling and (iii) 
elucidate potential relationships of immune and metabolic function in 






This study consisted of two distinct patient groups; routine oral supplementation of 
Bifidobacterium and Lactobacillus (i.e. Bif/Lacto group n=101 infants, 40 ≤ 1000g 
and 61 > 1000g), and a control non-supplemented group (i.e. control group n= 142, 
63 ≤ 1000g and 79 > 1000g  infants). Infants in the Bif/Lacto group were routinely 
prescribed an oral supplementation containing 109 colony forming units (CFU) of 
Bifidobacterium bifidum and 109 CFU of Lactobacillus acidophilus (Infloran®, 
Desma Healthcare). This supplementation was given twice daily as soon as enteral 
feeds commenced (usually on day 1 postnatal), until 34 weeks old for infants with 
a birthweight > 1000 g, and until discharge in ELBW infants (< 1000g). Each 
capsule of Infloran (250 mg) was dissolved in 2 ml of expressed breastmilk and/or 
sterile water and given to the infant via a nasogastric tube or by mouth. 
 
Inclusion criteria for the infants recruited were gestational age ≤ 34 weeks, and 
remanence in the same NICU for duration of the study. Infants diagnosed with 
NEC at the time of consent or with severe congenital abnormalities were excluded 
from the study. Premature infants enrolled belonged to four different Neonatal 
Intensive Care Units (NICUs) across England; infants from the Bif/Lacto Group 
came from Norfolk and Norwich University Hospital (NNUH, Norwich); infants 
from the control Group came from The Rosie Hospital (Cambridge), Queen 
Charlotte’s and Chelsea Hospital (London) and St Mary’s Hospital (London). All 
these NICUs utilised comparable antibiotic and antifungal policies. Cohorts were 
matched by gestational age (< 34 weeks gestation), sex, birth mode, time points of 
sample collection and diet across four different NICUs. 
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Ethical approval for the study 
Faecal collection from infants from NNUH and The Rosie Hospital was approved 
by the Faculty of Medical and Health Sciences Ethics Committee at the University 
of East Anglia (UEA) and followed the protocols laid out by the UEA 
Biorepository (Licence no: 11208). Faecal collection for Queen Charlotte’s and 
Chelsea Hospital and St Mary’s Hospital was approved by West London Research 
Ethics Committee (REC) under the REC approval reference number 10/H0711/39. 
In all cases, doctors and nurses recruited infants after parents gave written consent. 
 
Time points of sample collection for this study included <10 days, 10-29 days, 30-
49 days, >50 days. Clinical data collected on the premature infants included 
gestational age, delivery mode (C-section vs. vaginal), antibiotic courses received, 
and dietary information (see Appendix 2 for details of every infant recruited in this 
study).  
 
DNA extraction of stool samples from premature infants 
FastDNA Spin Kit for Soil (MP Biomedical, Santa Ana) was used to extract the 
bacterial DNA from the faeces samples following the protocol recommended by 
the manufacturer but extending the bead-beating step to 3 minutes. The DNA 
recovered was assessed using a Qubit® 2.0 fluorometer (Invitrogen).  
 
This study involved the extraction of 593 faecal samples. This job was carried out 
by myself, and the technicians working at the Hall lab (Jennifer Ketskemety and 
Lisa Chalken). 
 
16S rRNA gene sequencing: library preparation and bioinformatics analysis 
The 16S rRNA region (V1-V2) was amplified to determine the bacterial 
community composition on the premature infant stool samples. Primers used for 
library construction are detailed in table 7 and PCR conditions were: 1 cycle of 94 
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°C 3 min and 25 cycles of 94 °C for 45 s, 55 °C for 15 s and 72 °C for 30 s. 
Sequencing of the 16S RNA gene libraries was performed on the Illumina MiSeq 
platform with 300 bp paired end reads. 
 
Sequencing reads were filtered through quality control using trim galore (0.4.3) 
keeping a minimum quality threshold of phred 33 and minimum read length of 60 
of bases. Reads that passed the threshold were aligned against SILVA database 
(version: SILVA_132_SSURef_tax_silva) using BLASTN (ncbi-blast-2.2.25+; 
Max e-value 10e-3) separately for both pairs. After performing the BLASTN 
alignment, all output files were imported and annotated using the paired-end 
protocol of MEGAN on default LCA parameters.  
 
Table 7 Primer sequences for amplifying V1+V2 region of 16S rRNA gene using 
MiSeq Illumina 
9 forward (FW) primers 























16S library preparation was performed by myself, Jennifer Ketskemety and Lisa 
Chalken, as well as management of sequencing files with the sequencing provider. 
Initial QC and 16S rRNA gene bioinformatics analysis was led by Mr Shabhonam 




Statistical analyses and diversity calculations were completed using GraphPad 
(version7). Wilcoxon non-parametric test was used to look for statistical 
significance among external factors influencing Bifidobacterium. Non-parametric 
two tailed student t-test was used to estimate differences in pH values. I performed 
this analysis, except for non-metric multidimensional scaling (NMS) plots (Figure 
21), which was performed by Dr Matthew Dalby. 
 
Genomic DNA Extraction from bacterial isolates 
Isolation of strains present in the supplementation (Bifidobacterium bifidum and 
Lactobacillus acidophilus) as well as other potential pathogenic strains from the 
infants’ samples such as Staphylococcus, Escherichia, and Klebsiella was 
performed. Bifidobacterium strains were isolated using MRS (Difco) agar with 50 
mg/L of mupirocin, Baird-Parker agar (Oxoid) for Staphylococcus, and 
MacConkey agar for Escherichia and Klebsiella. 
 
DNA extraction of the isolates was prepared using an overnight pure culture in 
Brain Heart Infusion Broth (BHI). Bacterial pellets were resuspended in 2 ml 25% 
sucrose in 10 mM Tris and 1 mM EDTA at pH 8. Cells were subsequently lysed 
adding 50 µl 100 mg/ml lysozyme (Roche) and incubating the mixture at 37 °C for 
1 h. Following, 100 µl 20 mg/ml Proteinase K (Roche), 30 µl 10 mg/ml RNase A 
(Roche), 400 µl 0.5 M EDTA (pH 8.0) and 250 µl 10% Sarkosyl NL30 (Fisher) was 
added into the lysed bacterial suspension, incubated 1 h on ice and left overnight at 
50 °C. Next day protocol comprised washes of phenol-chloroform-isoamyl alcohol 
(PCIA, Sigma) using 15 ml gel-lock tubes (Qiagen). E Buffer (10mM Tris pH 8 
(Fisher Scientific, UK) was added to the sample to a final volume of 5 ml, mixed 
with 5 ml of PCIA (Sigma) and centrifuged for 15 min at 1792g. The CIA step was 
repeated three times, after which the final aqueous phase was transferred into a 
sterile Corning TM 50 ml centrifuge tube, and 2.5 volumes of ethanol (VWR 
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Chemicals, USA) were added, incubated for 15 min at -20 °C, and centrifuged 10 
min at 1792g and 4 °C. Finally, the pellet was washed twice with 10 ml of 70% 
ethanol and centrifuged at 1792g for 10 min, dried overnight, and re-suspended in 
300 µl of E Buffer. I performed the isolations of the bacterial strains and the DNA 
extraction. 
 
Whole genome sequencing analysis: library preparation and bioinformatics 
analysis 
DNA of pure cultures was subjected to multiplexed sequencing using standard 
Illumina library protocols followed by sequencing via HiSeq 2500 platform with 
125 bp paired end reads. Genome assemblies using pipeline described by Page et al 
143. All the assembled contigs were passed through prokka (1.12).  
 
Library preparation of the bacterial isolates was done at the Wellcome Sanger 
Institute (Cambridge) and bioinformatic analysis was carried out by Mr 
Shabhonam Caim. 
 
Determination of Minimal Inhibitory Concentration (MIC) of Infloran 
strains. 
Broth microdilution method144 was used to test the Minimal Inhibitory 
Concentration of the probiotic strains (Bifidobacterium bifidum and Lactobacillus 
acidophilus) against the routinely used antibiotics at NICUs (benzylpenicillin, 
gentamicin, vancomycin, metronidazole, meropenem and cefotaxime). Serial two 
fold dilutions of the antibiotics in MRS medium (Difco) were prepared and added 
to 10 µl from a fresh overnight culture of Bifidobacterium bifidum and 
Lactobacillus acidophilus. Microplates were incubated for 24 h at 37 °C under 
anaerobic conditions. Cell density was monitored using a plate reader (BMG 
Labtech, UK) at 595 nm. MICs were determined as the lowest concentration of 
antibiotic inhibiting any bacterial growth. Test were done in triplicate. I performed 
the MIC tests. 
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Metabolomic profiling using 1H- nuclear magnetic resonance spectroscopy 
(NMR) 
A subset of 157 paired faecal samples (75 from Bif/Lacto group, and 81 from 
control group) were analysed by standard one-dimensional (1D) 1H-NMR 
spectroscopy. The selection of these samples was performed randomly. 1D-NMR 
samples were normalised to 50 mg faecal content, added 700 µl of phosphate 
buffer (pH 7.4; 100% D2O) containing 1 mmol/L of 3-trimethylsilyl-1-[2,2,3,3-2H4] 
propionate (TSP), plus 1 mm diameter of zirconium beads, (BioSpec Products). 
Samples were bead beated using Precellys bead beater (Bertin) for 2 cycles of 40s 
at 6,500Hz speed145, centrifuged at 14,000 x g for 10 min and supernatant was 
transferred to NMR tubes. 1D-NMR spectra were acquired for each sample using a 
nuclear overhauser effect pulse sequence for water suppression as described by 
Beckonert and colleagues146. Spectra was imported into Matlab 9.4 (R2018a), 
manually corrected by removing signals corresponding to TSP and water and 
normalised using probabilistic quotient method. Data analysis was performed using 
orthogonal projection to latent structures discriminant analysis (OPLS-DA) and 
custom in-house scripts. Metabolites were assigned manually using Chenomx 7.0. 
 
I selected the samples for metabolomics analysis, prepared for metabolomics 
analysis and analysed them under the supervision Dr Jonathan Swann and Dr 
Fahmina Fardus at Imperial College (London). 
 
pH measurement of the faecal samples 
Faecal pH was measured on a subset of samples used in the metabolomics analysis 
(39 samples from the Bif/Lacto Group and 39 samples from the control Group). 
Samples selected for this pH analysis were used previously in the metabolomic 
analysis. Samples were weighed to 50 mg of faecal material, added 1ml of sterile 
water and used a glass electrode pH meter to measure the pH (Martini Mi151). I 
performed the pH measurements of the samples. 
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Kinetic growth curves of Staphylococcus, Klebsiella and Escherichia gut 
bacterial isolates using supernatant of Bifidobacterium bifidum from Infloran. 
The test was done using a 96 well plate including: 180 µl of B. bifidum supernatant, 
2 µl of an overnight culture of Staphylococcus, Klebsiella or E. coli and 10 µl of a 
10x BHI broth (pH adjusted to 6.3) to adjust for nutrient consumption. The plates 
were incubated in aerobic conditions at 37 °C and analysed every 15 min over a 
period of 24 h. The optical density (OD) at 595 nm was determined for each well 
using a plate reader (Tecan, Infinite 50) and samples were tested in triplicate. 
Controls were grown alongside each sample: (i) control for microbiological media 
BH (Brain Heart) broth and (ii) control of pH consisting of BH (Brain Heart) broth 
with pH adjusted to the supernatant of B. bifidum (6.3). I performed the kinetic 




In this study, a total of 591 stool samples from 224 premature infants from four 
Neonatal Intensive Care Units in UK (Norwich, Cambridge and London) were 
analysed. Two groups were included in this study; Bif/Lacto group (101 infants, 
routine oral Infloran supplementation), and the control group (133 infants, non-
supplemented infants). All infants recruited (n=234) were ≤ 34 weeks of 
gestational age, with 103 of them classified as ELBW <1000 g. Probiotic 
supplementation was given twice daily until 34 weeks old for infants with a 
birthweight >1000 g, and until discharge in ELBW infants (<1000 g). On average 
ELBW infants received a minimum of 20 days of probiotic supplementation and 
infants weighing >1000 g received an average of 14 days supplementation. The 
study excluded premature infants diagnosed with NEC at the time of sample 
collection or with severe congenital abnormalities. The study groups also 
comprised predominantly of premature infants who received breast milk or donor 
breastmilk (78% in Bif/Lacto Group and 77% control Group), mixed (breastmilk, 
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formula or donor breast milk, 19% Bif/Lacto Group and 20% control Group), and 
exclusively formula fed (4% Bif/Lacto Group, and 2% control Group). Stool 
samples were collected at four time points: t=1(<10 days), t=2 (11-29 days), t=3 
(20-49 days) and t=4 (>50 days). Figure 20 shows a summary of the study design 




Figure 20 Study design 
Figure highlighting number of premature infants recruited in each study cohort, 
times of stool collection and percentages of infants recruited detailing sex (M= male 
or F= female), birth mode (C= C-section or N= Natural birth) and diet (BM= 
breastmilk, DBM= donor breast milk, F= formula). 
 
Oral Bif/Lacto supplementation influences bacterial genus abundance and 
bacterial diversity  
To determine if supplementation with Bifidobacterium and Lactobacillus could 
alter the preterm gut microbiome a 16S rRNA gene bacterial profiling was 
performed on 101 infants who received routine oral supplementation, and 133 
infants non-supplemented as control group. Sequencing files with < 25,000 reads 
were discarded, due to my previous work indicating that the optimal threshold in 




Initial, clustering of premature infants samples using non-metric multidimensional 
scaling (NMDS) plots indicated a clear separation in gut microbiome profiles when 
comparing Bif/Lacto group and the control group. NMDS plots can be used when 
data does not have a normal distribution; the closer the points in the 2D 
representation the more similar their microbial communities. Bifidobacterium was 
the most prevalent genus in the Bif/Lacto group, while Staphylococcus, 
Escherichia, and Klebsiella were the most abundant in the control group (Figure 
21). Contrary to expectations, only a minority of premature infants in the Bif/Lacto 
group had detectable relative abundances of Lactobacillus, suggesting this taxon 




Figure 21 NMDS plots from Bif/Lacto group and control group differentiating time 
points of sample collection 
NMDS plots showing premature faecal samples clustered using a Bray-Curtis 
similarity matrix at (a) <10 days, (b) 11-29 days (c) 30-49 days and (d) at >50 days 
of age. Arrows indicate bacterial genus driving the separation points on the NMDS 
plots. 
 
Bar charts displaying the top twelve bacterial genera for all samples across the 
study period indicated that the premature faecal microbiome was typically 
dominated by a maximum of four bacterial genus; Bifidobacterium, 
Staphylococcus, Escherichia and Klebsiella (Figure 22). Bifidobacterium 
comprised > 30% of the overall relative abundances in the total microbiome for the 
Bif/Lacto group at all time points (Figure 22a), with control group infants having < 




but decreased across later time points, which may correlate with initial inoculation 
of skin associated bacteria. Surprisingly, Lactobacillus was only detected in a 
minority of infants, but with a higher relative abundance in Bif/Lacto infants 
compared to the Control group at all time points. Importantly, the Bif/Lacto group 
presented lower abundance of potential pathobiont bacteria (Klebsiella, 
Escherichia and Enterobacter) when compared to the control group. Overall these 
data, indicate that oral supplementation from birth may modulate the preterm 
microbiome, including ‘displacing’ other potentially pathogenic and commonly-
associated premature resident taxa. 
 
 
Figure 22 Genus abundance between Bif/Lacto group and control group  
Mean proportional abundance of the most common bacterial genus at each time point 
(<10 days, 11-29 days, 30-49 days and >50 days of age) for Bif/Lacto group (a), and 
control group (b). 
 
When plotting average Shannon diversity indexes (Figure 23a), the Bif/Lacto 
group presented a lower index than the control group, which may be due to the 
dominance of Bifidobacterium in these samples. Interestingly, the number of 
bacterial genus detected in the Bif/Lacto group was smaller during the first three 
time points of the study (up to 50 days) when compared to the control group, 










Figure 23 Shannon diversity index and bacterial genus detected among the study 
cohorts (Bif/Lacto and control group) 
a, Shannon diversity index increased more rapidly in the control group than in the 
Bif/Lacto. b, Number of bacterial genus detected from the start of the study to the 
end. Asterisks represent p < 0.05. 
 
External factors including birth weight and antibiotics negatively influenced 
Bifidobacterium abundance in recruited infants 
As shown above Bifidobacterium was the dominant taxa that differentiated 
between the two premature infant groups (Bif/Lacto and control). The influence 
that other external factors, such as gestational age, birth weight, antibiotics, 
delivery mode or diet, was also analysed. 
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A recent study by Korpella and colleagues highlighted that gestational age was the 
main determinant impacting the preterm microbiome148, with gut maturity 
correlating with Bifidobacterium abundance. To evaluate the influence of 
gestational age in this study, all infants studied were grouped into very low 
gestational age (<28 weeks) or low gestational age (≥28 weeks). Results indicate a 
tendency for lower relative abundance of Bifidobacterium in infants with very low 
gestational age (<28 weeks), however the differences shown among the two 
gestational age groups where not significant (Figure 24a). Using birth weight as a 
defining factor revealed that premature infants with extremely low birth weight 
(<1000 g) presented significantly lower relative abundance of Bifidobacterium 
(Figure 24b) up until day 29. As shown in Figure 24c there is a positive correlation 




Gestational age                                              Birth weight 
 













Figure 24 Effect of gestational age and birth weight on Bifidobacterium relative 
abundance 
a, Bifidobacterium abundance in premature infants with very low gestational age 
(<28 weeks) and low gestational age (≥28 weeks). b, Bifidobacterium abundance 
between very low birth weight (<1000 g) and low birth weight (>1000 g) infants. c, 
Gestational age correlated with birth weight (gr). Asterisks represent p values: *P < 
0.05, ***P < 0.001. 
 
Antibiotics have been shown to have a strong, but temporary effect, on the 
preterm microbiome49. Correlation of microbiome profiles from all infants 
recruited with antibiotic usage, revealed significant differences in 
Bifidobacterium abundance when comparing premature infants receiving 
antibiotics at the time of sample collection, with those who did not receive any 






Figure 25 Effect of antibiotics on Bifidobacterium relative abundance 
Bifidobacterium abundance in infants receiving antibiotics at the time of sample 
collection (Antibiotic yes) and infants who did not receive antibiotic treatment 
(Antibiotic no). Asterisks represent p values: *P < 0.05, **P < 0.01. 
 
Delivery mode (vaginal birth or C-section) is another external factor which 
determines whether the gut is primarily colonised by maternal vaginal and faecal 
microbiome, or by skin microbes149. This study evaluated the effect that delivery 
mode had on Bifidobacterium relative abundance, and surprisingly no significant 
differences where observed when comparing natural (n=133) versus C-section 
(n=101) birth (Figure 26), both in the Bif/Lacto group and control group. These 
data indicate that premature infants born by vaginal birth (45% of the infants 
recruited in this study) may not get the colonisation effects observed in their full-
term counterparts. In addition, ~80% of premature infants receive antibiotics 
during the first week of life150, which may significantly alter the initial microbial 
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a    All study samples 
 
b   Controls samples only 
 
Figure 26 Effect of delivery mode on Bifidobacterium abundance 
a, Bifidobacterium abundance in all study samples differentiating infants born by C-
section (blue) and vaginal birth (orange) b, Bifidobacterium abundance in control 
infants highlighting infants born by C-section (blue) and vaginal birth (orange). Data 
was grouped according to time points of sample collection.  
 
It is widely accepted that Bifidobacterium represents an important commensal in 
the infant gut, and that healthy breastfed infants are predominantly colonised by 
this taxa, which is linked to an ability to digest human milk oligosccharides148. 
Contrary to expectation, formula fed infants presented higher relative abundance of 
Bifidobacterium (Figure 27). However, only a very small proportion of infants 
were exclusively formula fed in this study (18 infants out of 234) making robust 
statistical analysis difficult. It is interesting to note that the formula given to these 
exclusively formula fed infants contained prebiotics (i.e. FOS), which has been 
































































                         All infants recruited 
 
Figure 27 Effect of diet on Bifidobacterium abundance 
Bifidobacterium abundance in infants receiving breastmilk (blue) or formula only 
(orange). BM = breastmilk, DBM = Donor breastmilk, EBM = Expressed breastmilk 
and F = formula. Asterisks represent p values: *P < 0.05, **P < 0.01 ***P < 0.001. 
Whole genome sequence analysis demonstrates gut colonisation of 
supplemented Bifidobacterium strain. 
Previous probiotic studies have indicated only transient or short-term colonisation 
of supplemented strains151, 152. Thus, next it was determined if the B. bifidum strain 
present in the supplementation (i.e. Infloran), was able to colonise the gut of the 
supplemented Bif/Lacto group. WGS analysis was performed, comparing Infloran 
B. bifidum (Infloran) to ten other Bifidobacterium isolates extracted from Bif/Lacto 
infants (five of them received supplementation at the time of sample collection and 
two had stopped supplementation). Phylogenetic core genome analysis showed 
more than 99.9% similarity among all the B. bifidum isolates (Figure 28), with 
pangenome analysis also indicating high sequence similarities (Figure 29). 
Notably, the study indicated four premature infants (P19, P8, P35, and P15) were 
found to harbour the same Infloran B. bifidum isolate. Interestingly, samples 
belonging to premature infant P8 were collected at 41 and 50 days after 
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Figure 28 Core genome tree from Bifidobacterium bifidum present in the oral 
supplementation and other Bifidobacterium species isolated from premature infants 
Comparison of core genomes from Bifidobacterium bifidum present in the oral 
supplementation, and ten other Bifidobacterium isolates from the study premature 
infants. Roary core gene alignment output was used to create a maximum likelihood 





Figure 29 Genome diagrams from Bifidobacterium bifidum (Infloran) and other 
Bifidobacterium 
BRIG software was used to compare whole genomes of Bifidobacterium bifidum 
present in the supplementation and other Bifidobacterium isolates. Similarity was 
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Minimal Inhibitory Concentration (MIC) testing of Bifidobacterium bifidum 
(Infloran) demonstrated susceptibility to the most common antibiotics used in 
NICUs. 
16S rRNA gene sequencing data indicated that Bifidobacterium abundance was 
significantly affected by antibiotic treatment (Figure 25). To probe this finding, a 
phenotypic antibiotic test was performed using Minimal Inhibitory Concentration 
(MIC) testing. Results showed B. bifidum (Infloran) presented a lower (MIC) 
breakpoint value than those put forward by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST153) to all antibiotics tested (i.e. 
benzylpenicillin, gentamicin and meropenem), which suggests this strain is 




Table 8 Minimal Inhibitory (MIC) concentrations for Bifidobacterium bifidum 
(Infloran) 
 
Antibiotic Bifidobacterium bifidum (Infloran) 
MIC (mg/L) Eucast value (mg/L) 
Benzylpenicillin 0.11 0.12 (ampicillin) 
Gentamicin 39 64 
Meropenem 0.095 ND 
 
Probiotic supplementation drives differences in faecal metabolomic profiles  
Metataxonomic profiling of both study groups (Bif/Lacto group indicated a clear 
separation in gut microbiome profiles. Thus, next it was determined whether these 
differences may also link to metabolome profiles of both cohorts using a subset of 
randomly selected faecal samples (n= 157) and untargeted NMR metabolomics 
analysis. 
 
Principal component analysis (PCA) of all the metabolites found in samples, 
showed clear group clustering, differentiating sample cohorts (Bif/Lacto group and 





Figure 30 Principal component analysis (PCA) plot of metabolite profile from 
Bif/Lacto group and control group 
PCA plot representing faecal metabolite profiles from Bif/Lacto group (light blue) 
and control group (dark blue). 
 
To further investigate whether these differences were maintained throughout the 
study, orthogonal signal corrected partial least squares discriminant analysis18 
(OPLS-DA) on the spectrum data was performed. The predicted performance of 
the OPLS-DA models (Q2Y) and the p-values obtained (all less than 0.01, Table 9), 
suggested metabolite differences observed continued throughout the study period. 
Bifidobacterium abundance was the main driver in the model that influenced these 
differences with a Q2Y = 0.44 and p value <0.01. It is interesting to note that the 
OLPS-DA model showed significant differences for Staphylococcus abundance in 




























Bifidobacterium abundance 0.44   0.29 0.20 0.01 
Time points of sample collection -0.01 -0.27 0.24 0.01 
Birth weight 0.08 -0.17 -0.01 NA 
Gestational age 0.06 -0.13 -0.125 NA 
Staphylococcus abundance 0.10 0.20 0.06 0.01 
Klebsiella abundance 0.002 -0.11 -0.13 NA 
Escherichia abundance -0.07 -0.002 -0.05 NA 
Enterococcus abundance -0.007 -0.15 -0.08 NA 
Streptococcus abundance -0.11 -0.13 -0.11 NA 
Left column indicates the different matrices used (Y). Models were evaluated using 
all samples or differentiating among cohorts (Bif/Lacto and control). NA = not 
applicable 
 
Next, a loading coefficient plot was generated to display the covariance between 
the Y-response matrix (Bif/Lacto or control Group) and the signal intensity of the 
metabolites in the NMR data; this allows detection of the metabolites responsible 
for differentiation between the study groups. Colours projected onto the coefficient 
plot indicated the correlation coefficient (R2) between each metabolite and the Y-
response variable (Figure 31), with red indicating strong significance and blue 




Figure 31 OPLS-DA loading plot on Bifidobacterium abundance 
OPLS-DA loading plot differentiating sample group. Peaks pointing upwards 
correspond to metabolites enhanced within the Bif/Lacto group, and peaks pointing 
downwards were elevated in the control group. 
 
Statistical analysis highlighted six metabolites which were significantly different 
throughout the study period: (i) acetate and lactate were enhanced in faecal samples 
from Bif/Lacto Group (Figures 32a-d), (ii) while sugars 3-Fucosyllactose (Figures 
32e-f), 2- Fucosyllactose (Figures 32e-f), arabinose (Figures 32g-h) and trehalose 




Figure 32 Summary of main 1D-NMR metabolites found in faeces from Bif/Lacto and 
control group 
a, Relative Acetate AUC levels b, Relative acetate AUC levels differentiating time point of sample 
collection c, Relative lactate AUC levels d, Relative lactate AUC levels differentiating time point of 
sample collection e, Relative trehalose and arabinose AUC levels f, Relative trehalose and arabinose 
AUC levels differentiating time point of sample collection g, Relative 2-fucosyllactose and 3-
fucosyllactose AUC levels h, Relative 2-fucosyllactose and 3-fucosyllactose AUC levels differentiating 
time point of sample collection. Time point of sample collection t=1 (>10days), t=2 (11-29 days), t=3 
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Acetate and lactate are microbial-derived short chain fatty acids (SCFAs), and 
fermentation products from Bifidobacterium, as well as other beneficial members 
of the gut microbiome such as Lactobacillus154. These SCFAs, and acetate in 
particular, have been shown to promote defence functions in host epithelial cells155. 
Interestingly, Bifidobacterium abundance appears to be correlated to acetate levels; 
samples with high level of Bifidobacterium abundance presented higher levels of 
acetate (Figure 33). 
 
Figure 33 Bifidobacterium reads, and acetate levels found in the Bif/Lacto Group 
and control group 
a, Bifidobacterium reads and acetate levels found in the Bif/Lacto Group and 
control group at time point of collection 1= >10 days b, Bifidobacterium reads and 
acetate levels found in the Bif/Lacto Group and control Group at time point of 
collection 2= 11-29 days c, Bifidobacterium reads and acetate levels found in the 
Bif/Lacto Group and control Group at time point of collection 3= 30-49 days d, 
Bifidobacterium reads and acetate levels found in the Bif/Lacto Group and control 
Group at time point of collection 4= >50 days. Bifidobacterium reads were 
displayed in left Y axis, and acetate levels were displayed in right Y axis. 
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2- Fucosyllactose and 3- Fucosyllactose are oligosaccharides naturally occurring in 
human breast milk, commonly known as HMOs. It is interesting to note that infants 
belonging to the control group had higher levels in faeces of these HMOs, than the 
Bif/Lacto Group (Figure 32e-f). Recent scientific studies have shown that B. 
bifidum plays an important role in degrading HMOs156, and the products produced 
from this metabolism, such as SCFAs, mediate cross-feeding amongst other 
Bifidobacterium species and strains and also other microbiome members. In this 
study infants belonging to the Bif/Lacto group presented high abundance of 
Bifidobacterium bifidum (supplemented strain), which could have contributed to 
the degradation of these HMOs and facilitated colonisation of other 
Bifidobacterium taxa. 
 
pH measurements from faeces from Bif/Lacto group were more acidic than 
control group, and were correlated with higher levels of acetate and lactate 
A recent study in breast-fed infants associated elevated Bifidobacterium abundance 
in the gut with a decrease of faecal pH157. To determine if there were differences in 
faecal pH of the Bif /Lacto group vs. the control group, a subset of 74 samples used 
in the metabolomic analysis were measured for pH. Faeces from infants in the 
Bif/Lacto group presented a significantly lower pH (5.79 ± 0.80, Figure 34a) than 
those in the control group (6.85 ± 0.58). Furthermore, this reduced pH in the 
Bif/Lacto group was maintained throughout the study (from birth to 50 days of life, 















Figure 34 pH faeces measurements from Bif/Lacto Group and control Group 
a, pH measurements from faeces samples belonging to Bif/Lacto Group and Control 
Group. b, pH measurements from Bif/Lacto Group and control Group detailing time 
points of sample collection t=1(<10 days), t=2 (11-29 days), t=3 (20-49 days) and 
t=4 (>50 days) c, Correlation between acetate and pH d, Correlation between lactate 
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Bifidobacterium bifidum (Infloran) supernatant inhibited growth of 
Staphylococcus haemolyticus isolated from premature infants’ samples 
Previous research studies have indicated that Bifidobacterium may directly inhibit 
opportunistic pathogens such as Staphylococcus epidermis158 or Escherichia coli159. 
To test the potential production of antimicrobials from B. bifidum (Infloran), 
kinetic growth curves were performed on several pathobionts isolates; 
Staphylococcus, Klebsiella and Escherichia. Supernatant from an overnight culture 
of B. bifidum (Infloran) including an extra dose of nutrients (see methods for 
details), was used to grow isolates, and optical density at 595 nm (OD595) was 
monitored during 24 hours in anaerobic conditions. Interestingly, there was a delay 
in growth for the S. haemolyticus isolate during the first 8 hours when compared to 
the control (Figure 35a) and suggests presence of a B. bifidum-derived 
antimicrobial. In the case of the Klebsiella pneumoniae and Escherichia coli 
isolates, there was no effect on growth when culturing the isolates with the 
supernatant of B. bifidum or when using media with lower pH (to mimic the 




Figure 35 Kinetic growth curves of Staphylococcus, Klebsiella and Escherichia 
isolates using supernatant of Bifidobacterium bifidum from Infloran  
Growth curves of Staphylococcus (a, b), Klebsiella (c) and Escherichia (d) bacterial 
isolates. Each graph comprises three different growth conditions: (i) ´control´ (red) 
the bacterial isolate is grown with a rich microbiological media (ii) ´control pH´ the 
bacterial isolate is grown with a rich microbiological media with pH adjusted to 
Infloran supernatant and (iii) ´Infloran´ isolate is grown using supernatant of 
Bifidobacterium bifidum (Infloran). 
 
To validate the findings obtained with Staphylococcus haemolyticus, the same 
growth curves were monitored using classical microbial counts (Figure 36). 
Unexpectedly, the results showed no differences between the growth observed 
when the Staphylococcus haemolyticus isolate was grown using supernatant of B. 
bifidum or with control samples, which may be due to the turbity of bacterial 





























































Figure 36 Growth curves of S. haemolyticus isolate on supernatant of 
Bifidobacterium bifidum (Infloran) 
Growth curves of S. haemolyticus isolate using supernatant of BH (yellow), BH with 
pH adjusted (orange) and Bifidobacterium bifidum supernatant (blue). 
 
Discussion 
Premature infants are exposed to a wide variety of clinical and environmental 
factors such as multiple antibiotic treatments, reduced exposure to maternal 
microbiome, reduced breastfeeding, and prolonged stays in NICU. This can 
negatively affect the early stages of bacterial gut colonisation49, and consequently 
impact on the long-term health outcomes of these infants. Oral supplementation 
with members of early life microbiome such as Bifidobacterium or Lactobacillus, 
has become an alternative for accelerating the establishment of a healthier gut 
microbiome in premature infants. Numerous clinical studies support that bacterial 
supplementation significantly reduces the risk of NEC and the incidence of 
nosocomial infections160-163. Notably, a recent clinical audit in the same NICU 
where the oral supplementation was administered (i.e. Norfolk and Norwich 
University Hospital), indicated a >50% reduction in NEC rates and late-onset 
sepsis when comparing 5-year epochs before and after introducing probiotic 
supplementation, with no episodes of probiotic ‘sepsis’ indicated164. However, 
before widespread uptake in NICUs across different countries, there is a pressing 
need to complement these findings with larger-scale meta-studies and state-of-the-
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art sequencing and metabolomic techniques, to better understand the complex 
dynamics of bacterial communities residing in the preterm gut microbiome. 
 
This study represents one the largest reported longitudinal studies of premature 
infants (n = 591 stool samples), and one of the very few where study groups 
(Bif/Lacto, control) were matched by gestational age (< 34 weeks gestation), sex, 
birth mode, time points of sample collection and diet across four different NICUs. 
Due to the large-scale nature of the study, 16S rRNA sequencing and analysis was 
used, rather than the significantly more expensive shotgun metagenomics 
approach. Notably, Bifidobacterium represented the most abundant taxa in the 
Bif/Lacto group, whilst Staphylococcus, Escherichia, and Klebsiella were the most 
prevalent in the control group. This analysis strongly suggested that 
supplementation with Bifidobacterium and Lactobacillus from birth in premature 
infants, augmented the abundance of Bifidobacterium and reduced the incidence of 
pathobionts which are common denizens of hospital environments. To date, most 
of the research studies analysing the preterm microbiome in infants not receiving 
probiotic supplementation, indicated low abundance of the favourable genus 
Bifidobacterium47, 49, 165. Bifidobacterium represents an important commensal 
bacteria in early life able to synthesize compounds which can influence host 
immunity (e.g. Bifidobacterium breve has been shown to produce the beneficial 
metabolite linoleic acid which has potential roles in immune modulation, 
anticarcinogenic, and antiobesity activities166), or promote the production of 
regulatory T cells ( CD4+ CD25+ Foxp3+) involved in fortifying the intestinal gut 
barrier167. Contrastingly, Lactobacillus acidophilus (Infloran) did not appear to 
colonise the lower part of the intestinal tract in premature infants. This latter 
finding agrees with a small research study done in 2016 using the same 
supplementation (Infloran) and seven infants168. Previous research studies have 
shown Lactobacillus is able to survive in acidic environments with 0.3% bile 
salts169, and a study using a single bioreactor to simulate the passage from stomach 
to intestines showed that Lactobacillus gasseri K7 presented a high survival rate in 
 112 
the stomach-intestine passage 170. There is the possibility that Lactobacillus 
acidophilus (Infloran) preferentially colonised the premature small intestine, but 
only a biopsy sample could be used to screen this part of the intestine, which was 
outwith the ethic boundaries of this study.  
 
As the Bifidobacterium genus was shown to be the predominant member in the 
supplemented group (Bif/Lacto) exerting a potential protective role against 
colonisation of pathobionts, the study determined which external factors were 
affecting the abundance of this taxa. Low birthweight and antibiotic treatment 
clearly impacted negatively on Bifidobacterium abundance (Figures 24 and 25), 
which is in agreement with previous studies49, 171. The study also validated 
antibiotic susceptibility of Bifidobacterium bifidum (Infloran) in vitro (Table 8), 
supporting the genomic findings. Surprisingly, when investigating the influence of 
delivery mode, premature infants born by vaginal birth did not seem to obtain the 
beneficial commensal bacteria observed in term infants (Figure 26), probably due 
to the high incidence of prophylactic antibiotic prescription given to premature 
infants during the first week of life172.  
 
It has been well documented that not all microbial supplementations have 
equivalent efficacy at colonising the premature gut151. Therefore, this study takes 
the advantage of whole-genome sequencing and its broad sequencing coverage to 
assess the colonisation of the supplemented Bifidobacterium strain. Results 
strongly suggested that Bifidobacterium bifidum from Infloran colonised the gut of 
premature infants in the Bif/Lacto group. The fact that the supplementation was 
given in early days (from first enteral feed) at a high dose (twice daily) and 
continued for a prolonged period, may have provided the optimal conditions for 
Bifidobacterium bifidum (Infloran) to establish and colonise the premature gut. In 
addition, it is interesting to note that the majority of the infants in the study were 
fed with breastmilk, and this particular species of Bifidobacterium has been shown 
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to be an avid utiliser of HMOs173 contributing to the establishment of other 
pioneering species of the gut.  
 
Metabolomic analysis on a subset of samples (n = 157) was performed to 
determine if the changes observed in the gut microbiome were reflected at the 
functional level, and to elucidate potential interactions involving host and bacteria. 
Faecal metabolomes from the Bif/Lacto group were distinct from the control group 
and indicated elevated levels of the short chain fatty acids (SCFAs) acetate and 
lactate. Notably, a recently study associated the production of SCFAs with a 
reduction on the faecal pH157, which correlated with our findings (Figure 32c). In 
early childhood SCFAs have been shown to play a key role in enhancing innate 
immunity174 and increasing the maturation of the enteric nervous system175. 
Moreover, a mouse study associated acetate production by Bifidobacterium to gut 
barrier function, preventing the infection from enterohaemorrhagic Escherichia 
coli O157:H7176. In contrast, the metabolome of premature infants from the control 
group were shown to have high levels of HMOs (2-fucosyllactose and 3-
fucosyllactose), probably due to the low levels of HMO bacterial utilisers in their 
gut. 
 
In vitro analysis measuring the potential production of bacteriocins using the 
supernatant of Bifidobacterium bifidum (Infloran) against other potential 
pathobionts (Staphylococcus, Escherichia and Klebsiella) did not reveal any impact 
on their bacterial growth (Figure 35). Previous research studies indicated the 
production of bacteriocins in Bifidobacterium is generally associated with late 
logarithmic phase or early stationary phase of growth, but considerable variation 
exists among species tested, microbiological media utilised and pH conditions 
used177. Further analysis optimising this test could be done, or alternatively, a more 
complex, but perhaps more informative system, could be trialled, using the model 
colon with a bacterial mock community representing the preterm microbiome. 
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Limitations of this study include that this was an observational study and was not 
planned as a randomised clinical study. It was not possible to make associations of 
the microbiome and metabolome profiles found with relevant clinical data of the 
premature infants studied. Looking at the effect of different antibiotic regimes or 
antibiotic dosing on the premature infant gut microbiome was also out of the scope 
of this work. Alongside the main microbiological findings of this study, this work 
provides context for further clinical trials focusing on future intervention studies in 
this at-risk infant population. 
 
Conclusions 
Infloran supplementation modified the microbiome and metabolome of premature 
infants residing at NICU. Antibiotic treatment and low birth weight are relevant 
factors influencing disturbances in the preterm microbiome, whilst delivery mode 
did not have a significant effect. Infloran supplementation exerted an important 
functional effect enhancing the abundance of short chain fatty acids in the 
supplemented group. 
 
The large-scale longitudinal study presented here, contributes to the growing 
knowledge of the preterm infant microbiome, and emphasizes that probiotic 
supplementation plays a crucial role in exerting protective functional effects on the 
preterm gut microbial communities.  
 
Future work 
This work has offered me the possibility of working closely with doctors and 
nurses. One of the main challenges of this study has been to obtain the clinical 
data. As the Bif/Lacto supplementation (Infloran) was so successful at colonising 
the preterm gut, I would continue this work by addressing in-depth clinical 
questions where there are still disagreements in probiotic supplementation studies. 
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Questions such as (i) is Infloran involved in helping premature infants gain 
weight178 during their stay at NICUs?, or (ii) does Infloran contribute to reduce 
NICU stay for premature infants? need answers in this field. 
 
Another interesting area to complement this work would be to evaluate the effects 
of probiotic supplementation on intestinal mucosa integrity. Commensal bacteria, 
SCFAs, and antimicrobial peptides are known to be key players at promoting 
health in the intestinal mucosa by facilitating the assembly of tight junctions, 
renewal of intestinal cells, and enhance production of mucin67, a mucus gel coat 
which forms a protective barrier. Research studies show commensal bacteria are 
involved in promoting IgA secretion from plasma cells within the gut lumen, 
defending the mucosa from invasion by pathogens and reducing proinflammatory 
signals179. It would be interesting to measure IgA as well as proinflammatory 
signals on a subset of faeces samples analysed in this study, to assess whether the 
Infloran supplementation is enhancing an effect on the mucosal integrity. 
 
On the genomic side, future research on microbial supplementation studies needs to 
include the utilization of shotgun metagenome profiling, which is becoming more 
affordable with the decrease in sequencing cost. This approach will provide more 
information of species and strain level information, as well as identify important 











Premature infants, particularly very low birth weight (VLBW, <1.5 kg), often 
receive prophylactic antibiotic treatments from birth, to prevent early onset 
infections. Notably, administration of antibiotics also disrupts the resident gut 
microbiome, and may create an important reservoir of resistant strains, and of 
transferable resistance genes, the so called ‘resistome’, which may correlate with 
the increasing incidence of antimicrobial resistance (AMR). This study evaluated 
the impact of antibiotic regimes on the preterm microbiome, and the ‘resistome’.  
 
Shotgun metagenomics was performed on longitudinal faecal samples isolated 
from VLBW infants (n=34) with/without an antibiotic course of benzylpenicillin 
and gentamicin (short and long courses). Bioinformatics analysis were used to 
characterise the taxonomic diversity, and the frequency of antibiotic resistance 
genes. The study cohorts were differentiated between VLBW infants who received 
probiotic supplementation (probiotic cohort) and VLBW infants who did not 
receive supplementation (no probiotic cohort), to elucidate whether 
supplementation contributes to re-establishment of the commensal gut microbiome 
after antibiotic treatment. 
 
Results indicate that antibiotics and the NICU environment significantly alter the 
preterm microbiome, with increased representation of potentially ‘pathogenic’ 
species such as Klebsiella pneumoniae, Escherichia coli and Staphylococcus spp. 
Probiotic-supplemented VLBW infants presented a higher relative abundance of 
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Bifidobacterium throughout the study period when compared to non-supplemented 
infants. The total reservoir of AMR genes within the two study cohorts did not 
significantly vary among the AMR gene categories detected, nor their AMR gene 
abundance. These findings may have implications for preliminary guidance for 
recommendations of the use of antibiotics in VLBW infants residing within 
neonatal intensive care units. 






Figure 37 Study pipeline 
Premature infants recruited in this study were very low birth (VLBW) infants (<1.5 
Kg) who received breastmilk or donor breastmilk during the first two weeks of life. 
This study includes two different cohorts of VLBW infants: no probiotic 
supplemented and probiotic supplemented. Samples were collected by nurses at 1st 
week (ranging from 5-8 days), 2nd week (ranging from 11-15 days) and 3rd week 
(ranging from 18-24 days). Shotgun metagenomic sequencing was performed to 




I contributed to the overall study design, recruited the samples, prepared them for 
genomic analysis, performed data analysis, and designed the final figures. Mr 
Shabhonam Caim ran the bioinformatic pipelines related to taxonomic, AMR gene 
detection and functional analysis. Dr Will Rowe designed a bespoke bioinformatic 
pipeline to assign AMR genes to specific taxa. Specific details of all authors’ 
contributions can be found within the Methods section. 
 
Introduction 
The immature immune system of premature infants increases their risk of 
developing neonatal infections e.g. bacteraemia/sepsis. Sepsis is a life-threatening 
condition triggered by the body’s immune system in response to a bacterial 
infection, which can damage vital organs and cause sudden death if not treated at 
an early stage180. Estimates indicate that 23% of neonatal deaths worldwide are 
caused by infections, and approximately half of these occur during the first week of 
life181, 182. Mortality rates associated with an early-onset sepsis episode increase 
with prematurity183. Very low birth weight (VLBW, <1.5 kg) infants represent the 
most vulnerable cohort of premature infants with elevated risk of developing early-
onset infections (EOIs)184. EOIs typically occur in the first 3 days of life and are 
normally caused by endogenous bacterial pathogens inhabiting the mother’s 
genitourinary tract (e.g. Group B Streptococcus, Escherichia coli, and 
Staphylococcus)183, which can be vertically transmitted to the infant before or 
during birth185, 186.  
 
To protect premature infants from acquiring an EOI, doctors often prescribe 
antibiotics empirically during the first days of life. The World Health Organisation 
guidelines recommends a combination of amoxicillin (a common penicillin) and 
gentamicin as a preventative measure for EOIs187. The duration of the antibiotic 
course is very subjective and is based on the clinician’s opinion, antepartum factors 
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and prematurity of the baby, and often varies from two to seven days. Notably, 
administration of antibiotics disrupts the resident preterm gut microbiome188. 
Therefore, it is important to understand how antibiotic usage impacts the 
developing preterm gut microbiome. Antibiotic treatment may have consequences 
for preterm metabolic and immune development189, and may also enhance the 
presence of antibiotic resistance genes (ARGs) in the gut, defined as the 
‘resistome’55.  
 
Some Neonatal Intensive Care Units (NICUs) use probiotic supplementation to 
modify the preterm gut microbiome and reduce the incidence of a devastating 
bowel disease called necrotising enterocolitis (NEC)77, 190, 191. Meta-analysis from 
several clinical trials have shown that probiotic supplementation using 
Bifidobacterium reduce the incidence of NEC in premature infants190, 192, 193. To 
date, there is a paucity of data available to evaluate the interplay between this 
supplementation and antibiotic therapy on the developing preterm gut microbiome 
and the preterm gut resistome. To date there is only one published study on 
premature infants analysing these interactions194. This study demonstrated a higher 
Bifidobacterium abundance in the probiotic group when compared to non-
supplemented infants. However the resistome was not significantly different when 
comparing probiotic supplemented very low birth weight infants (>28 weeks 
gestation), with more mature non-supplemented infants (28-31 weeks gestation) at 
4 weeks and 4 months. Thus, to further understand whether probiotic 
supplementation contributes to reduced AMR gene carriage, further more 
controlled studies are required e.g. with infants belonging to probiotic 
supplemented and non-supplemented groups, who also have the same gestational 
age and antibiotic regimes. 
 
In this study, shotgun metagenomics on faecal samples isolated from 34 VLBW 
infants was used to interrogate the evolution of the preterm gut microbiome and 
resistome throughout the first 3 weeks of life. The study includes infants with and 
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without antibiotic treatment to characterise their metataxonomic diversity, and 
frequency of antibiotic resistance genes. Furthermore, it includes two study cohorts 
(probiotic and non-probiotic supplemented) to evaluate if supplementation can re-
establish the commensal gut microbiome and reduce the preterm resistome after 
antibiotic treatment. This is the first preterm study where cohorts and control 
groups were matched by gestational age (< 33 weeks gestation), antibiotic 
treatment (i.e. benzylpenicillin and gentamicin), diet (mostly breastfeed), birth 
mode (predominantly born by C-section), and time points of sample collection. 
Genomic findings were validated using phenotypic testing (i.e. Minimal Inhibitory 
Concentration). 
 
Results from this study indicate that antibiotics and the NICU environment 
significantly altered the preterm microbiome, and increase representation of 
potentially multidrug ‘pathogenic’ species such as Klebsiella pneumoniae, 
Escherichia coli, Enterococcus faecalis and Enterobacter cloacae. The probiotic 
supplementation used in this study may contribute to reduced abundance of 
potential bacterial pathogens. Surprisingly, the AMR gene content from both study 
cohorts (non supplemented and probiotic supplemented) was comparable.  
 
Hypothesis and aims 
Hypothesis: Early life administration of antibiotics can lead to disruption of the 
preterm gut microbiome and also enhance the reservoir of antimicrobial resistance 
genes (the ‘resistome’). Probiotic supplementation can contribute to re-
establishment of the commensal gut microbiome after antibiotic treatment and 
reduce the reservoir of antimicrobial resistance genes. 
 
The study involved two aims/sub-sections: 
a) Evaluation of the taxonomic profiles of VLBW infants treated with and 
without antibiotic treatment to determine the impact of the antibiotic 
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stewardship on the bacterial populations inhabiting the preterm gut 
microbiome. As this study includes antibiotic-naive samples, the effect of 
the NICU environment can also be investigated. 
b) Evaluation of the VLBW preterm gut reservoir of antimicrobial resistance 
genes. This study evaluates whether antibiotic treatment increases the total 
AMR gene content in the preterm gut microbiome, and determines whether 




Subject recruitment  
Premature infants recruited in this study resided in three Neonatal Intensive Care 
Units (NICUs): Norfolk and Norwich University Hospital (NNUH, Norwich, UK), 
Queen Charlotte’s and Chelsea Hospital (London, UK) and St Mary’s Hospital 
(London, UK). Sample collection for NNUH was approved by the Faculty of 
Medical and Health Sciences Ethics Committee at University of East Anglia 
(UEA) and followed the protocols laid out by the UEA Biorepository (Licence no: 
11208). Sample collection for Queen Charlotte’s and Chelsea Hospital and St 
Mary’s Hospital was approved by West London Research Ethics Committee (REC) 
under the REC approval reference number 10/H0711/39. Doctors and nurses 
recruited infants after parents gave written consent. 
 
Sample collection  
All NICUs included in this study presented similar protocols for feeding, 
prescription of antibiotics and antifungal drugs. The main exception was that the 
NNUH routinely prescribed all VLBW an oral probiotic supplementation 
(Infloran®, Desma Healthcare, Switzerland) twice daily, whereas St Mary’s 
Hospital and Queen Charlotte’s and Chelsea Hospital did not use probiotic 
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supplementation. This supplementation contained Bifidobacterium bifidum and 
Lactobacillus acidophilus in a dose of 1 x 109 cfu of each species, and was given 
from birth until 34 weeks old.  
 
A total of 34 VLBW infants under 31 weeks gestation were recruited for this study, 
and were either treated with only benzylpenicillin and gentamicin (antibiotic 
treated) or no antibiotic treatment (control group) during the first days of life. We 
specifically selected infants who were given breastmilk or donor breastmilk during 
the first 2 weeks of life, with the aim of normalising feeding regimes between the 
two study cohorts. Faeces were collected at time points 1st, 2nd and 3rd week of their 
NICU stay. Details of the VLBW infants recruited for this study can be found in 
Appendix 2. I performed the selection of the samples included in this study. 
 
DNA extraction  
DNA extraction was performed using the FastDNA Spin Kit for Soil (MP 
Biomedical, Santa Ana) following the manufacturer’s instructions, but extending 
the bead-beating step to 3 minutes, and eluting the DNA with 55 °C sterile water. 
The DNA recovered from these samples was assessed using a Qubit® 2.0 
fluorometer (Invitrogen). I performed the DNA extractions. 
 
Shotgun metagenomics library preparation and sequencing 
Samples containing 500 ng of genomic DNA were placed into a Covaris plate with 
glass wells and DNA was sheared into fragments of approximately 450 bp. The 
sheared DNA was purified and concentrated using an SPRI-cleanup kit 
(Beckman,USA). Library construction entailed an end repair, A-tailing and adapter 
ligation steps. Adapter ligated samples were amplified and indexed by PCR using 
established Illumina paired end protocols. A portion of each library was used to 
create an equimolar pool and enriched libraries were subjected to 125 base paired 
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end sequencing on a HiSeq 2500 V4. Library preparation and sequencing were 
performed at the Sanger Institute, Cambridge, UK. 
 
Taxonomic and functional profile analyses  
Sequencing files were quality assessed with the FASTX-Toolkit. Subsequent 
taxonomic analysis was performed using MetaPhlAn v2.0 
(http://huttenhower.sph.harvard.edu/metaphlan2) and depicting of the paired read 
sequences was performed using R. Principal Coordinate Analysis (PCoA) was 
performed using Bray-Curtis distances on shotgun taxonomic profiles in MEGAN 
version 6.0. Functional annotation was performed using EggNOG mapper (version 
1.0.3) based on EggNOG orthology195 data. Mr Shabhonam Caim ran the 
bioinformatic analysis and I finalised the figures using MEGAN. 
 
Identifying antimicrobial resistance genes 
Presence/absence of AMR genes within the samples was performed using two 
different bioinformatics approaches: (i) linear approach where metagenomic 
contigs produced by MEGAHIT196 were aligned to the CARD database version 
2.0.1 (https://card.mcmaster.ca/download) using a filtering criteria of e-value 1e-10 
and 90% identity, and (ii) a non-linear approach which combines variation graph 
representation of gene sets with a Locality Sensitive Hashing (LSH) indexing 
scheme. This latter approach was performed in collaboration with Dr Will Rowe 
who is the developer of this pipeline197.  
 
Isolation and characterisation of Bifidobacterium, Enterococcus, 
Staphylococcus, Klebsiella and Escherichia strains from VLBW infant 
faeces 
In order to validate the results obtained from the genomic analysis, I performed 
bacterial isolation, targeting the most abundant bacterial taxa present in samples. 
50-25 mg of faecal sample was homogenised in 5 mL of phosphate buffer saline 
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(PBS) by vortexing. Homogenates were serially diluted to 10-4 in PBS buffer and 
aliquots of 100 ml were spread on different selected medium: MacConkey (Oxoid), 
MRS (Difcotm) with 50 mg/L mupirocin (Oxoid), Baird-Parker (Oxoid) and Slanetz 
and Bartley medium (Oxoid). Agar plates were incubated aerobically (MacConkey, 
Baird-Parker and Slanetz and Bartley agar) and anaerobically (MRS agar) at 37 °C 
over three days. Five colonies from each agar plate were streaked three consecutive 
times onto new nutrient agar plates to assure purity. The DNA was extracted using 
the FastDNA Spin Kit for Soil (MP Biomedical, Santa Ana). The 16S rRNA gene 
was PCR amplified with the primers: fD1 (5’- AGA GTT TGA TCC TGG CTC 
AG - 3’), fD2 (5’- AGA GTT TGA TCA TGG CTC AG - 3’) and rP1 (5’ - ACG 
GTT ACC TTG TTA CGA CTT - 3’)198. The PCR conditions were: 1 cycle of 94 
°C for 5 min, followed by 35 cycles of 94 °C for 1 min, 43 °C for 1 min, and 72 °C 
for 2 min followed by a final strand extension at 72 °C for 7 min. All amplicons 
were sequenced using an automated Sanger sequencing service (Eurofins 
Genomics, Luxembourg), and sequences were used to identify the species isolated 
using Basic Local Alignment Search Tool (BLAST). I performed this procedure. 
 
Determination of Minimal Inhibitory Concentration (MIC) for 
bacterial isolates 
Calculation of the Minimal Inhibitory Concentration (MIC) of bacterial isolates 
against commonly used antibiotics in NICUs was performed using the broth 
microdilution method199. Five Klebsiella pneumoniae isolates from baby M26 at 
time points 7, 14 and 21 days, were tested against benzylpenicillin and meropenem. 
Serial two-fold dilutions of these two antibiotics were added to sterile nutrient 
broth, and 10 µl from a fresh overnight culture of the isolates was added in each 
well. Microplates were incubated for 24 h at 37 °C under aerobic conditions. Cell 
density was monitored using a plate reader (BMG Labtech, UK) at 595 nm. MICs 
were determined as the lowest concentration of antibiotic inhibiting any bacterial 
growth. I performed this procedure. 
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DNA extraction from bacterial isolates for whole-genome analysis 
Overnight bacterial isolates were centrifuged, re-suspended in 30 ml of PBS 
(Sigma-Aldrich, UK) and centrifuged again. The pellet was re-suspended in 2 ml of 
25% sucrose (Fisher Scientific) in TE buffer (10 mM Tris and 1 mM EDTA at pH 
8.0) and 50 µl of Roche Lysozyme (Roche Molecular Systems, UK) at 100 mg/ml 
in 0.25 M Tris pH 8.0. The mixture was incubated at 37 °C for 1 h, and 100 µl of 
Proteinase K at 20 mg/ml (Roche Molecular Systems), 30 µl of RNase A at 10 
mg/ml (Roche Molecular Systems), 400 µl of 0.5 M EDTA pH 8.0 (VWR 
Chemicals), and 250 µl of freshly prepared 10% Sarkosyl NL30 (Sigma-Aldrich) 
were added. The mixture was incubated on ice for 2 h and transferred to a water 
bath at 50 °C overnight. Next, Elution Buffer (10 mM Tris pH 8.0 (Fisher 
Scientific) was added to the sample to a final volume of 5 ml, mixed with 5 ml 
Phenol:Chloroform:Isoamyl Alcohol (PCIA) (25:24:1) (Sigma-Aldrich) in a 
Qiagen MaXtract High Density tube (Qiagen, Germany) and centrifuged for 15 
min at 1792g. The aqueous phase was then transferred into a new Qiagen MaXtract 
High Density tube, made up with Elution Buffer to the volume of 5 ml, mixed with 
5 ml of PCIA, and centrifuged for 10 min at 1792g. This procedure was repeated, 
with 5 min centrifugation time. Next, the aqueous phase was transferred into a 
Qiagen MaXtract High Density tube, made up to 5 ml with Elution Buffer, mixed 
with 5 ml of Chloroform:Isoamyl Alcohol (CIA) (24:1) (Sigma-Aldrich, UK), and 
centrifuged for 5 min at 1792g. The CIA step was then repeated once more, after 
which the final aqueous phase was transferred into a sterile Corning TM 50 ml 
centrifuge tube, and 2.5 volumes of ethanol (Ethanol absolute AnalaR 
NORMAPUR®, VWR Chemicals, USA) were added. The sample was incubated 
for 15 min at 20 °C, and centrifuged for 10 min at 1792g at 4 °C. Finally, the pellet 
was washed with 10 ml of 70% ethanol and centrifuged at 1792g for 10 min twice, 






The preterm gut microbiome in non-probiotic supplemented VLBW 
infants is different from probiotic supplemented VLBW infants 
Shotgun metagenomics sequencing was used to capture the bacterial community 
profiles between the two study cohorts (non-probiotic supplemented and probiotic 
supplemented). Each cohort included VLBW infants treated with antibiotics 
(benzylpenicillin and gentamicin) from 3 to 8 days of treatment, and VLBW 
infants who did not receive any antibiotic treatment (considered as ‘control 
group’). 
 
I initially performed Bray Curtis distances and Principal Coordinate Analysis to 
determine the overall taxonomic profiles of the two study cohorts (non-probiotic 
and probiotic supplemented). PCoA visualisation indicated that each cohort 
clustered into two separate groups (Figure 38), suggesting the taxonomic profiles 




                               
      week 1            week 2 
 
 
           week 3 
 
Figure 38 Principal Coordinate Analysis (PCoA) from samples tested in the study 
PCoA plots were performed based on the Bray-Curtis distances calculated from the 
relative abundance of the taxonomic profiles. Samples were grouped according to 
the time point of collection: a) PCoA plot from samples analysed at 1st week of the 
study b) PCoA plot from samples analysed at 2nd week and c) PCoA plot from 
samples analysed at 3rd week. Samples from non-probiotic supplemented infants 
were highlighted in green, and samples from probiotic supplemented infants were 
marked in blue.  
 
The main differences between the two study cohorts were driven by the genus 
Bifidobacterium, which was consistently enhanced in the probiotic cohort 
throughout the study period, and the genera Escherichia and Klebsiella which were 





Figure 39 Bifidobacterium, Escherichia and Klebsiella abundance throughout the 
study period 
Relative abundance of Bifidobacterium (a), Escherichia (b) and Klebsiella (c) at the 
sample time points of the study: 1st week, 2nd week, and 3rd week. Samples were 
grouped into VLBW infants receiving probiotic treatment (highlighted with +) and 
VLBW infants non-supplemented (highlighted with -). 
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Antibiotic treatment and the NICU environment impact profiles of 
multidrug resistance bacteria within the preterm gut microbiome 
More in-depth visualisation of taxonomic profiles from the non-probiotic cohort, 
indicated that the most abundant bacterial species found were Klebsiella 
pneumoniae, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermis 
and Enterobacter cloacae (Figure 40). These bacteria have all previously been 
described as prevalent members of the gut microbiome of VLBW infants120, 200, 201. 
Interestingly, premature infants who received the longest antibiotic treatment 
(infants M26, M36 and M39), presented the highest levels of K. pneumoniae (90%-
96%), Klebsiella oxytoca (47%-49%) and Enterococcus faecalis (92%-33%) 
during the first two weeks of the study (Figure 40a and 40b). Taxonomic profile 
similarities at the 2nd and 3rd week of the study, in both the antibiotic and the non-
antibiotic group (Figure 40b and 40c), suggested the NICU environment may also 
play a role (in tandem with antibiotic treatment) at colonising the premature infant 




Figure 40 Comparison of bacterial profiles analysed for non-supplemented probiotic 
cohort (antibiotic vs non-antibiotic treatment) 
Relative abundance of each taxon was represented in percentage value, and bar 
colours represent different species found. Time points of study were classified as a) 
1st week of study, b) 2nd week of study and c) 3rd week of study. Asterisks represent 








































Streptococcus urinalis Clostridium perfringens
Figure X – Comparison of bacterial profiles analysed for no-supplemented probiotic cohort (antibiotic treated vs non antibiotic).
Relative abundance of each taxon was represented in percentage value, and bar colours represent different species found. Time points of 
study were classified as a) 1st week of study, b) 2nd week of study and c) 3rd week of study. More detailed information on the number of 



















































































































Propionibacterium avidum Staphylococcus hominis Streptococcus anginosus
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Microbial profiles for the probiotic supplemented cohort indicated key differences 
from the non-probiotic cohort. Overall, there was a predominance of 
Bifidobacterium bifidum throughout the study period; average abundance of this 
bacteria taxa per infant was 44% at 1st week of study, 56% at 2nd week, and 43% at 
3rd week (Figure 41). Notably, B. bifidum was present in the daily probiotic 
supplementation these infants received. Interestingly, colonisation of other 
Bifidobacterium species at the 2nd and 3rd week of the study was also observed, 
such as Bifidobacterium breve and Bifidobacterium longum (Figures 41b, and 41c). 
Different Bifidobacterium spp. and strains are known to colonise infants, and to 
potentially cross-feed within the bifidobacterial community202. I thus hypothesise 
that initial colonisation of B. bifidum at the 1st week of life, may promote 
establishment of subsequent bifidobacterial colonisers.  
 
It is important to highlight that other bacterial taxa such as K. pneumoniae, E. coli, 
E. faecalis, and E. cloacae, which were found in high abundance in the non-
probiotic cohort, were all present at low levels (e.g.: <10% for Escherichia coli and 
<6% for Klebsiella pneumoniae), with the only exception of three infants in this 
cohort (P48, P60 and P42, Figures 41a and 41c).  
 
The probiotic cohort was also affected by the antibiotic treatment with increased 
levels of Staphylococcus and Escherichia (Figure 41a infants P48, P75, P76, P74, 
P65 and P63) and reduced levels of Bifidobacterium during the 1st week of the 
study. Despite this, the cohort had a predominance of Bifidobacterium throughout 
the study period, which suggested this genus was able to displace other potential 
pathogenic bacteria present in the NICU environment.  
 
Overall, these data suggest that empiric antibiotic treatment favours the growth of 
potential pathogenic bacteria (e.g. Staphylococcus, Escherichia and Klebsiella) in 
both probiotic and non-probiotic treated cohorts. The NICU environment alongside 
the antibiotic treatment influenced the preterm gut microbiome in the non-probiotic 
 133 
cohort, whilst the probiotic supplementation may provide colonisation resistance 
against pathogenic bacteria.  
 
 
Figure 41 Comparison of bacterial profiles analysed for supplemented probiotic 
cohort (antibiotic treated vs non-antibiotic)  
Relative abundance of each taxon was represented in percentage value, and bar 
colours represent different species found. Time points of study were classified as a) 
1st week of study, b) 2nd week of study and c) 3rd week of study. Asterisks represent 
























Figure X – Comparison of bacterial profiles analysed for supplemented probiotic cohort (antibiotic treated vs non antibiotic).
Relative abundance f each taxon was represented in pe centage v lue, and bar colour  represent different species found. Time points of 
study were classified as a) 1st week of study, b) 2nd week of study and c) 3rd week of study. More detailed information on the number of 




























































































Functional bacterial categories from the non-probiotic supplemented 
VLBW infants and probiotic supplemented VLBW infants were 
comparable 
Functional pathways were calculated using EggNOG which allows determination 
of the functional annotations from sequencing data. EggNOG uses clusters of 
orthologous groups (OGs), in this case homologous sequences that started 
diverging from the same speciation event, which are later on functionally annotated 
using phylogenetic methods203. When comparing the functional categories from the 
non-probiotic and probiotic cohort, I did not observe significant differences (Figure 
42), which was in contrast to the observed differences in taxonomic profiles, shown 
in the previous section (Figures 40 and 41). Four categories predominated among 
both study cohorts: “Energy production and conversion (C)”, “Amino-acid 
transport (E)”, “Carbohydrate transport (G)” and “Inorganic ion transport (P)” 
(Figure 43). It is interesting to highlight that there was a big proportion of 





Figure 42 EggNOG functional category analysis 
Results from EggNOG functional category analysis for a) study samples belonging 
to probiotic cohort, and b) study samples belong to non-probiotic cohort. All 





































































































































































































































































































































































































































































































































































































































































































A. RNA processing and modification 
B. Chromatin structure
J. Translation, ribosomal structure and biogenesis
K. Transcription
L. Replication, recombination and repair 
Cellular processes and signaling
D. Cell cycle control, cell division
M. Cell wall biogenesis
N. Cell motility
O. Post-translation modification
T. Signal transduction  mechanisms
U. Intracellular trafficking
V. Defense mechanisms









P. Inorganic ion transport
Q Secondary metabolites




Figure 43 Average of EggNOG functional categories for non-probiotic and probiotic 
cohorts 
The letters on the x-axes represent the different EggNOG categories. The legend on 
the right-hand side explains the details of the functional categories. 
 
Prevalence of antimicrobial resistance genes in the non-probiotic and 
probiotic cohort was similar 
The presence of antimicrobial resistance genes within the two study cohorts 
(probiotic and non-probiotic) was calculated by initially aligning the metagenomic 
contigs to the Comprehensive Antibiotic Resistance Database (CARD). This 
approach provided an overall picture of the antimicrobial resistance gene profiles 
from the probiotic and non-probiotic cohort. In total, 229 different AMR genes 
were detected for the non-probiotic cohort and probiotic cohort. The average 
number of AMR genes identified per infant in the non-probiotic cohort was 27 
(ranging from 0-70) and in the probiotic cohort was 17 (ranging from 1-56), see 
Table 10. These values indicate there is variability within the subject cohorts, 




Table 10 AMR genes detected in the study cohorts. Samples are classified according 
to study cohorts (probiotic and non- probiotic). Cells are colour coded using a colour 
scale for different cell values. 
 
 
Interestingly, the total AMR gene content, when comparing samples treated with 
and without antibiotics within each cohort (probiotic and non-probiotic), was not 
significantly different (Table 10). However, an overall comparison of the cohorts 
indicated that the total AMR content trended towards higher in the non-probiotic 
cohort than the probiotic cohort, although p-values were not significant (1st week p-
value =1, 2nd week p-value=0.398 and 3rd week p-value= 0.230). A higher number 
of infant samples would be needed to obtain a statistical significance.  
 
When AMR genes were grouped according to mechanism of action, these aligned 
to 22 different antibiotic classes. Table 11 summarises the number of AMR genes 
(normalised per number of infants tested) for each antibiotic class. This table 
highlights study cohorts (probiotic and non-probiotic supplemented) as well as time 
points of the study (1st week, 2nd week, and 3rd week). The most prevalent antibiotic 
classes included antibiotic efflux pumps (commonly found in many bacterial 
M39 M26 M37 M38 M15 M16 M17 M29 M36
1st week 0 9 13 61 2 17 16 19 10
2nd week 51 10 7 62 11 59 58 18 16
3rd week 62 15 22 57 11 61 69 14 19
M7 M59 M60 Q48 M40 M55 M103 M56 Q29
1st week 51 12 12 13 ND 7 60 11 16
2nd week 70 8 19 12 67 10 1 16 11
3rd week 9 12 17 25 67 ND 61 ND 7
P69 P74 P65 P75 P76 P63 P46 P48 P79 P80
1st week 16 8 19 19 12 11 12 42 3 ND
2nd week 16 47 13 13 13 9 9 23 2 25
3rd week 18 30 56 56 ND 1 9 13 ND 12
P60 P62 P77
1st week 14 12 ND
2nd week 14 4 14














































taxa205), aminoglycoside resistance genes (confer resistance to gentamicin), b-
lactamases (confer resistance to benzylpenicillin) and bacitracin resistance (a 
common antibiotic used for topical applications). Contrary to expectations, there 
was not a higher abundance of aminoglycoside and b-lactamase genes during the 
first week when infants were administered antibiotics. Notably, the preterm gut 
microbiome appears to be colonised with a higher number of bacterial 
species/strains at the end of the study, (i.e. week 2 to 3) than at the earlier stages 
(i.e. week 1). Thus, simple qualitative analysis of presence or abundance of AMR 
genes may be of limited use to fully assess these differences. 
 
Table 11 Antimicrobial resistance genes detected for probiotic and non-probiotic 
cohort. Numbers represent the average of AMR genes detected using CARD 
database divided by the number of premature infants included in each group. AMR 
genes are grouped according to mechanism of action. Cells are colour coded using a 




1st week 2nd week 3rd week 1st week 2nd week 3rd week
Aminoglycoside 1.6 0.8 0.1 1.2 1.4 2.1
Efflux pump 5.4 8.4 9.6 7.4 14.2 14.4
Isoleucyl-tRNA synthetase (ileS) 1.0 1.0 1.0 0.0 0.0 0.0
Bacitracin 1.6 2.8 3.9 1.7 6.4 6.4
beta-lactamase 0.4 1.2 1.2 1.6 2.0 2.9
Fosfomycin 0.1 0.1 0.0 0.4 0.3 0.7
Fusidic acid 0.8 0.2 0.2 0.4 0.2 1.0
Lincosamide 0.1 0.1 0.1 0.1 0.2 0.0
Macrolide 1.3 0.8 0.6 0.6 0.9 0.3
Methicillin 0.8 0.5 0.4 0.4 0.2 0.3
Rifamycin 0.3 0.8 0.0 0.3 1.3 1.4
Streptothricin acetyltransferase 0.1 0.0 0.0 0.1 0.2 0.0
Sulfonamide 0.3 1.2 1.6 0.7 2.7 2.2
Tetracycline 0.3 0.8 0.8 0.3 0.9 1.2
Trimethoprim 0.8 0.8 0.6 0.7 1.2 1.9
Bacterial porin 0.0 0.0 0.1 0.1 0.0 0.1
Defensin 0.0 0.0 0.1 0.0 0.0 0.0
Streptogramin vat transferase 0.0 0.0 0.1 0.0 0.0 0.0
Porin to beta-lactams 0.0 0.0 0.1 0.0 0.0 0.0
Quinolone 0.0 0.0 0.1 0.0 0.0 0.0
Vancomycin 0.0 0.0 0.0 0.2 0.1 0.0
Probiotic group No probiotic group
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Assigning antimicrobial resistance genes to specific taxa using the 
GROOT pipeline 
Although some differences in the total AMR gene abundance was detected within 
the study cohorts, it is clinically important to determine whether a pathogen or a 
commensal bacteria carries specific AMR genes. A new bioinformatic tool called 
GROOT developed by Dr Will Rowe was used to assign antimicrobial resistance 
genes to specific taxa. This approach combined variation graph representation of 
gene sets with a Locality Sensitive Hashing (LSH) indexing scheme206. The 
bioinformatic work performed in this part of the study was carried out by Dr Will 
Rowe.  
 
Tables 12 and 13 summarise the results obtained when running the metagenomic 
shotgun data from this study using the GROOT pipeline. Overall, potentially 
pathogenic bacteria found in the study samples (e.g. Staphylococcus spp, 
Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, and Streptococcus 
anginosus) were the main carriers of the AMR genes detected, and commensal taxa 
like Bifidobacterium did not carry AMR genes with the only exception being infant 
P62 (Table 12). Interestingly, all the potential pathogenic bacteria detected 
harbored resistance genes towards the empiric antibiotic treatment used in this 
study (i.e. b-lactamases and aminoglycosides). These data suggest the empiric 
antibiotic treatment used in this study may not protect VLBW infants from 
potential pathogens, and it may actually favor growth of those strains that are also 
multidrug resistance.  
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top genus % classified top species % classified
aac(6')-aph(2'')_1_M13771 Aminoglycoside Staphylococcus 84 haemolyticus 69
aph(3')-III_1_M26832 Aminoglycoside Staphylococcus 83 haemolyticus 53
blaZ_36_AJ400722 b-lactamase Staphylococcus 84 haemolyticus 58
mecA_10_AB512767 b-lactamase Staphylococcus 84 haemolyticus 53
mecA_15_AB505628 b-lactamase Staphylococcus 82 haemolyticus 53
mph(C)_2_AF167161 Macrolide antibiotic Staphylococcus 84 haemolyticus 58
aac(6')-aph(2'')_1_M13771 Aminoglycoside Enterococcus 32 faecalis 31
aph(3')-III_1_M26832 Aminoglycoside Enterococcus 32 faecalis 31
erm(B)_1_JN899585 tetracycline resistance Enterococcus 41 faecalis 39
erm(B)_12_U18931 tetracycline resistance Enterococcus 41 faecalis 40
mecA_10_AB512767 b-lactamase Staphylococcus 53 epidermis 24
mecA_15_AB505628 b-lactamase Staphylococcus 55 epidermis 24
fosB_4_CP000029 fosfomycin thiol transferase Staphylococcus 52 epidermis 30
mecA_10_AB512767 b-lactamase Staphylococcus 63 epidermis 18
tet(W)_4_AJ427422 tetracycline resistance Bifidobacterium 99 bifidum 92
erm(C)_13_M13761 Macrolide antibiotic - - - -
tet(M)_7_FN433596 tetracycline resistance - - - -
aac(6')-aph(2'')_1_M13771 Aminoglycoside - - - -
blaZ_35_AJ302698 b-lactamase - - - -
blaZ_36_AJ400722 b-lactamase Staphylococcus 100 - -
tet(K)_4_U38428 tetracycline resistance Staphylococcus 83 - -
tet(K)_5_J01764 tetracycline resistance Staphylococcus 100 - -
aac_6__-aph_2____1_M13771Aminoglycoside Staphylococcus 79 haemolyticus 74
blaZ_36_AJ400722 b-lactamase Staphylococcus 75 haemolyticus 31
erm_C__3_M17990 tetracycline resistance Staphylococcus 20 - -
erm_C__13_M13761 tetracycline resistance Staphylococcus 25 - -
fusB_1_AM292600 fusidic acid Staphylococcus 100 epidermis 40
mecA_10_AB512767 b-lactamase Staphylococcus 71 haemolyticus 23
mecA_15_AB505628 b-lactamase Staphylococcus 71 haemolyticus 23
mph_C__2_AF167161 tetracycline resistance Staphylococcus 75 haemolyticus 35
tet_K__4_U38428 tetracycline resistance Staphylococcus 100 - -
tet(K)_5_J01764 tetracycline resistance Staphylococcus 100 - -
mph(C)_2_AF167161 Macrolide antibiotic Staphylococcus 100 - -
mecA_15_AB505628 b-lactamase - - - -
mecA_10_AB512767 b-lactamase - - - -
ASSOCIATED TAXA






















Table 13 AMR genes detected for non-probiotic cohort using GROOT 
 
Validation of the GROOT pipeline 
To test the GROOT pipeline, an infant heavily colonised with Klebsiella was 
selected (infant M26); the gut microbiome of this infant was heavily populated 
with K. pneumoniae at 7 and 14 days (Figure 40a-b), while at 18 days (Figure 40c), 
this infant presented with three different populations of Klebsiella (K. pneumoniae, 
top genus % classified top species % classified
M26 1st week blaSHV-11 b-lactamase Klebsiella 67 pneumoniae 40
M26 2nd week blaSHV-11 b-lactamase Klebsiella 77 pneumoniae 59
blaSHV-11 b-lactamase Klebsiella 78 pneumoniae 66
blaSHV-40 b-lactamase Klebsiella 78 pneumoniae 65
blaSHV-79 b-lactamase Klebsiella 77 pneumoniae 65
aadA1 Aminoglycoside Escherichia 97 coli 54
mphA Macrolide antibiotic Escherichia 95 coli 56
sul2 Sulfonamide antibiotic Escherichia 100 coli 67
dfrA1 Trimethoprim resistance Escherichia 97 coli 58
blaTEM-95 b-lactamase Escherichia 95 coli 56
tetB Tetracycline resistance Escherichia 90 coli 53
aadA1 Aminoglycoside Escherichia 97 coli 54
blaTEM-95 b-lactamase Escherichia 95 coli 56
drfA1 Trimethoprim resistance Escherichia 97 coli 58
mphA Macrolide antibiotic Escherichia 95 coli 57
sul2 Trimethoprim resistance Escherichia 100 coli 75
tetB Tetracycline resistance Escherichia 90 coli 54
aac6-aph2 Tetracycline resistance Staphylococcus 70 haemolyticus 64
ermC Tetracycline resistance Staphylococcus 50 haemolyticus 36
mecA b-lactamase Staphylococcus 66 haemolyticus 57
mphC Macrolide antibiotic Staphylococcus 76 haemolyticus 72
tetM Tetracycline resistance Enterococcus 98 faecalis 85
mecA b-lactamase
tetW Tetracycline resistance Bifidobacterium 100 breve 35
blaOXY-1 b-lactamase Klebsiella 94 LTGPAF-6F 14
tetW Tetracycline resistance Bifidobacterium 95 breve 34
aac6-aph2 Tetracycline resistance Staphylococcus 42 epidermis 18
blaZ-36 b-lactamase Staphylococcus 97 epidermis 18
fusB fusidic acid
aac6-aph2 Aminoglycoside
blaOXY-6 beta lactamase Klebsiella 33 pneumoniae 11
ermA Lincosamide  resistance Streptococcus 88 anginosus 58
tetO Tetracycline resistance Streptococcus 86 anginosus 38
blaTEM-95 b-lactamase Escherichia 62 coli 51
lnuB Lincosamide  resistance Enterococcus 98 faecalis 49
str1 Streptomycin resistance Enterococcus 98 faecalis 49
tetB Tetracycline resistance Escherichia 62 coli 57
dfrG Trimethoprim resistance Enterococcus 99 faecalis 99
cat5 chloramphenicol resistance Enterococcus 98 faecalis 49
ermB Macrolide antibiotic Enterococcus 98 faecalis 50
ermB Macrolide antibiotic Enterococcus 98 faecalis 51
str1 Streptomycin resistance Enterococcus 98 faecalis 49
aph3-III Aminoglycoside Enterococcus 98 faecalis 50
ant6-Ia Aminoglycoside Enterococcus 98 faecalis 51
dfrG Trimethoprim resistance Enterococcus 98 faecalis 96
tetB Tetracycline resistance Enterococcus 62 faecalis 57























K. oxytoca and K. unclassified). When running GROOT analysis on this infant, 
week 1 and week 2 associated K. pneumoniae encoded the blaSHV-11 allele, and 
at week 3, alleles blaSHV-11 blaSHV-40 and blaSHV-79 were present (Table 13). 
The difference between these three alleles is only five nucleotides, and notably 
blaSHV-40 has been shown to confer extended spectrum b-lactamase activity, 
whereas blaSHV-11 and blaSHV-79 have not207.  
 
To validate these results, five isolates of K. pneumoniae were isolated from these 
samples, and their antibiotic resistance phenotypes studied. The Minimal Inhibitory 
concentrations (MICs) against a common first line b-lactam antibiotic used in 
NICUs (benzylpenicillin), and meropenem, which is used in NICUs on suspicion 
of infection with Enterobacteriaceae with extended spectrum b-lactamase 
activity208 were obtained (Table 14). The MIC values for the five K. pneumoniae 
isolates against benzylpenicillin (30,000 mg/L) indicated this antibiotic is 
inefficient in killing, which was expected as all these isolates carried the blaSHV-
11 allele. MIC values using meropenem were also calculated and results were all 
above the epidemiological cut off set up by Eucast (http://www.eucast.org/), which 
suggested all isolates may display extended b-lactamase activity.  
 
Table 14 MICs of Klebsiella pneumoniae isolates 
 
 Isolate 



















Benzylpenicillin 30,000 30,000 30,000 30,000 30,000 




Isolation and validation of AMR strains detected by the GROOT 
pipeline  
 
To further validate the GROOT pipeline it is necessary to phenotypically test other 
potential AMR species/strains detected by GROOT in the study samples. 
Enterococcus, Enterobacter, Escherichia, and Staphylococcus are commonly found 
in the gut microbiome of VLBW infants. A number of these species such as 
Staphylococcus aureus, Klebsiella pneumoniae, and Enterococcus faecium are 
classified as ‘ESKAPE pathogens’, which have become a significant burden in 
hospitals, due to multi-drug resistance209.  
 
In preparation for this analysis I performed bacterial isolations from a 
representative subset of samples included in this study. Table 15 presents a 
summary of all the bacterial isolates I obtained and its corresponding identification 
using sequencing of their full 16S rRNA gene. Further work characterising the 
genomes and AMR gene carriage of these isolates, using whole genome 
sequencing approaches, is required to verify the assignment of AMR genes using 




Table 15 Bacterial isolates from a subset of VLBW infants included in this study and 







# Blast result (16S RNA gene sequence) 
P74C 
6 1 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
6 2 Escherichia fergusonii strain ATCC 35469 16S ribosomal RNA, complete sequence 
6 3 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
6 4 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
6 5 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
6 6 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
6 7 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
P74G 
23 1 Enterococcus faecalis strain NBRC 100480 16S ribosomal RNA gene, partial sequence 
23 3 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
23 4 Shigella sonnei strain CECT 4887 16S ribosomal RNA gene, partial sequence 
23 5 Escherichia fergusonii strain ATCC 35469 16S ribosomal RNA gene, partial sequence 
23 6 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
23 7 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
23 1 Bif Bifidobacterium breve strain DSM 20213 16S ribosomal RNA gene, partial sequence 
23 8 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
23 9 Staphylococcus epidermidis strain 21.1 16S ribosomal RNA gene, partial sequence 
P75B 
5 1 Bifidobacterium breve strain DSM 20213 16S ribosomal RNA gene, partial sequence 
5 7 Staphylococcus capitis strain ATCC 27840 16S ribosomal RNA gene, partial sequence 
5 9 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
P75F 
24 5 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
24 2 Escherichia fergusonii strain ATCC 35469 16S ribosomal RNA gene, partial sequence 
24 6 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
24 7 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
24 8 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
24 2 Bifidobacterium bifidum strain PRI 1 chromosome, complete genome 
20 4 Enterobacter xiangfangensis strain 10-17 16S ribosomal RNA gene, partial sequence 
P77L 
20 12 Staphylococcus haemolyticus strain JCM 2416 16S ribosomal RNA gene, partial sequence 
20 2 Enterococcus faecalis strain NBRC 100480 16S ribosomal RNA gene, partial sequence 
20 5 Enterococcus faecalis strain NBRC 100480 16S ribosomal RNA gene, partial sequence 
20 2 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
20 1 Enterobacter cloacae strain ATCC 13047 16S ribosomal RNA gene, partial sequence 
20 7 Enterobacter cloacae strain ATCC 13047 16S ribosomal RNA gene, partial sequence 
P77L 20 3 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
P62J 
18 1 Bifidobacterium bifidum strain 1579 16S ribosomal RNA gene, partial sequence 
18 2 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
18 3 Bif Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
18 3 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
18 4 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
18 A Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
18 6 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
18 5 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
18 B Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
P62C 
7 A Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
7 2 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
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7 3 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
7 C Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
7 D Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
7 B Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
P60L 
17 1 Bif Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
17 2 Enterobacter xiangfangensis strain 10-17 16S ribosomal RNA gene, partial sequence 
17 1 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
17 4 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
17 5 Staphylococcus aureus strain S33 R 16S ribosomal RNA, complete sequence 
17 6 Staphylococcus aureus strain S33 R 16S ribosomal RNA, complete sequence 
17 7 Staphylococcus aureus strain S33 R 16S ribosomal RNA, complete sequence 
17 8 Enterococcus faecalis strain NBRC 100480 16S ribosomal RNA gene, partial sequence 
17 9 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
P60F 
5 1 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
5 2 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
5 3 Bifidobacterium longum subsp. suillum strain Su 851 16S ribosomal RNA, partial sequence 
M26 
7 
7 1 Klebsiella pneumoniae strain QLR-3 16S ribosomal RNA gene, partial sequence 
7 2 Klebsiella pneumoniae strain QLR-3 16S ribosomal RNA gene, partial sequence 
M26 
18 
18 1 Klebsiella pneumoniae strain QLR-3 16S ribosomal RNA gene, partial sequence 
18 2 Klebsiella pneumoniae strain B-3-4 16S ribosomal RNA gene, partial sequence 
18 3 Klebsiella pneumoniae strain B-3-4 16S ribosomal RNA gene, partial sequence 
18 4 Klebsiella pneumoniae strain B-3-4 16S ribosomal RNA gene, partial sequence 
M7 8 
8 1 Enterococcus sp. H184 16S ribosomal RNA gene, partial sequence 
8 2 Escherichia coli strain noha905 16S ribosomal RNA gene, partial sequence 
8 2 bif Bifidobacterium breve strain DSM 20213 16S ribosomal RNA gene, partial sequence 
8 4 Enterococcus faecalis strain NBRC 100480 16S ribosomal RNA gene, partial sequence 
8 3 Enterococcus sp. H185 16S ribosomal RNA gene, partial sequence 
M7 
21 
21 1 Klebsiella michiganensis strain W14 16S ribosomal RNA gene, partial sequence 
21 2 Klebsiella sp. SI-AL-1B 16S ribosomal RNA gene, partial sequence 
21 3 Klebsiella michiganensis strain W14 16S ribosomal RNA gene, partial sequence 
21 7 Bifidobacterium breve strain DSM 20213 16S ribosomal RNA gene, partial sequence 
M16 
18 
18 1 Klebsiella pneumoniae strain DSM 30104 16S ribosomal RNA gene, partial sequence 
18 2 Klebsiella pneumoniae strain DSM 30104 16S ribosomal RNA gene, partial sequence 
18 3 Klebsiella pneumoniae strain DSM 30104 16S ribosomal RNA gene, partial sequence 
P48C 
8 1 Bifidobacterium animalis subsp. lactis strain YIT 4121 16S ribosomal RNA gene, partial sequence 
8 2 Bifidobacterium bifidum strain NBRC 100015 16S ribosomal RNA gene, partial sequence 
8 3 Bifidobacterium bifidum strain PRI 1 chromosome, complete genome 
M59 
22 
22 1 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
22 1 Bifidobacterium animalis subsp. lactis strain YIT 4121 16S ribosomal RNA gene, partial sequence 
22 4 Bifidobacterium bifidum strain PRI 1 chromosome, complete genome 
22 2 Bifidobacterium animalis subsp. lactis strain YIT 4121 16S ribosomal RNA gene, partial sequence 
22 8 Klebsiella oxytoca strain JCM1665 16S ribosomal RNA gene, partial sequence 
22 5 Enterobacter cloacae strain ATCC 13047 16S ribosomal RNA gene, partial sequence 
22 4 Enterococcus faecalis strain NBRC 100480 16S ribosomal RNA gene, partial sequence 
22 7 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 
22 3 Enterococcus saigonensis strain VE80 16S ribosomal RNA, partial sequence 
22 2 Enterococcus faecalis strain NBRC 100480 16S ribosomal RNA gene, partial sequence 
M38 
20 22 2 Bifidobacterium breve strain DRBB29 chromosome, complete genome 
M39 
22 
22 2 Staphylococcus epidermidis strain NBRC 100911 16S ribosomal RNA gene, partial sequence 




Premature infants, and in particular VLBW infants (<1.5 kg) are often administered 
empiric antibiotic treatment during the first week of life because they are extremely 
vulnerable to bacterial infections. Approximately 78%-87% of VLBW infants 
receive antibiotics within the first three days of life210, however, antibiotic 
treatment may affect the early stages of the developing host-microbiome 
ecoystem49, and consequently impact on long-term health outcomes. Some 
Neonatal Intensive Care Units (NICUs) have started to administer probiotic 
supplementation to modify the preterm gut microbiome, as studies have shown this 
reduces the incidence of bacterial sepsis and necrotising enterocolitis138, 168. To 
date, very few studies have evaluated the short-term effects of antibiotics on the 
VLBW infant gut microbiome, side by side with the effect of probiotic 
supplementation on the overall antimicrobial resistance carriage.  
 
This study represents one of the few longitudinal studies including VLBW infants 
(34 recruited and 95 stool samples), where antibiotic regimes were matched from 
two different study cohorts (with and without probiotic supplementation). All the 
infants in this study were born before the 33st week of gestation, weighed less than 
<1.5 kg, were mostly breastfed and born by C-section. One of the novelties of this 
study is that it comprises antibiotic-naïve premature infants who did not receive 
any antibiotic treatment (n=16 infants). Moreover, this is the first clinical 
premature study to also include this number of VLBW infants receiving no 
antibiotic treatment. Previous published studies have included fewer premature 
infants with no exposure to antibiotics (only two (1)204, and three (2)211) and 
crucially antibiotic regimes were not matched. Because of the difficulties in 
obtaining antibiotic-naïve VLBW infants, previously published research studies 
have used healthy term infants or late-premature infants (born at 36 weeks 
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gestation)212 whose gut maturation and NICU residency is very different to that of 
an VLBW infant. 
 
To understand the short-term effects associated with empiric antibiotic treatment 
and whether this contributes to enhance gut antimicrobial resistance carriage, 
whole-metagenome shotgun sequencing was performed on all study samples. By 
week 1 of the study, there was an increase of Escherichia coli and Staphylococcus 
spp in both study cohorts and a proliferation of Klebsiella spp and Enterococcus 
faecalis in the non-probiotic cohort. Notably, antibiotic treatment is known to 
increase Enterobacteriaceae 212 (e.g. Escherichia and Klebsiella) abundance and 
enhance the presence of multidrug-resistance bacteria213. As such, the results from 
this study concords with previous published studies, where Enterobacteriaceae and 
Enterococcaceae populations have been described as predominant populations in 
the preterm microbiome during the first month of life. Klebsiella spp, Escherichia 
coli, Enterococcus faecalis and Staphylococcus spp are common sepsis pathogens 
in VLBW infants214-216 and their presence in the preterm gut could predispose the 
at-risk premature infant to a bacterial infection.  
 
Interestingly, the results from the microbial functional analysis (Figure 43) did not 
show great differences among study individuals nor between study cohorts. This 
finding suggest that the main microbial functions remain conserved across hosts, 
despite the taxonomic perturbation observed by the antibiotic treatment. Enteric 
bacterial pathogens are known to impact three major physiological functions of the 
intestinal epithelium via various specific virulence factors: (i) disruption of the 
tight junction barrier (e.g. secreting proteases), (ii) dysregulation of intestinal ion 
transporters, and (iii) activation of the inflammatory response in the gastrointestinal 
mucosa217, 218. I hypothesize that greater variation in microbial functional pathways 
(and identification of virulence factors) will be found if the functional pathways 
were studied at a deeper level. 
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This study showed that alongside antibiotic treatment influencing the preterm gut 
microbiome, the NICU environment also plays an important role, especially in 
premature infants who did not receive probiotic supplementation. It is well known 
that hospital environments represent a reservoir of potential pathogens, in 
particular those who possess multidrug resistance to antibiotics. Staphylococcus 
aureus, Enterobacteriaceae (e.g. Escherichia coli, Klebsiella pneumoniae), 
Acinetobacter baumannii and Pseudomonas aeruginosa are some of the most 
common hospital-related pathogens characterised by having potential multidrug 
resistance mechanisms219, 220. All non-supplemented premature infants presented 
elevated levels of pathobionts (e.g. Klebsiella spp, Escherichia coli and 
Staphylococcus spp) in their gut until the very end of the study period (week 3) 
regardless of whether they received antibiotic treatment or not. This observation 
supports the notion that colonisation of the preterm gut by pathobionts is not only 
related to antibiotic treatment; the NICU environment also influences the preterm 
microbiome. In contrast, in the case of probiotic supplemented infants there was a 
predominance of Bifidobacterium spp. (Figure 41) in infants treated with and 
without antibiotic. Similar results were found in a preterm research study194 using 
the same probiotic supplementation; which showed a 64% relative abundance of 
Bifidobacterium from week 1 of the study. These results suggest that daily 
probiotic supplementation may induce colonisation resistance against hospital-
related pathogens and may facilitate a quicker recovery of the preterm gut 
microbiome after antibiotic treatment. Colonisation resistance of Bifidobacterium 
against common intestinal pathogens has been reported previously in in-vitro 
studies using different mechanisms: (i) synthesising antimicrobial products which 
impaired adhesion of Clostridioides difficile to enterocytes 221or (ii) producing 
acetate which improved the integrity of the epithelial barrier and reduced 
translocation of E. coli toxins176. 
 
Surprisingly, the total AMR content between infants treated with antibiotics and 
non-treated infants (probiotic and no probiotic) was not significantly different 
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(Table 10). However, this does correspond with the taxonomic profiles within the 
study cohorts, which are also similar (Figure 40 and Figure 41). This suggests that 
the gut antibiotic resistome may not only be established by antibiotic treatment; the 
colonisation of pathobionts from the NICU environment may also influence this 
outcome. Contrary to expectation, infants treated with empiric antibiotic treatment 
(penicillin and gentamicin) did not have a higher number of specific AMR genes 
against this treatment if week 1 is compared to week 2 and 3 (Table 11), which 
supports this latter statement.  
 
When comparing the AMR content of probiotic supplemented infants and non-
supplemented, the non-supplemented cohort had a higher number of AMR genes 
(Table 10) although the p-values did not show significance. A higher number of 
samples would be required to evaluate robustly whether the non-probiotic infants, 
containing higher levels of pathobionts in their gut, contained a higher AMR gene 
content. A similar study involving 66 premature infants was not able to find 
differences among the total AMR content when benchmarking probiotic and non-
probiotic premature infants194, which agrees with our findings. 
 
Even though the bioinformatics approach using the CARD database provided 
insight into the overall AMR gene content, a specific bioinformatic tool which 
could associate specific AMR genes to specific taxa was needed. One of the most 
relevant questions clinically is to determine whether a pathogen or a commensal 
bacterium is the carrier of specific AMR genes. GROOT was used in collaboration 
with Dr Will Rowe, to assign antimicrobial resistance genes to specific taxa. This 
approach successfully managed to associate most of the AMR genes detected to 
potential pathogenic bacteria (i.e. Staphylococcus spp, Enterococcus faecalis, 
Escherichia coli, Klebsiella pneumoniae, and Streptococcus anginosus). All these 
potential pathogens harbored resistance genes towards the empiric antibiotic 
treatment used in this study (i.e. b-lactamases and aminoglycosides), while none of 
the commensal bacteria were assigned AMR genes with the exemption of only one 
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infant. One of the main concerns regarding the use of prolonged empirical 
antibiotic therapy is that it perturbs the colonisation of the beneficial bacteria222. 
This data showed that the empiric antibiotic treatment used in this study was 
facilitating the growth of these potential pathogens and preventing the growth of 
commensal bacteria which normally do not encode AMR genes. 
 
Finally, the use of the GROOT pipeline highlighted specific information regarding 
the antimicrobial activity of the AMR genes detected. GROOT was able to 
associate an extended spectrum b-lactamase activity (blaSHV-40) to pathogenic K. 
pneumoniae from shotgun metagenomic data. This finding was validated 
phenotypically (Table 14). Further work will be needed to determine the 
applicability of this bioinformatic pipeline against other potential AMR 
species/strains (e.g. Staphylococcus, Enterobacter, Enterococcus or Escherichia) 
commonly found in the gut microbiome of VLBW infants. Whole-genome 
sequence of 96 bacterial isolates (Table 15) was prepared in order to examine 
whether the AMR genes detected using GROOT and metagenome data were also 
found in the genomes of these isolates. Phenotypic validation is also planned after 




The taxonomic analyses indicated clear differences between study cohorts (non-
probiotic and probiotic supplemented). Antibiotic treatment had a transient effect 
on the preterm gut microbiome, especially for VLBW infants not receiving 
probiotic supplementation. Probiotic supplemented VLBW infants had a higher 
relative abundance of Bifidobacterium throughout the study period, which may 
induce colonisation resistance against hospital-related pathogens.  
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The total AMR content within the two study cohorts did not significantly influence 
the AMR gene categories detected, nor their abundance. The use of the GROOT 
pipeline allowed most of the AMR genes detected to be associated with the 
potential pathogenic bacteria detected (i.e. Staphylococcus spp, Enterococcus 
faecalis, and Escherichia coli), while commensal bacteria did not carry AMR 
genes. This suggest empiric antibiotic treatment was not effective against these 
pathogens and may only be favoring the colonisation of these bacteria in the 
vulnerable preterm gut. 
 
More personalised antibiotic regimes should be used to treat VLBW infants, and 





Future plans for this study include continuation of analysis for another subset of 
VLBW infants heavily populated with other potential pathogenic bacteria such as 
Enterococcus, Enterobacter, Escherichia, and Staphylococcus, and to determine if 
the GROOT pipeline can robustly be applied to in-depth AMR analysis of shotgun 
metagenomic datasets. To further validate this data, whole genome sequencing of 
the bacterial isolates has been planned to verify whether the AMR genes found in 
the shotgun data using GROOT are also encoded with the genomes. 
 
I believe that to be able to administer more personalised antibiotic treatments will 
require faster microbial diagnosis methods. This idea forms the basis for the study 
described in the following Chapter, where MinION Nanopore technology was used 
to rapidly profile the preterm microbiome and resistome of premature infants 
suffering from sepsis. 
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To complement this study, I would include metabolomic analysis of the study 
samples. Alterations in the gut microbial populations may change the intra-
community metabolic interaction, and influence host metabolic, hormonal and 
immune homeostasis. Administration of antibiotic therapy in young mice has been 
associated with substantial increases in SCFAs (e.g. acetate, propionate and 
butyrate in the caecal contents), which, when delivered in increased quantities 
through the blood circulation to the liver, enhanced the production of fat223. The 
timeframe of this study is relatively short, but as the taxonomic profiles from the 
two study cohorts were very different, I hypothesise their metabolomic profiles 





Title: Rapid diagnostics of the preterm gut microbiome using MinION 
Nanopore technology for monitoring microbiota intervention strategies, and 
antibiotic resistance profiles 
 
Abstract 
MinION nanopore technology is an exciting new sequencing platform that offers 
the possibility of long reads that can be analysed in real time. These features, plus 
the compact and portable nature of this platform makes the MinION an attractive 
sequencing technology that can be applied to the field of microbiome monitoring 
and rapid clinical diagnostics. The work presented here demonstrates how MinION 
technology can be used to rapidly profile faecal samples from premature infants; to 
monitor colonisation of probiotic strains, and to profile samples obtained from 
infants suffering from sepsis or necrotising enterocolitis (NEC). Initially, the 
MinION technology was validated using a mock microbial community, and 
relevant clinical samples from the same infant were analysed at different time 
points, with benchmarking against Illumina technology. Next steps involved 
demonstration of how MinION technology can be used in clinical settings; utilising 
MinION technology to diagnose bacterial pathogens and antimicrobial resistant 
(AMR) profiles of premature infants suffering from NEC. Finally, a ‘real-time’ run 
was performed which involved timing all stages, from sample preparation, 
sequencing, to downstream real time analysis, which culminated in a <5h 
determination of the pathogenic bacteria and corresponding AMR profiles. 
Bacterial isolation of the bacterial pathogen and phenotypic antibiotic testing using 
Minimal Inhibitory Concentration (MIC) was performed to validate the MinION 
results.  
 






Figure 44 Graphical abstract summarising study pipeline 
This study aims to use MinION technology to profile faecal samples from healthy and 
critically ill premature infants. The work had several stages: a) Sequencing a microbial 
mock community using MinION and Illumina, b) Setting up conditions for MinION 
technology and testing flowcells R7.3 and R9.4 c) Diagnosing taxonomic and AMR 
profiles from premature infants with suspected NEC d) Performing a ‘real time’ run with 
a NEC infant where all the stages of the pipeline were timed. Bacterial isolation of the 
bacterial pathogen and phenotypic antibiotic testing using Minimal Inhibitory 
Concentration (MIC) was performed to validate the MinION findings 
a
b Monitoring disturbances in the preterm microbiota using MinION technology  
Sequence a mock community control using MinION and Illumina MiSeq
. Rapid diagnostic using MinION technology for preterms clinically diagnosed with suspected NEC
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Assessing sequencing depth with two preterms diagnosed with NEC (R9.4 flow cells) at 1h and 6h
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Authors’ contribution to this work 
The completion of this large and multi-disciplinary study has been in close 
collaboration with Dr Richard Leggett at Earlham Institute. I was involved in the 
design of the study and took the lead on selecting samples for the study, extracting 
DNA, analysing and graphing the data. Dr Richard Leggett developed the bespoke 
NanoOK RT MinION pipeline and carried out bioinformatics analysis. This work 
has been accepted in Nature Microbiology and I am joint first author with Dr 
Richard Leggett. Specific details of authors’ contributions can be found in the 
method section of this chapter. 
 
Introduction 
High throughput next generation DNA/RNA sequencing (NGS) platforms have 
revolutionised our ability to drive forward genomics research. Within the context 
of studying complex microbial communities, NGS has opened culture-independent 
and rapid profiling of samples in both environmental and clinical settings using 
both short-read sequencing (e.g. Illumina) and long-read (e.g. Pacific Biosciences 
(PacBio), and Oxford Nanopore Technologies).  
 
Current NGS platforms are expensive, and often occupy a large footprint, which 
makes their usage challenging to apply in the field or clinic. Notably, Oxford 
Nanopore Technologies released the MinION device in 2014, a pocket-sized 
Nanopore sequencing platform capable of producing sequencing runs similar to 
Illumina and PacBio. This portable and low-cost technology has the advantage that 
it can be used at the point of care, and it offers real-time sequencing224 therefore 
results are available in a matter of hours.  
 
One at-risk patient cohort who can benefit from this technology are premature 
infants. Premature infants are at high risk of acquiring bacterial infections (i.e. 
sepsis) and life threatening diseases (i.e. necrotising enterocolitis (NEC)) due to 
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their immature immune system225, underdeveloped gut physiology226 and long 
residency in the hospital environment (see Introduction Chapter). Furthermore, 
these infants often receive early and extended courses of antibiotic treatment 
during their stay at the neonatal intensive care unit (NICU), which significantly 
alters their gut microbiome and promotes the growth of multidrug-resistant 
bacteria. In recent years, some NICUs have introduced probiotic supplementation 
using common early life gut colonisers (e.g. Bifidobacterium and Lactobacillus) as 
microbiota therapies195, 227 to prevent premature infants acquiring gut bacterial 
infections. Therefore, these at-risk premature infants represent an important cohort 
for developing and optimising advances in microbial detection platforms. The fast 
turnaround time and long-read genomic data provided by MinION technology, 
could contribute to early patient diagnosis by identifying bacterial taxonomic 
profiles and antibiotic resistance genes in a timely fashion. 
 
This work demonstrates the ‘real-world’ utility of the MinION platform in the 
analysis of whole genome shotgun of metagenomic samples (i.e. faeces) from at 
risk premature infants. This study involved the development of a bespoke software 
(i.e. NanoOK RT) able to provide bacterial metataxonomic profiles and associate 
its antimicrobial resistance genes. Firstly, a 20 species human microbiome mock 
community was used to prove nanopore metagenomic data can be classified 
reliably and rapidly. Secondly using DNA from 3 different time points of one 
patient spanning 2 clinical interventions, the study captured the complete diversity 
of the immature gut microbiome and the dynamics it undergoes over time. 
Sequencing of these samples was paired with Illumina platform, and demonstrated 
identical taxonomic profiles and no significant bias in the nanopore sequencing. 
Thirdly, the MinION pipeline developed here was tested profiling samples from 
two healthy premature infants and two critically ill premature infants diagnosed 
with NEC. Finally, a ‘real-time’ run was performed which involved timing all 
stages of the pipeline and culminated in a less than 5h determination of the 
pathogenic bacteria and corresponding AMR profiles. Bacterial isolation of the 
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bacterial pathogen and phenotypic antibiotic testing were used to validate the 
findings. Results demonstrated MinION sequencers offer the ability to progress 
from clinical samples to tailored patient antimicrobial treatment in a few hours.  
 
Hypothesis and aims 
Hypothesis: The MinION nanopore sequencer will be able to profile rapidly faecal 
samples from premature infants to obtain bacterial metataxonomic profiles and 
characterise their antibiotic resistance profiles. 
 
The study involved four aims/sub-sections: 
i) Sequencing a bacterial mock community to evaluate the accuracy of 
MinION technology for metagenomic sample profiling and 
benchmarking results with Illumina sequencing. 
ii) Performing a longitudinal study using samples from the same patient, 
to test whether MinION technology can monitor microbial 
disturbances (e.g. antibiotic treatment, or probiotic supplementation) in 
the preterm gut microbiome and resistome. 
iii) Using a bespoke software (NanoOK RT pipeline developed by Dr 
Richard Leggett) to rapidly profile faeces from critically ill premature 
infants, to test if turnaround time is comparable to other rapid 
molecular tests used in the clinic. 
iv) Whole genome sequencing and phenotypic testing of one of the 
bacterial pathogens detected in this study, to validate the 
metataxonomic and resistome profiles obtained using MinION 




Genomic DNA from mock community 
Genomic DNA from a microbial mock community was used (HM-277D, BEI 
Resources, Manassas, VA). This mock community contained a mixture of 20 
bacterial strains. Details of the strains present in the mock community along with 
their concentrations are indicated in the table below.  
 
Table 16 Bacterial strains present in the microbial mock community (HM-277D, BEI 
Resources) 
Organism NCBI Reference Sequence 
Number of 
operons Concentration 
Acinetobacter baumannii, strain 5377 NC_009085 100,000 82 pg/ul 
Actinomyces odontolyticus, strain 1A.21 NZ_AAYI02000000 10,000 10 pg/ul 
Bacillus cereus, strain NRS 248 NC_003909 1,000,000 450 pg/ul 
Bacteroides vulgatus, strain NCTC 11154 NC_009614 10,000 7.6 pg/ul 
Clostridium beijerinckii, strain NCIMB 8052 NC_009617 1,000,000 440 pg/ul 
Deinococcus radiodurans, strain R1 (smooth) NC_001263 10,000 10 pg/ul 
Enterococcus faecalis, strain OG1RF NC_017316 10,000,000 7 pg/ul 
Escherichia coli, strain K12, substrain MG1655 NC_000913 10,000,000 6.8 ng/ul 
Helicobacter pylori, strain 26695 NC_000915 100,000 86 pg/ul 
Lactobacillus gasseri, strain 63 AM NC_008530 100,000 32 pg/ul 
Listeria monocytogenes, strain EGDe NC_003210 100,000 50 pg/ul 
Neisseria meningitides, strain MC58 NC_003112 100,000 58 pg/ul 
Propionibacterium acnes, strain KPA171202 NC_006085 100,000 88 pg/ul 
Pseudomonas aeruginosa, strain PAO1-LAC NC_002516 1,000,000 1.6 ng/ul 
Rhodobacter sphaeroides, strain ATH 2.4.1 NC_007493 10,000,000 14 ng/ul 
Staphylococcus aureus, strain TCH1516 NC_010079 1,000,000 590 pg/ul 
Staphylococcus epidermidis, FDA strain PCI 1200 NC_004461 10,000,000 5.1 ng/ul 
Streptococcus agalactiae, strain 2603 V/R NC_004116 1,000,000 32 pg/ul 
Streptococcus mutans, strain UA159 NC_004350 10,000,000 4.1 ng/ul  
Streptococcus pneumoniae, strain TIGR4 NC_003028 10,000 5.5 pg/ul 
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Illumina sequencing of mock community 
DNA was sheared (600ng) in a 60 µl volume on a Covaris S2 (Covaris, 
Massachusetts, USA) for 1 cycle of 40 s with a duty cycle of 5%, cycles per burst 
of 200 and intensity of 3. Illumina paired end libraries were constructed with 
inserts spanning from 600 bp to >1000 bp. Sheared DNA was then end-repaired 
using the NEB End Repair Module (NEB, Hitchin, UK), size selected with a 0.58 x 
Hi Prep bead clean-up (GC Biotech, The Netherlands) and followed by A tailing 
using the NEB A tailing module (NEB) and ligation of adapters using the NEB 
Blunt/TA Ligase Master Mix (NEB). Three 1x bead clean-ups were then 
undertaken to remove all traces of adapter dimers. DNA was then assessed by 
running an Agilent BioAnalyser High Sensitivity chip and quantified using the 
Kappa qPCR Illumina quantification kit. Finally, based on the qPCR results 9 pM 
DNA was sequenced on an Illumina MiSeq with 300 bp paired reads. This work 
was done in collaboration with Dr Darren Heavens at Earlham Institute. 
 
MinION sequencing of mock community 
A total of 1 µg of DNA was fragmented in a 46 µl volume in a Covaris G-tube 
(Covaris, Massachusetts, USA) at 6,000 rpm in an Eppendorf centrifuge 5417. 
MinION 2D libraries were prepared targeting inserts bigger than 8 kbp. Sheared 
DNA was then subjected to a repair step using the NEB FFPE repair mix (NEB, 
Hitchin, UK) and purified with a 1x Hi Prep bead clean-up (GC Biotech, Alphen 
aan den Rijn, The Netherlands). The repaired DNA was then end-repaired and A-
tailed using the NEBNext Ultra II End Repair and A-Tailing Module (NEB), 
purified with a 1x Hi Prep bead clean-up and then the AMX and HPA MinION 
adapters ligated using the NEB Blunt/TA Ligase Master Mix (NEB). An HP tether 
was then added and incubated for 10 min at room temperature followed by 10 min 
room temperature incubation with an equal volume of pre-washed MyOne C1 
beads (Thermo Fisher, Cambridge, UK). The library bound beads were washed 
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twice with bead binding buffer (ONT) before the final library eluted via a 10 min 
incubation at 37 ºC in the presence of the MinION Elution Buffer. The final library 
was then mixed with running buffer, fuel mix and nuclease free water and loaded 
onto an R7.3 flowcell following the manufacturer’s instructions. Sequencing data 
was collected for 48 h. Dr Darren Heavens performed the laboratory analysis, Dr 




Ethical approval and sample collection 
Subject recruitment for this study was approved by The Ethics Committee of the 
Faculty of Medical and Health Sciences in the University of East Anglia (Norwich, 
UK). Faeces collection protocol was in accordance with the Norwich Research 
Park (NRP) Biorepository Human Tissue Act 2004 (HTA, license number 11208). 
Recruitment of infants admitted to the Neonatal Intensive Care Unit (NICU) of the 
Norfolk and Norwich University Hospital (NNUH, Norwich, UK) was done by 
doctors or nurses with informed and written consent obtained from parents. All 
infants recruited in this study received oral probiotic supplementation containing 
Bifidobacterium bifidum and Lactobacillus acidophilus (i.e. Infloran®, Desma 
Healthcare, Switzerland) strains with a daily dose of 2 x 109 of each species. 
Collection of faecal samples was carried out by researchers and stored at -80 °C 
prior to DNA extraction.  
 
Clinical details of all the premature infants recruited for this study are detailed in 
the diagrams below. Figure 45 contains clinical details for the healthy premature 





Figure 45 Timeline diagrams for healthy premature infants (P106, P116, P103) 
Timeline diagrams indicating time points of faecal sample collection, duration of 
antibiotic, probiotic treatment, and relevant clinical observations. The timeline 
diagrams are divided in weeks and dots represent days within the scale. Blue dots 
indicate days of probiotic treatment, red dots antibiotic treatment, and black squares 
time points for sample collection. (a) timeline diagram for premature infant P106, 
(b) timeline diagram for premature infant P116 and (c) timeline diagram for 
premature infant P103. 
 
Supplementary Figure 1. Timeline diagrams for healthy preterms (P106, P116, P103).
Timeline diagrams indicating time points of faecal sample collection, duration of antibiotic, probiotic treatment, and 
relevant clinical observations. The timeline diagr ms are divided in weeks a d dots repres nt days within the scale. 
Blue dots indicate days of probiotic treatment, red dots antibiotic treatment, and black squares time points for sample 
collection. (a) timeline diagram for preterm P106, (b) timeline diagram for preterm P116 and (c) timeline diagram for 
preterm P103.












































Figure 46 Timeline diagrams for premature infants diagnosed with NEC (P49, P205 
and P8) 
Timeline diagrams indicating time points of faecal sample collection, duration of 
antibiotic, probiotic treatment, and relevant clinical observations. The timeline 
diagrams are divided in weeks and dots represent days within the scale. Blue dots 
indicate days of probiotic treatment, red dots antibiotic treatment, black squares time 
points for sample collection, letter H transfer of the premature infant to another 
hospital. Clinical observations highlight Bell stages of necrotising enterocolitis 
(Gregory, DeForge et al. 2011) commonly used by clinicians to assign the severity 
of this disease. (a) timeline diagram for premature infant P49, (b) timeline diagram 
for premature infant P205 and (c) timeline diagram for premature infant P8. 
  
Supplementary Figure 2. Timeline diagrams for pre erms diagnosed with NEC (P49, P205, P8 and P129).
Timeline diagrams indicating time points of faecal sample collection, duration of antibiotic, probiotic treatment, and relevant clinical 
observations. The timeline diagrams are divided in weeks and dots represent days within the scale. Blue dots indicate days of
probiotic treatment, red dots antibiotic treatment, black squares time points for sample collection, letter H transfer of the preterm to 
another hospital. Clinical observations highlight Bell stages of necrotising enterocolitis (Gregory, DeForge et al. 2011) commonly 
used by clinicians to assign the severity of this disease. (a) timeline diagram for preterm P49, (b) timeline diagram for preterm P205 
and (c) timeline diagram for preterm P8, (d) timeline diagram for preterm P129.
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DNA extraction of faecal samples 
Bacterial DNA was extracted from 100-150 mg of faecal material using the 
FastDNA Spin Kit for Soil (MP Biomedical, Santa Ana) following the 
manufacturer’s instructions but extending the bead-beating step to 1 min and 
eluting the DNA with 55 °C DES. The purity and concentration of the DNA was 
assessed using a NanoDrop 2000c Spectrophotometer and Qubit® 2.0 fluorometer. 
DNA concentrations higher than 25 ng/µl were considered acceptable to proceed 
further analysis. I performed this lab work and analysis. 
 
MinION shotgun library preparation and flowcells 
MinION 1D and MinION 2D libraries were prepared to assess if the clinical 
samples used in this study could be equally analysed. Both libraries differ in their 
preparation times. The preparation time for MinION 1D libraries is 30 min. 
MinION 1D library were constructed incubating 200 ng of DNA with 2.5 µl FRM 
for 1 min at 30 °C, then 1 min at 75 °C followed by the addition of 1 µl RAD and 
0.2 µl NEB Blunt/TA Ligase Master Mix (NEB), and room temperature incubation 
for 5 min. The final library DNA was mixed with running buffer containing fuel 
mix, library loading beads and nuclease free water. 
 
MinION 2D libraries, had an estimated preparation time of 2 h. This library was 
prepared following the same steps outlined for the mock community library 
preparation (for details see above). The final library DNA was eluted with same 
reagents specified above for MinION 1D libraries. 
 
Different MinION cells were used along the study. The MinION technology 
evolves very fast, and throughout the duration of this study R7.3 flowcell was used 




The table below details samples, MinION libraries and flowcells types used in this 
study.  
Table 17 Summary of samples used in this study detailing flowcell, sequencing kit 
and flow cell used 
 





1 Mock  R7.3 (MAP103) MAP006 2D 
2 P10N R7.3 (MAP103) MAP006 2D 
3 P10R (1) R7.3 (MAP103) MAP006 2D 
4 P10R (2) R7.3 (MAP103) MAP006 2D 
5 P10V (1) R7.3 (MAP103) MAP006 2D 
6 P10V (2) R7.3 (MAP103) MAP006 2D 
7 P8 R9.4 (MIN106) LSK208 2D 
8 P8 R9.4 (MIN106) RAD002 1D Rapid 
9 P8 R9.5 (MIN107) LSK108 1D Ligation 
10 P49A R9.5 (MIN107) LSK208 1D Ligation 
11 P205G R9.5 (MIN107) LSK208 1D Ligation 
12 P106I R9.5 (MIN107) LSK208 1D Ligation 
13 P116I R9.5 (MIN107) LSK208 1D Ligation 
14 P103M R9.5 (MIN107) RAD004 1D Rapid 
 
Mr Darren Heavens performed the MinION libraries and Dr Richard Leggett 
performed the bioinformatic analysis. I prepared the final figures of this analysis. 
 
Illumina HiSeq 2500 shotgun library preparation 
Illumina libraries for samples (P10N, P10R and P10V) were prepared using TruSeq 
Nano DNA Library Prep Kit following manufacturer’s instructions and sequenced 
using the HiSeq Illumina 2500 machine with 150 bp paired end reads. The Illumina 
library for P8 was prepared following the same protocol used for the mock 
community (see above) and run at 9 pM on an Illumina MiSeq with a 2 x 300 bp 
read metric. This work was done in collaboration with Mr Darren Heavens who 
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performed the laboratory analysis, Dr Richard Leggett performed the bioinformatic 
analysis and I prepared the final figures of this analysis. 
 
16S rRNA gene library preparation and bioinformatics analysis 
Libraries were constructed using bacterial DNA from samples P10N and P10V 
normalised to 5 ng ml-1. V4 region of the 16S rRNA gene was amplified using the 
following primers, 5’ AAT GAT ACG GCG ACC GAG ATC TAC A and, 5’ CAA 
GCA GAA GAC GGC ATA CGA GAT AAC T. PCR conditions used for this 
amplification were: 1 cycle of 94 °C 3 min and 25 cycles of 94 °C for 45 s, 55 °C 
for 15 s and 72 °C for 30 s using a 96 well Thermal Cycler PCR machine. 
Sequencing of the 16S RNA gene libraries was performed on the Illumina MiSeq 
platform with 250 bp paired end reads. 
 
Quality control was subjected to raw reads obtained using FASTX-Toolkit keeping 
a minimum quality threshold of 33 for at least 50% of the bases. Reads that passed 
the threshold were aligned against SILVA database (version: 
SILVA_119_SSURef_tax_silva) using BLASTN (ncbi-blast-2.2.25+; Max e-value 
10e-3) separately for both pairs. After performing the BLASTN alignment, all 
output files were imported and annotated using the paired-end protocol of 
MEGAN. This work was performed at Sanger Institute in Cambridge, I performed 
the bioinformatic analysis and prepared the final figure. 
 
Time series study for infant P10 
Illumina and MinION sequencing raw reads for samples P10N, P10V and P10R 
from infant P10 were analysed using the following bioinformatics pipelines. For 
the Illumina samples, we removed PCR duplicates (remove_pcr_duplicates.pl, 
script from https://github.com/richardmleggett/scripts), ran Trimmomatic61 to 
remove adaptors and applied a sliding window quality filter (size 4, mean quality 
greater than or equal to 15). A random set of 1,000,000 reads was subsampled 
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(subsample.pl script, https://github.com/richardmleggett/scripts) to represent the 
yield. These reads were used as the input to a blastn search of NCBI’s nt database.  
 
For the Nanopore sequencing, the analysis with the reads classified as ‘pass’ reads 
was followed (defined as 2D reads with a mean Q value >9) and performed no 
further pre-processing before running blastn. Taxonomic analysis was done using 
MEGAN630. The bioinformatics pipeline was run by Dr Richard Leggett and I 
prepared the final figures. 
 
‘Real-time’ study for premature infants using MinION Nanopore and 
NanoOK RT  
Both 1D and 2D Nanopore libraries were prepared using the SQK-RAD002 Rapid 
Sequencing Kit 1D and SQK-LSK208 Ligation Sequencing Kit 2D, respectively, 
and each library was sequenced on a R9.4 flowcell. Local basecalling through 
MinKNOW software was used to collect signal data.  
 
To enable real-time analysis of the MinION data, an improved version of NanoOK 
software229 was used. This new software NanoOK RT monitored a specified 
directory for FAST5 files as they were created. For each new file, a FASTA file 
was extracted automatically. FASTA files were grouped into batches of 500 to 
improve practicability, and each batch was BLAST searched against the NCBI nt 
database (downloaded February 2017) and the CARD database230 (v1.1.1, 
downloaded October 2016) of antibiotic resistance genes. NanoOK RT has also the 
advantage that it can write out command files for MEGAN, which allows detailed 
analysis of community composition, either as the run proceeds, or after completion. 
NanoOK RT is available as an extension to NanoOK, selectable as a run-time 
option, from https://github.com/TGAC/NanoOK. The development of this tool was 
done by Richard Leggett and further information can be found in the manuscript. 
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Complementing this bioinformatic tool, NanoOK Reporter, was also developed for 
this project. This tool provided a graphical user interface to monitor the run, view 
summaries of species, and antibiotic resistance genes identified. NanoOK Reporter 
is available from https://github.com/richardmleggett/NanoOKReporter and allows 
the user to browse through data in real time as batches are processed, or after all of 
the results were in using their timestamps to indicate when a result was first 
obtained. The summary data can be exported as plain text files, and these were 
subsequently used for later analysis (below). Dr Richard Leggett was the developer 
of this tool, I prepared the figures for my thesis. 
 
Generation of resistance heat maps 
CARD results were obtained from NanoOK Reporter and used the option save 
summary data as a plain text file. This saved a text file for the analysis at each time 
point (batches of timestamped 500 reads) summarising the counts of resistance 
genes identified up to that point. We took the latest time point file (chunk 459, 
available at https://github.com/richardmleggett/bambi) and extracted a list of the 
ARO (Antibiotic Resistance Ontology). Each unique ARO was manually assigned 
to an antibiotic group. We subsequently wrote a script (gather_heatmap_data.pl, 
same GitHub repository) to take the summary files, together with this mapping and 
to generate a file (BAMBI_P8_2D_Local_070317_hits.txt) summarising hits per 
group at each time point. An R script (plot_card_heatmap.R, same GitHub 
repository) took this file and rendered the heat map. Dr Richard Leggett developed 
this tool and I assigned the AMR genes detected to its corresponding antibiotic 
group. I prepared the final figures for my thesis. 
 
‘Walking out’ study from resistance genes to identify the encompassing 
bacteria 
A shell script was written to go through all the CARD BLAST hits and wrote each 
CARD hit and the corresponding nucleotide hits for the same read 
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(walk_out_preprocess.sh, available at https://github.com/richardmleggett/bambi). 
A second script (walk_out.pl) took the output from the first script and parsed it, 
read-by-read. If there was a hit in nucleotides that began at least 50 bases before 
the start of the CARD hit, or at least 50 bases after the end of the CARD hit, then 
this species was taken as the encompassing species. The script also recorded count 
of the number of times each species was seen. The person who performed this 
analysis was Dr Richard Leggett. I was involved in preparing the final figure. 
 
Isolation and biochemical characterisation of the P8 Klebsiella pneumoniae 
strain 
Faecal sample P8 was homogenised in 1 mL TBT buffer (100 mM Tris/HCl, pH 
8.0; 100 mM NaCl; 10 mM MgCl2•6H2O) at 1500 rpm for 1 h. Homogenates were 
serially diluted to 10-4 in TBT buffer and aliquots of 50µl were spread on 
MacConkey (Oxoid) agar plates and incubated aerobically at 37 °C overnight. 
 
Lactose-positive colonies (pink colour) were re-streaked on MacConkey agar three 
times to purify. Biochemical characterisation was performed using API 20E tests 
(Biomerieux) according to manufacturer’s instructions. This work was performed 
in collaboration with Mr Tom Brook. 
 
Determination of Minimal Inhibitory Concentration (MIC) for P8 Klebsiella 
pneumoniae isolate 
Broth microdilution method231 was used to calculate the Minimal Inhibitory 
Concentration (MIC) when antibiotic was added to the medium. MICs were 
determined as the lowest concentration of antibiotic inhibiting any bacterial 
growth.  
 
Samples used for this study were from a Klebsiella pneumoniae isolate from baby 
P8 (sample P8E). Serial two-fold dilutions of the most common antibiotics used at 
NICU (benzylpenicillin, gentamicin, vancomycin, metronidazole, meropenem and 
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cefotaxime) were added to sterile nutrient broth. A fresh overnight culture was 
used as bacterial inoculum (10 µl). Microplates were incubated for 24 h at 37 °C 
under aerobic conditions. Cell density was monitored using a plate reader (BMG 
Labtech, UK) at 595 nm. I performed this experiment and analysis. 
 
DNA extraction from P8 Klebsiella pneumoniae isolate for WGS analysis 
10 ml of an overnight culture of the Klebsiella pneumoniae isolate was centrifuged 
at 1792g for 10 min, re-suspended in 30 ml of Phosphate Buffered Saline (PBS) 
(Sigma-Aldrich, UK) and centrifuged again. The pellet was then re-suspended in 2 
ml of 25% sucrose (Fisher Scientific, USA) in TE (10 mM Tris (Fisher Scientific, 
USA) and 1 mM EDTA at pH 8.0 (VWR Chemicals, USA); 50 µl of Roche 
Lysozyme (Roche Molecular Systems, UK) at 100 mg/ml in 0.25 M Tris pH 8.0 
was added. The mixture was incubated at 37 oC for 1 h, and 100 µl of Proteinase K 
at 20 mg/ml (Roche Molecular Systems, UK), 30 µl of RNase A at 10 mg/ml 
(Roche Molecular Systems, UK), 400 µl of 0.5 M EDTA pH 8.0 (VWR Chemicals, 
USA), and 250 µl of freshly prepared 10% Sarkosyl NL30 (Sigma-Aldrich, UK) 
were added. The mixture was then incubated on ice for 2 h and subsequently 
transferred to a water bath at 50 oC overnight. Next, E Buffer (10 mM Tris pH8.0 
(Fisher Scientific, UK)) was added to the sample to a final volume of 5 ml, mixed 
with 5 ml Phenol:Chloroform:Isoamyl Alcohol (PCIA) (25:24:1) (Sigma-Aldrich, 
UK) in a Qiagen MaXtract High Density tube (Qiagen, DE) and centrifuged for 15 
min at 1792g. The aqueous phase was transferred into a new Qiagen MaXtract 
High Density tube, made up with E Buffer to the volume of 5 ml if necessary, 
mixed with 5 ml of PCIA, and centrifuged for 10 min at 1792g. This procedure was 
repeated, with 5 min centrifugation time. Next, the aqueous phase was transferred 
into a Qiagen MaXtract High Density tube, made up to 5 ml with E Buffer if 
necessary, mixed with 5 ml of Chloroform:Isoamyl Alcohol (CIA) (24:1) (Sigma-
Aldrich, UK), and centrifuged for 5 min at 1792g. The CIA step was repeated once 
more, after which the final aqueous phase was transferred into a sterile Corning TM 
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50ml centrifuge tube, and 2.5 volumes of ethanol (Ethanol absolute AnalaR 
NORMAPUR®, VWR Chemicals, USA) were added. The sample was incubated 
for 15 min at -20 oC, then centrifuged for 10 min at 1792g  and 4 oC. Finally, the 
DNA pellet was washed with 10 ml of 70% ethanol and centrifuged at 1792g for 
10 min twice, dried overnight, and re-suspended in 300 µl of E Buffer. This 
analysis was done by Mr Tom Brook. 
 
Whole genome sequencing library preparation and sequencing of P8 Klebsiella 
pneumoniae isolate 
DNA samples containing 500 ng genomic DNA were analysed. DNA was sheared 
into fragments of 400-600 bp using a Covaris plate with glass wells and AFA 
fibres. SPRI clean-up kit (Beckman, USA) was used to remove smaller sized 
fragments and concentrate the sheared DNA samples. Whole genome library 
construction performed by a liquid handling robot comprised end repair, A-tailing 
and adapter ligation reactions. Adapter ligated samples were subsequently 
amplified using the following PCR conditions: 5 min 95 °C, 10 cycles of (30 sec 
98 °C, 30 sec 65 °C, 1 min 72 °C) and 10 min at 72 °C. LabChip GX was then used 
to size and assess the quality of the libraries and determine pooling volumes for 
each library using Beckman Coulter Biomek NXp (span-8). Final pools were 
finally loaded on the HiSeq 2500 sequencers. Sequencing was done at Sanger. 
 
AMR gene characterisation of P8 Klebsiella pneumoniae isolate 
Presence or absence testing of AMR genes was performed on one Klebsiella 
pneumoniae isolate assembled using Velvet. Contigs were aligned using BLAST 
(v2.2.30) against the CARD database under double filtering criteria of expected e-
value 1e-10 and 90% identity. Customised in-house scripts were used to generate a 
data matrix that was then used to construct a heat map using the R heatmap2 
package. This part of the work was performed by Mr Shabhonam Caim. I grouped 
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Sequencing of a microbial mock community using MinION and Illumina 
technology 
To evaluate the accuracy of MinION technology at sequencing metagenomics 
samples, a bacterial mock community mixture (HM-276D, BEI Resources, 
Manassas, VA) of known composition and abundance was sequenced. MinION 
results were validated with Illumina technology, using it as a research ‘standard’. 
 
Initial yield and length metric results from the MinION sequencing data showed 
that one flowcell (R7.3) produced 148,441 total reads, with 71,675 reads passing 
default quality filter, with a mean size of 3,047 bp, and longest read size of 40,561 
bp. Table 18.  
 
Table 18 Nanopore flow cell version and yield for mock community  
 


















1 Mock  R7.3 (MAP103) MAP006 2D 148,441 71,675 3,047 5,497 40,561 
 
 
When comparing the taxonomic assignments obtained for each bacterial species 
using MinION and Illumina technology, results showed broadly similar abundance 
levels across both platforms (Figure 47). In some cases, a greater proportion of 
Nanopore reads were assigned at species level rather than genus or family, while in 
other cases, a greater proportion of Illumina reads were able to be assigned to 
species level. This can be explained by the nature of the longer reads, in some 
cases the longer length of Nanopore reads will provide better specificity, however 
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Figure 47 Sequencing of microbial mock community (HM-277D, BEI Resources) 
using Illumina MiSeq and Oxford Nanopore Technologies MinION sequencing 
MEGAN taxonomy tree representing species assigned from the mock community 
control sequenced by Illumina MiSeq (green) and ONT MinION (brown). The height 
of the bars represents the number of reads assigned for each species taxa. (*) 
represents species assigned by Megan but not specified as members of the 
community. 
 
Monitoring microbial disturbances in the preterm gut microbiome using 
MinION 
The utility of the MinION platform in a clinical setting was determined next. Three 
different faecal samples (from days 13, 28 and 64 after birth) from one premature 
infant (P10) were used to monitor the diversity of the immature gut microbiome, 
Figure 1. Sequencing of microbial mock community (HM-277D, BEI Resources) using Illumina MiSeq and Oxford
Nanopore Technologies MinION sequencing.
(a) MEGAN taxonomy tree representing species assigned from the mock community as sequenced by Illumina MiSeq
(green) and ONT MinION (brown). The height of the bars indicates the relative number of reads assigned which are
highlighted next to the species name. A (*) represents species assigned by MEGAN but not specified as members of the
mock community.
(b) Correlation plot of normalised genus abundance in Illumina (x-axis) and Nanopore (y-axis) data with Pearson’s r = 0.91.






and study responses to clinical interventions. Results were benchmarked to ‘gold 
standard’ Illumina sequencing technology, both 16S rRNA amplicon and 
metagenomic sequencing. To standardise results from these different sequencing 
technologies, the DNA extraction protocol was kept consistent. 
 
When comparing the taxonomic assignments obtained using MinION vs. Illumina 
it was observed that the results were comparable for the majority of the bacterial 
genera present in infant P10. Results from the most abundant bacteria detected 
Klebsiella, Enterobacter, Veillonella, Staphylococcus and Bifidobacterium were 
similar among the samples tested (Figure 48b). Interestingly, sample P10N 
(collected when the infant was receiving probiotic supplementation) confirmed 
colonisation of Bifidobacterium bifidum, and confirmed the ability of MinION to 
detect a known species in a complex microbial community from a patient sample. 
Subsequent samples (P10R and P10V) were collected after probiotic 
supplementation had stopped, and after additional courses of antibiotics. 
Furthermore, MinION analysis also detected presence of Enterobacter cloacae (in 
sample P10R), a well-known late onset sepsis (LOS) pathogen in premature 
infants232, which correlated with the clinical diagnosis of suspected sepsis at the 
time of sample collection (Figure 48a).  
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Figure 48 Longitudinal study on premature infant P10 using MinION and Illumina 
sequencing 
(a) Timeline diagram of premature infant P10 indicating times of faecal sample 
collection (P10N, P10R and P10V), duration of antibiotic and probiotic treatment, 
and relevant clinical observations. The timeline diagram is divided into weeks and 
dots represent days within the scale. Blue dots represent days of probiotic treatment, 
red dots antibiotic treatment, black squares time points for sample collection and 
letter H transfer of the premature infant to another hospital.  
(b) Sequencing data from ONT MinION and Illumina HiSeq 2500 from premature 
infant P10. Pie charts represents taxonomic profiles at different time points P10N, 
P10R and P10V, as assigned by MEGAN. The top row corresponds to results 
obtained using MinION sequencing and bottom row displays results using Illumina 
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When comparing Illumina results to 16S rRNA gene data (Figure 49) similar 
taxonomic profiles were obtained. It is important to highlight that in some cases, 
the short 16S rRNA gene reads failed to differentiate some bacteria taxa even at 
genus level e.g. members of the family Enterobacteriaceae, which comprises 
commensal gut bacteria as well as opportunistic pathogens, and whose full-length 
16S rRNA genes are often indistinguishable from one another. 
 
Figure 49 Megan taxonomic tree comparing assignments obtained by Illumina HiSeq 
2500 WGS, ONT MinION, and Illumina 16S rRNA gene sequencing 
Megan taxonomic tree showing bacteria taxa identified and their corresponding 
abundances. The height of the bars represents the number of reads assigned for each 
species taxa. Samples highlighted in red belong to sample P10N sequenced using 
Illumina HiSeq 2500 WGS, ONT MinION, and Illumina 16S rRNA gene 
sequencing. Samples highlighted in blue belong to sample P10V sequenced using 
Illumina HiSeq 2500 WGS, ONT MinION, and Illumina 16S rRNA gene 
sequencing. 
 
To assess whether sequencing depth covered the total bacterial diversity present in 
the samples tested, rarefaction curves were performed and compared to Illumina 
technology (Figure 50). Results from this comparison showed that for both 
sequencing technologies most species were detected at approximately 25,000 
reads, highlighted by the fact that the rarefaction curves reached saturation at this 
point. This result indicated that the level of coverage of MinION and Illumina 

















which are known to have a less diverse gut microbiome when compared to adult 
samples47.  
 
Figure 50 Rarefaction curves comparing MinION and Illumina HiSeq 2500 for 
premature infant P10  
Rarefaction curves representing number of species (leaves) detected in the 
taxonomic tree vs number of reads sampled. Three samples from premature infant 
P10 were analysed: samples (P10N-N, P10R-N and P10V-N) were sequenced with 
MinION technology, while samples (P10N-I, P10R-I and P10V-I) were sequenced 
with Illumina technology. 
 
Finally, a characterisation of the AMR profile in premature infant P10 was 
performed using the CARD database (a popular bioinformatic database use to trace 
antibiotic resistance genes) with comparison between MinION and Illumina 
sequencing data (Figure 51). Overall four groups of AMR genes were detected in 
high abundance including efflux pumps, β-lactams, aminoglycosides and 
fluoroquinolones. Elevated expression of efflux pumps has previously been 
observed in clinical multidrug resistant isolates, including e.g. AcrAB-TolC233, 
which was detected in the three samples analysed. β-lactamase and aminoglycoside 
genes confer resistance to the antibiotics prescribed to preterm infant P10 
(benzylpenicillin and gentamicin), while fluoroquinolone resistance genes correlate 
with the heavy use of fluoroquinolone antibiotics in hospitals234 . Furthermore, the 
detection of AMR genes specific for certain species such as FosA2 present in 
Taxonomy rarefaction plot for P10NRV_Nanopore_Illumina_comparison.megan




















































































Enterobacter cloacae (for sample P10R), illustrates the ability of the MinION 
technology to not only detect the pool of AMR genes present in the samples tested, 
but also determine the species taxa-specific AMR genes. 
 
Figure 51 Heat map displaying presence or absence of AMR hits found in premature 
infant P10 using MinION and Illumina HiSeq 2500 
Three samples of preterm P10 were analysed and sequenced using MinION (P10N-
N, P10R-N and P10V-N), and Illumina technology (P10N-I, P10R-I and P10V-I). 
(a) Heat map representing efflux pumps inhibitors or regulators genes found in 
samples P10N, P10R and P10V. (b) Heat map highlighting b-lactamases. (c) Heat 
map showing (1) aminocoumarin resistance genes (2) aminoglycosides resistance 
(3) bacitracin resistance (4) colistin resistance (5) erythromycin resistance (6) 
fluoroquinolone resistance (7) fosfomycin resistance (8) mucopirocin resistance (9) 
quinolone resistance (10) streptothricin resistance (11) sulphonamide resistance (12) 
tetracycline resistance (13) trimethoprim resistance. AMR genes were grouped 
according to sequence similarity. AMR genes were grouped according to sequence 
similarity.  
  
a       efflux pumps/regulators genes
Supplementary Figure 4. Heat maps displaying presence or absence of AMR hits found in preterm P10 using MinION and Illumina HiSeq 2500.
Three samples of preterm P10 were analysed and sequenced using MinION (P10N-N, P10R-N and P10V-N), and Illumina technology (P10N-I, P10R-I and P10V-I). (a) 
Heat map representing efflux pumps inhibitors or regulators genes found in samples P10N, P10R and P10V. (b) Heat map highlighting b-lactamases. (c) Heat map 
showing (1) aminocoumarin resistance genes (2) aminoglycosides r sistance (3) bacitracin resistance (4) colistin resistance (5) erythromycin resistance (6) 
fluoroquinolone resistance (7) fosfomycin resistance (8) mucopirocin resistance (9) quinolone resistance (10) streptothricin resistance (11) sulphonamide resistance 
(12) tetracycline resistance (13) trimethoprim resistance. AMR genes were grouped according to sequence similarity. Further information on genes detected can be 
found in Supplementary Table 2.
b     b-lactamases
c     other
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Using MinION technology to profile samples from healthy premature infants 
receiving probiotic supplementation 
To validate the optimised MinION pipeline, two samples from healthy premature 
infants P106 and P116 (clinical details see Figure 45) were sequenced. The 
taxonomic profiles of these infants indicated that a dominant bifidobacterial gut 
microbiome profile correlated with improved health (Figure 52). Interestingly, 
MinION was able to detect B. bifidum which was present in the probiotic 
supplementation. Furthermore their ‘resistome’ was markedly reduced in 





Figure 52 Rapid diagnostic of healthy premature infants P106 and P116 receiving 
probiotic supplementation 
(a), (b) Taxonomic profiles obtained using MinION technology for premature infants P106 
and P116, respectively. Figure legend comprises the 8 most abundant taxonomic taxa 
obtained.  
(c), (d) Heat maps displaying number of CARD database hits detected among the most 
common groups of antibiotic resistance genes found in premature infants P106 and P116. 
Top and lower panel indicate the hours since sequencing start, and the number of reads 
analysed, respectively within this timeframe.  
 
New bioinformatics tools utilise MinION specific features for improved rapid 
characterisation of gut-associated pathogenic bacteria and resistance profiles 
New bioinformatic tools (NanoOK RT and NanoOK Reporter) were developed by 
Dr Richard Leggett to add real-time functionality to the optimised MinION 
pipeline. These tools were able to provide a report with the most prevalent AMR 
a b
Supplementary Figure 6. Rapid diagnostic of healthy preter s P106 and P116 receiving probiotic supplementation.
(a), (b)Taxonomic profiles obtained using MinION technology for preterms P106 and P116, respectively. Figure legend comprises the 
8 most abundant taxonomic taxa obtained. Further information on all the bacteria taxa and the number of reads obtained can be
found in Supplementary Table 3.
(c), (d) Heat maps displaying number of CARD database hits detected among the most common groups of antibiotic resistance 
genes found in preterms P106 and P116. Top and lower panel indicate the hours since sequencing started and the number of reads 
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genes, and perform a ‘walkout’ analysis from the AMR genes into flanking DNA 
of the host bacteria containing these genes. 
 
Using these bespoke bioinformatics tools, three samples from three critically ill 
infants suffering from NEC (P49, P205 and P8) were profiled (clinical details of 
these premature infants can be found in the Figure 46). For this study, the latest 
flowcell version available R9.4 was used. Taxonomic results show that infants P49 
and P205 samples both contained high proportions of E. cloacae (Figure 53). 
Analysis of the ‘resistome’ of these infants highlighted a significant number of 
AMR genes, particularly in P205 (i.e. aminoglycoside resistance and b-
lactamases), which were detected within minutes of sequencing start (Figure 53b-
d). Although these babies had E. cloacae dominated gut microbiome profiles, and a 
significant community ‘resistome’, they also harboured other potentially 
pathogenic bacteria (e.g. Klebsiella pneumoniae), highlighting the clinical 
importance of determining which bacteria are harbouring AMR genes for 
downstream treatment options. 
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Figure 53 Rapid diagnostic using MinION technology for premature infants 
clinically diagnosed with suspected NEC (P49 and P205) 
(a), (c) Taxonomic profiles comparing results obtained at 1h and 6h since sequencing 
started. Results for premature infant P49 are highlighted in a and for premature infant 
P205 are highlighted in c. Figure legends comprise the 8 most abundant taxonomic 
taxa obtained.  
(b), (d) Heat maps displaying number of CARD database hits detected among the 
most common groups of antibiotic resistance genes found in premature infant P49 
and P205, respectively. Top and lower panel indicate the hours since sequencing 
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Figure 4. Rapid diagnostic using MinION technology for preterms clinically diagnosed with suspected NEC (P49 and P205).
(a), (c) Taxonomic profiles comparing results btained at 1h and 6h since sequencing started. Results for preterm P49 are highlighted in a and 
for preterm P205 are highlighted in c. Figure legends comprise the 8 most abundant taxonomic taxa obtained. Further information on all the 
bacteria taxa and the number of reads obtained can be found in Supplementary Table 3.
(b), (d) Heat maps displaying number of CARD database hits detected among the most common groups of antibiotic resistance genes found in
preterm P49 and P205, respectively. Top and lower panel indicate the hours since sequencing started and the number of reads analyzed.
Further information on all the AMR genes obtained can be found in Supplementary Table 5.
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As MinION reads are typically longer than Illumina reads, a ‘walkout’ approach 
was used to extract additional information by examining flanking sequences either 
side of each AMR hit, and searching the NCBI nt database for hits that were 
independent (defined as ≥ 50 bp) from the AMR sequence. Results of this analysis 
showed that the vast majority of AMR genes of infant P205, mapped back to E. 
cloacae (88%, Figure 54a), which was also the dominant species taxonomically, 
with the remaining resistance genes (6%) associated with B. longum (i.e. mupirocin 
resistance). Contrastingly, although infant P49 had very similar levels of E. cloacae 
compared to infant P205, only 60% of AMR hits were associated with E. cloacae. 
Klebsiella represented a small proportion taxonomically in P49 (~13%), however 
Klebsiella species (K. pneumoniae, K. michiganensis and K. oxytoca) appeared to 
encode a range of AMR genes (e.g. OXA-2 (b-lactamases), CRP and mexB (efflux 
pumps) and patA and mfd (fluoroquinolone resistance)), making up >30% of total 
AMR genes present in this infant sample (Figure 55b and Appendix 4). These data 
highlight that MinION sequencing data coupled with the NanoOK Reporter 
analysis software is able to map specific AMR determinants to specific pathogenic 








Figure 54 Walkout study for premature infants P205 and P49 reported by NanoOK 
RT software 
(a) Results from independent hits (defined as ⋝ 50 bp overlap from the AMR 
sequence) at 6 hours of sequencing for premature infant P205. 
(b) Results from independent hits (defined as ⋝ 50 bp overlap from the AMR 
sequence) at 6 hours of sequencing for premature infant P49. 
 
Next, a ‘real-time’ run (from sample preparation to data analysis) using MinION 
R9.4 flow cells and 1D libraries was performed. The faecal sample chosen for this 
analysis came from a premature infant (P8) clinically diagnosed with suspected 
NEC (clinical details in Figure 46c, methods section). This infant was exposed, 
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before sample collection, to 43 days of non-concurrent antibiotic treatments (i.e. 
benzylpenicillin, gentamicin, meropenem, tazocin, vancomycin, flucloxacillin, 
metronidazole and amoxicillin). Current rapid clinical microbiology tests can take 
between 36 and 48 h if strain susceptibility to antibiotics is determined. All stages 
of this run were timed including sample preparation (90 min), DNA quality control 
(45 min), 1D MinION library preparation and loading onto the MinION flow cell 
(1 h and 45 min), and sequencing-and-data analysis (8 min for first specific AMR 




Figure 55 Timeframe diagram for ‘real time’ run performed for rapid diagnostic of 
premature infant (P8) suffering from NEC  
Step 1 (red, 2h 25min): Sample collection, DNA extraction and quality control. Step 2 
(yellow, 1h 45min): 1D library preparation incorporating bead clean up and DNA repair. Step 
3 (green): data analysis using local base calling and NanoOK RT. Pathogen detection 
(Klebsiella pneumoniae) and K. pneumoniae specific AMR genes were first detected at 4 
hours and 8 minutes (1,500 reads analysed). Left side of the panel indicates clinical symptoms 
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Prescription of GENERAL 
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48:00 End of the run
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(Klebsiella pneumoniae, 20,000 reads + AMR genes) 
4:08
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This run generated a total of 1.37 million reads in a full 48 hour run. By 1 h after 
sequencing start (5 h total), the pipeline had analysed 20,000 reads and K. 
pneumoniae accounted for around 70% of reads. These reads were much longer 
(N50 3,479 bp) than the previous 2D runs from samples P49 and P205 (Table 19), 
meaning that at the 1h time point NanoOK RT and NanoOK Reporter had analysed 
over 3x more sequence data in this new 1D run. 
 
Table 19 MinION runs of premature infants suffering from NEC 
 
















P8 R9.5 (MIN107) LSK108 1D Ligation 1,369,544 1,838 3,479 897,734 
P49A R9.5 (MIN107) LSK208 1D Ligation 84,527 1,046 1,338 34,975 
P205G R9.5 (MIN107) LSK208 1D Ligation 2,745,619 966 1,102 11,619 
 
 
The first 500 reads immediately indicated a dominance of K. pneumoniae (a 
potential causative organism that has been associated with NEC pathogenesis in 
premature infants235), as well as Proteus mirabilis. To further verify enough of the 
bacterial diversity was sequenced at 1 h time point, a comparison with the 
taxonomic profile at 6 h was performed; time-point chosen due to clinical 
relevance to NEC deterioration (101,000 reads, 10 h total time). This comparison 
verified that there were no significant qualitative differences between the two 




Figure 56 Rapid diagnostic of premature infant P8 clinically diagnosed with 
suspected NEC 
Taxonomic profiles obtained using MinION technology at 1h, and 6h since 
sequencing started. Figure legend comprises the 12 most abundant taxonomic taxa 
obtained.  
 
As highlighted previously, it is clinically important to detect AMR genes in 
metagenomic samples from premature infants to guide appropriate antibiotic 
prescription. In this ‘real-time’ run it was determined how rapidly we could map 
AMR genes to the CARD database. Figure 57 shows the huge number of AMR 
gene classes detected throughout the run, including polymyxin, aminoglycoside, 
tetracycline, quinolone resistance, β-lactamases and efflux pumps, all of which 
were detected in as little as 1 h after sequencing start. K. pneumoniae-specific SHV 
variants236 were detected as early as 6 min (at 1,500 reads, 4 h 8 min total time), 
whilst other lower abundance AMR genes in the sample, such as those conferring 
trimethoprim, sulphonamide and streptothricin resistance, were not detected until 
3-4 h post sequencing (7-8 h total).  
c
Figure 7. Rapid diagnostic of preterm P8 clinically diagnosed with suspected NEC.
(a) Taxonomic profiles obtained using MinION technology at 1h, and 6h since sequencing started. Figure legend comprises the 8 most abundant taxa 
classified. Further information on reads assigned can be found in Supplementary Table 3.
(b) Correlation plot of species-level normalised assigned read counts at 1h and 6h, with Pearson’s r of 1.00.
(c) Heat map displaying number of CARD database hits detected among the most common groups of antibiotic resistance genes found in preterm P8. Top 
and lower panel indicate the hours since sequencing started and the number of reads analyzed, respectively within this timeframe. Further information on 
all the AMR genes obtained can be found in Supplementary Table 4.
(d) Walkout study of preterm P8 reported by NanoOK RT software showing taxa containing AMR genes. Results shown are for independent bacterial hits 
(defined as ⋝ 50 bp away from the AMR sequence), at 6 hours of sequencing.
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Figure 57 Rapid diagnostic of AMR genes detected for premature infant P8 clinically 
diagnosed with suspected NEC  
Heat map displaying number of CARD database hits detected among the most 
common groups of antibiotic resistance genes found in premature infant P8. Top and 
lower panel indicate the hours since sequencing started and the number of reads 
analysed, respectively within this timeframe.  
 
Finally, when using NanoOK Reporter to perform AMR ‘walkout’ analysis on this 
infant sample, the majority (~90%) of AMR genes within the whole metagenomic 
sample mapped to K. pneumoniae (Figure 58, Appendix 4), including multidrug 
exporters such as acrB or oqxA, conferring resistance to tetracycline, 
chloramphenicol, and fluoroquinolones, vanSC (resistance to vancomycin), tet 41 
(resistance to tetracycline) and dfrA20 (resistance to trimethoprim). There were 
also specific AMR gene cassettes to P. mirabilis including OXA-63, which can 
confer cephalosporin resistance, and tet34 resistance to tetracycline. 
 
a
Figure 7. Rapid diagnostic of preterm P8 clinically diagnosed with suspected NEC.
(a) Taxonomic profiles obtained using MinION technology at 1h, and 6h since sequencing started. Figure legend comprises 
the 12 most abundant taxonomic taxa obtained. Further information on all the bacteria taxa and the number of reads obtained 
can be found in Supplementary Table 3.
(b) Heat map displaying number of CARD database hits detected among the most common groups of antibiotic resistance 
genes found in preterm P8. Top and lower panel indicate the hours since sequencing started and the number of reads 
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Figure 58 Walkout study of premature infant P8 reported by NanoOK RT software 
Results from independent hits (defined as ⋝ 50 bp overlap from the AMR sequence) 
at 6 hours of sequencing. 
Genomic characterisation of Klebsiella pneumoniae isolate from premature 
infant P8  
To validate the metagenomic genotypic data using NanoOK RT tool and its 
‘walkout’ analysis, K. pneumoniae was isolated from patient P8, with whole 
genome sequencing (WGS, using both Illumina and MinION) performed. The 
same AMR pipeline using CARD database was used to compared the results. Many 
of the AMR genes/groups detected in the ‘walk-out’ analysis from the 
metagenomic sample P8 correlated with both the Illumina and MinION whole 
genome sequencing data of the isolate (Figure 59). A significant proportion (~60%) 
of the resistance genes/groups in the metagenomics ‘walk-out’ and isolate WGS 
correlated with efflux pumps (e.g. group mdt-mds-acr-mtr, group mdt-mex-sme, 
group mex-acr, and group oqx-mex-amr), whilst other ‘hits’ correlated to known K. 
pneumoniae AMR genes/groups including b-lactamases genes (e.g. group SHV-




Figure 59 AMR genes associated to Klebsiella pneumoniae from a metagenomic 
sample compared to those found in a Klebsiella pneumoniae isolate from the same 
sample 
Heat maps displaying AMR genes associated to Klebsiella pneumoniae from faecal 
sample P8 and AMR genes detected from a Klebsiella pneumoniae isolate from the 
same sample. Sequencing of the metagenomic sample was performed for only 6h 
using MinION and NanoOK RT tool (highlighted as ‘P8’’). Sequencing and 
assembly of the Klebsiella pneumoniae isolate was performed using both MinION 
(‘Isolate MinION’) and Illumina HiSeq (‘isolate Illumina’’). AMR genes were 
grouped according to sequence similarity.  
 
Overall these results indicate MinION metagenomic sequencing using NanoOK 
Reporter and ‘walkout’ analysis is faster and provides robust clinically relevant 
AMR data that may help guide antibiotic treatment. 
Phenotypic characterisation of Klebsiella pneumoniae isolate from premature 
infant P8  
Antibiotic resistance phenotype of the same K. pneumoniae isolate was tested 
against the seven most commonly used antibiotics in NICUs (Table 20). 
Supplementary Figure 7. AMR genes associated to Klebsiella pneumoniae from a metagenomic sample P8 compared to 
those found in P8 Klebsiella pneumoniae isolate.
Heat maps displaying AMR genes associated to Klebsiella pneumoniae from faecal sample P8 and AMR genes detected from a 
Klebsiella pneumoniae isolate from the same sample. Sequencing of the metagenomic sample was performed for only 6h using 
MinION and NanoOK RT tool (highlighted as ‘P8’’). Sequencing and assembly of the Klebsiella pneumoniae isolate was performed 
using both MinION (‘Isolate MinION’) and Illumina HiSeq (‘isolate Illumina’’). AMR genes were grouped according to sequence 
similarity. Further details of specific gene names can be found in Supplementary. Table 8.
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Interestingly, the K. pneumoniae isolate was found to have a higher minimum 
inhibitory concentration (MIC) breakpoint value for those antibiotics that were 
prescribed to the premature infant P8 i.e. benzylpenicillin, amoxicillin, 
metronidazole, gentamicin and vancomycin. In contrast, the only MIC breakpoint 
value lower than those put forward by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST153) was for cefotaxime, an antibiotic not 
prescribed to the infant at sample collection point. Notably, these data also 
correlated with the AMR data generated by NanoOK reporter and the ‘walkout 
analysis’, with the only exception of metronidazole resistance, which was only 
detected after WGS of the isolate (gene msba, Appendix 4).  
 
Table 20 Broth microdilution test for Klebsiella pneumoniae isolate from baby P8 
(sample P8E) and Eucast values 
 
Antibiotic MIC (mg/L) Eucast (mg/L) 
Gentamicin 3.12 2 
Benzylpenicillin 780 No data 
Amoxicillin 3,900 >512 
Metronidazole 1,250 No data 
Vancomycin 1,562 No data 
Meropenem 6,25 0.125 





This work demonstrates that MinION technology can be used at clinical point of 
care for profiling microbial communities and corresponding AMR determinants, 
which may facilitate antibiotic treatment guidance, ultimately improving patient 
outcomes. This technology is smaller, faster and cheaper than any other sequencing 
technologies currently available (e.g. Illumina platforms). Using a combination of 
improved Nanopore sequencing chemistries, and bespoke Nanopore analysis 
packages (NanoOK RT and NanoOK Reporter, developed by Dr Richard Leggett), 
the MinION platform can successfully profile known metagenomes, and clinical 
samples from critically ill premature infants. Importantly, MinION sequencing data 
using the new R9.4 flow cells were comparable in discriminatory power to the 
conventional Illumina sequencing platform and provided clinically relevant 
information within just 5 h from sample receipt.  
 
Initially, it was important to benchmark the MinION against a known metagenomic 
sample (mock community), to determine the usability of this new technology. 
Results indicated that the MinION is suitable for detection of a wide range of 
microbes, which is in agreement with a previous study also using R7.3 flow 
cells237. When testing longitudinal samples from a premature infant residing in 
NICU and sequenced the same samples using Illumina as a gold standard, results 
showed analyses were comparable for both sequencing platforms, detecting the 
probiotic strain (i.e. B. bifidum) during the supplementation period, and the 
pathogenic strain E. cloacae during sepsis episodes (Figure 48b). The investigation 
of AMR genes detected by MinION and Illumina, revealed that both sequencing 
platforms generated reads mapping to genes with similar antibiotic resistance 
mechanisms (Figure 51), and only 4 genes (mphC, fusB, sat-4 and vanRG) with 
unique resistance mechanisms out of all 146 AMR genes were detected exclusively 
by Illumina. This result may be correlated to the lower MinION read count, and so 
could be mitigated by ongoing improvements in MinION technology. Notably, we 
observed the presence of AMR genes that corresponded to prescribed antibiotics; 
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β-lactamase and aminoglycoside genes (conferring resistance to benzylpenicillin 
and gentamicin respectively), while fluoroquinolone resistance genes did not 
correlate to any prescribed antibiotics, and so may relate to AMR gene transfer of 
strains from other sources. Thus, AMR profiling using MinION technology may be 
able to guide clinical treatment decisions at an earlier stage of patient care. 
 
For critically ill patients, rapid actionable information is crucial for improving 
patient outcomes. Thus, it was demonstrated that the entire pipeline of sample 
preparation, library construction, sequencing and analysis could be carried out 
rapidly and in ‘real-time’. Importantly, the most recent flow cells (R9.4) were used 
for this study, which have an improved error rate (~5-7% for 1D) and yield. 
Specifically, for this study new bioinformatic tools (NanoOK RT and NanoOK 
Reporter) were developed by Richard Leggett to improve functionality. Two ill 
infants were initially diagnosed with suspected NEC, P49 and P205. Taxonomic 
results showed both samples presented high levels of E. cloacae, and a significant 
resistome, which may correlate with the extensive course of antibiotics the infants 
received (Figure 53). Importantly, additional analysis using the new NanoOK 
Reporter functionality, allowed determination of what specific taxa harboured these 
AMR genes, and efflux pumps, including E. cloacae, which was the dominant 
species present (Figure 54). Interestingly, although Klebsiella spp. represented a 
more minor component of the P49 microbial community they appeared to harbour 
> 30% of the total AMR genes present. Thus, in patient P49 a poorly chosen 
antibiotic treatment could target Klebsiella and miss the predominant E. cloacae or 
could target only E. cloacae leading to an increase in Klebsiella pathogenic 
species, whereas the best treatment would target both sets of pathogenic species. 
Performing a ‘walkout’ study rather than de novo metagenomic assembly is 
considerably less compute intensive. These data indicated that relevant AMR genes 
detected in a metagenomic sample and further mapped to known pathogenic 
species may facilitate tailored antibiotic treatment strategies for critically ill 
patients.  
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Next, a real-life diagnostic approach was executed by performing a real-time run. 
The sample for this experiment was from an extremely ill premature infant P8 
(born after 26 weeks’ gestation with a birthweight of only 508 g), who had 
received multiple courses of antibiotics since birth (46 days of antibiotic treatment 
out of 63 days of life at sample collection) and presented suspicion of NEC at the 
time of sample collection.  
 
Initial attempts to real-time sequence infant P8 were unsuccessful, due to problems 
related to quality of flow cells and base calling. A third attempt was needed to 
generate impressively high yields (101,000 reads) at only 6 hour of sequencing and 
1.37 million reads in a full 48 hour run. Taxonomic profiling in real time revealed a 
K. pneumoniae-dominated profile, after just 1 h of sequencing (~20,000 reads), 
enabling to confidently ‘call’ this potential pathogen. This analysis was further 
strengthened as more sequencing at 6 h, gave almost identical microbial profiles 
(Figure 56). K. pneumoniae has been linked to NEC (and is supported by 
corresponding clinical observations), with overgrowth in the intestine linked to 
pathological inflammatory cascades, facilitated by a ‘leaky’ epithelial barrier238. It 
should be noted that the single species domination in this sample facilitates early 
detection at lower read depth and low-level pathogen abundance would require 
deeper sequencing. Profiling of additional more complex samples from NEC 
diagnosed infants (i.e. P49 and P205) also indicates distinct and differential 
microbiome profiles (when compared to P8) also at 1 h post sequencing start 
(Figure 53), highlighting how rapid diagnosis of pathogen overgrowth is possible 
using R9.4 Nanopore flow cells.  
 
Whilst detection of individual pathogens is important, a critical additional requisite 
is identification of AMR profiles so that tailored antibiotic treatment can be used. 
Real-time analysis of MinION data using NanoOK RT highlighted the presence of 
a significant metagenomic ‘resistome’, including presence of colistin resistance, a 
last resort antibiotic, by the detection of genes arnA239, PmrB240 and PmrC. It was 
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noted the greater the sequencing depth the greater the number of AMR genes 
detected, although importantly there was a significant number of AMR genes 
detected as rapidly as 1 h after sequencing start, including β-lactamases, quinolone, 
aminoglycoside, and tetracycline resistance genes (Figure 57). 
 
To further benchmark the MinION pipeline developed, the pathogenic K. 
pneumoniae strain was isolated, sequenced and tested phenotypically (MIC test). 
Notably, WGS (both Illumina and MinION) indicated agreement with resistance 
genes determined by the MinION metagenomic run,  and the ‘walkout’ approach 
(Figure 59). When subjecting strains to MIC testing (current gold standard for 
profiling AMR), phenotypic resistance was observed to all main groups of 
antibiotics that had been prescribed to infant P8, Table 20). There was good 
association between AMR gene sequence detection and MIC testing, i.e. group 
SHV-LEN-OKP and β-lactam antibiotics, aac and aph genes and gentamicin, and 
van genes resistant to vancomycin which highlights that MinION could be 
extremely useful for rapid AMR profiling (Appendix 4). Only metronidazole 
resistance was identified via MIC testing, that was not present in the MinION 
metagenomic analysis. The corresponding resistance gene was only detected in the 
isolate whole genome sequencing data (gene msba, Appendix 4). As such it is 
expected that rapid analysis using MinION sequencing, would inform early and 
more appropriate antibiotic choices for patient care, halting the rapid deterioration 
observed in critically ill patients.  
 
This work indicated that MinION metagenomic profiling can provide robust, 
clinically useable data in less than 5 hours. In comparison to standard sequencing 
platforms such as Illumina MiSeq sequencing (paired 250 bp reads) and PacBIO 
(>15,000 bp reads) where obtaining first sequencing results normally take ~39 
hours241 or ~7 hours242, respectively. Profiling preterm faecal samples using 
MinION technology as a routine basis could offer insights into overall preterm 
microbiome dynamics, and could complement other rapid molecular diagnostics 
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tests currently used for detecting bacterial bloodstream infections such as 
QuickFISH technology or MALDI-TOF243. The QuickFISH technology uses a 
fluorescent peptide nucleic acid probe able to target the bacterial 16S rRNA gene 
and has the advantage that it is extremely fast (~20 min turnaround time) but has 
the disadvantage that only known bacterial pathogens can be traced. In contrast, the 
MALDI-TOF approach using mass spectrometry can identify any bacteria directly 
from blood culture in approximately 1 hour. QuickFISH and MALDI-TOF 
technologies have the disadvantage that they cannot perform AMR profile. 
 
Nevertheless, this application has limitations if the sample is not treated adequately 
to remove human cells, and presents difficulties to detect bacterial pathogens in 
very low amounts244. Overall the fast turnaround time, high sensitivity and vast 
amount of data provided by the MinION Nanopore pipeline developed in this 
study, makes this technology very attractive to complement the current rapid 
molecular diagnostics tests used in the clinic. 
 
Conclusion 
This work demonstrates that MinION technology has the potential to diagnose, in 
‘real time’, premature infants suffering from NEC, and to monitor the effectiveness 
of microbiota therapy (probiotic supplementation). Data obtained may allow 
clinicians to rapidly tailor antibiotic treatment strategies in a rapid (~6 h decision 
from sample receipt) and timely manner. The utility of this approach was 
confirmed when compared to Illumina metagenomic sequencing and isolation and 
characterisation of K. pneumoniae strain including WGS and phenotypic (i.e. MIC) 
testing. This suggests that MinION may be used in a clinical setting, potentially 
improving health care strategies and antibiotic stewardship for at-risk premature 




This work has probed the applicability of MinION technology for diagnosing 
faecal samples from critically ill premature infants suffering from sepsis or NEC. I 
envisage future work where we can use this technology in a broader scale, perhaps 
using the PromethION technology, which allows you to profile higher number of 
samples (up to 48 flowcells in one run). It would be very informative to run several 
samples from premature infants residing in the same ward or hospital, to perform 
epidemiological studies to evaluate whether there are correlations among the 
bacterial groups at taxonomic and resistome level. Currently the MinION error rate 
(3% for 2D and 6% for 1D using R9.4 flowcells245) does not allow to distinguish 
between closely related alleles of AMR genes, and published work has tackled this 
issue by assembling the raw reads246. However, it is conceivable that continued 
improvements in Nanopore chemistry and base calling algorithms could improve 
raw read accuracy, to the point that intermediate assembly is not necessary prior to 
AMR gene identification so long read length could be then be used to give a 
greater insight of the location of the AMR genes (i.e. plasmid or genome) or 





Premature infants represent an at-risk patient cohort exposed to multiple potential 
microbiota ‘damaging’ post-natal factors from the first day of life; infections 
related to maternal health, caesarean delivery, prolonged antibiotic courses, 
difficulties in establishing breastfeeding, and prolonged residency in the NICUs. 
The gut microbiome in premature infants is characterised by overall reduced 
bacterial diversity, but high levels of potentially pathogenic bacteria (e.g. 
Klebsiella, Escherichia or Staphylococcus) and low levels of beneficial genera 
Bifidobacterium235. Many studies have associated a decrease in the abundance of 
beneficial microbes in premature infants, to a higher incidence of developing; (i) 
neonatal-associated bacterial infections/sepsis or necrotising enterocolitis247, 248 
(NEC), and (ii) later onset diseases in childhood, such as atopy249 or obesity250.  
 
There are several ways to beneficially modify the preterm microbiome, including 
maximising the exposure to breastmilk, or donor breast milk if absent, or 
administering probiotics orally. The potential beneficial role exerted by commensal 
bacteria (e.g. Bifidobacterium and Lactobacillus) has been reported in several 
meta-analyses which have shown reductions in NEC and sepsis incidence138, 168. 
Interestingly, many of these studies highlight that only the genus Bifidobacterium 
colonises the gut long-term, and that some probiotic mixtures are not as effective as 
others. More information about the efficacy of probiotic strains is essential to be 
able to improve preterm health. In this context, the use of next generation 
sequencing approaches (e.g. 16S rRNA gene or whole-genome shotgun 
sequencing) can provide important insights to help guide future clinical trials at 
optimising probiotic therapies ahead of promoting large-scale administration. 
 
In this study, a 16S rRNA gene sequencing pipeline was optimised to depict the 
complexity of the gut microbiome in premature infants with and without probiotic 
supplementation (Chapter 1). 16S rRNA profiling is a cost-efficient sequencing 
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method, that is useful in large scale projects (e.g. clinical trials) involving hundreds 
or thousands of samples. This metataxonomic profiling provides the added 
advantage that it can sequence samples with a very low bacterial content (e.g. 
faecal samples from premature infants), due to the PCR-mediated amplification 
step. This work emphasizes the importance of; (i) choosing an adequate DNA 
extraction method, and (ii) targeting the hypervariable region of the 16S rRNA 
gene which offers the most representative bacterial community profile. 
 
The optimised 16S rRNA gene sequencing pipeline was used to assess the 
effectiveness of the probiotic supplementation Infloran®, a probiotic mix of 
Bifidobacterium bifidum and Lactobacillus acidophilus, on the preterm 
microbiome. This study represents the largest reported longitudinal study currently 
performed in premature infants (to our knowledge), and included 591 stool samples 
from 234 infants. This large body of work included many scientists, clinicians, and 
nurses, and I had the privilege to lead this work from establishing SOPs, obtaining 
ethical consent, engaging with health practitioners, recruiting patients, and right 
through to its publication. The main findings from this study (Chapter 2) were that 
(i) Infloran® supplementation beneficially modified the preterm microbiome by 
enhancing Bifidobacterium populations and reducing potential pathogenic bacteria, 
and (ii) probiotic supplementation contributed to augment the abundance of short 
chain fatty acids (i.e. acetate and lactate) in the supplemented group. The 
importance of this work is that it emphasises the exerting protective functional 
effects of microbial therapies on the preterm gut microbial communities, and 
contributes to provide evidence for changing clinical practice in NICUs.  
 
In recent times, there has been an increase in our knowledge of the human gut 
microbiome which has allowed the characterisation of gut microbiome profiles in 
health and disease. This has opened the door to new preventive microbiota 
therapies called Live Bio-Therapeutic Products (LBPs), which are probiotics used 
for prevention, treatment or cure of a disease251. A mechanistic understanding of 
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how probiotic supplementation provides health benefits to premature infants is yet 
to be determined, such an understanding would help justify changes in clinical 
policies among neonatal intensive care units. An important question concerns the 
mechanism(s) whereby health benefits are derived from microbial 
supplementation. This could be elucidated by focusing on the following questions:  
(i) How does Bifidobacterium contribute to provide colonisation resistance 
against other potential bacterial pathogens? 
(ii) How important is the role of infant diet or prebiotics to achieve a successful 
colonisation of Bifidobacterium in the preterm gut? 
  
Advances in the application of high-throughput shotgun metagenomic sequencing 
are expected to significantly contribute to answering some of these key questions. 
Shotgun metagenomic profiling, by virtue of sequencing the genomes of whole 
bacterial communities, can provide detailed information on the species/strain level, 
as well as identify important bacterial functional pathways such as genes involved 
in antimicrobial resistance. Approximately 78%-87% of premature infants receive 
antibiotics prophylactically within the first three days of life210, which are 
administered to prevent episodes of early-sepsis. Antibiotics are well-known to 
influence the composition of the preterm gut microbiome and, importantly, 
enhance the presence of antibiotic resistance genes (ARGs), which can be 
detrimental when fighting bacterial infections. In the work presented here, whole-
metagenome shotgun sequencing was performed on 95 stool samples from 34 
premature infants (Chapter 3). The aim of this work was to evaluate the short-term 
effects associated with prophylactic antibiotic treatment on the preterm gut 
microbiome, and to determine whether this practise contributes to enhanced gut-
associated antimicrobial resistance carriage. An important novelty of this study 
relates to the fact that several ‘sample sets´ included samples from premature 
infants receiving probiotic supplementation (to probe the role of this treatment 
regime on the carriage of AMR genes within the preterm gut microbiome), and 
samples from premature infants that did not receive supplementation (to explore 
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the impact of antibiotics alone in driving AMR over time in at-risk populations). 
The latter was particularly innovative as the administration of antibiotics in 
premature infants is so widespread, and yet this study managed to recruit 11 
premature infants who did not receive antibiotic treatment. Unexpectedly, it 
appears that (short-term) prophylactic antibiotic treatment had only a transient 
effect on the preterm gut, while the NICU environment appeared to more 
significantly alter preterm-associated microbial communities. Another surprising 
finding came from comparison of the total reservoir of AMR genes between infants 
treated with or without antibiotics, there was no significant difference in the profile 
of gene categories and their abundance. Furthermore, AMR genes conferring 
resistance to the prophylactic antibiotic treatments were already present in all 
bacterial pathogens detected. These findings may have implications for preliminary 
guidance for recommendations of the use of prophylactic antibiotic treatment in 
premature infants. 
 
The above data highlights that a more personalised antibiotic regime should be 
used to protect at-risk premature infants. Blood cultures are currently the “gold 
standard” for diagnosis of blood stream infections and characterisation of their 
antimicrobial susceptibility. The turnaround time of this technique is usually within 
18 to 24 h252, which highlights the necessity to use faster microbiological diagnosis 
techniques for at-risk patients. MinION Nanopore sequencing presents an attractive 
alternative to rapidly profile faecal samples from critically-ill premature infants 
suffering from necrotising enterocolitis or sepsis. The work performed in Chapter 4 
of this thesis demonstrates that MinION technology can rapidly diagnose bacterial 
pathogens as well as its AMR gene content in less than 6 h from sample receipt. 
However, there are still a few considerations to be able to implement this approach 
in large-scale testing: (i) this technology should be more affordable and (ii) able to 
sequence a larger number of samples. PromethION from Oxford Nanopore, uses 
the same technology as MinION but offers the possibility of sequencing 48 
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samples at the same time253. If cost are reduced, we may soon see the use of 
PromethION for routine microbial diagnosis in clinical laboratories. 
 
Overall, this multidisciplinary clinically-relevant work using high-throughput 
sequencing (i.e. 16S rRNA gene sequencing and shotgun metagenome sequencing) 
provides novel insights into the preterm gut microbiome in health and disease. In 
particular, it emphasises the protective role that probiotic supplementation plays 
when administered to premature infants, and the risks of using antibiotic treatment 
prophylactically. It also evaluates the applicability of a state-of-the-art technology 
such as MinION Nanopore platform for prompt microbial diagnostics. More 
fundamentally, this work illustrates how next-generation sequencing platforms 
linked to laboratory science can translate knowledge into a clinical application. 
Future considerations into how research institutions, pharmaceutical industry and 
clinicians must find ways to collaborate and integrate their knowledge is needed, to 





Number of raw read counts for shotgun and 16S rRNA gene sequencing data 
 
Samples for Shotgun sequencing    
 





V3J S1_1.fastq 9,536,453 8,420,963 
  
  S1_2.fastq 9,536,453   
  
AP8C S2_1.fastq 12,382,963 10,589,359 
  
  S2_2.fastq 12,382,963   
  
P29F S3_1.fastq 10,896,924 9,622,411 
  
  S3_2.fastq 10,896,924   
  
 Samples for 16S rRNA sequencing using PE     
 
Baby ID Shotgun samples Raw_read count 
After Quality 
filter 
in MEGAN (Paired 
when possible) 
 
  V1+V2+V3       
 
AP1E AP1E.27F_R1.fastq 154,509 146,552   
 
  AP1E.27F_R2.fastq 154,509 124,575 108,497 
 
AP25E AP25E.27F_R1.fastq 155,207 147,971   
 
  AP25E.27F_R2.fastq 155,207 122,997 270,759 
 
AP5D AP5D.27F_R1.fastq 101,963 97,419   
 
  AP5D.27F_R2.fastq 101,963 80,605 178,024 
 
AP8C AP8C.27F_R1.fastq 83,883 80,074   
 
  AP8C.27F_R2.fastq 83,883 66,301 146,371 
 
P29F P29F.27F_R1.fastq 100,264 95,214   
 
  P29F.27F_R2.fastq 100,264 75,983 171,169 
 
P30N P30N.27F_R1.fastq 113,827 108,139   
 
  P30N.27F_R2.fastq 113,827 88,764 196,897 
 
P31B P31B.27F_R1.fastq 104,542 100,022   
 
  P31B.27F_R2.fastq 104,542 83,931 183,910 
 
P35C P35C.27F_R1.fastq 131,266 124,227   
 
  P35C.27F_R2.fastq 131,266 101,482 225,702 
 
V2A V2A.27F_R1.fastq 104,410 99,819   
 
  V2A.27F_R2.fastq 104,410 80,254 180,052 
 
V3J V3J.27F_R1.fastq 94,344 90,100   
 
  V3J.27F_R2.fastq 94,344 72,869 162,932 
 
  V4+V5       
 
AP1E AP1E.530F_R1.fastq 1,079,921 1,054,856   
 
  AP1E.530F_R2.fastq 1,079,921 940,830 1,995,544 
 
AP25E AP25E.530F_R1.fastq 542,529 527,076   
 
  AP25E.530F_R2.fastq 542,529 444,981 967,069   
AP5D AP5D.530F_R1.fastq 754,988 737,055     
  AP5D.530F_R2.fastq 754,988 648,579 1,385,492 
 
AP8C AP8C.530F_R1.fastq 489,498 477,261   
 
 203 
  AP8C.530F_R2.fastq 489,498 415,314 892,360 
 
P29F P29F.530F_R1.fastq 469,124 457,067   
 
  P29F.530F_R2.fastq 469,124 394,279 846,302 
 
P30N P30N.530F_R1.fastq 576,331 564,022   
 
  P30N.530F_R2.fastq 576,331 493,048 1,056,787 
 
P31B P31B.530F_R1.fastq 423,862 413,347   
 
  P31B.530F_R2.fastq 423,862 363,728 776,976 
 
P35C P35C.530F_R1.fastq 492,809 483,177   
 
  P35C.530F_R2.fastq 492,809 429,850 912,978 
 
V2A V2A.530F_R1.fastq 679,918 662,228   
 
  V2A.530F_R2.fastq 679,918 574,822 1,236,324 
 
V3J V3J.530F_R1.fastq 418,955 408,725   
 
  V3J.530F_R2.fastq 418,955 356,165 763,712 
 
  V6+V7+V8       
 
AP1E AP1E.926F_R1.fastq 148,260 142,900   
 
  AP1E.926F_R2.fastq 148,260 117,216 260,092 
 
AP25E AP25E.926F_R1.fastq 139,882 135,615   
 
  AP25E.926F_R2.fastq 139,882 115,599 251,211 
 
AP5D AP5D.926F_R1.fastq 98,244 94,729   
 
  AP5D.926F_R2.fastq 98,244 80,025 174,754 
 
AP8C AP8C.926F_R1.fastq 99,080 95,770   
 
  AP8C.926F_R2.fastq 99,080 81,301 177,054 
 
P29F P29F.926F_R1.fastq 66,289 63,985   
 
  P29F.926F_R2.fastq 66,289 50,986 114,970 
 
P30N P30N.926F_R1.fastq 101,995 98,807   
 
  P30N.926F_R2.fastq 101,995 84,480 183,269 
 
P31B P31B.926F_R1.fastq 131,601 126,617   
 
  P31B.926F_R2.fastq 131,601 100,729 227,339 
 
P35C P35C.926F_R1.fastq 120,933 116,860   
 
  P35C.926F_R2.fastq 120,933 96,829 213,685 
 
V2A V2A.926F_R1.fastq 99,339 94,646   
 
  V2A.926F_R2.fastq 99,339 68,738 163,384 
 
V3J V3J.926F_R1.fastq 126,399 121,345   
 
  V3J.926F_R2.fastq 126,399 92,676 213,519 
 
Samples for 16S rRNA sequencing using QIIME       




  V1+V2+V3       
 
AP1E AP1E.27F_R1.fastq 154,509 149,927 74,768   
  AP1E.27F_R2.fastq 154,509     73,286 
AP25E AP25E.27F_R1.fastq 155,207 149,309 66,989   
  AP25E.27F_R2.fastq 155,207     66,233 
AP5D AP5D.27F_R1.fastq 101,963 96,606 31,555   
  AP5D.27F_R2.fastq 101,963     29,589 
AP8C AP8C.27F_R1.fastq 83,883 79,707 28,356   
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  AP8C.27F_R2.fastq 83,883     25,808 
P29F P29F.27F_R1.fastq 100,264 95,641 37,141   
  P29F.27F_R2.fastq 100,264     35,173 
P30N P30N.27F_R1.fastq 113,827 106,924 32,515   
  P30N.27F_R2.fastq 113,827     31,450 
P31B P31B.27F_R1.fastq 104,542 100,864 44,990   
  P31B.27F_R2.fastq 104,542     41,677 
P35C P35C.27F_R1.fastq 131,266 122,234 36,039   
  P35C.27F_R2.fastq 131,266     34,051 
V2A V2A.27F_R1.fastq 104,410 102,296 59,276   
  V2A.27F_R2.fastq 104,410     57,969 
V3J V3J.27F_R1.fastq 94,344 92,210 51,365   
  V3J.27F_R2.fastq 94,344     46,407 
  V4+V5         
AP1E AP1E.530F_R1.fastq 1,079,921 1,078,121 1,052,924   
  AP1E.530F_R2.fastq 1,079,921     1,028,760 
AP25E AP25E.530F_R1.fastq 542,529 541,235 521,658   
  AP25E.530F_R2.fastq 542,529     504,693 
AP5D AP5D.530F_R1.fastq 754,988 753,758 733,507   
  AP5D.530F_R2.fastq 754,988     715,114 
AP8C AP8C.530F_R1.fastq 489,498 488,558 474,597   
  AP8C.530F_R2.fastq 489,498     450,256 
P29F P29F.530F_R1.fastq 469,124 467,292 452,341   
  P29F.530F_R2.fastq 469,124     430,128 
P30N P30N.530F_R1.fastq 576,331 575,366 560,498   
  P30N.530F_R2.fastq 576,331     546,603 
P31B P31B.530F_R1.fastq 423,862 423,043 412,194   
  P31B.530F_R2.fastq 423,862     396,517 
P35C P35C.530F_R1.fastq 492,809 491,243 479,886   
  P35C.530F_R2.fastq 492,809     462,862 
V2A V2A.530F_R1.fastq 679,918 678,285 658,393   
  V2A.530F_R2.fastq 679,918     635,528 
V3J V3J.530F_R1.fastq 418,955 417,757 405,838   
  V3J.530F_R2.fastq 418,955     384,789 
  V6+V7+V8 
        
AP1E AP1E.926F_R1.fastq 148,260 146,736 99,832   
  AP1E.926F_R2.fastq 148,260     94,851 
AP25E AP25E.926F_R1.fastq 139,882 138,988 103,182   
  AP25E.926F_R2.fastq 139,882     101,554 
AP5D AP5D.926F_R1.fastq 98,244 97,503 69,336   
  AP5D.926F_R2.fastq 98,244     62,979 
AP8C AP8C.926F_R1.fastq 99,080 98,425 71,562   
  AP8C.926F_R2.fastq 99,080     59,316 
P29F P29F.926F_R1.fastq 66,289 65,658 41,768   
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  P29F.926F_R2.fastq 66,289     36,853 
P30N P30N.926F_R1.fastq 101,995 101,345 74,108   
  P30N.926F_R2.fastq 101,995     69,663 
P31B P31B.926F_R1.fastq 131,601 129,856 76,795   
  P31B.926F_R2.fastq 131,601     31,552 
P35C P35C.926F_R1.fastq 120,933 119,842 82,133   
  P35C.926F_R2.fastq 120,933     61,947 
V2A V2A.926F_R1.fastq 99,339 97,790 48,016   
  V2A.926F_R2.fastq 99,339     45,181 
V3J V3J.926F_R1.fastq 126,399 124,563 70,010   
























AP10A F C 710 26 y BM NA Addenbrookes Control 
AP10E F C 710 26 n BM NA Addenbrookes Control 
AP11A M C 740 25 n BM NA Addenbrookes Control 
AP12B F C 785 25 n BM_F NA Addenbrookes Control 
AP12D F C 785 25 n BM_F NA Addenbrookes Control 
AP12G F C 785 25 n BM NA Addenbrookes Control 
AP12I F C 785 25 n BM NA Addenbrookes Control 
AP14A F V 980 27 n BM NA Addenbrookes Control 
AP16B F V 1190 34 y BM NA Addenbrookes Control 
AP16C F V 1190 34 n BM NA Addenbrookes Control 
AP17A M C 1400 30 y BM NA Addenbrookes Control 
AP19A M V 1180 27 y BM NA Addenbrookes Control 
AP19C M V 1180 27 n BM NA Addenbrookes Control 
AP19E M V 1180 27 y BM NA Addenbrookes Control 
AP1D F C 830 25 y BM NA Addenbrookes Control 
AP1E F C 830 25 n BM NA Addenbrookes Control 
AP1F F C 830 25 n BM NA Addenbrookes Control 
AP1J F C 830 25 n BM NA Addenbrookes Control 
AP20B F V 710 25 y BM NA Addenbrookes Control 
AP20D F V 710 25 n BM NA Addenbrookes Control 
AP21 F V 790 25 n BM NA Addenbrookes Control 
AP21C F V 790 25 n BM NA Addenbrookes Control 
AP21D F V 790 25 y BM NA Addenbrookes Control 
AP21E F V 790 25 n BM NA Addenbrookes Control 
AP22B F C 605 25 n BM NA Addenbrookes Control 
AP22D F C 605 25 y BM NA Addenbrookes Control 
AP23H F C 700 25 n BM NA Addenbrookes Control 
AP24A F V 785 28 NA NA NA Addenbrookes Control 
AP25C F C 785 25 n BM_DBM NA 
Addenbrooke
s Control 
AP25F F C 785 25 n BM NA Addenbrookes Control 
AP26A F C 830 27 n BM NA Addenbrookes Control 
AP28A M C 985 26 n BM NA Addenbrookes Control 
AP28C M C 985 26 n BM NA Addenbrookes Control 
AP2D F V 600 24 n BM NA Addenbrookes Control 
AP2F F V 600 24 n BM NA Addenbrookes Control 
AP2J F V 600 24 n BM NA Addenbrookes Control 
AP2K F V 600 24 n BM NA Addenbrookes Control 
AP3B F V 1520 29 y BM NA Addenbrookes Control 
AP3C F V 1520 29 n BM NA Addenbrookes Control 
AP3D F V 1520 29 n BM_F NA Addenbrookes Control 
AP3E F V 1520 29 n BM_F NA Addenbrookes Control 
AP5A F V 800 25 y BM NA Addenbrookes Control 
AP5B F V 800 25 y BM NA Addenbrookes Control 
AP5H F V 800 25 n BM_F NA Addenbrookes Control 
AP5I F V 800 25 n BM_F NA Addenbrookes Control 
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AP6B M C 570 28 y BM NA Addenbrookes Control 
AP6F M C 570 28 n BM NA Addenbrookes Control 
AP6I M C 570 28 n BM NA Addenbrookes Control 
AP6O M C 570 28 n BM NA Addenbrookes Control 
AP8B M V 576 23 n BM NA Addenbrookes Control 
AP9C F C 1020 29 n BM NA Addenbrookes Control 
M100.1 M V 1380 30 n BM_DBM NA Imperial Control 
M100.2 M V 1380 30 n BM_DBM NA Imperial Control 
M101.1 M C 1320 30 n BM_DBM NA Imperial Control 
M101.2 M C 1320 30 n BM_DBM NA Imperial Control 
M103.1 F C 1210 28 n BM NA Imperial Control 
M103.2 F C 1210 28 n BM_F NA Imperial Control 
M111.1 F V 1380 30 n BM_DBM NA Imperial Control 
M111.2 F V 1380 30 n BM_DBM NA Imperial Control 
M114.1 F V 1535 30 y BM NA Imperial Control 
M114.2 F V 1535 30 n BM NA Imperial Control 
M115.2 F C 1476 30 n BM_DBM NA Imperial Control 
M118.1 F V 1190 30 n BM_DBM NA Imperial Control 
M118.2 F V 1190 30 n BM_F NA Imperial Control 
M121.1 F C 1270 29 n BM_DBM NA Imperial Control 
M121.2 F C 1270 29 n BM_DBM NA Imperial Control 
M121.3 F C 1270 29 n BM NA Imperial Control 
M121.4 F C 1270 29 n BM NA Imperial Control 
M121.5 F C 1270 29 n BM NA Imperial Control 
M122.1 M V 1005 27 n BM NA Imperial Control 
M122.3 M V 1005 27 n BM NA Imperial Control 
M122.6 M V 1005 27 n BM NA Imperial Control 
M123.1 M V 1950 31 y BM NA Imperial Control 
M123.2 M V 1950 31 n BM NA Imperial Control 
M124.1 F C 1567 31 n F NA Imperial Control 
M125.2 M C 1230 31 n F NA Imperial Control 
M126.1 M C 1470 29 n BM NA Imperial Control 
M126.3 M C 1470 29 n BM NA Imperial Control 
M126.4 M C 1470 29 n BM NA Imperial Control 
M127.1 F C 1080 30 y BM_DBM NA Imperial Control 
M127.2 F C 1080 30 n BM_DBM NA Imperial Control 
M128.1 M C 1320 30 n BM_DBM NA Imperial Control 
M129.1 F C 800 29 n BM_DBM NA Imperial Control 
M129.2 F C 800 29 n BM_F NA Imperial Control 
M130.1 M C 975 31 n BM_DBM NA Imperial Control 
M131.1 F C 1640 30 n BM_F NA Imperial Control 
M131.2 F C 1640 30 n BM_F NA Imperial Control 
M134.1 F C 1371 31 n BM_F NA Imperial Control 
M135.1 F C 1750 31 n BM_F NA Imperial Control 
M135.2 F C 1750 31 n BM_F NA Imperial Control 
M15.1 M C 1370 30 n BM NA Imperial Control 
M15.2 M C 1370 30 n BM NA Imperial Control 
M15.3 M C 1370 30 n BM NA Imperial Control 
M15.4 M C 1370 30 n BM NA Imperial Control 
M15.5 M C 1370 30 n BM NA Imperial Control 
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M15.6 M C 1370 30 n BM NA Imperial Control 
M16.1 M C 1340 29 n BM NA Imperial Control 
M16.2 M C 1340 29 n BM NA Imperial Control 
M17.1 M C 1200 29 n BM NA Imperial Control 
M17.2 M C 1200 29 n BM NA Imperial Control 
M18.1 F C 1100 29 n BM NA Imperial Control 
M18.2 F C 1100 29 n BM NA Imperial Control 
M22.1 M C 1260 31 n BM NA Imperial Control 
M22.2 M C 1260 31 n BM_F NA Imperial Control 
M26.1 F C 1100 28 n BM_F NA Imperial Control 
M26.2 F C 1100 28 n BM_F NA Imperial Control 
M27.1 F C 923 31 y BM NA Imperial Control 
M27.2 F C 923 31 n BM NA Imperial Control 
M27.3 F C 923 31 n BM NA Imperial Control 
M29.1 F C 1100 28 n BM NA Imperial Control 
M29.2 F C 1100 28 n BM NA Imperial Control 
M36.1 F V 1780 31 y BM NA Imperial Control 
M36.2 F V 1780 31 y BM NA Imperial Control 
M36.3 F V 1780 31 n BM NA Imperial Control 
M37.1 F V 1320 31 n BM_F NA Imperial Control 
M37.2 F V 1320 31 n BM_F NA Imperial Control 
M37.3 F V 1320 31 n BM_F NA Imperial Control 
M37.4 F V 1320 31 n BM_F NA Imperial Control 
M37.5 F V 1320 31 n BM_F NA Imperial Control 
M38.1 M C 1110 29 n BM_DBM NA Imperial Control 
M38.2 M C 1110 29 n BM_DBM NA Imperial Control 
M39.1 F V 1330 28 n BM_DBM NA Imperial Control 
M39.2 F V 1330 28 n BM_DBM NA Imperial Control 
M39.3 F V 1330 28 n BM NA Imperial Control 
M39.4 F V 1330 28 n BM NA Imperial Control 
M54.1 M C 1000 28 n BM_DBM NA Imperial Control 
M54.2 M C 1000 28 n BM_DBM NA Imperial Control 
M55.1 F C 1100 28 n BM_DBM NA Imperial Control 
M55.2 F C 1100 28 n BM_DBM NA Imperial Control 
M56.1 F C 950 28 n BM_DBM NA Imperial Control 
M56.2 F C 950 28 n BM_DBM NA Imperial Control 
M58.1 M C 980 28 n BM_DBM NA Imperial Control 
M58.2 M C 980 28 n BM NA Imperial Control 
M59.1 F C 1000 28 n BM_DBM NA Imperial Control 
M59.2 F C 1000 28 n BM NA Imperial Control 
M60.1 F C 950 28 n BM_DBM NA Imperial Control 
M60.2 F C 950 28 n BM NA Imperial Control 
M62.1 M C 1840 31 n F NA Imperial Control 
M62.2 M C 1840 31 n BM_F NA Imperial Control 
M63.1 M V 1830 31 y BM_F NA Imperial Control 
M63.2 M V 1830 31 n BM_F NA Imperial Control 
M65.1 M V 1100 28 y BM_F NA Imperial Control 
M65.2 M V 1100 28 y BM_F NA Imperial Control 
M7.1 M V 1460 31 n BM_F NA Imperial Control 
M7.2 M V 1460 31 n BM_F NA Imperial Control 
 209 
M7.3 M V 1460 31 n BM_F NA Imperial Control 
M70.1 F V 1720 31 n BM_F NA Imperial Control 
M70.2 F V 1720 31 n BM_F NA Imperial Control 
M73.1 M C 1730 31 n BM NA Imperial Control 
M73.2 M C 1730 31 n BM NA Imperial Control 
M77.1 F C 1300 30 n BM_DBM NA Imperial Control 
M77.2 F C 1300 30 n BM_DBM NA Imperial Control 
M77.3 F C 1300 30 n BM NA Imperial Control 
M78.1 M V 1360 29 y BM_F NA Imperial Control 
M78.2 M V 1360 29 n BM_F NA Imperial Control 
M79.1 F C 1260 30 n BM_DBM NA Imperial Control 
M79.2 F C 1260 30 n BM NA Imperial Control 
M82.1 M C 1100 30 y BM_DBM NA Imperial Control 
M82.2 M C 1100 30 n BM_DBM NA Imperial Control 
M84.1 M C 1630 30 y BM_DBM NA Imperial Control 
M84.2 M C 1630 30 n BM_F NA Imperial Control 
M85.1 M C 1350 30 n BM_F NA Imperial Control 
M85.2 M C 1350 30 n BM_DBM NA Imperial Control 
M86.1 F C 1090 30 n BM NA Imperial Control 
M86.2 F C 1090 30 n BM_DBM NA Imperial Control 
M87.1 M C 920 27 n BM_DBM NA Imperial Control 
M87.2 M C 1081 27 n BM_DBM NA Imperial Control 
M87.3 M C 1080 27 n BM_DBM NA Imperial Control 
M88.1 M C 920 27 n BM_DBM NA Imperial Control 
M88.2 M C 920 27 n BM_DBM NA Imperial Control 
M88.3 M C 920 27 n BM_DBM NA Imperial Control 
M88.4 M C 920 27 n BM_DBM NA Imperial Control 
M89.1 F C 1215 30 y BM_DBM NA Imperial Control 
M89.2 F C 1215 30 n BM_DBM NA Imperial Control 
M90.1 F C 1275 30 n BM_DBM NA Imperial Control 
M90.2 F C 1275 30 n BM_DBM NA Imperial Control 
M91.1 F V 1090 29 y BM_DBM NA Imperial Control 
M91.2 F V 1090 29 n BM_DBM NA Imperial Control 
M91.3 F V 1090 29 n BM_DBM NA Imperial Control 
M92.1 M V 1270 28 n BM_DBM NA Imperial Control 
M92.2 M V 1270 28 n BM NA Imperial Control 
M92.3 M V 1270 28 n BM NA Imperial Control 
M93.1 M V 978 29 y BM_DBM NA Imperial Control 
M93.2 M V 978 29 n BM_DBM NA Imperial Control 
M93.3 M V 978 29 n BM NA Imperial Control 
M94.1 M V 1040 28 y BM_DBM NA Imperial Control 
M94.2 M V 1040 28 n BM_DBM NA Imperial Control 
M94.3 M V 1040 28 n BM_F NA Imperial Control 
M95.1 M V 1410 29 y BM_DBM NA Imperial Control 
M95.2 M V 1410 29 n BM NA Imperial Control 
M95.3 M V 1410 29 n BM NA Imperial Control 
M95.4 M V 1410 29 n BM NA Imperial Control 
P100A M C 750 28 y BM 4 NNUH Probiotic 
P100H M C 750 28 n BM 14 NNUH Probiotic 
P102F F V 1930 31 y BM 7 NNUH Probiotic 
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P102J F V 1930 31 n BM 11 NNUH Probiotic 
P103A F C 1065 30 n BM 7 NNUH Probiotic 
P103G F C 1065 30 n BM 11 NNUH Probiotic 
P103O F C 1065 30 n BM 20 NNUH Probiotic 
P104E M C 1200 27 y BM 10 NNUH Probiotic 
P104K M C 1200 27 n BM_F 39 NNUH Probiotic 
P104L M C 1200 27 n BM 39 NNUH Probiotic 
P105E M V 1410 30 n BM 9 NNUH Probiotic 
P105I M V 1410 30 n BM 14 NNUH Probiotic 
P105L M V 1410 30 y BM 24 NNUH Probiotic 
P106C F V 1402 30 n BM 4 NNUH Probiotic 
P106H F V 1402 30 y BM 10 NNUH Probiotic 
P106M F V 1402 30 n BM 31 NNUH Probiotic 
P107B F C 1515 33 n BM 0 NNUH Probiotic 
P108C F V 549 24 y BM 17 NNUH Probiotic 
P108K F V 549 24 n BM 42 NNUH Probiotic 
P108M F V 549 24 n BM 63 NNUH Probiotic 
P109D F C 1315 31 n BM_DBM 17 NNUH Probiotic 
P10N M V 1050 26 n BM 9 NNUH Probiotic 
P10T M V 1050 26 NA BM 18 NNUH Probiotic 
P10V M V 1050 26 NA NA 18 NNUH Probiotic 
P110B F V 567 23 n BM 14 NNUH Probiotic 
P110P F V 567 23 n BM 44 NNUH Probiotic 
P110Q F V 567 23 y BM 55 NNUH Probiotic 
P111C F V 602 24 y BM 11 NNUH Probiotic 
P111D F V 602 24 y BM 12 NNUH Probiotic 
P111G F V 602 24 n BM 37 NNUH Probiotic 
P111H F V 602 24 n BM 39 NNUH Probiotic 
P111O F V 602 24 n BM 60 NNUH Probiotic 
P112C M C 1151 29 y BM 6 NNUH Probiotic 
P112H M C 1151 29 n BM 14 NNUH Probiotic 
P112N M C 1151 29 n BM 35 NNUH Probiotic 
P113A F V 1385 29 n F 17 NNUH Probiotic 
P113F F V 1385 29 n F 36 NNUH Probiotic 
P114B F V 1260 29 n F 18 NNUH Probiotic 
P114H F V 1260 29 n F 42 NNUH Probiotic 
P115C F C 554 25 y BM 14 NNUH Probiotic 
P115M F C 554 25 n DBM 41 NNUH Probiotic 
P116F M V 685 24 n BM 11 NNUH Probiotic 
P117B F V 930 26 y BM 11 NNUH Probiotic 
P118E M C 1485 33 y BM 10 NNUH Probiotic 
P118G M C 1485 33 n BM 13 NNUH Probiotic 
P119B F V 1420 33 n BM 6 NNUH Probiotic 
P119D F V 1420 33 n NA 6 NNUH Probiotic 
P11F M C 1640 30 y BM 18 NNUH Probiotic 
P120B M C 624 27 n BM 9 NNUH Probiotic 
P120K M C 624 27 y BM 34 NNUH Probiotic 
P12A M V 1000 26 y BM 2 NNUH Probiotic 
P12F M V 1000 26 n BM 10 NNUH Probiotic 
P12K M V 1000 26 n BM 31 NNUH Probiotic 
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P12M M V 1000 26 n BM 31 NNUH Probiotic 
P13A F C 700 25 y BM 2 NNUH Probiotic 
P14C F V 1400 32 y BM_F 4 NNUH Probiotic 
P14F F V 1400 32 n BM_F 10 NNUH Probiotic 
P15G F V 1520 32 n BM_F 6 NNUH Probiotic 
P15I F V 1520 32 n BM_F 9 NNUH Probiotic 
P16D F V 707 24 y BM 6 NNUH Probiotic 
P16J F V 707 24 y BM 13 NNUH Probiotic 
P16S F V 707 24 n BM 46 NNUH Probiotic 
P16V F V 707 24 n BM 46 NNUH Probiotic 
P17A F V 774 24 y BM 4 NNUH Probiotic 
P17B F V 774 24 y BM 6 NNUH Probiotic 
P18D F V 750 26 n BM_DBM 17 NNUH Probiotic 
P18H F V 750 26 n BM_DBM 18 NNUH Probiotic 
P18I F V 750 26 n BM_DBM 18 NNUH Probiotic 
P18K F V 750 26 n BM_DBM 18 NNUH Probiotic 
P19K M V 780 24 y BM 9 NNUH Probiotic 
P19S M V 780 24 n NA 9 NNUH Probiotic 
P20B M V 1000 29 n BM 4 NNUH Probiotic 
P20H M V 1000 29 n BM 10 NNUH Probiotic 
P20O M V 1000 29 n BM 39 NNUH Probiotic 
P20Q M V 1000 29 n BM 39 NNUH Probiotic 
P21A F V 1209 29 n BM 5 NNUH Probiotic 
P21D F V 1209 29 n BM 7 NNUH Probiotic 
P21L F V 1209 29 n BM 14 NNUH Probiotic 
P21U F V 1209 29 n BM 44 NNUH Probiotic 
P22 M C 1443 31 y BM 5 NNUH Probiotic 
P22A M C 1443 31 n BM 6 NNUH Probiotic 
P23C M C 975 31 n BM 6 NNUH Probiotic 
P23D M C 975 31 n BM 6 NNUH Probiotic 
P24B F C 1215 31 y BM 5 NNUH Probiotic 
P24G F C 1215 31 n BM 11 NNUH Probiotic 
P25O F V 860 25 y BM_DBM 12 NNUH Probiotic 
P25S F V 860 25 n NA 58 NNUH Probiotic 
P27F M C 1229 32 y BM 7 NNUH Probiotic 
P27J M C 1229 32 y BM 12 NNUH Probiotic 
P28A M V 780 25 y BM_DBM 0 NNUH Probiotic 
P28G M V 780 25 y BM_DBM 6 NNUH Probiotic 
P28R M V 780 25 n BM_DBM 20 NNUH Probiotic 
P29C M V 935 26 y BM 1 NNUH Probiotic 
P29G M V 935 26 y BM 6 NNUH Probiotic 
P29L M V 935 26 n BM 39 NNUH Probiotic 
P31Y F V 605 23 n BM 85 NNUH Probiotic 
P32C F C 775 26 y BM 3 NNUH Probiotic 
P32H F C 775 26 y BM 10 NNUH Probiotic 
P32O F C 775 26 n BM 53 NNUH Probiotic 
P33 M C 1170 28 y BM 4 NNUH Probiotic 
P33E M C 1170 28 n BM 13 NNUH Probiotic 
P33J M C 1170 28 n BM 39 NNUH Probiotic 
P35E M V 565 23 y BM 14 NNUH Probiotic 
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P35M M V 565 23 y BM 39 NNUH Probiotic 
P35P M V 565 23 n BM 52 NNUH Probiotic 
P37C M C 1050 32 y BM 11 NNUH Probiotic 
P38E F C 950 33 n BM 11 NNUH Probiotic 
P38K.1 F C 950 33 n NA 48 NNUH Probiotic 
P38K.2 F C 950 33 n NA 48 NNUH Probiotic 
P39C M C 1129 27 n BM 13 NNUH Probiotic 
P39D M C 1129 27 n BM 13 NNUH Probiotic 
P39K M C 1129 27 n NA 53 NNUH Probiotic 
P40H M C 1039 27 y BM 12 NNUH Probiotic 
P40S M C 1039 27 n BM_F 42 NNUH Probiotic 
P40V M C 1039 27 y F 53 NNUH Probiotic 
P41 M C 795 25 y BM 2 NNUH Probiotic 
P41D M C 795 25 n BM 8 NNUH Probiotic 
P42H F V 1384 29 n DBM 20 NNUH Probiotic 
P42I F V 1384 29 n DBM 31 NNUH Probiotic 
P45C M V 1372 30 n F 6 NNUH Probiotic 
P45D M V 1372 30 n F 7 NNUH Probiotic 
P45H M V 1372 30 n F 12 NNUH Probiotic 
P46 M V 1700 30 n BM_F 6 NNUH Probiotic 
P46E M V 1700 30 n BM_F 11 NNUH Probiotic 
P47F F C 1485 32 y BM_F 4 NNUH Probiotic 
P47M F C 1485 32 n BM_F 9 NNUH Probiotic 
P48C M V 1425 30 y BM_F 6 NNUH Probiotic 
P48K M V 1425 30 n F 9 NNUH Probiotic 
P48P M V 1425 30 n BM_F 22 NNUH Probiotic 
P49D M V 1785 33 y F 0 NNUH Probiotic 
P50F F V 935 25 n BM 10 NNUH Probiotic 
P50H F V 935 25 n BM 15 NNUH Probiotic 
P50L F V 935 25 n BM 38 NNUH Probiotic 
P51E F V 1434 31 y BM 1 NNUH Probiotic 
P51J F V 1434 31 n BM 9 NNUH Probiotic 
P51K F V 1434 31 n BM 11 NNUH Probiotic 
P51O F V 1434 31 n BM 20 NNUH Probiotic 
P51P F V 1434 31 n BM_F NA NNUH Probiotic 
P52F M V 900 27 y BM 7 NNUH Probiotic 
P52H M V 900 27 n NA 39 NNUH Probiotic 
P53D M V 1250 27 y BM_DBM 3 NNUH Probiotic 
P53G M V 1250 27 n BM_DBM 13 NNUH Probiotic 
P53K M V 1250 27 y BM_DBM 19 NNUH Probiotic 
P53L M V 1250 27 n BM_F 40 NNUH Probiotic 
P53O M V 1250 27 n NA 40 NNUH Probiotic 
P55B F C 749 29 y BM 8 NNUH Probiotic 
P55D F C 749 29 n BM 12 NNUH Probiotic 
P55E F C 749 29 n BM 13 NNUH Probiotic 
P55L F C 749 29 n BM 39 NNUH Probiotic 
P55N F C 749 29 n BM 44 NNUH Probiotic 
P56A M C 1110 27 y BM 4 NNUH Probiotic 
P56D M C 1110 27 n BM 10 NNUH Probiotic 
P56H M C 1110 27 n BM 41 NNUH Probiotic 
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P57E F C 900 26 n BM 6 NNUH Probiotic 
P57M F C 900 26 n BM 13 NNUH Probiotic 
P57O F C 900 26 n BM 19 NNUH Probiotic 
P58H F C 1010 26 y BM 3 NNUH Probiotic 
P58K F C 1010 26 n BM 9 NNUH Probiotic 
P59E F C 784 32 n BM 31 NNUH Probiotic 
P60F F C 1230 33 n BM 3 NNUH Probiotic 
P60I F C 1230 33 n BM 7 NNUH Probiotic 
P60K F C 1230 33 n BM 13 NNUH Probiotic 
P61C M V 562 24 y NA 12 NNUH Probiotic 
P61F M V 562 24 n BM 39 NNUH Probiotic 
P61N M V 562 24 n BM 64 NNUH Probiotic 
P62A F C 940 30 n BM 2 NNUH Probiotic 
P62F F C 940 30 n BM 8 NNUH Probiotic 
P62H F C 940 30 n BM_F 13 NNUH Probiotic 
P62L F C 940 30 n F 24 NNUH Probiotic 
P63C M V 1374 30 n BM 6 NNUH Probiotic 
P63I M V 1374 30 n BM 11 NNUH Probiotic 
P63N M V 1374 30 n F 28 NNUH Probiotic 
P64E M V 992 30 n BM_DBM 7 NNUH Probiotic 
P64G M V 992 30 n BM_DBM 11 NNUH Probiotic 
P64H M V 992 30 n F 14 NNUH Probiotic 
P64M M V 992 30 n F 28 NNUH Probiotic 
P64O M V 992 30 n F 28 NNUH Probiotic 
P65C F V 1477 30 n BM_DBM 6 NNUH Probiotic 
P65H F V 1477 30 n F 11 NNUH Probiotic 
P65J F V 1477 30 n F 13 NNUH Probiotic 
P65N F V 1477 30 n F 28 NNUH Probiotic 
P65Q F V 670 30 n F 28 NNUH Probiotic 
P66C F C 670 31 y BM 0 NNUH Probiotic 
P66D F C 670 31 y BM 10 NNUH Probiotic 
P66J F C 670 31 n F 23 NNUH Probiotic 
P66M F C 670 31 n F 23 NNUH Probiotic 
P67F F C 800 25 n BM_F 14 NNUH Probiotic 
P67J F C 800 25 y BM 36 NNUH Probiotic 
P67K F C 800 25 n NA 37 NNUH Probiotic 
P68B M C 858 25 y BM 9 NNUH Probiotic 
P68E M C 858 25 n BM 17 NNUH Probiotic 
P68I.1 M C 858 25 n BM 37 NNUH Probiotic 
P68I.2 M C 858 25 n BM 37 NNUH Probiotic 
P69A M C 1520 31 n BM 5 NNUH Probiotic 
P69C M C 1520 31 n BM 8 NNUH Probiotic 
P69E M C 1520 31 n BM 11 NNUH Probiotic 
P69I M C 1520 31 n NA 18 NNUH Probiotic 
P70H M C 1255 30 n BM 12 NNUH Probiotic 
P70M M C 1255 30 n F 28 NNUH Probiotic 
P71G F C 1065 31 n BM 8 NNUH Probiotic 
P71N F C 1065 31 n NA 17 NNUH Probiotic 
P71O F C 1065 31 n NA 17 NNUH Probiotic 
P72D M C 1454 30 y BM_F 3 NNUH Probiotic 
 214 
P72G M C 1454 30 n BM_F 7 NNUH Probiotic 
P73C F C 1504 30 n BM 4 NNUH Probiotic 
P73D F C 1504 30 n BM 9 NNUH Probiotic 
P74B M C 1382 31 y BM 2 NNUH Probiotic 
P74D M C 1382 31 n BM 7 NNUH Probiotic 
P74F M C 1382 31 n BM 13 NNUH Probiotic 
P74H M C 1382 31 n NA 19 NNUH Probiotic 
P75B M V 1262 27 y BM 5 NNUH Probiotic 
P75D M V 1262 27 n BM 12 NNUH Probiotic 
P75K M V 1262 27 n BM 44 NNUH Probiotic 
P75M M V 1262 27 n BM_DBM 44 NNUH Probiotic 
P76B M V 1409 27 y BM 3 NNUH Probiotic 
P76E M V 1409 27 n BM 5 NNUH Probiotic 
P76H M V 1409 27 n BM 11 NNUH Probiotic 
P76K M V 1409 27 n BM 23 NNUH Probiotic 
P76N M V 1409 27 n BM 42 NNUH Probiotic 
P76P M V 1409 27 n BM 42 NNUH Probiotic 
P77H F C 1110 30 n BM 8 NNUH Probiotic 
P77O F C 1110 30 n NA 17 NNUH Probiotic 
P78C F C 1236 32 y BM_DBM 4 NNUH Probiotic 
P78G F C 1236 32 n F 10 NNUH Probiotic 
P79B M C 1544 30 y BM_DBM 2 NNUH Probiotic 
P79D M C 1544 30 n F 7 NNUH Probiotic 
P79G M C 1544 30 n F 13 NNUH Probiotic 
P79J M C 1544 30 n NA 24 NNUH Probiotic 
P80A M V 831 25 y BM 3 NNUH Probiotic 
P80B M V 831 25 n BM 11 NNUH Probiotic 
P80D M V 831 25 n BM 13 NNUH Probiotic 
P80J M V 831 25 n BM 49 NNUH Probiotic 
P80L M V 831 25 n BM 62 NNUH Probiotic 
P81B M C 960 26 n BM 6 NNUH Probiotic 
P81F M C 960 26 n BM 13 NNUH Probiotic 
P81L M C 960 26 n BM 39 NNUH Probiotic 
P81N M C 960 26 n NA 48 NNUH Probiotic 
P82A M C 920 28 y BM 2 NNUH Probiotic 
P82F M C 920 28 n BM 9 NNUH Probiotic 
P82O M C 920 28 n F 39 NNUH Probiotic 
P82R M C 920 28 y F 39 NNUH Probiotic 
P83B F C 1030 32 y BM 5 NNUH Probiotic 
P83D F C 1030 32 n BM 9 NNUH Probiotic 
P83G F C 1030 32 n BM 12 NNUH Probiotic 
P85B M C 1224 30 y BM 7 NNUH Probiotic 
P85D M C 1224 30 n BM 9 NNUH Probiotic 
P85E M C 1224 30 n BM 11 NNUH Probiotic 
P85H M C 1224 30 n NA 15 NNUH Probiotic 
P86E.1 M C 1400 31 n BM 9 NNUH Probiotic 
P86E.2 M C 1400 31 n BM 9 NNUH Probiotic 
P86J M C 1400 31 n BM 18 NNUH Probiotic 
P86L M C 1400 31 n NA 18 NNUH Probiotic 
P91E F V 700 24 y BM 14 NNUH Probiotic 
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P91K F V 700 24 n BM 40 NNUH Probiotic 
P91N F V 700 24 n BM 58 NNUH Probiotic 
P95C F C 1100 30 n BM 7 NNUH Probiotic 
P95G F C 1100 30 n BM 14 NNUH Probiotic 
P95N F C 1100 30 n BM 27 NNUH Probiotic 
P96D M V 694 25 n BM 12 NNUH Probiotic 
P96G M V 694 25 n BM 20 NNUH Probiotic 
P96M M V 694 25 n NA 27 NNUH Probiotic 
P96N M V 694 25 n NA 27 NNUH Probiotic 
P97O M V 530 24 n BM 30 NNUH Probiotic 
P97T M V 530 24 n BM 49 NNUH Probiotic 
P98C M V 685 24 n BM 14 NNUH Probiotic 
P98J M V 685 24 y BM 32 NNUH Probiotic 
P98N M V 685 24 n BM 50 NNUH Probiotic 
P9G M V 964 26 y BM_DBM 13 NNUH Probiotic 
P9P M V 964 26 n BM_DBM 21 NNUH Probiotic 
Q1.1 M C 1125 26 n BM_DBM NA Imperial Control 
Q1.2 M C 1125 26 n BM_DBM NA Imperial Control 
Q1.3 M C 1125 26 n BM NA Imperial Control 
Q101.1 M C 1035 28 n BM NA Imperial Control 
Q101.2 M C 1035 28 n BM NA Imperial Control 
Q101.3 M C 1035 28 n BM NA Imperial Control 
Q101.4 M C 1035 28 n BM NA Imperial Control 
Q105.1 F C 1000 26 y BM_DBM NA Imperial Control 
Q105.2 F C 1000 26 y BM_DBM NA Imperial Control 
Q105.3 F C 1000 26 n BM_DBM NA Imperial Control 
Q105.4 F C 1000 26 n BM_F NA Imperial Control 
Q107.1 M C 905 26 y BM_DBM NA Imperial Control 
Q107.2 M C 905 26 n BM_DBM NA Imperial Control 
Q107.3 M C 905 26 n BM_DBM NA Imperial Control 
Q109.1 F V 1005 27 y BM NA Imperial Control 
Q109.2 F V 1005 27 n BM NA Imperial Control 
Q112.1 F C 1450 31 n BM_F NA Imperial Control 
Q112.2 F C 1450 31 n BM NA Imperial Control 
Q113.1 F C 815 26 y BM_DBM NA Imperial Control 
Q113.2 F C 815 26 y BM NA Imperial Control 
Q113.3 F C 815 26 n BM NA Imperial Control 
Q113.4 F C 815 26 n BM NA Imperial Control 
Q116.1 M V 1200 29 y BM_DBM NA Imperial Control 
Q116.2 M V 1200 29 n BM_DBM NA Imperial Control 
Q117.1 F V 625 25 n BM_DBM NA Imperial Control 
Q117.2 F V 625 25 n BM_DBM NA Imperial Control 
Q117.3 F V 625 25 n BM NA Imperial Control 
Q119.1 F V 1540 31 n BM_DBM NA Imperial Control 
Q119.2 F V 1540 31 n BM_DBM NA Imperial Control 
Q121.1 F V 560 25 y BM_DBM NA Imperial Control 
Q121.2 F V 560 25 n BM NA Imperial Control 
Q121.3 F V 560 25 n BM NA Imperial Control 
Q122.1 F V 690 25 y BM_DBM NA Imperial Control 
Q122.2 F V 690 25 y BM NA Imperial Control 
 216 
Q122.3 F V 690 25 n BM NA Imperial Control 
Q128.1 M C 1215 28 n BM_DBM NA Imperial Control 
Q128.2 M C 1215 28 n BM_DBM NA Imperial Control 
Q128.3 M C 1215 28 y BM NA Imperial Control 
Q129.1 M V 570 23 n BM_F NA Imperial Control 
Q129.2 M V 570 23 n BM_F NA Imperial Control 
Q13.1 F C 770 29 n BM_DBM NA Imperial Control 
Q13.2 F C 770 29 n BM_DBM NA Imperial Control 
Q13.3 F C 770 29 n BM NA Imperial Control 
Q13.4 F C 770 29 n BM NA Imperial Control 
Q131 M V 1565 29 y BM NA Imperial Control 
Q131.1 M V 1565 29 y BM_DBM NA Imperial Control 
Q133.2 F V 805 26 n BM_DBM NA Imperial Control 
Q133.3 F V 805 26 n BM_DBM NA Imperial Control 
Q133.4 F V 805 26 n BM NA Imperial Control 
Q133.5 F V 805 26 n BM NA Imperial Control 
Q142.1 M V 1800 31 n BM_DBM NA Imperial Control 
Q142.2 M V 1800 31 n BM NA Imperial Control 
Q142.3 M V 1800 31 n BM NA Imperial Control 
Q144.1 M C 1270 31 y BM NA Imperial Control 
Q144.2 M C 1270 31 n BM NA Imperial Control 
Q15.1 F V 630 25 n BM NA Imperial Control 
Q15.2 F V 630 25 n BM NA Imperial Control 
Q157.1 F C 835 26 y BM NA Imperial Control 
Q157.2 F C 835 26 y BM NA Imperial Control 
Q157.3 F C 835 26 n BM NA Imperial Control 
Q157.4 F C 835 26 n BM NA Imperial Control 
Q159.1 M V 890 26 y BM_DBM NA Imperial Control 
Q159.2 M V 890 26 n BM NA Imperial Control 
Q159.3 M V 890 26 n BM NA Imperial Control 
Q159.4 M V 890 26 n BM NA Imperial Control 
Q161.1 F V 860 25 y BM_DBM NA Imperial Control 
Q161.2 F V 860 25 n BM_DBM NA Imperial Control 
Q161.3 F V 860 25 n BM_F NA Imperial Control 
Q164.1 M V 640 24 n BM_DBM NA Imperial Control 
Q164.2 M V 640 24 n BM NA Imperial Control 
Q167.1 F V 865 26 n BM_DBM NA Imperial Control 
Q167.2 F V 865 26 n BM NA Imperial Control 
Q167.3 F V 865 26 n BM NA Imperial Control 
Q167.4 F V 865 26 n BM NA Imperial Control 
Q168.1 F V 880 26 y BM_DBM NA Imperial Control 
Q168.2 F V 880 26 n BM NA Imperial Control 
Q168.3 F V 880 26 n BM NA Imperial Control 
Q168.4 F V 880 26 n BM NA Imperial Control 
Q169.1 F C 1665 31 y BM_DBM NA Imperial Control 
Q169.2 F C 1665 31 n BM NA Imperial Control 
Q170.1 F C 1525 31 y BM_DBM NA Imperial Control 
Q170.2 F C 1525 31 n BM NA Imperial Control 
Q175.1 M V 755 24 y BM NA Imperial Control 
Q175.2 M V 755 24 n BM NA Imperial Control 
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Q175.3 M V 755 24 n BM NA Imperial Control 
Q175.4 M V 755 24 n BM NA Imperial Control 
Q182.1 F C 1150 27 n BM NA Imperial Control 
Q182.2 F C 1150 27 n BM NA Imperial Control 
Q183.1 M V 510 23 n BM_DBM NA Imperial Control 
Q183.2 M V 510 23 n BM_DBM NA Imperial Control 
Q187.1 F V 1550 30 n BM_DBM NA Imperial Control 
Q187.2 F V 1550 30 n BM NA Imperial Control 
Q189.1 M V 750 25 n BM_DBM NA Imperial Control 
Q189.2 M V 750 25 n BM_DBM NA Imperial Control 
Q189.3 M V 750 25 n BM_DBM NA Imperial Control 
Q189.4 M V 750 25 n BM NA Imperial Control 
Q200.1 M V 730 25 y BM_DBM NA Imperial Control 
Q200.2 M V 730 25 n BM_DBM NA Imperial Control 
Q200.3 M V 730 25 n BM NA Imperial Control 
Q216.1 M C 1150 28 y BM_DBM NA Imperial Control 
Q219.1 M C 810 26 y BM_DBM NA Imperial Control 
Q219.2 M C 810 26 n BM NA Imperial Control 
Q219.3 M C 810 26 n BM NA Imperial Control 
Q22.1 F C 1060 31 n BM_DBM NA Imperial Control 
Q22.2 F C 1060 31 n BM_DBM NA Imperial Control 
Q226.1 M C 660 24 y DBM NA Imperial Control 
Q226.2 M C 660 24 y DBM NA Imperial Control 
Q226.3 M C 660 24 n DBM NA Imperial Control 
Q23.1 F C 1690 31 n F NA Imperial Control 
Q25.1 M V 1400 28 n BM NA Imperial Control 
Q25.2 M V 1400 28 n BM NA Imperial Control 
Q26.1 M V 840 26 n BM NA Imperial Control 
Q26.2 M V 840 26 n BM NA Imperial Control 
Q27.1 M V 600 24 n BM_DBM NA Imperial Control 
Q27.2 M V 600 24 n BM_DBM NA Imperial Control 
Q28.1 F C 860 30 n BM_DBM NA Imperial Control 
Q28.2 F C 860 30 n BM_DBM NA Imperial Control 
Q28.3 F C 860 30 n BM NA Imperial Control 
Q29.1 F C 950 30 n BM_DBM NA Imperial Control 
Q29.2 F C 950 30 n BM NA Imperial Control 
Q3.1 F V 1885 31 y BM_DBM NA Imperial Control 
Q3.2 F V 1885 31 y BM_DBM NA Imperial Control 
Q31.1 M V 960 25 y BM_DBM NA Imperial Control 
Q31.2 M V 960 25 n BM NA Imperial Control 
Q31.3 M V 960 25 n BM NA Imperial Control 
Q33.1 F V 1000 26 y BM_DBM NA Imperial Control 
Q33.2 F V 1000 26 y BM_DBM NA Imperial Control 
Q33.3 F V 1000 26 n BM NA Imperial Control 
Q33.4 F V 1000 26 n BM NA Imperial Control 
Q48.1 F C 1200 28 n BM_DBM NA Imperial Control 
Q48.2 F C 1200 28 n BM NA Imperial Control 
Q48.3 F C 1200 28 n BM NA Imperial Control 
Q49.1 M V 770 23 y BM_DBM NA Imperial Control 
Q49.2 M V 770 23 y BM_DBM NA Imperial Control 
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Q49.3 M V 770 23 n BM NA Imperial Control 
Q49.4 M V 770 23 n BM NA Imperial Control 
Q5.1 F C 780 31 y BM_DBM NA Imperial Control 
Q52.1 F V 990 26 n BM_DBM NA Imperial Control 
Q52.4 F V 990 26 n BM_DBM NA Imperial Control 
Q55.2 M V 765 25 y BM_DBM NA Imperial Control 
Q55.3 M V 765 25 n BM_DBM NA Imperial Control 
Q58.1 M C 920 26 n BM_DBM NA Imperial Control 
Q58.2 M C 920 26 n BM_DBM NA Imperial Control 
Q58.3 M C 920 26 n BM_F NA Imperial Control 
Q60.1 M V 650 24 y BM_DBM NA Imperial Control 
Q60.2 M V 650 24 y BM_DBM NA Imperial Control 
Q60.3 M V 650 24 n BM NA Imperial Control 
Q60.4 M V 650 24 n BM NA Imperial Control 
Q65.1 M V 915 26 n BM_DBM NA Imperial Control 
Q65.2 M V 915 26 n BM NA Imperial Control 
Q70.1 F V 535 26 n BM_DBM NA Imperial Control 
Q70.2 F V 535 26 n BM_DBM NA Imperial Control 
Q70.3 F V 535 26 n BM NA Imperial Control 
Q70.4 F V 535 26 n BM NA Imperial Control 
Q83.1 F V 850 25 y BM_DBM NA Imperial Control 
Q83.2 F V 850 25 n BM_DBM NA Imperial Control 
Q83.3 F V 850 25 n BM_DBM NA Imperial Control 
Q83.4 F V 850 25 n BM NA Imperial Control 
Q87.1 F C 1025 27 n BM_DBM NA Imperial Control 
Q87.2 F C 1025 27 n BM_DBM NA Imperial Control 
Q87.3 F C 1025 27 n BM NA Imperial Control 
Q89.1 F C 1246 31 n BM_F NA Imperial Control 
Q89.2 F C 1246 31 n BM_F NA Imperial Control 
Q95.3 M V 1695 31 n BM_F NA Imperial Control 








Metadata all infants samples 
 


































M15 St Mary’s 30 1370 y 3 C section n 4 14 21 y y Y 
M16 St Mary’s 29 1340 y 3 C section n 7 14 21 y y Y 
M17 St Mary’s 29 1230 y 3 C section n 7 13 21 y y Y 
M26 St Mary’s 28 1322 y 6 C section n 5 14 18 y y Y 
M29 St Mary’s 28 934 y 3 C section n 9 14 22 y y Y 
M36 St Mary’s 31 426 y 6 C section n 8 14 20 y y Y 
M37 St Mary’s 31 697 y 2 C section n 7 14 21 y y Y 
M38 St Mary’s 29 500 y 3 C section n 5 12 20 y y Y 
M39 St Mary’s 28 870 y 5 NVD n 8 14 22 y y Y 
M7 St Mary’s 31 627 n 0 NVD n 5 11 21 y y Y 
M40 St Mary’s 30 1320 n 0 C section n 10 13 21 y y Y 
M54 St Mary’s 28 980 n 0 C section n 5 14 16 y y Y 
M55 St Mary’s 28 1330 n 0 C section n 5 13 16 y y Y 
M56 St Mary’s 28 1200 n 0 C section n 5 14 16 y y Y 
M59 St Mary’s 28 980 n 0 C section n 4 14 22 y y Y 
M60 St Mary’s 28 1100 n 0 C section n 5 14 22 y y Y 
M103 St Mary’s 28 1380 n 0 C section n 8 14 21 y y N 
Q48 Queen Charlotte’s 28 770 n 0 C section n 6 15 18 y y Y 
Q29 Queen Charlotte’s 30 800 n 0 C section n 5 14 21 y y Y 
P80 NNUH 25 831 y 3 NVD y 3 13 20 y y Y 
P63 NNUH 26 1374 y 2 NVD y 7 15 19 y y N 
P65 NNUH 27 1477 y 2 NVD y 6 13 20 y y N 
P42 NNUH 29 1384 y 2 C section y 7 15 22 y y Y 
P69 NNUH 30 1420 y 3 C section y 6 12 22 y y Y 
P74 NNUH 31 1382 y 3 C section y 5 15 23 y y Y 
P79 NNUH 30 1444 y 3 C section y 7 14 20 y y Y 
P46 NNUH 30 1400 y 3 NVD y 8 14 23 y y Y 
P75 NNUH 31 1262 y 4 NVD y 5 12 24 y y Y 
P76 NNUH 31 1409 y 4 NVD y 5 14 17 y y Y 
P70 NNUH 30 1255 y 5 C section y 9 13 20 y y Y 
P48 NNUH 30 1425 y 8 NVD y 6 11 20 y y N 
P60 NNUH 33 1230 n 0 C section y 5 15 17 y y Y 
P62 NNUH 30 940 n 0 C section y 6 15 25 y y Y 






AMR genes detected using ´walk-out´ analysis 
 
Premature infant P205       
ReadId HostHit CARDhit PercentId 
a6230d05-2515-4dba-b7a8-
ca2c1c8641f2 Enterobacter cloacae ARO:3001830|ACT-7 92.49 
21ccabe7-78be-4380-980c-
1711baa4262a Enterobacter cloacae ARO:3001847|ACT-27 84.07 
06711712-3445-4f0e-aa08-
d5871266f0f2 Enterobacter cloacae ARO:3000263|marA 80.55 
5d6c65f0-4052-4757-b78c-
d03a289bed10 Enterobacter cloacae ARO:3000518|CRP 80.22 
e9737391-a8da-4065-a05b-
9b4d68ae6fae Enterobacter cloacae ARO:3001847|ACT-27 87.8 
97c715ce-77be-42ec-8abd-
818d0639f5ba Enterobacter cloacae ARO:3001847|ACT-27 92.42 
f5749dfb-899e-485c-ac14-
36d0b1604f78 Enterobacter cloacae ARO:3000216|acrB 81.27 
7ac77a00-ef2f-4ad1-b8ad-
21e3a560f46b Enterobacter cloacae ARO:3000518|CRP 84.28 
2d78108b-a656-4131-9971-
f8c9bdbe8fcb Enterobacter cloacae ARO:3001847|ACT-27 83.73 
e7f46d19-4b9b-4d78-8ca1-ffffc95393d5 Enterobacter cloacae ARO:3000216|acrB 80.23 
5e153150-2529-4306-8158-
ba7d5d0364ba Enterobacter cloacae ARO:3000216|acrB 85.65 
72877490-fab6-4758-b03c-
f776ef0b8bf2 Enterobacter cloacae ARO:3000207|acrA 82.16 
422f7d5f-bb7b-4974-a87f-
1cae04d268eb Enterobacter cloacae ARO:3001852|ACT-32 85.86 
36f70b32-15fd-4e0b-9c94-
c72571398d84 Enterobacter cloacae ARO:3000825|robA 87.63 
fd8df6a0-46fd-46ac-999c-fa4360c28137 Enterobacter cloacae ARO:3000207|acrA 81.88 
596959bb-1080-4e0e-8e85-
4a4680f494f6 Enterobacter cloacae ARO:3000216|acrB 82.89 
6c2e0f17-ace8-4b8a-ac1a-
6e8641d31b20 Staphylococcus aureus ARO:3000178|tetK 87.33 
62390dfc-a944-4800-8d46-
0cba10eb984b Enterobacter cloacae ARO:3000216|acrB 81.74 
b05b78e9-11d5-4c14-8f19-
1b454be2cee1 Enterobacter cloacae ARO:3000207|acrA 80.79 
6eb576bc-f12b-4ad8-8254-
1bc558df12f3 Enterobacter cloacae ARO:3000518|CRP 86.62 
2e9be510-cee3-4d37-a9f9-




33c374dab7b6 Enterobacter cloacae ARO:3003923|oqxB 80 
7a7673a6-76bf-4fb1-bee0-
a32fe7984e2b Enterobacter cloacae ARO:3000825|robA 87.98 
9e58203e-11f7-4af4-ba02-
a2ae863e2dae Enterobacter cloacae ARO:3000825|robA 90.8 
2430d2e3-5d3b-48fb-ac0e-
93ba1c3aef61 Enterobacter cloacae ARO:3000216|acrB 86.97 
d0f48c2e-1fce-4e96-91d8-




epidermidis ARO:3000391|norA 91.76 
0d203ae2-92e8-4857-a62e-
b0b2261ca109 Enterobacter cloacae ARO:3000830|cpxA 82.08 
4959c7c0-b8a8-4d3a-9349-
366a80503caa Enterobacter cloacae ARO:3000825|robA 86.56 
0a2a5933-d089-4141-a799-
62b1793485da Enterobacter cloacae ARO:3000207|acrA 81.55 
0a2a5933-d089-4141-a799-
62b1793485da Enterobacter cloacae ARO:3000216|acrB 86.05 
80c018ef-42bd-4065-b9e8-
2d72be33fe22 Enterobacter cloacae ARO:3001847|ACT-27 87.9 
53f66feb-0c21-4350-91d5-
7336b0a3e1a6 Enterobacter cloacae ARO:3000516|emrR 80.23 
 221 
c7ae6143-4c0a-4461-8144-
3ba574a28392 Enterobacter cloacae ARO:3000263|marA 81.34 
88cd3c99-d367-4081-b159-
84d0fc4723ba Enterobacter cloacae ARO:3000216|acrB 84.58 
59a120c7-7304-41f6-a29a-
35b850dcb777 Enterobacter cloacae ARO:3000516|emrR 80.86 
2444d78b-0d6a-42f2-9890-
6ee409f14642 Enterobacter cloacae ARO:3000216|acrB 82.73 
74838f01-7aa8-41bb-a0cc-




b1572c550824 Enterobacter cloacae ARO:3000216|acrB 81.86 
61006e14-9728-41bb-9dc7-
bee206cbb447 Enterobacter cloacae ARO:3001830|ACT-7 87.91 
da80e898-1db6-486e-89c5-
8c2f4492c07c Enterobacter cloacae ARO:3000216|acrB 85.98 
441bd110-51c2-43cd-a7c6-
2f020a67c665 Enterobacter cloacae ARO:3001838|ACT-17 90.18 
5344e7b2-4f4b-40b7-a8d9-246df4ff16f8 Enterobacter cloacae ARO:3003830|aminocoumarin 80.07 
e85a7508-990e-4b04-9d3d-
0b96f9997fdc Enterobacter cloacae ARO:3000825|robA 92.09 
9acedb62-5294-484d-9607-
85ef39e904c9 Enterobacter cloacae ARO:3001830|ACT-7 87.03 
9a625860-7ef5-463a-ac2b-
db3be186d263 Enterobacter cloacae ARO:3000518|CRP 80.27 
3990f624-29a8-43ea-aa60-




epidermidis ARO:3000178|tetK 81.15 
891b762f-f208-4ae6-a277-
4ae7e5c1a218 Enterobacter cloacae ARO:3003923|oqxB 81.27 
d3435b65-399a-4fcb-96cc-
bc48622d7d33 Enterobacter cloacae ARO:3000024|patA 82.03 
573348b9-cffb-4031-9a2a-
de6f0d031565 Enterobacter cloacae ARO:3000831|cpxR 82.18 
23d8a370-8c05-49d6-b76f-
98e5236e7f5c Enterobacter cloacae ARO:3003923|oqxB 85.25 
1f4ac2fe-2bda-4199-84ba-
a3cd11ce9905 Enterobacter cloacae ARO:3000216|acrB 86.6 
5980533b-417e-4ed2-89b5-
ca5915ae781b Enterobacter cloacae ARO:3000518|CRP 81.05 
8b2d4d7b-033e-4d8e-8dc0-
ae5fc2f162c0 Enterobacter cloacae ARO:3000216|acrB 82.09 
a9b8a9d2-4169-439f-b81f-
86f7aeb26104 Enterobacter cloacae ARO:3000516|emrR 80.81 
ea17b316-c02a-4d3c-8cfe-
6400d4637d49 Enterobacter cloacae ARO:3003830|aminocoumarin 81.86 
ff1a6349-9052-428e-99a9-
ee815bec7fa8 Enterobacter cloacae ARO:3003923|oqxB 82.45 
a931a60e-9b0c-4060-b63a-
cbdd5b18aafd Enterobacter cloacae ARO:3000825|robA 89.91 
c5a78e7c-cfb8-4a9d-a908-ef0661a9f1bf Enterobacter cloacae ARO:3000216|acrB 81.25 
eedee14d-0334-4b3b-bb7a-
548af8313df8 Enterobacter cloacae ARO:3000216|acrB 87.16 
6c7790e5-113b-4776-8547-
e26c385f0612 Enterobacter cloacae ARO:3003923|oqxB 85.98 
6a2d759b-46e1-4bef-90a2-
e6403c80c827 Enterobacter cloacae ARO:3000825|robA 88.62 
c6c66581-6bc0-4963-9359-
2f2637ef15e5 Enterobacter cloacae ARO:3000207|acrA 82.96 
e182c38e-78ae-4ce0-9b09-
02ae9354c9af Enterobacter cloacae ARO:3003923|oqxB 80.56 
552ed409-7858-440a-a17e-
d1faeab3291b Enterobacter cloacae ARO:3000378|mexB 80.52 
3beef42b-228a-4e1f-944c-
2825884f2317 Enterobacter cloacae ARO:3000825|robA 88.62 
45066790-3a2a-46be-b8d3-
ee3ccad20174 Enterobacter cloacae ARO:3000518|CRP 80.07 
6c7924ba-266c-467c-9538-




620895bdcdd7 Enterobacter cloacae ARO:3001847|ACT-27 88.09 
bd244e08-c8f8-4d77-ada3-
7c0a3571b679 Enterobacter cloacae ARO:3000825|robA 82.52 
 222 
a8809e59-3177-493f-b265-
2b7d339917c1 Enterobacter cloacae ARO:3000825|robA 83.1 
a17e8faf-3be1-440c-ab75-bf1f1cbae7ce Enterobacter cloacae ARO:3000676|H-NS 83.33 
72cf1ebe-0519-402c-bf31-cbbfc327d1f9 Enterobacter cloacae ARO:3000825|robA 86.28 
b6d3d7d8-e4b7-47d7-811a-
63d1a944b5fc Staphylococcus agnetis ARO:3000621|PC1 86.74 
0ce42433-1841-4a60-85c7-
cd3114db09ba Enterobacter cloacae ARO:3000216|acrB 89.41 
0ce42433-1841-4a60-85c7-
cd3114db09ba Enterobacter cloacae ARO:3000207|acrA 85.41 
e1a9361f-d0bd-436d-9d31-
68182782a221 Enterobacter cloacae ARO:3001847|ACT-27 89.56 
698d6aaf-2b12-4f07-98f9-fac76da7c22b Enterobacter cloacae ARO:3000216|acrB 83.76 
88b26a17-c557-4b40-8bf2-
1df1979591ce Enterobacter cloacae ARO:3000825|robA 86.08 
9f0bf21d-3357-4b65-bd50-
55315e5af285 Enterococcus faecalis ARO:3003551|emeA 86.67 
f9ed9409-c4ac-41d4-909a-
4c9b05b7965e Enterobacter cloacae ARO:3000825|robA 90.83 
93817556-55d5-4cf0-9708-
8a5b4a2e97ca Enterobacter cloacae ARO:3000825|robA 86.05 
2a12d450-7bb0-43ff-94b9-
6b33fc351a8d Enterobacter cloacae ARO:3000825|robA 87.28 
e7a5ee68-9551-44b7-b576-
040c50773ee4 Enterobacter cloacae ARO:3000074|emrB 80.12 
813b78aa-9691-4572-83e2-
f04b7a6feb0c Enterobacter cloacae ARO:3000216|acrB 83.3 
abc27985-629b-4861-9cb3-
00c465b66422 Enterobacter cloacae ARO:3003923|oqxB 83.04 
4f2147e4-54ac-4794-88a1-
e0062ab48502 Enterobacter cloacae ARO:3000207|acrA 80.02 
fad1cbe8-6a16-473a-bd5e-
03bf823f9128 Enterobacter cloacae ARO:3003830|aminocoumarin 80.56 
3cf4b3aa-3ec5-4c85-998d-
a1adba583564 Enterobacter cloacae ARO:3001830|ACT-7 89.61 
3cf4b3aa-3ec5-4c85-998d-
a1adba583564 Enterobacter cloacae ARO:3001835|ACT-13 80.46 
51eb719d-a46f-4a39-8296-
47440423b9cc Enterobacter cloacae ARO:3000216|acrB 80.13 
d2672dc7-9169-48f3-bf3c-
f7fad231db4b Enterobacter cloacae ARO:3000516|emrR 80.36 
96ed2db9-787f-439c-86bd-
5f212a780596 Enterobacter cloacae ARO:3000676|H-NS 81.44 
d87de989-8812-4a9e-b7fb-
b35ff1721361 Enterobacter cloacae ARO:3000216|acrB 85.32 
3b188190-c84d-4998-9e12-
47c4f0daab23 Enterobacter cloacae ARO:3003922|oqxA 82.35 
02b911f0-96f3-43e8-bf8f-
be1aae5620ab Enterobacter cloacae ARO:3000518|CRP 85.54 
8ff0da3b-babc-423c-9d88-
0d4d8f1e96e1 Enterobacter cloacae ARO:3001847|ACT-27 86.31 
8dcb6bea-f718-4473-ab70-
511ef5ed9e50 Enterobacter cloacae ARO:3001847|ACT-27 86.08 
f0dbc62f-f25a-457c-88b0-c01b8c50c264 Enterobacter cloacae ARO:3000825|robA 90.17 
82975174-7bde-43ca-ae07-
a366167ceb5e Enterobacter cloacae ARO:3003922|oqxA 80.39 
0c24ee70-b1ab-4f09-93ac-
ed4517ef95c6 Enterobacter cloacae ARO:3001830|ACT-7 87.18 
cbd94876-73a6-400c-8f3c-
e5c0d795579c Enterobacter cloacae ARO:3000676|H-NS 81.75 
f9f76a9d-3bf6-4fd1-a939-
d52d8c70e381 Enterobacter cloacae ARO:3000207|acrA 83.7 
11e16b29-62b8-4fb1-9da0-
5d689f43e7bf Enterobacter cloacae ARO:3000074|emrB 80.25 
7b7873b0-6280-4194-9166-
9f1505bd8a6a Enterobacter cloacae ARO:3000518|CRP 85 
bb402264-f0dd-450f-a713-
def0d2210a07 Enterobacter cloacae ARO:3000825|robA 91.09 
42d724bd-72a4-4679-b71f-
66654fb9df3b Enterobacter cloacae ARO:3000216|acrB 83.94 
7eb7c099-3079-41e3-8b9a-
ed2b40083767 Enterobacter cloacae ARO:3000074|emrB 80.2 
40274626-3298-42e5-b1f0-
fe296e7dde61 Enterobacter cloacae ARO:3001847|ACT-27 89.01 
 223 
6c498d0d-19a9-449d-933a-acfbf4696ffd Enterobacter cloacae ARO:3000825|robA 92.28 
04c9220b-d30e-4c69-b912-
31c322043a02 Enterobacter cloacae ARO:3003830|aminocoumarin 81.3 
7e3ca015-5728-4fcf-b856-
7c10861f8bd4 Enterobacter cloacae ARO:3000518|CRP 80.18 
f610f670-9ea4-48ea-8b4f-
4ded4c579c56 Enterobacter cloacae ARO:3000825|robA 94.12 
999a2f97-a9e1-4d55-9fb4-
8bc9991c8b06 Enterobacter cloacae ARO:3001847|ACT-27 82.06 
52780a08-4745-4498-ae5b-
8bd292ef56c7 Enterobacter cloacae ARO:3003923|oqxB 84.25 
52780a08-4745-4498-ae5b-
8bd292ef56c7 Enterobacter cloacae ARO:3003922|oqxA 82.74 
055e51e4-603c-4639-980c-
82489d65189d Enterobacter cloacae ARO:3000825|robA 93.38 
a511e3c9-8d55-48f8-bb62-
1795a94f91c8 Enterobacter cloacae ARO:3000825|robA 87.73 
1b5209ae-f1af-4009-9e2a-
7c7c3222fbbd Enterobacter cloacae ARO:3003830|aminocoumarin 80.63 
916b2c80-ca3a-436d-a9e2-
246e5c0374dc Enterobacter cloacae ARO:3000207|acrA 82.09 
2a4c6971-558c-4021-967c-
fef1e19746a0 Enterobacter cloacae ARO:3001847|ACT-27 84.45 
3847bb05-4cd5-451e-89f6-
c4474b75f0a4 Staphylococcus aureus ARO:3000319|mphC 87.69 
f451ef19-b6d3-4ce6-9e19-
0112ad00db52 Enterobacter cloacae ARO:3001841|ACT-20 89.43 
f451ef19-b6d3-4ce6-9e19-
0112ad00db52 Enterobacter cloacae ARO:3001844|ACT-24 87.94 
0e9e7263-d1a2-4024-b9b3-
f856c59e8f0d Enterobacter cloacae ARO:3001330|mdtD 80.91 
32eccf9d-f2cd-40b4-a508-




cb400672018f Enterobacter cloacae ARO:3003922|oqxA 80.52 
ae965e8e-7975-493d-bed7-
d9eb13ae852e Staphylococcus sp. ARO:3002865|dfrC 94.64 
7f94bcbb-b7d1-4f84-95bd-
7f295a19d1ec Enterobacter cloacae ARO:3000825|robA 84.75 
aaab3d6d-81c4-46c8-bd1b-
87fe239140a7 Enterobacter cloacae ARO:3000825|robA 87.56 
fb8543ec-677f-4b4a-9376-
07197f73ac79 Enterobacter cloacae ARO:3000825|robA 89.16 
667800f2-afa0-4220-9571-
2f7346f31557 Enterobacter cloacae ARO:3001838|ACT-17 87.6 
21565350-9b24-4ff1-9aab-
2cc8b0fb1da7 Enterobacter cloacae ARO:3003922|oqxA 80 
28e7293a-6a72-48e6-a53f-
7002e7de7e41 Enterobacter cloacae ARO:3001847|ACT-27 90.17 
ea7670e5-33f0-440f-a055-
cbd162dab44e Enterobacter cloacae ARO:3000024|patA 86.14 
f5ca607d-ae8a-48a1-ba56-
4b650f847f8a Enterobacter cloacae ARO:3000516|emrR 80.92 
9d7d8110-2d57-4ddd-852f-
4adda279f7b2 Enterobacter cloacae ARO:3003830|aminocoumarin 80.59 
9ef4cc10-940a-4479-9bc9-6c4f1b6df541 Enterobacter cloacae ARO:3000207|acrA 82.53 




epidermidis ARO:3000391|norA 84.42 
b5d68c2a-d46f-4e96-a91f-
23dd4b5b3254 Enterobacter cloacae ARO:3000216|acrB 82.46 
d332f063-53f6-4841-bdad-
58119c9cd320 Enterobacter cloacae ARO:3000518|CRP 88.28 
bbe4fa20-1e81-4dba-aedd-
6c7d76309d27 Enterobacter cloacae ARO:3000825|robA 89.79 
6073cb30-9d34-4283-8c1f-
58d5164dbb64 Staphylococcus aureus ARO:3000489|sav1866 89.47 
2570266c-977e-4e30-8550-
219d6054d660 Enterobacter cloacae ARO:3000825|robA 89.7 
eea3c8b5-e265-4e89-97c1-




5c15f420632b Enterobacter cloacae ARO:3003923|oqxB 82.95 
 224 
72bfe536-8263-4dac-a12a-
d57f179d91e2 Enterobacter cloacae ARO:3001847|ACT-27 88.32 
f3e2a04b-bde0-4bc2-915e-
d52d16ba6829 Enterobacter cloacae ARO:3000825|robA 82.25 
bae0dbaf-4a1c-4eed-b72f-e66963ceff20 Enterobacter cloacae ARO:3001830|ACT-7 85.95 
8199e22a-86a3-4be6-9b20-
d77bca024021 Enterobacter cloacae ARO:3000518|CRP 81.07 
24b127e6-2e4f-48e0-9b4f-




epidermidis ARO:3000391|norA 91.07 
2d741a20-0401-4f99-80a9-44f2bfd1f75f Enterobacter cloacae ARO:3000676|H-NS 80.39 
b43fa09d-204c-44b1-b942-




22195485f52d Enterobacter cloacae ARO:3001852|ACT-32 81.47 
db38add8-c5ab-4d41-9ea6-
7b8d41d9386f Enterobacter cloacae ARO:3000216|acrB 85.21 
4a1e86cb-99c4-4701-8bd2-f5e87fffe5f0 Enterobacter cloacae ARO:3000825|robA 89.85 
a30d4421-adac-458e-b4b9-
3b1774dc8b79 Enterobacter cloacae ARO:3000825|robA 87.5 
f2bb02f0-36a9-4190-b2d1-
a1ab69a12c34 Enterobacter cloacae ARO:3000518|CRP 80.91 
25ef2467-a8d4-4273-b93b-
5218a4ee7bf6 Enterobacter cloacae ARO:3000516|emrR 80.27 
663e81ab-fa1b-4a8e-9d1e-
8487430932b5 Enterobacter cloacae ARO:3000825|robA 92.94 
22d84bd0-0701-4e17-878d-
079c7bb3f732 Enterobacter cloacae ARO:3001837|ACT-15 87.33 
e2db8a3e-a993-412d-aa46-
08a2c24850a0 Enterobacter cloacae ARO:3001847|ACT-27 85.31 
4663a1e4-cc8d-488d-926d-
4d4840b22917 Enterobacter cloacae ARO:3001830|ACT-7 88.47 
350aae2c-9ee6-4378-96ea-
7753fa4085ca Enterobacter cloacae ARO:3003052|smeB 82.4 
69dc61e4-e5d6-4fda-80f8-5e91f81f3e9f Enterobacter cloacae ARO:3000825|robA 89.94 
e2ed961e-ccb8-457e-b509-
ac5663aa5869 Enterobacter cloacae ARO:3000825|robA 86.55 
fddab6a1-bc90-4149-ae60-
1a0e4f5bd9da Staphylococcus aureus ARO:3003552|fusB 92.91 
94ab3fd2-1393-4742-abc1-
a1eca3c8c506 Enterobacter cloacae ARO:3003923|oqxB 81.44 
8a57793b-71be-41ca-ab08-




687799f8674a Enterobacter cloacae ARO:3000516|emrR 82.25 
bf062aa4-6aaa-4527-b85b-
11a87084f149 Enterobacter cloacae ARO:3000825|robA 89.06 
5b169490-bffe-4247-83c1-
b5575cbb9182 Enterobacter cloacae ARO:3000518|CRP 81.02 
5344a661-caa2-4cb6-9277-
33a1e6345b66 Enterobacter cloacae ARO:3000825|robA 82.75 
b89ea282-c02d-4335-8c1a-
5a6b654835d4 Enterobacter cloacae ARO:3003830|aminocoumarin 82.78 
348b56b4-09fe-4eae-9479-
7746f85efd33 Enterobacter cloacae ARO:3001847|ACT-27 88.97 
6ad64be2-e0c7-442f-b018-
bc068f8f1c56 Enterobacter cloacae ARO:3000518|CRP 84.82 
f80f4175-6173-4bb4-bcef-
7ed04494653f Enterobacter cloacae ARO:3003830|aminocoumarin 85.56 
8c0fee91-03d9-441a-a7d1-
3c4529680bf6 Enterobacter cloacae ARO:3001838|ACT-17 88.33 
e205f7ce-93e0-4d85-8c84-
c0ffe6a059e9 Enterobacter cloacae ARO:3000825|robA 87.12 
8255e212-2060-469d-89bd-
af605d518772 Enterobacter cloacae ARO:3000676|H-NS 84.51 
bf433851-a61c-4c49-ab8f-dcfd5619f7ad Enterobacter cloacae ARO:3000216|acrB 84.56 
c66ba70b-9d35-49aa-8e3b-
37a67c4a2a05 Enterobacter cloacae ARO:3000216|acrB 81.12 
23769754-d4b8-4f9b-8dc5-
7c8d4dbe4a1f Enterobacter cloacae ARO:3000825|robA 94.58 
c24c3b2d-f48d-4d50-ae13-









09b3aec83d0a Enterobacter cloacae ARO:3000825|robA 87.21 
bda016a7-8e2d-4e3e-aee0-
22846b0f1022 Enterobacter cloacae ARO:3000216|acrB 87.78 
b6620a1d-fa42-48c6-80f9-
57d7c7163ec9 Enterobacter cloacae ARO:3000825|robA 88.85 
5655384a-97b1-4bca-92ba-
d76d470c2287 Enterobacter cloacae ARO:3000024|patA 83.77 
bac878dc-aa43-4d93-8a50-
104b52e2537d Enterobacter cloacae ARO:3000825|robA 85.29 
3eb2bf64-0680-4e96-8159-
0cdf8b4a287e Enterobacter cloacae ARO:3001847|ACT-27 86.64 
f44572cc-46a0-43e1-b8fa-f1fa12094dae Enterobacter cloacae ARO:3003922|oqxA 81.38 
c4836dc2-48c1-4847-bc8e-
4861d13044ff Enterobacter cloacae ARO:3001837|ACT-15 81.79 
4c0b7765-1ebd-4d9f-a0a6-
cceb205e74e9 Enterobacter cloacae ARO:3001841|ACT-20 89.74 
1272efbe-6724-4f1d-8087-
675badae6e3c Enterobacter cloacae ARO:3000518|CRP 80.98 
89c31618-d87e-44de-9e93-
8743ce2dc961 Staphylococcus aureus ARO:3000565|tet38 92.77 
1665e7ce-f95c-4310-a952-
23b5b7c5537e Enterobacter cloacae ARO:3002986|bacA 80 
9ba6d334-7fea-4d5c-ad8c-
c9b15b3385b4 Enterobacter cloacae ARO:3000825|robA 91.47 




12900deb0757 Enterobacter cloacae ARO:3000825|robA 90.44 
de03e5d0-a059-4d98-aba8-
016e9428028e Enterobacter cloacae ARO:3000216|acrB 83.33 
c7e936d7-e9b7-4d23-b6be-
16bfcb6448ad Enterobacter cloacae ARO:3000216|acrB 85.03 
a44dd817-ecba-47b9-a22f-
1165f37986c6 Enterobacter cloacae ARO:3000825|robA 89.93 
c7867f2a-1239-45ee-959b-
3b3c37dd1e22 Enterobacter cloacae ARO:3000516|emrR 80 
42443bf3-32d2-4409-a5a8-




db802d5db2cf Enterobacter cloacae ARO:3000216|acrB 86.79 
c03abea3-3ba6-435f-81e6-
db802d5db2cf Enterobacter cloacae ARO:3000207|acrA 80.39 
49e126a3-c81a-43a9-9f1e-
fb87b01bbfae Enterobacter cloacae ARO:3000263|marA 80.69 
260f2442-25a9-49b8-ae71-
a4d3bd5a90da Enterobacter cloacae ARO:3000024|patA 82.11 
f9cd6825-da96-41f6-8f24-
1038042ea252 Enterobacter cloacae ARO:3000216|acrB 84.97 
032f84d1-d86e-4023-9a4c-
3e542f676097 Enterobacter cloacae ARO:3001830|ACT-7 89.78 
1e3f4985-b652-4e4d-8985-
9cabaeedbfd5 Enterobacter cloacae ARO:3001847|ACT-27 90.34 
2c1c704a-c4a8-4076-bcd3-




epidermidis ARO:3000815|mgrA 81.51 
4109a90c-dbdc-4054-94dc-




a3a9a07c1cee Enterobacter cloacae ARO:3000216|acrB 84.3 
b1751ba0-2e2f-4d7c-82d8-
97ca49dcc3dd Enterobacter cloacae ARO:3000216|acrB 85.04 
9d19f1a9-b303-4063-ae32-








b069503b5ca6 Enterobacter cloacae ARO:3003830|aminocoumarin 82.39 
03f91857-86da-4acd-b36a-
95b39e4d0eca Enterobacter cloacae ARO:3000216|acrB 84.55 
d3a11e7f-30fe-4d10-a998-
5cd9882dbe96 Enterobacter cloacae ARO:3003830|aminocoumarin 82.33 
 226 
b6b3bb67-bc02-49f4-9aa5-
fa7fb3335e5e Enterobacter cloacae ARO:3000207|acrA 80.74 
07f4777d-4693-439c-a26f-
22de2f5eae01 Enterobacter cloacae ARO:3001847|ACT-27 89.91 




3ce351cb4041 Enterobacter cloacae ARO:3000024|patA 84.48 
76344f68-6cb5-40bd-88bb-
5d5778326e33 Enterobacter cloacae ARO:3000074|emrB 81.48 
d0265621-ea04-4c18-a0f7-
2a097d6b3e70 Enterobacter cloacae ARO:3000825|robA 91.45 
dbe51358-3c9f-4f29-a0e7-5c195b3f4d7f Enterobacter cloacae ARO:3003923|oqxB 80.83 
ab83a28c-d4d7-46ee-89b3-
db32bb6ae83f Enterobacter cloacae ARO:3001847|ACT-27 81.37 
d01f0f55-340b-4545-b89d-




epidermidis ARO:3000391|norA 85.11 
935800ce-aed8-42f2-8c19-
a5fe69f5ed69 Enterobacter cloacae ARO:3000216|acrB 86.86 
30c1fd4b-1101-432a-8fbc-
c706eadb14b7 Enterobacter cloacae ARO:3000830|cpxA 84.08 
5bab8604-4d1c-420a-bfff-
93d87c814b4a Enterobacter cloacae ARO:3001847|ACT-27 85.97 
180b8ec6-9b19-4990-b23f-




epidermidis ARO:3000391|norA 91.31 
a01c2d35-c91c-4e21-aa1d-
f7c6dcb1de38 Enterobacter cloacae ARO:3001847|ACT-27 91.24 
fb91fac1-49fc-46fc-9ccc-bf86ddbec371 Enterobacter cloacae ARO:3000216|acrB 87.08 
ac97b774-3adb-4e48-bb3d-
cee5a4465fd3 Enterobacter cloacae ARO:3000216|acrB 84.24 
ee6a2d79-036d-4177-83c3-
7816b8c57128 Enterobacter cloacae ARO:3000825|robA 86.64 
7b8963fc-94c2-47e2-94f1-
32a6e1821c78 Enterobacter cloacae ARO:3000518|CRP 80.46 
ff6f2b7b-aa79-4d5b-9547-
c1a0c3b231e1 Enterobacter cloacae ARO:3001827|ACT-16 92.42 
af55976d-db21-48ed-905a-
db10c84ee82c Enterobacter cloacae ARO:3000825|robA 92.48 
76966873-8e08-4f38-9992-
41069b0503b9 Enterobacter cloacae ARO:3000825|robA 92.08 
baf97fe0-89da-4b16-b49e-
e9c07019828a Enterobacter cloacae ARO:3000516|emrR 81.89 
d372165f-1305-44b6-8d0b-
286ed95d032b Enterobacter cloacae ARO:3000216|acrB 82.51 
9d990e0b-32cb-4c5b-8b16-
691186de4218 Enterobacter cloacae ARO:3000216|acrB 86.82 
7c856173-37f4-48b9-b4c1-
d9b3b9a5ec55 Enterobacter cloacae ARO:3000825|robA 87.39 
86ce881e-c448-47f1-b038-
b32af1b2043d Enterobacter cloacae ARO:3000216|acrB 84.02 
b11eada9-5296-4d7c-b1b8-
baf321341dfd Enterobacter cloacae ARO:3003830|aminocoumarin 86.55 
acd97355-ff91-4e95-aad1-
05828db01de1 Enterobacter cloacae ARO:3000825|robA 87.08 
2a7a928c-1fd7-4f20-9f7c-dfa23313f87e Enterobacter cloacae ARO:3000825|robA 83.28 
49714ad4-15c2-4351-9634-
2c006d74365e Enterobacter cloacae ARO:3003052|smeB 80.17 
a03a7ac4-cf42-48ab-9a09-
fed171602b86 Enterobacter cloacae ARO:3003922|oqxA 82.15 
88f7a13d-8793-48de-a437-
dc31e9837f56 Enterobacter cloacae ARO:3000825|robA 91.7 
ff2f8d31-d44c-4227-956e-
52bbbebe8c6e Enterobacter cloacae ARO:3001847|ACT-27 90.13 
b599750a-1355-4d21-b728-
a79104395d6c Enterobacter cloacae ARO:3001830|ACT-7 86.99 
bdfbf434-7986-4863-b446-
b60391be475e Enterobacter cloacae ARO:3000825|robA 86.9 
7a750b24-299e-479e-b775-
d0778f969d16 Enterobacter cloacae ARO:3001830|ACT-7 81.64 
 227 
87b8c612-a900-452e-8546-




epidermidis ARO:3000815|mgrA 80.13 
7f1d8e27-c945-4a0f-90fe-0722c29cf966 Enterobacter cloacae ARO:3003830|aminocoumarin 82.25 
3c1fa6d5-ea7d-42ea-9270-
64d14bcd8340 Enterobacter cloacae ARO:3001847|ACT-27 85.35 
745225f0-3508-47fe-ad8c-ee032f8ef516 Enterobacter cloacae ARO:3003922|oqxA 81.36 
3ad29102-931b-4e4a-9566-
c35bfa3c4676 Enterobacter cloacae ARO:3003923|oqxB 81.29 
70605f8e-989e-4cd0-bb46-
3f08841d7f38 Enterobacter cloacae ARO:3003830|aminocoumarin 83.1 
2ac12f94-4e03-41b4-9b95-
359ea5d50b25 Enterobacter cloacae ARO:3001847|ACT-27 84.27 
4261f469-47d5-447e-b361-
76c4f96f730e Enterobacter cloacae ARO:3000518|CRP 80.78 
60acb22c-06a3-4f6f-9a31-
665f617e738b Enterobacter cloacae ARO:3000825|robA 86.04 
f69e6290-a2d9-435c-a97e-
468eca40df09 Enterobacter cloacae ARO:3000216|acrB 83.9 
3d233b38-67e1-4b3e-b387-
9754620b1895 Enterobacter cloacae ARO:3001830|ACT-7 86.59 
45ebefff-41a3-468a-a556-7e8acbc2d09c Enterobacter cloacae ARO:3000216|acrB 83.06 
50695ab2-0773-47b5-93de-
690f31615b5b Enterobacter cloacae ARO:3001830|ACT-7 84.22 
bdf8fd43-64c1-4a98-83fd-




523fe99def25 Enterobacter cloacae ARO:3000825|robA 88.57 
3870b25d-5ca8-495c-893b-
1179784cb2ea Enterobacter cloacae ARO:3000825|robA 87.68 
cd6b68bb-24b1-4686-8bc8-
805302c964c2 Enterobacter cloacae ARO:3000216|acrB 82.35 
cd6b68bb-24b1-4686-8bc8-
805302c964c2 Enterobacter cloacae ARO:3000207|acrA 80.12 
0ed7ee3a-2798-4990-834b-
e381b57cfd41 Enterobacter cloacae ARO:3003923|oqxB 80.76 
102a872f-06ce-44d3-aadc-
7bd1d23bf4c7 Enterobacter cloacae ARO:3000207|acrA 82.51 
1de11fb5-bd40-4bd5-9e06-
7e4c8974cd6b Enterobacter cloacae ARO:3000216|acrB 82.2 
55b45c2d-ae52-4806-bf34-
deeac9db9eb9 Enterobacter cloacae ARO:3001830|ACT-7 84.04 
7102b733-1118-40e6-8674-
a2a747a7215b Enterobacter cloacae ARO:3000216|acrB 83.38 
e809e1dd-be57-47cd-9720-




epidermidis ARO:3000391|norA 91.6 
10c0c348-7d1d-481a-b473-
70903097cd54 Enterobacter cloacae ARO:3000024|patA 82.25 
dee76079-bec5-42f2-b7fd-
0dbd3af894e2 Enterobacter cloacae ARO:3000825|robA 88.63 
123fdf7f-0e40-4614-8d8a-
ce446a9a18b9 Enterobacter cloacae ARO:3001847|ACT-27 85.81 
f1738fbb-082c-455f-a37f-c53d4a02e635 Enterobacter cloacae ARO:3000825|robA 82.1 
47add2d8-3a27-493b-88a2-
aab83d6c8e7a Enterobacter cloacae ARO:3000516|emrR 85.02 
3cd2cf89-4dd3-4b06-9503-
bd0b82012a06 Staphylococcus sp. ARO:3002865|dfrC 93.53 
e2bc3aaa-d70b-4515-b93d-
e0d9fb686c59 Enterobacter cloacae ARO:3001855|ACT-35 90.64 
df45a006-9a7a-4903-a3c4-fbfa9a8bffaa Enterobacter cloacae ARO:3003830|aminocoumarin 80.87 
3b5a5719-3959-467b-b449-
d61b5670be0d Enterobacter cloacae ARO:3001830|ACT-7 86.41 
13b27338-2936-4d77-9de1-
92fc43ce9647 Enterobacter cloacae ARO:3000216|acrB 88.04 
13b27338-2936-4d77-9de1-
92fc43ce9647 Enterobacter cloacae ARO:3000207|acrA 80.98 
92097703-993f-4510-84f8-
d1d77adc92fb Enterobacter cloacae ARO:3000825|robA 88.26 
a3236a89-6486-47ba-9d9a-
08bda0948368 Enterobacter cloacae ARO:3001847|ACT-27 84.71 
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9eb5afec-7fa1-4c29-a2bd-
a0979bddef80 Enterobacter cloacae ARO:3001830|ACT-7 88.34 
d0fc27e0-59fc-4436-864c-0633fb0bc6a7 Enterobacter cloacae ARO:3000216|acrB 83.83 
d9d649ec-f17f-4da4-8ba0-
5e1571cade00 Enterobacter cloacae ARO:3000825|robA 86.22 
7378552d-7df5-43ed-af73-
aba395002533 Enterobacter cloacae ARO:3000825|robA 86.6 
745ec8b0-e3fc-4804-94cf-
73dfbe723565 Enterobacter cloacae ARO:3000825|robA 89.06 
20e0b6df-7ce5-439e-a78e-
5e69a4739aca Enterobacter cloacae ARO:3003923|oqxB 81.45 
cfdbab9f-e466-4fa2-8b52-
7095aa47b13e Enterobacter cloacae ARO:3001847|ACT-27 90.88 
e41d5968-31ba-42c5-9aae-
63cf883f38ea Enterobacter cloacae ARO:3003923|oqxB 80.28 
4cf972fd-5714-457b-8cc8-fb13d69fae73 Enterobacter cloacae ARO:3000216|acrB 86.86 
0f62822f-595f-4ea7-af20-996d2800bdca Enterobacter cloacae ARO:3000024|patA 82.04 
58a261eb-af50-4f8e-8274-
a1d0957f793d Enterobacter cloacae ARO:3000216|acrB 85.62 
19c6b05c-44f2-4ede-a48a-
3b0b1f6f606b Staphylococcus aureus ARO:3000178|tetK 93.07 
61db4f9d-f2a2-4e2e-8e2b-
49d274a47ae8 Enterobacter cloacae ARO:3001847|ACT-27 85.67 
baab5c8f-4c7d-4025-b64b-
de6ea8d3b772 Enterobacter cloacae ARO:3000825|robA 83.05 
aee7d4e5-6522-46d2-9166-
0c63ac6cd533 Enterobacter cloacae ARO:3001838|ACT-17 83.43 
69818f09-17fe-4ca4-8c14-52fa18f175cd 
Staphylococcus 
epidermidis ARO:3002865|dfrC 86.8 
4d9873dd-95a9-4e5a-90cf-
b5dd5f5be000 Enterobacter cloacae ARO:3000216|acrB 84.77 
4183590e-b46d-4e48-a2b2-
393f1f8b341a Enterobacter cloacae ARO:3000518|CRP 81.59 
be59d6ba-efcd-4dac-a125-
95b58781e076 Staphylococcus aureus ARO:3000565|tet38 90.03 
6d048e84-e508-49e5-928d-
f2ff3be8c7ae Enterobacter cloacae ARO:3003052|smeB 80.27 
65c6d41f-dc8e-40da-b31d-
e39f57c9ee2d Enterobacter cloacae ARO:3000024|patA 82.68 
4863462e-b815-46ff-ac0b-182fed55a7fa Enterobacter cloacae ARO:3001830|ACT-7 89.29 
242197b8-c77d-44c8-a5ef-
141d1c9a9f85 Enterobacter cloacae ARO:3003830|aminocoumarin 84.95 
b112784e-9b86-48f4-a0e4-
7335c0b16089 Staphylococcus aureus ARO:3000319|mphC 82.05 
710d6982-c115-4090-abc1-
db1a27ed4da0 Enterobacter cloacae ARO:3003923|oqxB 80.22 
b5392b9d-9fcf-4a6a-bdf6-cab8186af6bc Enterobacter cloacae ARO:3003830|aminocoumarin 81.15 
4a3e07a7-d0c9-4ce0-82ce-
e07d2ca9e58e Enterobacter cloacae ARO:3000825|robA 81.56 
67709be3-d47f-4fe4-afa2-
ca7725a031ec Enterobacter cloacae ARO:3003830|aminocoumarin 80.58 
0670f02b-a4a3-49d3-91fd-
48bd315759f3 Enterobacter cloacae ARO:3000516|emrR 81.36 
45354294-6290-4840-8a6b-
7c03c5ae7fff Enterobacter cloacae ARO:3000676|H-NS 82.18 
e003b557-268d-4bc3-b17f-
65c6108bf929 Enterobacter cloacae ARO:3000216|acrB 85.87 
e003b557-268d-4bc3-b17f-
65c6108bf929 Enterobacter cloacae ARO:3000207|acrA 88.4 
9e65bad7-a126-4ac7-80f1-
7267c38e3ae4 Enterobacter cloacae ARO:3000825|robA 88.27 
53ac5c0c-c464-499f-92da-
0a7e147adf9c Enterobacter cloacae ARO:3003923|oqxB 83.76 
a5681e7a-0fa7-43cb-8821-
c2fb5f4d5374 Staphylococcus aureus ARO:3000839|arlS 85.11 
4614b18f-91d8-4560-983c-
0444d3922207 Enterobacter cloacae ARO:3000825|robA 90.77 
49c03996-e325-49df-b620-
22b1f9e19dec Enterobacter cloacae ARO:3000825|robA 87.74 
a8db2f99-abab-44f4-bf41-
017b7993094b Enterobacter cloacae ARO:3001827|ACT-16 86.76 
980bf7ff-d76f-4cbb-b9fc-717ae22bb8aa Enterobacter cloacae ARO:3000024|patA 82.87 
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62cb336b-92c5-46a9-a052-
e4e549016d85 Enterobacter cloacae ARO:3000825|robA 87.11 
15bc9687-72f4-49ea-8bc6-
4db2c5651d5a Enterobacter cloacae ARO:3001830|ACT-7 90 




f40dc421f1eb Staphylococcus aureus ARO:3000565|tet38 86.88 
3d3693d5-d69e-424e-bdd2-
ecd6ef8e422d Enterobacter cloacae ARO:3000518|CRP 80.27 
d937ef46-bacc-4b72-8a99-
255341bb587a Enterobacter cloacae ARO:3000825|robA 89.48 
39f7ceb5-2708-409b-89d3-
ffdb67c06ee0 Enterobacter cloacae ARO:3000024|patA 82.38 
c60da8ee-50ef-4811-862c-
a9fdec598c84 Enterobacter cloacae ARO:3000825|robA 86.75 
6a569535-ad42-4068-a36e-
bb44865ac3ea Staphylococcus pasteuri ARO:3003552|fusB 90.04 
4245efaa-15f2-4462-8d52-
4a9612939542 Enterobacter cloacae ARO:3000825|robA 80.92 
a5cc147f-d5cd-4d05-b5ec-2f6da0868ef4 Enterobacter cloacae ARO:3000830|cpxA 80.53 
a7f31cf0-5682-441b-a0c5-
8791a124de30 Enterobacter cloacae ARO:3000825|robA 85.77 
4d8e3717-0326-46d2-bb92-
ddab30826b5e Enterobacter cloacae ARO:3000825|robA 89.42 
4cf7b469-1788-4431-9361-
086cfda3c0b5 Enterobacter cloacae ARO:3000825|robA 89.84 
c657130d-1345-4dd4-b47b-




87f7cbbd807f Enterobacter cloacae ARO:3001852|ACT-32 86.27 
1b4fbcdf-9518-4e6f-9ebb-




epidermidis ARO:3000391|norA 85.27 
0c6d0673-37d2-497b-9fbc-
657f4a6b8258 Enterobacter cloacae ARO:3000825|robA 90.58 
421853b7-bded-4a09-ae38-




06f30c688632 Enterobacter cloacae ARO:3000216|acrB 83.09 
26480c28-d561-4343-b7d8-
9550b44ff7dc Enterobacter cloacae ARO:3001852|ACT-32 85.96 
1265726e-fa61-4a8c-880c-
94d2d3af12a0 Enterobacter cloacae ARO:3000825|robA 90.18 
f1f41081-bfec-43ad-af7b-0311f02d1839 Enterobacter cloacae ARO:3000207|acrA 82.35 
8c4c03b3-f421-4621-aa84-
4e6bed8d1b48 Enterobacter cloacae ARO:3001830|ACT-7 87.89 
c86abdc8-e6ed-42da-aa05-
fa26178ec3c0 Enterobacter cloacae ARO:3000831|cpxR 80.18 
d511931e-6f13-46b6-a26c-
bb79acd406e3 Enterobacter cloacae ARO:3003830|aminocoumarin 80.69 
31762543-e0f0-4da7-b9bc-
edb98dc03462 Enterobacter cloacae ARO:3000216|acrB 84.11 
b081d4f8-6ef2-46bd-b200-
5213b5ca5c57 Enterobacter cloacae ARO:3000518|CRP 85.71 
7479f87b-31f5-476c-8b43-
be7123e3689a Enterobacter cloacae ARO:3003171|ACT-36 80 
2a70f844-6a7e-4556-9490-
fdc2c062b8ca Enterobacter cloacae ARO:3000518|CRP 82.61 
d2930048-e3d1-4baa-91a1-
d3272a55e912 Enterobacter cloacae ARO:3003830|aminocoumarin 82.05 
6619eb6a-42a0-43d8-bad7-
9f9f0da357c0 Enterobacter cloacae ARO:3001847|ACT-27 92.11 
e9af0f71-1965-4689-87b7-
f59d348114bc Enterobacter cloacae ARO:3003830|aminocoumarin 81.07 
4f41b849-d87b-4237-ac8e-
b52c4e806175 Enterobacter cloacae ARO:3003923|oqxB 81.7 
b4c1a038-b2ce-40cb-bacd-
c2bb605e28ed Enterobacter cloacae ARO:3000216|acrB 84.36 
7eec9347-b96e-4720-b737-
11cf0114322f Enterobacter cloacae ARO:3000216|acrB 84.19 
6529bb19-76fa-4a74-9d4b-
794a50008839 Staphylococcus aureus ARO:3000026|mepA 87.09 
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b32e718f-8dc4-43a4-a62b-
9d56c89ebb81 Enterobacter cloacae ARO:3000216|acrB 86.72 
d7968db9-937a-49e7-9e37-




e72bfff5c093 Enterobacter cloacae ARO:3000216|acrB 81.65 
0db6077b-5ddb-4df8-b779-
7bca33e7e18e Enterobacter cloacae ARO:3003923|oqxB 82.44 
27109828-c59f-4e9e-a200-
f211c404c85d Enterobacter cloacae ARO:3000216|acrB 85.61 
f83b40e5-62b4-4c1e-947c-
c0c768fdf53e Enterobacter cloacae ARO:3000216|acrB 85.37 
125484c0-cca3-46c3-a9bf-
f49a5c2bd294 Enterobacter cloacae ARO:3003923|oqxB 82.61 
1bfb46ef-14dd-4478-b9fd-
943356018e6b Enterobacter cloacae ARO:3000216|acrB 86.06 
84de5e6c-1fdc-4043-956d-
79bf2be5d8b9 Enterobacter cloacae ARO:3000825|robA 88.87 
edbbf562-2ba5-44aa-b760-
d2e8bd7872b0 Enterobacter cloacae ARO:3003923|oqxB 80.48 
144dba86-2cec-4573-a6f6-
8b926dc202b0 Enterobacter cloacae ARO:3000216|acrB 88.81 
a5bceeda-4362-4b17-b712-
e42fc3a37d4f Enterobacter cloacae ARO:3000216|acrB 83.56 
20d2ac74-c0b4-4c1b-b216-
d754f2ceac7f Enterobacter cloacae ARO:3000216|acrB 82.95 
dfaa8bb2-2b00-4fdf-a9b1-
1255575056d5 Enterobacter cloacae ARO:3000207|acrA 80.15 
6fa36aaf-fc72-4d38-a579-
4d310483c327 Enterobacter cloacae ARO:3001847|ACT-27 81.4 
c11e80a0-44d8-4555-a40d-
10d47faa8095 Enterobacter cloacae ARO:3003923|oqxB 83.75 
bf16f014-d3e7-4950-8bbc-
f3e9ca5b83a4 Enterobacter cloacae ARO:3000024|patA 80.36 
2723a479-637b-41e3-83a2-
0e615ae6d38a Enterobacter cloacae ARO:3003923|oqxB 81.35 
47605658-1db2-461a-bf67-
7befaf114f97 Enterobacter cloacae ARO:3000216|acrB 83.21 
0610ae51-57a5-4a17-9a99-
626932d55e12 Enterobacter cloacae ARO:3003923|oqxB 82.23 
1e725a77-f61e-4ec0-bc85-
109fb5229773 Enterobacter cloacae ARO:3000216|acrB 84.97 
f513ca5a-4342-4342-9857-
e8dcf6d52d1a Enterobacter cloacae ARO:3000216|acrB 87.15 
8b19fec1-eab8-4d7b-b733-
8506cca134f8 Enterobacter cloacae ARO:3000216|acrB 81.16 
e00c03e8-07e5-45bb-afa3-
cc1ebac7ba94 Enterobacter cloacae ARO:3000216|acrB 80.5 
a43cd2f2-ea3b-43c2-9384-c40d72f4f9f7 Enterobacter cloacae ARO:3003922|oqxA 82.48 
d5a3c3c1-e95d-41f7-80ca-
116133be327b Enterobacter cloacae ARO:3000216|acrB 82.77 
e64515af-074f-4b21-99a2-918fff1f0532 Enterobacter cloacae ARO:3003830|aminocoumarin 80.37 
cafd7216-9deb-41e8-a7cf-
c3a700833c58 Enterobacter cloacae ARO:3000825|robA 83.79 
3da9f4c9-3835-41f0-94ec-
7a296ac16436 Enterobacter cloacae ARO:3000216|acrB 81.11 
653a0230-6546-4b55-914e-
6af0fa10d75f Enterobacter cloacae ARO:3000216|acrB 85.6 
800c9247-0dc5-498a-ae8a-
731b75f06a03 Enterobacter cloacae ARO:3001830|ACT-7 85.43 
f65b4bff-98a0-4dcb-8704-
970c4c851b08 Enterobacter cloacae ARO:3003923|oqxB 81.75 
b31e93a0-2641-4721-ac5b-
18658a63a855 Enterobacter cloacae ARO:3003923|oqxB 80.06 
12cbe5a0-88a7-4cbf-b3b9-








42f4aaede0b8 Enterobacter cloacae ARO:3000825|robA 83.66 
f79b4a65-46c7-415a-a304-
99c758e5c6c8 Enterobacter cloacae ARO:3000216|acrB 83.96 
badb38e1-69bc-4807-b5d2-
2b1333e61b66 Enterobacter cloacae ARO:3000216|acrB 87.76 
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ae9d6662-eb70-4b1a-abef-
e982010716bb Enterobacter cloacae ARO:3000216|acrB 81.49 
adda52a3-a077-4191-a284-
8e62bb1395e7 Enterobacter cloacae ARO:3000216|acrB 83.37 
dd98abf7-d944-47f2-9839-
2331ca2f4204 Enterobacter cloacae ARO:3001847|ACT-27 91.7 
7e545135-07d6-4d9c-b8ca-
9de190ed67da Enterobacter cloacae ARO:3001830|ACT-7 84.53 
58a4171a-0b66-4c21-8bc1-
b58fe461fe26 Enterobacter cloacae ARO:3000216|acrB 82.15 
88ba283a-d701-4c61-ae8d-
784ce73da985 Enterobacter cloacae ARO:3003923|oqxB 80.87 
8bffc7b7-a5cf-479c-ba2e-501a4222ea24 Enterobacter cloacae ARO:3001852|ACT-32 88.77 
27f74a85-bd12-4890-acf6-
8ae5183080a2 Enterobacter cloacae ARO:3000207|acrA 82.02 
b5e0e619-054a-4919-803f-
0981f0d95604 Enterobacter cloacae ARO:3000216|acrB 82.25 
04375fc5-2671-436a-97e7-
529b75895cd1 Enterobacter cloacae ARO:3000216|acrB 85.23 
3755ce18-9476-40d5-b285-
8e74f74844eb Enterobacter cloacae ARO:3003923|oqxB 82.34 
fc459e79-f868-4325-9740-
06af9b3e3302 Enterobacter cloacae ARO:3000216|acrB 81.86 
d49c37cd-9ce3-49a1-8ad0-
2b7ecfc03d82 Enterobacter cloacae ARO:3000024|patA 82.47 
2a167c6c-91b2-4ad4-8994-




91c5782ccc3a Enterobacter cloacae ARO:3000216|acrB 85.1 
a01f724f-d205-4dab-b5a4-
06b5f18a29d9 Enterobacter cloacae ARO:3001830|ACT-7 83.84 
06c775d3-f1f8-45f8-92aa-
a6ab47293992 Enterobacter cloacae ARO:3000216|acrB 81.47 
955e1891-4872-4bc4-bcca-




f6b290918f14 Enterobacter cloacae ARO:3000825|robA 89.18 
689348de-dc9d-454c-bd1c-
36d3d09949e9 Enterobacter cloacae ARO:3000216|acrB 83.65 
f7854cff-4f7f-40ac-825b-2ecc9d2db956 Enterobacter cloacae ARO:3000216|acrB 80.5 
16d08a0e-32a3-4835-bb10-
3d4ca03452d5 Enterobacter cloacae ARO:3000216|acrB 84.76 
58b4fdee-617b-4dc0-bf9f-
1a7fd62d3255 Enterobacter cloacae ARO:3000216|acrB 81.49 
3f7e3627-c812-4162-aae1-
6baf223e9372 Enterobacter cloacae ARO:3000216|acrB 86.6 
d94758df-80a0-4c4d-8c27-




epidermidis ARO:3000391|norA 86.04 
3b940043-2f74-48cb-9412-
38c9b3a46327 Enterobacter cloacae ARO:3000216|acrB 83.67 
029eba72-9c14-44ad-80ec-
42682ea29933 Enterobacter cloacae ARO:3000216|acrB 83.06 
ebf228e4-4e18-42c1-8af9-
248780e86ca1 Enterobacter cloacae ARO:3000216|acrB 85.57 
41c5ea5f-278b-4122-8b40-
39345fde3b0b Enterobacter cloacae ARO:3000216|acrB 82.47 
60f5eae3-22ed-4b25-9ba9-
c15bf81333e5 Enterobacter cloacae ARO:3000216|acrB 81.94 
88dcbacf-d778-4bec-ac39-
448b38eecfe3 Enterobacter cloacae ARO:3000216|acrB 86.24 
63af0068-4de6-4ae5-89a2-
d769f419b561 Enterobacter cloacae ARO:3000216|acrB 80.97 
34f8eec5-5ef8-4190-ab0c-
e4991294b680 Enterobacter cloacae ARO:3000216|acrB 81.24 
94f4e554-7141-4801-a447-
27af41d757cf Enterobacter cloacae ARO:3000216|acrB 83.1 
ca192605-d280-43a2-9fad-
c8ad24ae021f Enterobacter cloacae ARO:3000216|acrB 81.09 
909675c8-d491-44c3-b2bc-
15b997fc9111 Enterobacter cloacae ARO:3003923|oqxB 80.85 
6a6ed231-5efd-499d-ac09-





c78970871e2c Enterobacter cloacae ARO:3000516|emrR 80.21 
7e4c40e2-7b03-4c07-b351-




3e835d5fdf84 Enterobacter cloacae ARO:3000216|acrB 84.91 
c5c1bbed-496c-4291-85e5-
62d35ec11beb Enterobacter cloacae ARO:3000216|acrB 83.31 
5f30e900-427f-4e12-ad5c-




fe5fe24e00dd Enterobacter cloacae ARO:3003923|oqxB 83.77 
0cede423-40c1-471f-a362-
8aedf69b76fd Enterobacter cloacae ARO:3000216|acrB 87.21 
5e9f6456-c5c5-4e71-acb6-
ab7ad52b82c3 Enterobacter cloacae ARO:3001852|ACT-32 88.25 
d6cb969f-9f0e-42fc-8890-c4a55129f9d4 Enterobacter cloacae ARO:3000825|robA 90.09 
96b0d7b3-a9c8-4866-baed-
4ced7e97d4d1 Enterobacter cloacae ARO:3000216|acrB 81.97 
e3d2db0d-d00f-4ed2-96e3-
4ec1f9f864aa Enterobacter cloacae ARO:3000216|acrB 84.05 
64adbbf8-5968-460b-99d1-
368385f10f18 Enterobacter cloacae ARO:3000216|acrB 82.47 
db76f47e-8c85-474f-bbca-




3925e8562aef Enterobacter cloacae ARO:3000216|acrB 83.48 
a44ab211-0537-48b2-91a4-
17f4f69ba469 Enterobacter cloacae ARO:3000216|acrB 83.66 
5b88fcbb-9026-484f-80d3-
7e9173702499 Enterobacter cloacae ARO:3000207|acrA 80.93 
08f39e9a-82de-43ef-b3e7-
4b6bc747d16a Enterobacter cloacae ARO:3003922|oqxA 81.42 
bb2b2f5a-3986-476f-a643-
1c717fa3499e Enterobacter cloacae ARO:3001830|ACT-7 87.05 
568b229a-f9e2-4fe7-91ba-
9ee419bc9507 Enterobacter cloacae ARO:3001852|ACT-32 84.03 
fecfff03-0a45-46db-8c6e-a38f759d59dc Enterobacter cloacae ARO:3000825|robA 91.16 
426bdc5c-496e-4597-85e3-
8aebba6375d5 Enterobacter cloacae ARO:3001830|ACT-7 87.58 
acdc7a1d-41bd-47d9-a383-
9176c8140332 Enterobacter cloacae ARO:3000216|acrB 84.51 
184026b4-96b2-445c-b0cd-




2fe6994e58e0 Enterobacter cloacae ARO:3001830|ACT-7 88.23 
05e64a0e-8f0a-480d-95a4-
093627237006 Enterobacter cloacae ARO:3000216|acrB 86.55 
aed638fc-bbb2-43c7-8e6d-
862eb3e14f62 Enterobacter cloacae ARO:3001847|ACT-27 84.93 
af429be7-0130-47ba-8fba-
d4f1504c0044 Enterobacter cloacae ARO:3000216|acrB 86.52 
f2e3c00c-6a48-4b8b-808b-8f4bf4f178c6 Enterobacter cloacae ARO:3000825|robA 89.84 
5867ad01-119b-4235-ae53-
14eb085ca7e9 Enterobacter cloacae ARO:3000216|acrB 84.54 
d9068b6b-bbff-410f-96ee-
b01e2df6d6f7 Enterobacter cloacae ARO:3000216|acrB 83.29 
0b7c84ce-b53a-4208-ba4c-
6288986f8cf7 Enterobacter cloacae ARO:3000216|acrB 83.66 
a399b430-3463-48e7-b357-
9e9c5312cfdc Enterobacter cloacae ARO:3000216|acrB 80.01 
c3d55761-568b-46ba-9288-
250d2467fe5b Enterobacter cloacae ARO:3000216|acrB 84.14 
a709fa42-0809-4bd9-ae9a-
6a67b5e29431 Enterobacter cloacae ARO:3000216|acrB 86.82 
35121759-754d-4173-8fe7-
e571d2d1eec8 Enterobacter cloacae ARO:3003922|oqxA 80.34 
27ef056f-15cb-4810-a7d6-
1aa0ca6cc9e6 Enterobacter cloacae ARO:3000216|acrB 85.32 
1874c0be-96f8-47dd-9dfb-
3853c4b8d89a Enterobacter cloacae ARO:3000216|acrB 87.57 
bf2eb1e2-9eae-4d73-bf08-
33458cdabe1b Enterobacter cloacae ARO:3000216|acrB 83.11 
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e468c043-fb0e-4698-a135-
d18dbd7734e5 Enterobacter cloacae ARO:3003830|aminocoumarin 80.68 
907c2a82-8183-4ae4-be49-
35dbe0288623 Enterobacter cloacae ARO:3001855|ACT-35 80.73 
25b050ff-a629-46d8-a5e2-1ee0f8514cdf Enterobacter cloacae ARO:3000216|acrB 84.2 
4b2a1a60-84c3-46e0-8cfb-




epidermidis ARO:3000178|tetK 84.34 
ae2af016-f0a4-4a7e-b2b9-
13ac65cc5bee Enterobacter cloacae ARO:3000216|acrB 86.46 
be9a070d-569e-4e2b-ba5e-
ad86adabbcbb Enterobacter cloacae ARO:3000216|acrB 83 
ba87282c-1121-4f7d-896d-
efdc5755720b Enterobacter cloacae ARO:3000216|acrB 82.43 
a548cef3-4979-4af1-85df-
2c25b4909e7c Enterobacter cloacae ARO:3000825|robA 85.42 




8ba7a2ec0830 Enterobacter cloacae ARO:3003923|oqxB 80.56 
c7d0534e-7fa6-4ab6-b8bf-
f5fb6b22e669 Enterobacter cloacae ARO:3000216|acrB 85.71 
2c09ea17-fcea-40b5-a776-
fd0ada899f05 Enterobacter cloacae ARO:3000216|acrB 81.7 
2cd4b54e-cf09-487d-b1b5-
81d4610e5809 Enterobacter cloacae ARO:3000216|acrB 87.98 
4dd7d0e8-5634-4cf1-98cf-
1b0db485731b Enterobacter cloacae ARO:3001845|ACT-25 81.32 
594a9df9-fc45-4eb5-a624-
144aa175532c Enterobacter cloacae ARO:3000074|emrB 81.4 
f0bf0a87-d629-4c3a-891a-
9f97569d9d45 Enterobacter cloacae ARO:3000216|acrB 84.52 
90567112-b392-4905-98a9-
74edc3933d5b Enterobacter cloacae ARO:3000825|robA 91.29 
4f7baa88-b0b7-4151-b752-








599530d1fe4b Enterobacter cloacae ARO:3000216|acrB 84.85 
b9c05677-b9c0-48df-95b3-




epidermidis ARO:3000178|tetK 90.42 
8842d1b9-81de-4a4c-aa91-
5200ce8f7160 Bifidobacterium longum 
ARO:3003730|Bifidobacterium 
ileS 81.76 
15bfa662-21ba-47ae-8edf-adbef9d53cfc Enterobacter cloacae ARO:3000216|acrB 83.1 
6e5a871c-021c-4513-8f47-
87cf32c3994e Enterobacter cloacae ARO:3000216|acrB 80.52 
e5d34cf2-1baa-4418-a19e-




1aefbc3c839e Enterobacter cloacae ARO:3003922|oqxA 81.49 
b06dd381-1fc1-4efc-8658-
ae775041b46d Enterobacter cloacae ARO:3000825|robA 91.07 
32a9e278-67e3-4227-8637-
b089a89f48f0 Enterobacter cloacae ARO:3000216|acrB 82.28 
e34b20ec-5fd4-4d5c-8c18-
9aff9e401e63 Enterobacter cloacae ARO:3000825|robA 83.56 
b268b1dd-625f-4aaa-b931-
0a3d1f903bbc Enterobacter cloacae ARO:3001852|ACT-32 87.67 
7ace70d6-76ab-40df-9927-
e204cef94f24 Enterobacter cloacae ARO:3000216|acrB 82.84 
0a3f4c73-9541-4996-8a8f-
c170c3a9ace8 Enterobacter cloacae ARO:3000216|acrB 85.75 
2f6bf428-e746-4b64-b943-
e344c8623313 Enterobacter cloacae ARO:3000216|acrB 85.3 
0566c1ff-5793-4d1a-b2ca-d76ffab2205f Enterobacter cloacae ARO:3003923|oqxB 82.79 
ea06077c-a7e5-4f01-8ecc-




5838ad4e7927 Enterobacter cloacae ARO:3001830|ACT-7 84.12 
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84408555-b1d4-4e3e-982c-
2a8900005b09 Enterobacter cloacae ARO:3000216|acrB 82.41 
53a58acc-1918-4e28-bace-
bea515b5f114 Enterobacter cloacae ARO:3000216|acrB 83.33 
74b0c43f-7b62-4a31-81ad-
4ffc77166a60 Enterobacter cloacae ARO:3001847|ACT-27 84.68 
ec5a5ffa-c7e1-4dea-b558-




a358e0bb0c13 Enterobacter cloacae ARO:3000216|acrB 81.25 
22cf8878-9c88-42bf-9660-376a4b9e3f5f Enterobacter cloacae ARO:3000216|acrB 81.67 
90293e18-41a8-4517-8101-
12970195fc48 Enterobacter cloacae ARO:3000216|acrB 84.69 
28c6e144-4a0d-4a1e-847e-
257b7538b0a9 Enterobacter cloacae ARO:3000216|acrB 81.82 
eadbe995-831f-4b80-91ae-
92c66d1768ac Enterobacter cloacae ARO:3000825|robA 90.29 
ac207589-ed6b-4e26-9520-
3727099b22d2 Enterobacter cloacae ARO:3003923|oqxB 81.29 
405f0ec9-ca8d-4894-a4ca-




9915dbc2208c Enterobacter cloacae ARO:3001852|ACT-32 86.89 
6777697d-b1fc-4d9c-84f6-
db09a7afc16a Enterobacter cloacae ARO:3000825|robA 85.13 
b6a35cce-f46b-4182-8546-
b3126b375bda Enterobacter cloacae ARO:3003923|oqxB 81.72 
ca8c9d57-ae2a-4cd8-9d64-
97a97c7a6e35 Enterobacter cloacae ARO:3000216|acrB 80.74 
de2b9b47-61a6-4c3b-a6eb-
ef1161c2a917 Enterobacter cloacae ARO:3001852|ACT-32 83.78 
23eb4ae5-8bce-4dee-a436-
83d7ea392278 Enterobacter cloacae ARO:3000216|acrB 83.36 
d105fc30-fdb8-4fa2-b870-
5499b47e74f0 Enterobacter cloacae ARO:3001838|ACT-17 86.33 
7c465b29-8292-4a97-b466-
776f9f5ace35 Enterobacter cloacae ARO:3000216|acrB 81.98 
d6188072-1394-4fb0-a53e-
e7174de29c86 Enterobacter cloacae ARO:3001827|ACT-16 84.59 
60a30b56-86fc-4f41-b7ff-
08ee18a68d3b Enterobacter cloacae ARO:3001852|ACT-32 88.15 
fd057855-7daa-4d52-b867-




eeedd3cf5a2a Enterobacter cloacae ARO:3003922|oqxA 82.78 
71e35480-d15b-45c0-9f10-
5b4972837000 Enterobacter cloacae ARO:3001845|ACT-25 82.89 
0704e2c8-2c06-4ddb-bb3c-
dfe9d00866d8 Enterobacter cloacae ARO:3001852|ACT-32 83.74 
fdc55421-36eb-4851-99d6-
1bf5e5d04aea Enterobacter cloacae ARO:3000825|robA 84.45 
e1fdbeeb-8985-46b5-bc5e-
feda07db0662 Enterobacter cloacae ARO:3000216|acrB 85.48 
dd87e8f6-562c-4e37-b090-
61dbe1802a9f Enterobacter cloacae ARO:3000216|acrB 80.9 
a01f8751-9111-43cf-b4a4-a4489492f13f Enterobacter cloacae ARO:3001852|ACT-32 91.07 
a7a45e38-8776-491c-8bd8-
4bb40da5e369 Enterobacter cloacae ARO:3001847|ACT-27 87.81 
2f4fbe0a-ced8-42f6-a5c7-8ff2f8c1233c Enterobacter cloacae ARO:3003830|aminocoumarin 80.15 
c3332952-d03a-457f-93f7-
d877e4927941 Enterobacter cloacae ARO:3000216|acrB 83.16 
9169da3f-118c-4075-902f-
2bb0c192ecca Enterobacter cloacae ARO:3000216|acrB 83.84 
b3859b91-e83d-448e-aed8-
0372e75059d5 Enterobacter cloacae ARO:3000216|acrB 83.04 
949e2260-6be9-4566-9a45-
a1c05e940c23 Enterobacter cloacae ARO:3000825|robA 86.09 
f84def54-c041-4b40-8e7c-
130bcd0467e5 Enterobacter cloacae ARO:3000216|acrB 85.5 
8c92e865-e976-44fb-8ace-
242086bb26fc Enterobacter cloacae ARO:3001830|ACT-7 84.56 
8c92e865-e976-44fb-8ace-
242086bb26fc Enterobacter cloacae ARO:3001839|ACT-18 83.49 
a5af37d7-00a4-4ffd-9831-da6f2d8417f4 Enterobacter cloacae ARO:3000216|acrB 82.52 
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bd94a22d-d554-4322-a3a9-
244cd4a2e435 Enterobacter cloacae ARO:3000825|robA 87.03 
6e772918-2d01-4cb9-9cdb-
27c468d77b3d Enterobacter cloacae ARO:3000216|acrB 80.09 
335dabc5-a1de-4dda-b3cc-
20ee1d971c2a Enterobacter cloacae ARO:3000825|robA 90.36 
fa605de9-c429-49c3-9ca8-
3c39702c7516 Enterobacter cloacae ARO:3001830|ACT-7 89.31 
8822c019-a7e2-43a3-9850-
8069fe36b569 Enterobacter cloacae ARO:3001847|ACT-27 88.75 
91df06cb-0c7a-4c68-9998-
eea922f182ee Enterobacter cloacae ARO:3003923|oqxB 81.17 
5588dae4-9d57-428c-a953-
6cdfae47ca07 Enterobacter cloacae ARO:3003923|oqxB 82.75 
ebe65798-8ba2-413d-bf8f-
b0124494c0ea Enterobacter cloacae ARO:3000216|acrB 81.93 
    
Premature infant P49       
ReadId HostHit CARDhit PercentId 
9f0f9a0b-6fe1-4a75-938f-dfc23d4db4d2 Escherichia coli ARO:3001397|OXA-2 80.46 
43962585-c65f-4aea-8206-
b51480c82537 Enterobacter cloacae ARO:3000825|robA 81.34 
9f9cc129-8097-4d1f-97c8-
aa0ccbbe756c Enterobacter cloacae ARO:3000825|robA 90.61 
92eaf722-df44-4365-a8db-
07d259356b37 Klebsiella pneumoniae ARO:3001397|OXA-2 88.02 
1e8a4a88-f0b8-423f-aba1-
de54058ae3ca Enterobacter cloacae ARO:3000216|acrB 90.54 
1f44caa1-0583-439a-b131-
d9702fd434cc Klebsiella pneumoniae ARO:3001397|OXA-2 90.07 
1f44caa1-0583-439a-b131-
d9702fd434cc Klebsiella pneumoniae ARO:3001397|OXA-2 86.15 
ba11cd47-e6ca-40d9-ba63-
4ff556a8aa26 Enterobacter cloacae ARO:3000825|robA 89.84 
8e2be451-e215-42b9-8c61-
688cd4e1bf9f Klebsiella michiganensis ARO:3000024|patA 80.45 
2800067b-11af-4835-9d8a-
accb104478d7 Enterobacter cloacae ARO:3001839|ACT-18 90.83 
f75b2cb7-dab3-4976-a535-
30323fc6ddb5 Enterobacter cloacae ARO:3001839|ACT-18 84.65 
8f706682-d0dc-4ecd-9c6a-
5c83b424fbd2 Enterobacter cloacae ARO:3000074|emrB 81.17 
f93c2543-62e6-4571-a016-
6159520b5bbd Klebsiella pneumoniae ARO:3001397|OXA-2 81.7 
e43018b6-dcda-4ad4-aa71-
62142beb26c1 Enterobacter cloacae ARO:3003923|oqxB 82.51 
    
Premature infant P8       
ReadId HostHit CARDhit PercentId 
91c109a9-4197-4db2-b4de-
1899ed8405b1 Klebsiella pneumoniae ARO:3003923|oqxB 83.18 
91c109a9-4197-4db2-b4de-
1899ed8405b1 Klebsiella pneumoniae ARO:3003922|oqxA 84.34 
3dbb4270-a451-4088-8514-
3113ad8b11fd Klebsiella pneumoniae ARO:3002831|vgaC 87.07 
e491ce14-95f8-40a3-979f-cfbe9fc3bd2c Klebsiella pneumoniae ARO:3003154|SHV-187 85.02 
9b9162e2-097a-42b4-9eb5-
d24ab62aca19 Escherichia coli ARO:3002831|vgaC 85.34 
ea828b01-5736-4bd9-b047-
ef49d4a66c1f Klebsiella pneumoniae ARO:3002831|vgaC 86.53 
4b76be2a-5061-44e3-a74c-
9a3ed625231b Klebsiella pneumoniae ARO:3001181|SHV-137 83.95 
a4d9e191-0bb6-4d4e-9537-
bb2de59452a5 Klebsiella pneumoniae ARO:3003923|oqxB 82.64 
ef9078d6-de7f-44a8-b76b-
3c3f63987f33 Klebsiella pneumoniae ARO:3003923|oqxB 85.54 
e4274fd5-7b82-4b49-8803-
432a1109055e Klebsiella pneumoniae ARO:3003923|oqxB 88.68 
deefa3bf-74ae-40ab-9f63-
d257e4954b09 Klebsiella pneumoniae ARO:3000676|H-NS 80.1 
291250ff-f781-4fc5-9393-6fbf4248f720 Escherichia coli ARO:3003922|oqxA 86.17 
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9eeabd98-9050-436f-b757-
7ff5445b4c2f Proteus mirabilis ARO:3002670|cat 89.12 
fabbb72e-615b-487a-83b4-
786a6e57bb84 Klebsiella pneumoniae ARO:3003923|oqxB 86.84 
5708db1c-d312-4c9e-b710-
b83e16df0824 Klebsiella pneumoniae ARO:3001191|SHV-152 83.18 
06a44d06-9a6e-4d99-bec5-
014ea00c4e1a Escherichia coli ARO:3002831|vgaC 85.71 
36efa0b2-29f5-49b9-81d5-
bd63e854d92b Shigella flexneri ARO:3002601|aadA 86.25 
36efa0b2-29f5-49b9-81d5-
bd63e854d92b Shigella flexneri ARO:3002854|dfrA1 89.63 
36efa0b2-29f5-49b9-81d5-
bd63e854d92b Shigella flexneri ARO:3002895|sat-1 87.11 
8fa05c8e-7b7b-47e8-8c94-e04760daffcc Klebsiella pneumoniae ARO:3003209|FosA5 84.04 
978d00a7-e56f-4734-85c7-
8f6468eb31fc Klebsiella pneumoniae ARO:3001068|SHV-9 84.33 
94107794-e610-483e-a9b0-
262b3a3b5ce1 Klebsiella pneumoniae ARO:3003923|oqxB 83.43 
11fe1704-d265-497c-b7d1-
82b3177655b0 Shigella flexneri ARO:3002601|aadA 92.4 
11fe1704-d265-497c-b7d1-
82b3177655b0 Shigella flexneri ARO:3002895|sat-1 93.93 
11fe1704-d265-497c-b7d1-
82b3177655b0 Shigella flexneri ARO:3002854|dfrA1 91.25 
11dd0010-f065-4ef1-b1ee-
b4a87a1e0234 Klebsiella pneumoniae ARO:3003923|oqxB 87.22 
11dd0010-f065-4ef1-b1ee-
b4a87a1e0234 Klebsiella pneumoniae ARO:3003922|oqxA 87.64 
f420290b-60c0-44ba-b403-
570d157ad714 Klebsiella pneumoniae ARO:3000024|patA 82.44 
8eda44d2-eb8f-4ca5-92fa-
199d2b2bb191 Klebsiella pneumoniae ARO:3003830|aminocoumarin 81.89 
c418092f-f317-4930-b1eb-
9333a3b50f8d Klebsiella pneumoniae ARO:3003923|oqxB 84.94 
70249fee-7fda-405f-a88a-
492e9daa3825 Klebsiella pneumoniae ARO:3002831|vgaC 80.87 
58e8f118-0279-4884-b815-
4b1dad5cdabd Klebsiella pneumoniae ARO:3003922|oqxA 83.54 
803acbc6-b004-42cb-8810-
ff01ecfb6608 Proteus mirabilis ARO:3002670|cat 84.75 
7ae51fb0-8476-4f73-9648-
4d5199e8f3f6 Klebsiella pneumoniae ARO:3003922|oqxA 87.29 
deb6ae0c-247e-48a4-ac54-
61d9ffaa32d7 Klebsiella pneumoniae ARO:3002831|vgaC 87.92 
416fdf9a-524c-4c18-b0cd-
1d6726577c2e Klebsiella pneumoniae ARO:3003922|oqxA 86.97 
416fdf9a-524c-4c18-b0cd-
1d6726577c2e Klebsiella pneumoniae ARO:3003923|oqxB 87.2 
30a17c45-3589-4892-a21e-
72656458044f Escherichia fergusonii ARO:3002831|vgaC 87.07 
ae9eec6d-b8b7-488e-9c73-
9a6792094653 Klebsiella pneumoniae ARO:3001191|SHV-152 83.92 
26f62185-131f-4784-8f0e-
4e0fbd57d5bb Escherichia coli ARO:3002831|vgaC 88.28 
2ef1633d-f513-4cd3-b8c0-
e9b3ef7367a7 Klebsiella pneumoniae ARO:3003922|oqxA 88.95 
4ca686b0-7954-44d2-9bff-
b810c912b6ed Klebsiella pneumoniae ARO:3000518|CRP 81.1 
68aee99e-e2ca-43ae-98e4-
afae4c8b5964 Klebsiella pneumoniae ARO:3003923|oqxB 84.76 
68aee99e-e2ca-43ae-98e4-
afae4c8b5964 Klebsiella pneumoniae ARO:3003922|oqxA 88.11 
bd102361-6156-42ac-a750-
353389c29ef5 Escherichia coli ARO:3002831|vgaC 83.9 
0274146f-d932-4ab9-8056-
fd88a879dc56 Proteus mirabilis ARO:3000177|tetJ 89.11 
0213c7e0-4fc4-4c35-9f29-
b1bc5d57bf76 Proteus mirabilis ARO:3000177|tetJ 90.5 
0e58708e-36be-4a0e-a6c6-
c1b7420640cb Escherichia coli ARO:3002831|vgaC 82.82 
d3e58f03-ef82-437d-84ea-
d9ec9be82baa Klebsiella pneumoniae ARO:3003922|oqxA 84.68 
2ecd147d-e3e2-49af-8e08-
1c74ea752712 Escherichia coli ARO:3002831|vgaC 84.48 
 237 
9bf41674-83a4-409b-a5be-
472b5c2ef163 Klebsiella pneumoniae ARO:3003152|SHV-185 86.28 
db145b6c-51bc-4701-8f89-
defb8c008ee4 Klebsiella pneumoniae ARO:3003923|oqxB 89.52 
db145b6c-51bc-4701-8f89-
defb8c008ee4 Klebsiella pneumoniae ARO:3003922|oqxA 87.22 
4b8cc3ab-656f-4027-ac04-e01ddf92c0f3 Escherichia coli ARO:3002831|vgaC 89.22 
c96c2a28-9d08-4572-80fc-
da193ac5a80e Klebsiella pneumoniae ARO:3003923|oqxB 88.56 
b519efda-0873-4fc1-91a9-
8ad9bbe68f57 Klebsiella pneumoniae ARO:3003209|FosA5 86.56 
ca566715-e763-4e21-8aa9-
796d6b3336f0 Klebsiella pneumoniae ARO:3003923|oqxB 82.37 
ca566715-e763-4e21-8aa9-
796d6b3336f0 Klebsiella pneumoniae ARO:3003922|oqxA 81.67 
f8456b52-980d-48ac-bc09-
b18e04a88a76 Klebsiella pneumoniae ARO:3003209|FosA5 85 
185577b4-5519-4674-a2db-
5fcb3835bbb1 Klebsiella pneumoniae ARO:3001096|SHV-38 86.98 
730c231c-cee8-474d-857a-
f09d4d085038 Klebsiella pneumoniae ARO:3003922|oqxA 84.62 
936730d0-438a-4a85-9274-
75d172ef4c56 Proteus mirabilis ARO:3002670|cat 87.08 
d1a03b1e-69b0-4633-9168-
8c11dbd21948 Klebsiella pneumoniae ARO:3003922|oqxA 81.4 
20a7ea01-94de-4074-9d51-
db7e46a4ce28 Klebsiella pneumoniae ARO:3001193|SHV-154 85.45 
cb52655d-1a93-4570-ada9-
f1c84a81b719 Klebsiella pneumoniae ARO:3003209|FosA5 84.47 
bf34b2b3-efca-455c-8c39-
165c930b8e6a Klebsiella pneumoniae ARO:3003922|oqxA 87.39 
bf34b2b3-efca-455c-8c39-
165c930b8e6a Klebsiella pneumoniae ARO:3003923|oqxB 89.15 
a05233b7-df27-41c3-b1f9-
5f2598d9c26d Klebsiella pneumoniae ARO:3001137|SHV-83 81.03 
ab12799c-a61e-46ba-9047-
b0ad5e709718 Escherichia coli ARO:3002831|vgaC 80.33 
6f63c035-b433-4c90-95f6-
025bbfdab1ea Escherichia coli ARO:3002831|vgaC 91.14 
0272afc5-e974-4c2c-af3c-cff5b69919e2 Shigella flexneri ARO:3002601|aadA 89.26 
0272afc5-e974-4c2c-af3c-cff5b69919e2 Shigella flexneri ARO:3002854|dfrA1 94.14 
0272afc5-e974-4c2c-af3c-cff5b69919e2 Shigella flexneri ARO:3002895|sat-1 86.58 
85f7edfd-25d9-423e-ae59-
b1d3f56bc263 Klebsiella pneumoniae ARO:3002831|vgaC 91.6 
f8d9bb9d-342c-474d-8be4-
475cf72e3142 Klebsiella pneumoniae ARO:3003155|SHV-188 84.44 
be929281-3ee0-4beb-80ce-
8b34da29dd8e Klebsiella pneumoniae ARO:3001191|SHV-152 85.16 
6bcc0b9e-8f4e-4085-9f91-
542c2018ee30 Klebsiella pneumoniae ARO:3003922|oqxA 85.8 
20034209-49a0-4c16-91bb-
3c537f7d180b Klebsiella pneumoniae ARO:3003923|oqxB 80.59 
20034209-49a0-4c16-91bb-
3c537f7d180b Klebsiella pneumoniae ARO:3003922|oqxA 82 
db271f06-e250-4e53-991a-
7da4664b0bb1 Klebsiella pneumoniae ARO:3003922|oqxA 81.61 
613712fe-44d8-4dd6-935d-
26b741a6194f Escherichia coli ARO:3002831|vgaC 88.41 
f4a007b4-8e36-4a48-a154-
8bdeea83f10b Klebsiella pneumoniae ARO:3003209|FosA5 84.65 
3e415653-15e5-4d4c-86c6-
c23ddadd3983 Salmonella sp. ARO:3002621|aadA24 81.57 
ea16dcc5-0a3c-4fbf-a26b-65000580f23a Escherichia coli ARO:3003923|oqxB 80.15 
c6c91a73-365d-4e57-9822-
c34a69794e5c Klebsiella pneumoniae ARO:3003209|FosA5 91.9 
24e83392-0351-4b93-974d-
3e4b479aa90f Klebsiella pneumoniae ARO:3000676|H-NS 82.33 
28329d1f-39b8-4222-b803-
75fb1fcec0cb Pasteurella multocida ARO:3002621|aadA24 85.54 
ef24885e-3c4e-43c5-ae38-
db3817ffa528 Klebsiella pneumoniae ARO:3002831|vgaC 91.45 
78bb2cb5-91c1-46af-8edf-8a3dfecfe0cf Klebsiella pneumoniae ARO:3001128|SHV-74 84.81 
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aaecf687-1cf0-494f-b15f-747a33782d67 Klebsiella pneumoniae ARO:3002831|vgaC 88.16 
48e15219-cc6c-44d4-b464-
e3f0caefea66 Klebsiella pneumoniae ARO:3003923|oqxB 80.45 
e7610d2e-0e08-4f3b-acac-
b588ad67b167 Klebsiella pneumoniae ARO:3003923|oqxB 83.67 
e7610d2e-0e08-4f3b-acac-
b588ad67b167 Klebsiella pneumoniae ARO:3003922|oqxA 81.17 
e44ac170-6230-44a9-bb6a-
8e26aa15ec2d Escherichia coli ARO:3002831|vgaC 89.29 
74cf7c41-f97b-4390-98f4-af250139b1d7 Escherichia coli ARO:3002831|vgaC 85.96 
4181ee03-3184-445c-92ba-
d4d32994e116 Escherichia fergusonii ARO:3002831|vgaC 89.61 
f6ecc73a-74d8-46c2-befc-
793c923da76e Klebsiella pneumoniae ARO:3003923|oqxB 87.67 
4afb2689-dfe4-4d52-b897-
068d961bd28a Shigella dysenteriae ARO:3002854|dfrA1 80 
464d8021-1a1b-420c-a538-
107c5a10e25e Klebsiella pneumoniae ARO:3003209|FosA5 82.4 
5b49a546-1311-4f04-98f0-
91b55e9e4e08 Klebsiella pneumoniae ARO:3001070|SHV-11 89.9 
9d48e2fc-98e5-48c3-9050-
0cf1081d24f3 Shigella flexneri ARO:3002601|aadA 85.85 
9d48e2fc-98e5-48c3-9050-
0cf1081d24f3 Shigella flexneri ARO:3002895|sat-1 82.59 
9d48e2fc-98e5-48c3-9050-
0cf1081d24f3 Shigella flexneri ARO:3002854|dfrA1 83.57 
062d12bf-c862-4a7c-b0c5-
08a2707c51ba Klebsiella pneumoniae ARO:3001137|SHV-83 90.38 
72d04edc-31ab-4dee-989e-
10c138a4955f Klebsiella pneumoniae ARO:3003923|oqxB 84.43 
5236051a-e03c-4b52-a6b7-
d1e493d0ff53 Klebsiella pneumoniae ARO:3003209|FosA5 85.34 
b2868101-9c5e-4871-aea9-
bf64436b6a98 Klebsiella pneumoniae ARO:3002831|vgaC 88.46 
a1c2e5ee-7fb7-4d09-ba29-
9aa275115479 Shigella flexneri ARO:3002601|aadA 81 
a1c2e5ee-7fb7-4d09-ba29-
9aa275115479 Shigella flexneri ARO:3002854|dfrA1 83.2 
a1c2e5ee-7fb7-4d09-ba29-
9aa275115479 Shigella flexneri ARO:3002895|sat-1 81.26 
c0c55578-ccdd-4b27-95ba-
ebd35df3e7bf Klebsiella pneumoniae ARO:3003923|oqxB 84.02 
59183d11-cc29-4f16-8d41-
5ea53ca3474b Klebsiella pneumoniae ARO:3001096|SHV-38 89.29 
87adc2b6-fb40-46d2-a2a1-
81f87086bd10 Klebsiella pneumoniae ARO:3001123|SHV-69 80.6 
131d1fb8-557c-428a-9f63-
8e81849d3398 Klebsiella pneumoniae ARO:3003209|FosA5 85.29 
1bf87f12-2c88-4c19-8d73-
0403b1e97f57 Escherichia coli ARO:3002831|vgaC 90.13 
85967a6a-cb34-4adb-9612-
1988c01b8251 Klebsiella pneumoniae ARO:3001123|SHV-69 84.14 
e4bef367-82cf-4044-ac93-8fadc6a327a9 Klebsiella pneumoniae ARO:3003154|SHV-187 88.59 
05c1a531-ab36-4d4d-b87d-
552cabe85db9 Klebsiella pneumoniae ARO:3000794|mdtC 81.46 
3139b264-7368-48e8-a01a-
6466301330d1 Klebsiella pneumoniae ARO:3001092|SHV-34 90.11 
2d2e272a-0162-4328-9f25-
d96168dd23d5 Escherichia coli ARO:3002831|vgaC 91.95 
8d336d92-9b3e-46ba-b4a1-
ece8f6c4a07d Proteus mirabilis ARO:3002670|cat 80.92 
d8bcfbf9-e353-4fdc-9f28-9ee62d09aece Klebsiella pneumoniae ARO:3001096|SHV-38 92.05 
4928531a-fdc9-4fa9-9dac-c90fe4c356f6 Klebsiella pneumoniae ARO:3003209|FosA5 82.52 
91d8975a-10e2-40b6-9fb4-
fc3e83047ae4 Shigella flexneri ARO:3002601|aadA 89.34 
906a5f6b-6477-4b4e-ac26-
b4e3c7c2f109 Klebsiella pneumoniae ARO:3002831|vgaC 87.65 
a94be529-7648-4ba2-bd17-
028d4d71189c Klebsiella pneumoniae ARO:3003922|oqxA 80.17 
0ffb3dcd-e9e1-4e2f-849a-
6b16103f6e44 Proteus mirabilis ARO:3002670|cat 84.66 
5e97ce63-356a-482c-9900-
5b2ffed2336b Klebsiella pneumoniae ARO:3003154|SHV-187 90.02 
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1a6a2f2b-9d56-41bc-a02f-ffea55be4c29 Klebsiella pneumoniae ARO:3003922|oqxA 83.85 
5a6d3107-59ff-46f0-937f-4a248b43c5cc Klebsiella pneumoniae ARO:3003922|oqxA 85.19 
ae154d69-70b6-443c-94b1-
381d546ae864 Klebsiella pneumoniae ARO:3003209|FosA5 86.73 
11b36bea-b0da-4532-8b69-
bd1359b5cb33 Klebsiella pneumoniae ARO:3003922|oqxA 83.49 
89b10ac5-4fe8-4ae9-b5a6-
3b651e361945 Proteus mirabilis ARO:3000177|tetJ 88.46 
d71e1959-8cda-478d-bad2-
41e03c59e741 Klebsiella pneumoniae ARO:3003154|SHV-187 83.35 
8e94e7ea-2d84-4c91-a3f6-
739773b63a4e Klebsiella pneumoniae ARO:3003209|FosA5 83.95 
644d0352-ee02-46c1-a934-
9d8d28cf7198 Escherichia coli ARO:3002831|vgaC 82.76 
30cd6edf-265d-40a1-90c0-
8f8d23a385df Klebsiella pneumoniae ARO:3003923|oqxB 88.54 
a7b949ea-4723-4aef-9a17-
093b094d9091 Klebsiella pneumoniae ARO:3001161|SHV-112 80.83 
78775584-6065-496f-88b9-
5a568da14c97 Klebsiella pneumoniae ARO:3003922|oqxA 82.19 
2b4f4c3d-761c-4784-a4df-
261abc84524b Klebsiella pneumoniae ARO:3003923|oqxB 87.96 
2b4f4c3d-761c-4784-a4df-
261abc84524b Klebsiella pneumoniae ARO:3003922|oqxA 93.67 
24116c54-5aee-4baa-b830-
c8946ce0fa22 Klebsiella pneumoniae ARO:3000676|H-NS 80.55 
91d184fa-5909-443f-bf87-
a8230c2e4701 Klebsiella pneumoniae ARO:3003209|FosA5 86.16 
dcd773ab-ca81-470b-92c5-
d2a9d4f80634 Klebsiella pneumoniae ARO:3003209|FosA5 85.91 
5dd293cd-91e7-47c5-a73a-
d35b7f861e78 Klebsiella pneumoniae ARO:3003923|oqxB 84.53 
5d1fdce7-c78f-4cea-8cac-0ade6cb16e27 Klebsiella pneumoniae ARO:3003209|FosA5 87.79 
d7b4149d-7d7b-443e-9171-
4f7329f8f8f6 Klebsiella pneumoniae ARO:3002831|vgaC 86.13 
7230612b-5daa-4f00-996a-
be3604667bbe Escherichia coli ARO:3002831|vgaC 88.36 
c473d5d3-2810-4b2d-8fa5-
91c7b3cab428 Klebsiella pneumoniae ARO:3003922|oqxA 86.74 
d27bb6a8-8cd2-4304-bba5-
d4c2e4c10193 Proteus mirabilis ARO:3002670|cat 85.44 
cb2b7ce6-286f-4c80-9536-
a62e1cba3788 Klebsiella pneumoniae ARO:3001137|SHV-83 88.33 
26d78d67-dc51-432a-8aae-
a5f583a9e438 Klebsiella pneumoniae ARO:3003209|FosA5 81.75 
eac54dfe-c098-4966-8332-
bb0f899345a4 Klebsiella pneumoniae ARO:3002831|vgaC 86.67 
4755fb9a-ca22-4e07-bf0b-
1c0e1ebfe473 Klebsiella pneumoniae ARO:3003923|oqxB 84.75 
b8d5b736-7871-4ac5-8bdb-
faaba65cf6c5 Klebsiella pneumoniae ARO:3003922|oqxA 82.04 
22ae98e3-bd7a-4850-a8b1-
1f6c91831f9b Klebsiella pneumoniae ARO:3002831|vgaC 87.87 
e94c6a7c-df7e-40f9-8083-
312b7d4f218a Escherichia coli ARO:3002831|vgaC 86.58 
5e0a1236-4891-466e-a75e-
ea1977c51d0b Escherichia coli ARO:3003923|oqxB 90.37 
34ec617c-7b1b-46cf-be91-
b8e5076475b7 Klebsiella pneumoniae ARO:3003923|oqxB 80.49 
8e9889d2-af51-454b-ab44-
70c9c73a7822 Klebsiella pneumoniae ARO:3003923|oqxB 82.42 
8e9889d2-af51-454b-ab44-
70c9c73a7822 Klebsiella pneumoniae ARO:3003922|oqxA 80.31 
d5374a8c-99e2-4689-8ac0-
4d47d4378e21 Klebsiella pneumoniae ARO:3003923|oqxB 82.93 
4ba8db7b-fda5-41de-8e7c-
d539e9845f5c Klebsiella pneumoniae ARO:3003923|oqxB 85.62 
0366488f-579f-41e2-b29d-
301350bc5f25 Klebsiella pneumoniae ARO:3000024|patA 82.38 
f57c3e0a-0117-4b7f-9853-
8944dd18dc80 Escherichia coli ARO:3002831|vgaC 86.64 
97652b2b-ea18-456c-bba8-
ccc27b43cf91 Klebsiella pneumoniae ARO:3003923|oqxB 88.45 
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ec8556bb-3e71-4c47-8d88-
30b84554d51e Klebsiella pneumoniae ARO:3003154|SHV-187 82.11 
445b6f7d-94cc-4ec7-bc6b-
5782daf10c7b Klebsiella pneumoniae ARO:3002831|vgaC 81.4 
d04a054e-4de4-4e3e-94c8-
fa0d3bae0904 Klebsiella pneumoniae ARO:3000216|acrB 80.16 
1abf83b8-cca3-48a7-99a3-
a0d60e81bb8e Escherichia coli ARO:3003923|oqxB 88.32 
dd526b48-a811-486a-91ea-
0c2e8fa76b47 Klebsiella pneumoniae ARO:3003923|oqxB 88.2 
54a89240-f72b-4dd1-adea-
5f6a1219bc0a Klebsiella pneumoniae ARO:3003923|oqxB 87.56 
c6ab4c1e-a65f-46c6-9f5c-56606f406288 Klebsiella pneumoniae ARO:3000793|mdtB 81.42 
a54dff89-39cb-4a5a-8ed7-2f7322894cdf Klebsiella pneumoniae ARO:3000216|acrB 80.86 
263b363a-581d-4929-8172-
bcbce75abc1e Klebsiella pneumoniae ARO:3003923|oqxB 88.47 
06588c97-8d0c-448b-a662-
7ed7468df794 Klebsiella pneumoniae ARO:3003922|oqxA 89.99 
9860e432-7ac5-48e7-8391-
97ea6181dd55 Klebsiella pneumoniae ARO:3003923|oqxB 85.01 
d084769d-7727-43a1-84cc-
eadd5f778972 Klebsiella pneumoniae ARO:3003923|oqxB 86.66 
a28b8f7d-7a13-4b12-b89a-
8a975d0bd8e8 Escherichia coli ARO:3003923|oqxB 90.83 
225d2d92-d924-42d4-86d6-
56586dce52fb Klebsiella pneumoniae ARO:3003923|oqxB 88.49 
6d12b038-0afd-4290-a35c-
8da3dcf4dfde Klebsiella pneumoniae ARO:3003923|oqxB 85.5 
591b3413-be96-42ee-9a63-
71b1c42abfd9 Klebsiella pneumoniae ARO:3000216|acrB 80.66 
e58361b7-e4e4-4af5-8983-
a2174d588b4a Klebsiella pneumoniae ARO:3003923|oqxB 89.96 
407531b5-5749-4efd-b40a-
4952a8ea3b74 Klebsiella pneumoniae ARO:3003923|oqxB 83.76 
ee541880-521a-4289-b2fc-
b07712bbe554 Klebsiella pneumoniae ARO:3003923|oqxB 84.77 
0248ad22-c428-462c-9c6a-
61fff7172b06 Klebsiella pneumoniae ARO:3003923|oqxB 80.05 
05bdc6c2-8333-458f-b05b-
ebf8145be288 Klebsiella pneumoniae ARO:3003923|oqxB 82.31 
7380dc40-6398-4665-822a-
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